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Osteoporosis is a skeletal disease characterized by low bone mass that 
often results in fracture. Mechanical loading of the skeleton is a promising 
approach to maintain or recover bone mass. Mouse models of in vivo 
loading differentially increase bone mass in cortical and cancellous sites. The 
molecular mechanisms behind this anabolic response to mechanical loading 
need to be determined and compared between cortical and cancellous bone. 
This knowledge could enhance the development of drug therapies to 
increase bone formation in osteoporotic patients.  
After developing a method to isolate high-quality RNA from marrow-
free mouse cortical and cancellous bone, differences in gene transcription 
were determined at baseline and at two time points following mechanical 
loading of wild-type mice. Cortical and cancellous bone exhibited different 
transcriptional profiles at baseline and in response to mechanical loading. 
Enhanced Wnt signaling dominated the response in cortical bone at both 
 time points, but in cancellous bone only at the early time point. In cancellous 
bone at the later time point, many muscle-related genes were downregulated.  
Decreased bioavailable estrogen levels are a major cause of bone loss 
in postmenopausal women. Estrogen signaling through estrogen receptor 
alpha (ERa) has been found to be particularly important in regulating bone 
mass and the skeletal response to mechanical loading. We recently showed 
that mice lacking ERa in osteoblasts and osteocytes (pOC-ERaKO) had an 
increased adaptive response to mechanical loading, particularly in cancellous 
bone. The molecular mechanisms of functional adaptation to load in the 
context of decreased estrogen signaling are not fully elucidated, particularly 
in cortical versus cancellous sites. We examined transcription in cortical 
versus cancellous bone of tibiae from littermate control (LC) and pOC-
ERaKO mice. pOC-ERaKO mice had a blunted transcriptional response to 
mechanical loading in cortical bone compared to littermate controls, but had 
an increased response in cancellous bone. This work demonstrates the 
importance of examining cortical and cancellous bone separately, and that 
next-generation sequencing is a powerful tool for discovering the complete 
transcriptional mechanisms responsible for mechanical loading-related bone 
anabolism.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Cortical and Cancellous Bone 
 
Bones are composite structures consisting of an exterior cortical shell and 
an inner cancellous network. This structure is essential for the demands 
placed on the skeleton, providing a form that meets the function of 
maintaining structure and resisting fracture. Cancellous (spongy) bone is a 
porous network of individual rods and plates called trabeculae and is found 
in the metaphysis of long bones. Cancellous bone has a large surface area 
with trabeculae surrounded by bone marrow, contributing to high metabolic 
activity. Cortical (compact) bone is a dense structure consisting of basic units 
known as osteons that are roughly cylindrical and have a central Haversian 
canal containing blood vessels and nerves surrounded by concentrically 
arranged lamellae of bone matrix (Figure 1.1). Long bones have a large 
diaphyseal cavity containing bone marrow.  
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In addition to the differences in structure and metabolic activity, cortical 
and cancellous bone differ in their initial development (modeling), 
attainment, and gain/loss of bone mass (remodeling). Cortical bone initiates 
from the bone collar and expands through coordinated periosteal apposition 
and endosteal resorption. Conversely, cancellous bone arises from cartilage 
precursors at the growth plate. But it has recently been shown that both 
tissues can arise from hypertrophic chondrocytes that can become 
osteoblasts and osteocytes that contribute to cancellous bone, the 
endosteum, and mature bone [3, 4]. Cortical and cancellous bone mass 
increase during growth, but cortical bone mass stabilizes at skeletal maturity 
and decreases during aging [5], while cancellous bone decreases immediately 
after reaching peak bone mass without a stabilization phase [6]. Alteration of 
 
Figure 1.1 The bones of the human appendicular skeleton, such as the 
femur, consist of porous cancellous bone in the metaphysis at the distal 
and proximal ends (circled), dense cortical bone forming a shell (boxed) 
and a large diaphyseal space containing bone marrow. Cancellous low-
power scanning electron microscope image adapted from [1], cortical 
image from [2].  
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bone size and shape are mediated by three different cell types located on the 
bone surface and within the mineralized matrix. 
Osteoblasts and osteoclasts are located on the bone surface and perform 
the physical work of adding and removing bone, respectively. Osteoblasts 
derive from the mesenchymal cell lineage and can be identified by their 
cuboidal morphology and alkaline phosphatase (ALP) activity. Osteoclasts 
derive from hematopoietic stem cells, are multinucleated and are often 
identified by their expression of tartrate-resistant acid phosphatase (TRAP).  
Osteocytes are terminally differentiated osteoblasts that have been 
embedded in the mineralized bone matrix and compose over 90% of all 
bone cells. They have a stellate cell shape; their cell bodies are located in 
lacunae, and long dendritic processes reside in channels in the bone matrix 
known as canaliculi. This lacuno-canalicular network connects osteocytes to 
one another and to the bone surface. Osteocytes are, therefore, thought to 
be important in cell-to-cell signaling and orchestrating the activity of 
osteoblasts and osteoclasts.  
Normal bone homeostasis is characterized by a constant self-renewal 
known as remodeling, which continually removes old bone and replaces it 
with new bone. As the skeleton ages, the amount of bone formed during 
each remodeling cycle decreases due to decreased osteoblastogenesis [7]. 
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Additionally, women experience a distinctive change in skeletal homeostasis 
at the onset of menopause, when estrogen declines. Changes in bone 
homeostasis that cause an overall decline in bone mass result in a disease 
known as osteoporosis.  
 
1.2 Osteoporosis  
 
Osteoporosis is one of the most common musculoskeletal disorders. 
It is characterized by decreased bone mass as the skeleton ages, which is 
correlated with a reduction in estrogen production in females at menopause. 
This decrease in bone mass produces weaker skeletal structures that are 
sometimes unable to bear everyday loads, which can result in fracture at 
corticocancellous sites including the spine, proximal femur, and distal radius 
(Figure 1.2) [8]. One in three women and one in five men over the age of 50 
will experience an osteoporosis-related fracture. The cost of treating these 
fractures in an increasingly aged population is predicted to reach $25 billion 
by 2025 [9]. Furthermore, patients who suffer an osteoporosis-related non-
vertebral fracture are at higher risk of subsequent fracture within one year, 
and treatments for patients who incur subsequent fractures are significantly 
more costly [10]. Even more importantly, women who experience a hip 
fracture have two-fold increased mortality in the year following the fracture 
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[11]. Osteoporotic fractures decrease quality of life, increase mortality, and 
create significant treatment-related costs.  
 
Osteoporosis particularly affects post-menopausal women. At 
menopause, bioavailable estrogen declines significantly, as does bone mass, 
placing women at a high risk for fracture [14]. Declines in sex hormones 
with age in males are more gradual but produce similar effects [15, 16]. 
Estrogen deficiency increases bone turnover (the rate at which remodeling 
occurs), increases resorption by reducing osteoclast apoptosis [17], and 
increases osteoblast apoptosis and thus decreases formation [18]. The 
mechanisms of action of estrogen on bone will be introduced further in 
section 1.4 Signaling in bone response to mechanical loading. 
 Current osteoporosis treatments are largely anti-resorptive, meaning 
that they block bone resorption by acting on the osteoclast. Anti-resorptive 
 
Figure 1.2  Osteoporosis decreases bone mass and increases the risk 
of fracture A) Representative micro-CT reconstructions of lumbar spine 
samples from a young normal (left) and a postmenopausal osteoporotic 
(right) woman (reproduced from [12]). B) In osteoporotic patients a fall 
from standing height can cause fracture. These fractures often occur at 
corticocancellous sites, such as the proximal femur (adapted from [13]). 
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drugs include bisphosphonates and selective estrogen receptor modulators 
(SERMs). Bisphosphonates are a commonly used drug therapy for 
osteoporosis. These agents bind to bone surfaces and block bone loss by 
causing osteoclast apoptosis upon resorption. Bisphosphonates increase 
bone mass and reduce vertebral fracture rates by 70% and non-vertebral 
fracture rates by 40% [19]. Following chronic use, they have been implicated 
in rare fractures in patients [20, 21]. Selective estrogen receptor modulators 
(SERMs) were developed as estrogen-like compounds that lack the steroid 
structure of estrogens, but possess a tertiary structure that allows them to act 
as either estrogen receptor agonists or antagonists. Thus, SERMs would 
ideally have the positive effects of estrogen on bone, without increased risk 
of breast and endometrial cancers.  
 Ultimately, therapies to increase bone mass instead of blocking bone 
loss could be more beneficial to patients. The only FDA-approved anabolic 
drug is parathyroid hormone (PTH), or teriparatide. When administered 
intermittently, PTH is strongly osteogenic [22] and decreases vertebral and 
nonvertebral fracture in postmenopausal women at high risk for fracture 
[23]. Other anabolic drugs are currently in clinical trials, including anti-
sclerostin antibody. Sclerostin is an antagonist of Wnt signaling, and 
blocking this antagonism with an antibody increases bone mineral density by 
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17.7% at the spine and 6.2% at the hip [24].  Sclerostin’s mechanism of 
action and the Wnt signaling pathway will be introduced further in section 
1.4 Signaling in bone response to mechanical loading. While a few 
anabolic drugs are in the pipeline, a promising method for the discovery of 
new targets for bone anabolism arises from the fact that bone is 
mechanosensitive. 
 
1.3 Bone Mechanosensitivity 
 
Bone responds robustly to biophysical cues. Physical forces are 
important in skeletal development [25-27] and in remodeling of the adult 
skeleton [28]. In adults, increased loads cause bone hypertrophy [29] and the 
absence of mechanical forces due to immobilization [30] or space flight [31] 
decreases bone mass. Clinically, mechanical loading enhances cancellous 
bone mineral acquisition during growth [32, 33] and is a promising treatment 
to prevent bone loss in older individuals [34-37]. In vivo animal models were 
developed to further characterize the anabolic response of bone to 
mechanical loading. 
Mouse models of in vivo mechanical loading including tibial bending [38, 
39] and ulnar [40] and tibial compression [41, 42] have been developed to 
examine mechanical loading in bone. Tibial compression has distinct 
advantages due to the ability to examine both cortical and cancellous 
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responses (unlike the ulna) and the fact that loads are applied along the 
physiologic loading axis (unlike bending). A mechanical loading waveform 
consisting of 4 cycles per second, for 1200 cycles per day for two weeks at a 
load level engendering 1200 µe at the tibial midshaft has consistently 
increased bone mass at cortical and cancellous sites [41, 43-46]. Loading 
increased bone volume fraction (BV/TV) at the tibial metaphysis in a 
cancellous site by 60%, while the cortical area at the tibial midshaft was 
increased by 30%, indicating that cancellous bone may respond more than 
cortical to mechanical stimuli in growing mice (Figure 1.3) [45].   
 
 
Figure 1.3 In vivo mechanical loading of the mouse tibia is anabolic. A) 
Schematic of the in vivo tibial loading device. The tibia is in red with cyclic loading 
initiating from an electromagnetic actuator at the foot while a load cell at the 
rigidly held knee provides force feedback control. B) The applied waveform 
consists of a 4 cycles per second triangular impulse to cause mid diaphyseal strains 
of 1200 microstrain (right axis), typically a peak load of 9N (left axis). C) 
Representative microCT images depict increases in metaphyseal cancellous and 
diaphyseal cortical bone following two weeks of tibial loading, which is quantified 
as a 60% increase in D) bone volume fraction (BV/TV) at the metaphysis and a 
30% increase in E) cortical area at the diaphysis [45].  
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While tissue-level responses have been well-documented, a greater 
understanding of the molecular mechanisms has the potential to uncover 
new targets for the pharmacologic treatment of osteoporosis. Furthermore, 
more focus has been given to cortical bone response to load in the past, so a 
more in-depth examination of cancellous bone may prove useful in 
developing drugs to target the corticocancellous sites more frequently 
affected by osteoporosis. Previously, studies have demonstrated the 
importance of several signaling pathways in mechanotransduction including 
Wnt/b-catenin, parathyroid hormone (PTH), IGF, integrins, BMP/SMAD, 
and estrogen signaling.  
 
1.4 Signaling in Bone Response to Mechanical Loading 
 
 The response of bone to mechanical loading does not appear to occur 
through a single mechanically sensitive pathway. Rather, in vitro and in vivo 
experiments have highlighted the importance of several independent 
pathways and crosstalk between these pathways. Important pathways include 
Wnt/b-catenin, PTH, IGF and integrins, and BMP/SMAD (Figure 1.4). 
Furthermore, combined studies of the role of estrogen signaling in 
osteoporosis and the anabolic effects of mechanical loading on bone have 
provided evidence that estrogen receptors are involved in loading-related 
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osteogenesis and that significant crosstalk exists between estrogen signaling 
and other mechanosensing pathways [47-49]. Studies have relied on reverse 
genetics approaches; a known pathway or signaling molecule has been 
assayed in vitro or genetically modified in vivo to study its effects on 
mechanotransduction.  
 
1.4.1 Wnt/b-catenin signaling  
 One of the most important signaling pathways in bone development, 
homeostasis, and response to mechanical loading is the Wnt/b-catenin (or 
“canonical Wnt”) pathway. The role of this pathway in bone health was 
indicated clinically by the discovery of genetic mutations responsible for two 
opposing bone phenotypes. Children with the autosomal recessive disorder 
osteoporosis-pseudoglioma syndrome (OPPG) have very low bone mass and 
are prone to developing fractures and deformation [50]. In contrast, kindred 
were identified with extremely high bone density, wide and deep mandibles, 
and bony palates [51]. Genetic studies found both bone disorders were 
caused by mutations in low-density lipoprotein receptor-related protein 5 
(LRP5). LRP5 is a co-receptor for Wnt, and these findings suggested a link 
between Wnt signaling through LRP5 and bone density. The canonical Wnt 
pathway affects bone by regulating b-catenin stabilization and subcellular 
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location. Under basal conditions Wnt signaling is not active and b-catenin is 
degraded in the cytoplasm, partially due to the action of glycogen synthase 
kinase 3 beta (GSK3b).  
 
 
 
Figure 1.4. Schematic of the major signaling pathways thought to 
mediate bone’s response to mechanical loading. When a mechanical 
stimulus is sensed by a bone cell, signal transduction can occur through 
several individual pathways that also have significant overlap in 
downstream effectors. A) Wnt/b-catenin signaling causes b-catenin 
stabilization and translocation to the nucleus and drives pro-osteogenic 
gene expression. Important antagonists of Wnt/b-catenin signaling are 
Sclerostin and Dkk1. B) PTH signaling has several downstream effectors 
including b-catenin, cAMP/PKA leading to Creb translocation, PI3K/Akt 
and MAPK. C) IGF1 and Integrins interact and mediate similar 
downstream events such as PI3K/Akt and MAPK/Erk, which can also be 
initiated by D) BMP signaling. Phosphorylation of Smad 1/5/8 is another 
important downstream signal caused by BMP. Several of these pathways 
are modulated by ERa.  
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Wnts bind to the co-receptors LRP5 (or 6) and Frizzled (FZD) and block 
the degradation of b-catenin causing accumulation in the cytoplasm, 
translocation to the nucleus and recruitment of transcriptional co-activators 
to stimulate expression of osteogenic genes. Wnt antagonists such as 
sclerostin (SOST) and dickkopf-1 (DKK1) block LRP5/6 and b-catenin is 
degraded in the cytoplasm (Figure 1.4.A) [52, 53].  
To examine the role of the canonical Wnt pathway in bone’s adaptive 
response to load, mice with gain- or loss-of-function mutations in Lrp5 were 
developed. Mice expressing the mutated form of Lrp5 that increases bone 
mass in humans had a similar phenotype with high bone mass and increased 
strength [54] and an increased osteogenic response to in vivo mechanical 
loading [55, 56]. Loss-of-function mutations in Lrp5 caused a low bone mass 
phenotype [57, 58] and a decreased responsiveness to mechanical loading 
[59]. These studies showed that Wnt signaling played an important role in 
skeletal mechanotransduction. Similarly, transgenic mice with high levels of 
the inhibitor sclerostin failed to activate the Wnt pathway and did not display 
an anabolic response to mechanical stimulation, indicating that Sost 
downregulation is necessary for mechanotransduction [60]. However, mice 
lacking sclerostin had increased cortical bone volume and greater mineral 
apposition rate (MAR) and bone formation rate (BFR) than control mice 
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following cyclic loading, indicating that there is a sclerostin- (and thus Wnt-) 
independent mechanism of bone anabolism in response to mechanical 
loading [61].  
1.4.3 PTH signaling 
 Parathyroid hormone was initially recognized as a major regulator of 
removal of calcium from the skeleton by stimulating bone resorption. 
However, it was discovered that intermittent doses of PTH are strongly 
osteogenic which, as previously mentioned, has led to PTH being the only 
approved drug for the anabolic treatment of osteoporosis. PTH acts by 
binding to a seven-transmembrane receptor (PTH1R) and activating 
phosphatidyl-inositol-3 kinase (PI3K) and the Akt pathway and the mitogen-
activated protein kinase (MAPK) cascade. PTH appears to interact with Wnt 
signaling, as PTH treatment increased mRNA levels of Lrp6, Frizzled and b-
catenin, while decreasing levels of Dkk1 in rat distal metaphyseal bone in 
vivo [62].  Furthermore, PTH1R physically interacts with Lrp6 and facilitates 
its recruitment of intracellular Wnt pathway components (Figure 1.4.B) 
[63].  
 PTH and mechanical loading seem to have synergistic anabolic effects 
on bone. In vivo, mechanical loading enhanced the anabolic effects of 
intermittent PTH (iPTH) on trabecular and cortical bone in mice [64]. In a 
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model of periprosthetic cancellous bone adaptation, mechanical loading and 
iPTH had a small additive effect on bone volume compared to iPTH alone 
[65].  
1.4.4 IGF signaling and integrins 
 IGF-1 and integrin signaling share common downstream effectors 
such as MAPK and Akt, and it is thought that mechanical stimulation results 
in activation of both pathways and ultimately results in amplification of pro-
survival (Akt) and proliferation (MAPK) signals (Figure 1.4.C) [66]. Insulin-
like growth factor (IGF) signaling initiates with IGF1 binding to the IGF-1 
receptor. Integrins are membrane-bound single pass receptors that form 
heterodimers that consist of an a and b subunit and interact with the 
extracellular matrix (ECM). Downstream signaling of both IGF-1 and 
integrins proceeds along two main pathways. The mitogen-activated protein 
kinase (MAPK) pathway results in the nuclear translocation of Erk1/2 and 
subsequent activation of transcription factors such as Elk1 and C-jun and 
increased Cyclin D1, a cell cycle regulator that increases proliferation. In 
addition, phosphatidyl-inositol-3 kinase (PI3K) activates protein kinase B 
(PKB, also known as Akt) which blocks apoptosis and increases cyclin D1 
following nuclear translocation [66].  
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 Studies have revealed a role for IGF-1 and integrin signaling in 
mediating the skeletal response to mechanical load. In vitro observations 
indicated that IGF-1 production is increased in osteocytes and osteoblasts 
following mechanical loading [67, 68]. Primary mouse osteoblasts subjected 
to a single period of dynamic strain activated IGF-1 receptor, PI3K 
phosphorylation of Akt, inhibition of GSK-3b, and increased activation of 
b-catenin [69]. Transgenic mice that overexpress IGF-1 in osteoblasts have 
increased periosteal bone formation in response to mechanical loading [38] 
while osteoblast-specific IGF-1 conditional knockout mice failed to respond 
to biomechanical stimuli in the periosteum or trabecular bone [70]. Integrin-
mediated signaling pathways have been implicated in mechanotransduction 
in bone. Mechanical stimulation by stretching activates ERK in an integrin-
dependent manner in MLO-Y4 osteocytic cells [71]. In vivo deletion of b1 
integrins from cortical osteocytes reduces load-induced bone formation [72] 
and while control mice showed decreased Sost expression due to mechanical 
loading, mice deficient in integrins in osteoblast lineage cells did not [73]. 
Hindlimb unloading of adult mice, intended to cause bone loss, actually 
increased cross-sectional area and moments of inertia in mice lacking b1 
integrins indicating that integrins mediate mechanotransduction sensing in 
vivo [74].  
 16 
 
1.4.5 BMP/SMAD signaling 
The BMP/SMAD pathway is another key component in the response 
to mechanical loading.  SMADs are a family of transcription factors that are 
regulated by the members of the transforming growth factor-b (TGF-b) 
family of molecules, TGF-b and bone morphogenetic proteins (BMPs). 
BMPs signal through a multimeric cell surface complex consisting of two 
type I receptors and two type II receptors. After ligand binding, type II 
receptors phosphorylate the type I receptors. Activated type I receptors 
recruit and phosphorylate Smads 1/5/8, which form trimers with Smad4 and 
translocate to the nucleus (Figure 1.4.D) [75]. The importance of the TGF-
b superfamily in skeletal development is demonstrated by genetic disorders 
such as activating mutations in a type I BMP receptor (Alk2) which leads to 
fibrodysplasia ossificans progressiva, a disorder characterized by ectopic 
bone formation in soft tissues [76].  
In the context of mechanotransduction, osteoblasts subjected to 
dynamic compressive forces or fluid flow strain had increased SMAD 1/5/8 
phosphorylation, a sign of increased BMP signaling [77, 78]. The 
administration of BMP7 in conjunction with in vivo mechanical loading 
enhanced bone formation [79] and BMPs are upregulated in mice following 
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mechanical loading [80, 81]. However, decreased BMP signaling through 
conditional knockout of BMP receptor 1a (BMPR1a) enhanced trabecular 
bone volume in response to treadmill exercise due to decreased levels of 
osteoclasts [82]. Furthermore, Bmp2 conditional knockout in osteoblasts did 
not impair bone formation following mechanical loading [83].    
  
1.4.6 Estrogen signaling  
 Estrogen signaling proceeds through two different estrogen receptors, 
ERa and ERb, which are localized to the cytoplasm. In classical signaling, 
estrogen binds either receptor, the receptor dimerizes and autp-
phosphorylates, and then this complex can either directly bind to DNA 
estrogen response elements found in the control regions of genes or it can 
affect other intracellular signaling pathways. In 1994 a male patient presented 
with unfused growth plates and osteoporosis due to an inactivating point 
mutation in ESR1, the gene encoding ERa [84]. This finding caused an 
increased interest in the mechanisms of ERa signaling. Human 
polymorphisms in ESR1 have since been linked with bone mineral density, 
fracture risk, and response to exercise [85-89].   
Animal models have been developed to examine the effects of 
estrogen on the skeleton. Ovariectomy (OVX) of rodents recapitulated the 
 18 
bone loss seen in humans at menopause [90, 91]. However, the removal of 
circulating estrogen has pleiotropic systemic effects, which does not allow 
the examination of effects on bone specifically. Estrogen regulates bone 
maintenance through two different receptors: estrogen receptor-alpha (ERa) 
and -beta (ERb). Initially, whole body knockout (KO) methods were used to 
remove estrogen receptors in all cells. Global ERa KO had more 
pronounced effects on bone than ERb deficiency, indicating that ERa may 
be more crucial for estrogen’s effects on bone [92]. But confounding effects 
such as increased body and uterine mass, increased circulating estrogen, and 
decreased IGF-1 were observed in global KO mice [93]. Body mass, 
estrogen, and IGF-1 can have independent effects on bone mass, which 
complicates the interpretation of bone changes and led to the development 
of bone-specific estrogen receptor KO mice. 
 Conditional estrogen receptor-alpha KO mice have been created to 
remove the receptor from osteoclasts [94, 95], osteoblast precursors [96], 
mature osteoblasts [96-98], and osteocytes [99, 100]. These studies 
demonstrate the complexity of estrogen signaling in cancellous and cortical 
bone of female mice (Table 1.1). Our lab has used an osteocalcin-cre (OC-
Cre) mouse to knock out ERa in osteoblasts [98]. Female pOC-ERaKO 
mice had 35% decreased cancellous bone mass and decreased osteoblast 
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activity in the proximal tibia. Cortical bone mass was also decreased at the 
tibial midshaft by 8%, indicating that the effects of estrogen signaling 
deficiency may be more pronounced in cancellous than cortical bone of 
females.  
Table 1.1 Bone mass changes in female bone-specific ERa 
knockouts 
Cell-specific Promoter Cancellous Cortical 
Osteoblast progenitor Prx1 [96] No change Decreased 
Osteoblast precursor Osx1 [96] No change Decreased 
Mature Osteoblasts OC [97, 98] Decreased Decreased 
Col1a1 [96] No change No change 
Osteocytes Dmp1 [100] Decreased No change 
Osteoclasts Ctsk [95] Decreased No change 
LysM [94] Decreased No change 
 
 ERa plays a role in loading-induced osteogenesis either directly or 
through crosstalk with other mechanosensing pathways. In vivo, skeletally 
mature female mice lacking ERa (ERa-/-) globally had three-fold lower 
response to mechanical loading of the ulna [101]. ERa-/- mice also had 
severely reduced osteogenic response to axial tibial loading with significantly 
lower increases in cortical area than in wild-type mice [102].  
Estrogen receptor’s effects in mechanotransduction are complicated, 
however, as data from conditional knockout studies in different bone cell 
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lineages are conflicting (Table 1.2). In osteoblast progenitors (Prx1-cre) and 
precursors (Osx1-cre), removal of ERa decreased the response to 
mechanical loading in cortical bone [103]. When ERa was removed from 
osteocytes (Dmp1-cre), the cortical response to tibial loading was similar to 
littermate controls [99]. For these studies, cancellous bone changes were not 
reported. Our lab, using the previously mentioned ERa conditional 
knockout in mature osteoblasts (OC-cre, pOC-ERaKO), showed that 
mechanical loading increased cortical and cancellous bone mass to a greater 
extent in female pOC-ERaKO mice than their littermate controls [46].  
Table 1.2 Response to mechanical loading in female bone-specific 
ERa knockouts compared to littermate controls 
Cell-specific Promoter Cancellous Cortical 
Osteoblast progenitors Prx1 [103] Not examined Decreased 
Osteoblast precursor Osx1[103] Not examined Decreased 
Mature Osteoblasts OC [46] Increased Increased 
Osteocytes Dmp1 [99] Not examined Similar 
 
Evidence of ERa crosstalk with other signaling pathways has been 
determined using primary osteoblasts exposed to strain. A single short 
period of dynamic mechanical strain increased nuclear accumulation of b-
catenin, and this effect was blocked by an estrogen receptor inhibitor and 
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was absent in osteoblasts from mice lacking ERa [104]. ERa physically 
associated with IGF1R and was necessary for the strain-related IGF1R 
activation of AKT [69]. Estrogen and shear stress independently induced 
ERK and MAPK signaling and increased Cox-2 expression. When 
combined, estrogen and shear stress augmented these responses. When cells 
were treated with an estrogen receptor inhibitor or when b1 integrins were 
blocked, the responses to estrogen and shear stress were inhibited, indicating 
that estrogen augments shear stress responsiveness via estrogen receptor-
mediated increases in b1 integrins [105]. Many of these suggested crosstalk 
events are highlighted in Figure 1.4. 
 
1.5 Differential gene expression following in vivo mechanical loading 
Unbiased forward genetics techniques may allow the discovery of new 
pathways that influence mechanosensing. Forward genetics approaches 
identify genes responsible for a particular phenotype or mechanistic 
response to a perturbation. One approach to further characterize the skeletal 
response to mechanical loading and discover new targets and pathways is to 
examine the changes in gene expression following in vivo mechanical 
loading.  
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Differential gene expression in response to in vivo mechanical loading 
has been examined with quantitative polymerase chain reaction (qPCR) [56, 
60, 106-110] or microarray [81, 104]. qPCR is limited due to the relatively 
small number of candidate genes that can be examined. Microarray panels 
contain thousands of genes but still rely on probes for known genes and are 
semi-quantitative. Despite their limitations, qPCR and microarray studies 
have contributed to our knowledge of mechanotransduction in bone.  
The importance of the Wnt/b-catenin pathway for the adaptive 
response to in vivo mechanical loading has been verified with qPCR and 
microarray. Genes involved in the Wnt/b-catenin pathway such as Wnt10b, 
Wnt2b, Fzd2, Crebbp, Sfrp1, Wisp2, and Cyclin D1 were differentially 
expressed in loaded versus control tibiae following mechanical loading [56, 
104]. Axial compression of bone was found to reduce osteocyte expression 
of sclerostin (Sost) [60, 106, 108]. Mice lacking the matricellular protein 
periostin did not exhibit increased bone mass following loading and Sost 
expression was not inhibited, indicating that Sost downregulation is required 
for the adaptive response to mechanical loading and is regulated by periostin 
[106]. Hindlimb suspension, which causes mechanical unloading of the bone, 
increased Sost expression in cortical bone from whole tibiae [108], while 
unloading via botox injection decreased Sost in metaphyseal cortical and 
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cancellous bone but increased Sost in diaphyseal cortical bone [111], 
indicating that there may be site-specific differences in the response to 
mechanical stimuli.  
Determinations of gene expression changes following mechanical 
loading using microarray have demonstrated the importance of estrogen 
signaling in mechanotransduction. The transcriptional response of mouse 
bones to loading was markedly reduced and delayed in ERa global knockout 
mice compared with wild-type littermates [81]. In contrast to the 642 genes 
differentially expressed three hours after tibial loading in wild-type mice, 
only 26 genes were differentially expressed in the tibiae of ERa mice. Three 
hours following tibial compression wild-type mice had differential 
expression of six genes involved in Wnt signaling but only one gene was 
differentially expressed in mice lacking ERa [104].  
The limited in vivo gene expression studies are from cortical or whole 
bone samples and usually do not account for marrow contamination. Several 
in vivo loading studies performed loading of the ulna, which is a purely 
cortical site with a small marrow cavity [60, 80, 107, 108, 110, 112]. Tibial 
loading studies extracted RNA from whole bone without marrow removal 
[109], after marrow flushing [56, 106], or after marrow centrifugation [81, 
104]. Marrow is highly cellular and is likely to significantly affect gene 
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expression determination. One exception is a study that examined cancellous 
response to mechanical loading in the mouse vertebra using microarray 
[113]. However, this study did not compare the cancellous response to 
cortical bone and used collagenase digestion to remove marrow, which has 
been shown to affect the expression of bone transcripts [114]. The 
examination of differential gene expression with qPCR or microarray from 
cancellous bone of the mouse tibia is challenging due to small tissue quantity 
at that site, but next-generation sequencing techniques are promising for this 
application. 
RNA sequencing (RNA-seq) is a next-generation sequencing 
technique that allows the quantitative determination of differential gene 
expression across the entire transcriptome in very small tissue samples. 
RNA-seq is superior to microarray in detecting low-abundance transcripts, 
differentiating biologically critical isoforms, and identifying genetic variants. 
Furthermore, RNA-seq has a broader dynamic range than microarray, 
allowing for the determination of more differentially expressed genes with 
higher fold-change [115].  
RNA-seq is widely used in many scientific fields and is beginning to 
gain traction in the musculoskeletal field. The Warman group has pioneered 
RNA-seq in bone to examine the phenotype of Lrp5 mutations and 
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treatments [114, 116, 117]. Other studies have used RNA-seq to examine the 
developmental effects of Dlx5 deletion [118] and mechanosensitive genes 
during skeletal development [119]. RNA-seq has not yet been used to 
discover differentially expressed genes following in vivo loading but it has 
been used to examine osteocyte response to fluid flow in vitro [120]. RNA-
seq could be used to examine marrow-free cancellous and cortical bone of 
mice in the context of estrogen signaling to provide a wealth of knowledge 
of transcription in response to in vivo mechanical loading. Data on the 
transcriptional response of cancellous bone to mechanical loading is lacking 
and could identify new targets for the treatment of osteoporosis in 
corticocancellous sites.  
 
1.6 Aims 
 
 Osteoporotic fractures are a significant public health risk that can 
decrease quality of life and increase mortality. Osteoporosis is at least partly 
caused by decreased estrogen signaling, which has been recapitulated in 
mouse models. Mechanical forces can increase cortical and cancellous bone 
mass at the tissue level, but the signaling events underlying this increase 
remain largely unknown, particularly in cancellous bone. If the molecular 
mechanisms behind bone anabolism in response to mechanical loading and 
in the context of decreased estrogen signaling were more completely 
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understood, bone-restoring therapeutics could be developed to treat bone 
loss due to osteoporosis. This thesis aims to better elucidate the 
transcriptional response behind mechanical loading-induced bone anabolism 
in cortical and cancellous bone separately when estrogen signaling is intact 
and when it is decreased.  
 
Aim 1 
 Our first aim was to develop a method to measure gene expression in 
marrow-free cortical and cancellous bone. The high incidence of fragility 
fractures in corticocancellous bone locations, plus the fact that individual 
skeletal sites exhibit different responsiveness to load and disease, emphasizes 
the need to document separately gene expression in cortical and cancellous 
bone. A further confounding factor is marrow contamination since its high 
cellularity may effect gene expression measurements. We isolated RNA from 
cortical and cancellous bone of intact mouse tibiae, and also after marrow 
removal by flushing or centrifugation. We performed histology to determine 
if centrifugation was more effective than flushing in removing marrow. 
Bone- and marrow-related gene expression in cortical and cancellous bone 
and bone marrow further demonstrated the effectiveness of marrow removal 
techniques.  
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Aim 2 
 Our second aim was to determine the transcriptional response to 
mechanical loading in cortical and cancellous bone separately. Mechanical 
loading is an anabolic stimulus that increases bone mass, and thus a 
promising method to counteract osteoporosis-related bone loss. The 
mechanism of this anabolism remains unclear, and needs to be established 
for both cortical and cancellous envelopes individually. We hypothesized 
that cortical and cancellous bone display different gene expression profiles at 
baseline and in response to mechanical loading. To test this hypothesis, the 
left tibiae of 10-week-old female C57Bl/6 mice were subjected to one 
session of axial tibial compression and euthanized 3 and 24 hours following 
loading. The right limb served as the contralateral control. We performed 
RNA-seq on marrow-free metaphyseal samples from the cortical shell and 
the cancellous core to determine differential gene expression at baseline 
(control limb) and in response to load. Differential expression was verified 
with qPCR.  
 
Aim 3 
 Our third aim was to elucidate differences in the transcriptional 
response to mechanical loading in cortical versus cancellous bone with 
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deficient estrogen signaling. Decreased estrogen at the onset of menopause 
coincides with a precipitous decline in bone mass. Estrogen may also play a 
role in mechanotransduction. At the tissue level, mice lacking estrogen 
receptor alpha have decreased bone mass but increased capacity for 
adaptation in response to external mechanical loads when compared to 
littermate controls, particularly in cancellous bone. The molecular 
mechanism behind this increased anabolism is not well understood. We 
hypothesized that cortical and cancellous bone display different gene 
expression profiles at baseline and in response to mechanical loading and 
that mice lacking estrogen receptor alpha in bone cells have an increased 
response compared to littermate controls. To test this hypothesis, the left 
tibiae of 10-week-old female pOC-ERaKO and littermate control mice were 
subjected to one session of axial tibial compression and euthanized 3 and 24 
hours following loading. The right limb served as the contralateral control. 
To examine the possible systemic effects of loading, a third group of naïve 
(never loaded) littermate control animals were examined. We performed 
RNA-seq on marrow-free metaphyseal samples from the cortical shell and 
the cancellous core to determine differential gene expression in response to 
load (versus contralateral control) and differential gene expression in naïve 
cortical and cancellous bone. Differential expression was verified with qPCR.  
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CHAPTER 21 
A METHOD FOR ISOLATING HIGH QUALITY RNA FROM 
MOUSE CORTICAL AND CANCELLOUS BONE 
 
2.1 Introduction 
 
Osteoporosis is a skeletal disease characterized by low bone mass that 
often results in fracture. A majority of osteoporotic fractures occur at 
cortico-cancellous sites such as the proximal femur, distal forearm, and 
vertebra [1, 2]. At these sites bone is a composite tissue consisting of an 
outer cortical shell surrounding and inner cancellous network. Mouse models 
have been developed to understand the etiology of osteoporosis and to 
identify possible treatments for osteoporosis-related bone decline. 
Biophysical stimuli, including mechanical loading, are a promising approach 
to maintain and recover bone mass. In vivo loading often elicits a greater 
response in cancellous than cortical bone sites, increasing metaphyseal 
cancellous bone volume fraction by 49-73% and diaphyseal cortical area by 
41% in the mouse tibia [3, 4]. But different loading protocols can alter 
cancellous and cortical bone responses selectively; some stimulate cancellous 
____________________ 
1Kelly NH, Schimenti JC, Ross FP, van der Meulen MCH. A method for 
isolating high quality RNA from mouse cortical and cancellous bone. 
Bone. 2014;68:1-5. 
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bone to a greater extent, while others mainly affect cortical bone [5], 
indicating that differences in mechanoresponsiveness may exist in cortical 
and cancellous bone. 
To identify the nature and degree of change in these two bone tissues 
requires definitive data on which genes are altered at cortical and cancellous 
sites following manipulation of test animals. To date this information is 
largely unknown, as most studies have used approaches that are derived 
from homogenized bone tissues.  
 The cellular and molecular mechanisms driving load-induced 
anabolism at the tissue level have been examined using both quantitative 
real-time polymerase chain reaction (qPCR) and microarray [6-9]. These 
studies have examined tissues from whole bones, homogenizing cortical and 
cancellous bone. In contrast, only a single study examined the loading 
response in cancellous bone from the mouse vertebrae, but did not compare 
the response to cortical bone [10]. Furthermore, marrow cells have been left 
in place [8], removed by flushing [7], centrifugation [6, 9], or sequential 
collagenase digestion [10, 11]. Collagenase digestion has been shown to 
affect expression of bone-related genes [12], but this effect may depend on 
the type of collagenase used; endotoxin-free collagenase had a less 
detrimental effect on RNA quality [13]. However, failure to remove the 
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highly cellular marrow component may result in extensive contamination of 
RNA isolated from unfractionated bone. The relative efficacy of flushing to 
centrifugation has not been studied, nor has the degree of bone marrow 
presence on gene expression. More importantly, gene expression has not 
been reported in minimally contaminated cortical versus cancellous bone, a 
challenging endeavor in murine models. 
 We describe a method to isolate high quality RNA from cortical and, 
separately, cancellous bone with almost no contamination from marrow 
cells. Both the quantity and quality of the RNA are suitable for 
transcriptome studies, providing the ability to compare cancellous and 
cortical tissues to elucidate differences in cellular and molecular mechanisms 
at these two sites.  
 
2.2 Materials and methods 
 
2.2.1 Animals 
 Fifteen 11-week-old male C57Bl/6 mice were euthanized and their 
tibiae rapidly dissected for histology (left leg) or RNA isolation and analysis 
(right leg). The epiphysis, all soft tissues, periosteum, fibula, and the very 
distal end were removed. In five mice, bone marrow of the tibia was not 
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removed (no marrow removal, NMR group). In another five mice, marrow 
was flushed with 1 mL of phosphate buffered saline (PBS) by inserting a 26-
gauge needle into the distal tibia. The tibiae in the third group were 
centrifuged for 20 s at 16,100 g at room temperature in nested 
microcentrifuge tubes, where the inner tube (0.2 mL) had holes created with 
a 26-gauge needle to allow marrow to travel into the outer tube (0.65 mL). 
Tibiae were cut approximately 5 mm distal to the growth plate to isolate the 
metaphysis. The metaphysis was held with forceps so the proximal end was 
perpendicular to a 1 mm biopsy punch with plunger (33-31AA-P Miltex, 
Integra LifeSciences Corp., Plainsboro, NJ, USA), which was used to 
mechanically separate a cancellous core from the cortical shell (Figure 2.1). 
The IACUC of Cornell University approved all animal procedures.  
 
2.2.2 Histology 
 Cancellous and cortical samples were placed in 10% formalin for 24 h 
for fixation, and decalcified in 45% formic acid for 4 days with daily 
exchange of the solution. Samples were processed and embedded in paraffin 
and sectioned longitudinally (6 µm sections, Leica RM2255, Buffalo Grove, 
IL, USA). Sectioned samples were stained with hematoxylin and eosin 
(H&E).  
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2.2.3 RNA isolation from bone 
 RNA isolation was performed using Trizol (Life Technologies, 
Carlsbad, CA, USA) and RNeasy Mini kit (Qiagen, Germantown, MD, USA) 
as described previously [8]. Briefly, cancellous and cortical samples (n=30) 
were pulverized in liquid nitrogen-cooled flasks (Mikro-dismembrator S, 
Sartorius Stedim Biotech, Bohemia, NY, USA). Following pulverization, 
 
Figure 2.1 Schematic of cortical and cancellous bone sample preparation. 
Tibiae were rapidly dissected and soft tissues, periosteum, epiphysis, fibula, 
and distal end were removed. Marrow was left intact (group 1), flushed 
with 1 mL of PBS using a 26 g needle inserted distally (group 2), or 
centrifuged in nested microcentrifuge tubes for 20 s at 16,100 g (group 3). 
Tibiae were cut approximately 5 mm distal to the proximal end to isolate 
the metaphysis, and a 1 mm biopsy punch mechanically separated a 
cancellous core from the cortical shell.  
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Trizol (Life Technologies) was added to the flasks and the powdered 
bone/Trizol mix was incubated at room temperature for 45 min. 300 µL of 
chloroform was added to the samples, vortexed for 15 s, and decanted into 
phase lock gel tubes (PLG, heavy, 5 Prime, Gaithersburg, MD, USA). 
Samples were centrifuged for 15 min at 4°C and 11,500 rpm, to separate the 
nucleic acid phase (~600 µL), which was removed and added to an equal 
volume of 70% ethanol. This mixture was applied to purification columns 
(RNeasy Mini kit, Qiagen) following the manufacturer’s instructions, 
including a DNase digestion (RNase free DNase kit, Qiagen). A final volume 
of 30 µL of RNA was eluted, and purity and quantity were tested using a 
spectrophotometer (NanoDrop 1000, Thermo Scientific, Wilmington, DE, 
USA) and RNA Quality Number (RQN) using a fragment analyzer 
(Advanced Analytical Technologies, Inc., Ames, IA, USA).  
 
2.2.4 RNA isolation from marrow 
 Marrow from centrifuged bones (n=3) was placed in RNAlater 
(Qiagen) at 4°C until RNA isolation. Samples were centrifuged for 5 min, 
RNAlater was removed, and 600 µL of lysis buffer with b-mercaptoethanol 
(Buffer RLT, Qiagen) was added (as described in RNeasy Mini instructions). 
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Samples were homogenized by passing through an 18-gauge needle, and the 
supernatant (~600 µL) was added to ethanol and applied to columns for 
RNA purification as described above.  
 
2.2.5 Gene expression 
 RNA was reverse transcribed to cDNA following the manufacturer’s 
instructions (High Capacity cDNA Reverse Transcription kit, Life 
Technologies) and brought to 5 ng/µL with RNase-free water. A final 
volume of 20 µL containing 2X SYBR Green (Perfecta SYBR Green 
Fastmix, with ROX, Quanta Biosciences, Gaithersburg, MD) was assayed by 
triplicate qPCR using 40 cycles of denaturing (95°C, 15 s) and 
annealing/elongation (60°C, 60 s) (7300 Real-Time PCR System, Life 
Technologies). Primers for genes that are highly expressed in bone (Collagen 
type 1 alpha 1, Col1a1, and bone gamma-carboxyglutamic acid-containing 
protein, Bglap) and marrow (intracellular adhesion molecule 4, Icam4) were 
designed (available upon request). Cycles to threshold (CT) was determined 
for each gene and compared to the reference gene Gapdh. NMR, flushed, 
and centrifuged groups and marrow samples are presented as relative 
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expression compared to Gapdh (2-DCT). Fold-change to cortical and 
cancellous NMR groups was calculated by the 2-DDCT method [14].  
 
2.2.6 Statistics 
 To test differences in relative gene expression between cancellous and 
cortical bone sites, and fold-change compared to NMR, a two-factor 
ANOVA (main effects: marrow removal and site) with interaction (marrow 
removal * site) was used with a Tukey’s HSD post-hoc (JMP Pro 10, SAS, 
Cary, NC, USA). To test for differences in gene expression between marrow 
and cancellous and cortical bone with marrow, a one-way ANOVA was used 
with Tukey’s HSD post-hoc. Significance was set at p<0.05.  
 
2.3 Results 
2.3.1 Histology 
 To determine if centrifugation was more effective than flushing, we 
performed histology with H&E of longitudinal sections of cancellous and 
cortical bone (Figure 2.2). Cortical (top panels) and cancellous bone 
(bottom panels) contained significant marrow that was removed 
incompletely by flushing. In marked contrast, marrow was barely detectable 
in centrifuged samples.  
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2.3.2 RNA quantity/quality 
 We also determined if sufficient, high quality RNA could be extracted 
from cortical and cancellous bone separately and the effect of marrow 
contamination on RNA quantity. Intact bone had more RNA than flushed 
or centrifuged bone. The mean (±SD) concentration of cortical samples was 
447 (±70), 279 (±13) and 45 (±37) ng/µL for NMR, flushed, and centrifuged 
bone, respectively, while those for analogous cancellous samples was 186 
 
Figure 2.2 Centrifugation removes marrow more effectively than flushing 
in cortical and cancellous bone. Representative longitudinal 6 µm sections 
of (A-C) cortical and (D-F) cancellous bone stained with H&E of (A,D) 
bones with no marrow removal, (B,E) bones where bone marrow has been 
flushed, and (C,F) bones that have been centrifuged to remove marrow. 
Top row within each bone site is lower magnification and black rectangle 
outlines region of higher magnification shown on bottom row. Scale bar = 
400 µm. 
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(±54), 132 (±33) and 28 (±7) ng/µL. The average concentration for marrow 
samples was 191 (±130) ng/µL. The 260/280 ratio was within an acceptable 
range (1.8-2.1) for all samples. Cancellous samples were of higher quality 
than their cortical counterparts with a mean (±SD) RQN of 6.3 (±0.7) and 
4.4 (±0.4), respectively.  
 
2.3.3 Gene expression 
 We examined bone- and marrow-related gene expression in cortical 
and cancellous bone as well as bone marrow and the effect of bone marrow 
contamination. Centrifuged cortical bone had 12- and 13-fold higher 
expression of Col1a1 and Bglap than bone with marrow, while the analogous 
data for centrifuged cancellous bone were 30- and 31-fold higher, 
respectively (Figure 2.3). Flushing also increased bone-related gene 
expression when compared to no marrow removal, but this effect was not 
significant (2-fold and 3-fold, Col1a1 and Bglap in cortical and cancellous 
bone, respectively). The absolute expression of Col1a1 and Bglap was lower  
in cancellous compared to cortical bone. Finally, marrow samples had 
extremely low expression of bone-related genes, ranging from 71-fold to 
930-fold less than bone with marrow. 
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Figure 2.3 Centrifugation resulted in higher expression of bone related 
genes and lower expression of a gene in bone marrow. Top panels show 
relative expression to Gapdh (2-DCT) and bottom panels are fold-change 
to NMR group (2-DDCT). (A) Col1a1 was 12- and 30-fold more highly 
expressed in centrifuged cortical and cancellous bone, respectively, when 
compared to NMR. Col1a1 expression in flushed bone was not 
significantly different than bone with marrow. Marrow had very low 
relative expression of Col1a1 that was 932- and 307- fold lower than 
cortical and cancellous bone with marrow, respectively (values above bar). 
(B) Bglap was 13- and 31-fold more highly expressed in centrifuged cortical 
and cancellous bone, respectively, when compared to NMR. Bglap 
expression was not significantly changed in flushed bone compared to 
bone with marrow. Marrow had very low relative expression of Bglap that 
was 261- and 71-fold lower than cortical and cancellous bone with 
marrow, respectively (values above bar). (C) Icam4 expression was 
decreased in centrifuged cortical and cancellous bone when compared to 
NMR. Icam4 expression was similar in NMR, flushed bone, and marrow as 
indicated by dashed line at a fold-change value of one. Marrow had similar 
Icam4 expression to bone with marrow. Data are mean±SD, n=3-5 per 
group. *Main effect of site: cancellous different from cortical. Brackets 
indicate main effect of marrow removal: no marrow removal or marrow 
and flushed different from centrifuged. a-cGroups with different letters are 
significantly different by Tukey HSD post-hoc. †Cortical NMR different 
from cancellous NMR and marrow groups by one-way ANOVA.  
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Centrifugation, but not flushing, decreased the expression of a gene 
that is highly expressed in bone marrow (Figure 2.3). Icam4 expression in 
centrifuged cortical and cancellous bone was 3- and 2- fold lower, 
respectively, than intact bone and similar in both tissues. Flushing did not 
alter Icam4 expression. Marrow samples and cortical and cancellous bone 
with marrow had similar expression of Icam4. 
 
2.4 Discussion 
 We initiated these experiments based on our desire to perform more 
detailed analysis beyond our well-established tissue-level detailing of changes 
in cortical and cancellous bone following in vivo loading. Moreover, our 
recent report on the sexually-dimorphic and tissue-specific responses 
following loading of mice lacking estrogen receptor-alpha provided further 
impetus to pursue cellular- and molecular-based studies [15]. Finally, a 
review of the literature revealed no publications documenting the goals and 
techniques described here.  
 We show that RNA can be successfully isolated from centrifuged 
cortical and cancellous tissues of the mouse tibia separately and used for 
gene expression analysis. The ability to measure gene expression separately 
in cortical and cancellous bone is an important achievement. For example, 
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we discovered that the expression of two highly-expressed bone genes varies 
between the two tissue types. While both methods decreased marrow 
contamination, centrifugation removed marrow more completely than 
flushing in both cortical and cancellous sites when compared to intact bone. 
Quantitatively, this removal of contaminating marrow cells allowed bone 
transcripts to be more easily detected by qPCR. Bone genes were as much as 
31-fold more highly expressed in centrifuged bone, while the expression of a 
marrow gene was decreased as much as 3-fold.  
 The ability to examine transcriptional activity in cortical and 
cancellous bone separately from a mouse is a significant achievement that 
has the potential to impact osteoporosis and mechanotransduction research. 
Cancellous bone, the major modulator of osteoporosis-associated fragility 
fractures, may respond differently to mechanical loading than the adjacent 
cortical compartment; this subject remains completely unexplored. While 
several studies in rodents have examined gene expression in cancellous bone 
[10, 16, 17], none have compared expression to the cortical bone at the same 
location in the mouse. Importantly, here cancellous bone from 
unmanipulated wild-type mice had lower expression levels of bone-related 
genes than cortical bone, demonstrating the importance of examining these 
sites separately. Moreover, these site-specific differences are likely to vary 
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with age, sex, genetic background or exposure to a wide range of 
environmental, lifestyle, or drug treatment-related simuli.  
 Although we have shown that centrifugation is an efficient method of 
marrow removal, heterogeneous cells are likely to still exist in the bone 
samples: for example, adherent hematopoetic and endothelial cells and a 
mixture of osteoblasts and osteocytes. Further work should determine the 
exact cellular makeup of our bone samples, including a marker of endothelial 
cells, such as CD31. The amount of RNA obtained from these bone sites 
after centrifugation was relatively small, limiting the number of genes that 
can be examined with qPCR. However, the RNA was of high quality and is 
appropriate for gene expression profiling with RNA sequencing, which 
requires much less input material. 
 
2.4.1 Conclusions 
 Cancellous and cortical bone can be isolated separately from the 
mouse tibia for RNA isolation and used for gene expression studies. In all 
future studies examining bone gene expression centrifugation should be 
adopted for removing bone marrow from bone tissue since it is more 
efficient than flushing. The separate examination of cancellous and cortical 
bone has the potential to elucidate the differential response to mechanical 
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loading as well as genetic manipulations resulting in different bone 
phenotypes in these sites. 
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CHAPTER 31 
TRANSCRIPTIONAL PROFILING OF CORTICAL VERSUS 
CANCELLOUS BONE FROM MECHANICALLY-LOADED 
MURINE TIBIAE REVEALS DIFFERENTIAL GENE 
EXPRESSION 
 
3.1 Introduction 
Osteoporosis is characterized by bone loss that often leads to fracture 
of corticocancellous sites such as the hip, spine, and wrist [1, 2]. The 
majority of current drug treatments are anti-catabolic and decrease the 
resorption of bone by osteoclasts. In contrast, parathyroid hormone (PTH) 
is the only FDA-approved anabolic drug proven to increase bone formation 
[3]. A promising route to discover other anabolic drug targets arises from the 
fact that bone is mechanosensitive.  
Mechanical loading of the skeleton by exercise in humans increases 
bone mineral density [4-7].  In mouse models in vivo compression of the 
tibia allows for the application of controlled loads and differentially increases 
bone mass in cortical (Ct) and cancellous (Cn) sites [8-10]. The molecular 
 
____________________ 
1Kelly NH, Schimenti JC, Ross FP, van der Meulen MCH. Transcriptional 
profiling of cortical versus cancellous bone from mechanically-loaded 
murine tibiae reveals differential gene expression. Bone. 2016;86:22-29.  
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 mechanisms behind this anabolic response to mechanical loading need to be 
determined and compared between cancellous and cortical bone. This  
 knowledge may enhance the development of drug therapies to increase 
bone formation in osteoporotic patients.  
 Gene expression following in vivo tibial compression in mice has 
been examined with qPCR and microarray of cortical or homogenized 
cortical and cancellous bone [11-14]. Wnt/β catenin signaling [11, 12] and 
estrogen receptor alpha signaling [11, 14] are involved in the anabolic 
loading response. Limitations of previous work include the combined 
examination of cortical and cancellous bone and the biased determination of 
pathways and genes of interest. Moreover, the presence of large numbers of 
contaminating bone marrow cells is likely to skew further any findings. RNA 
sequencing has become the standard method to examine total gene 
transcription at any point in time. Unlike qPCR or microarray techniques 
RNA sequencing is unbiased and does not examine a predetermined set of 
genes. Furthermore, RNA-seq requires a relatively small amount of input 
material (>10-100ng), and thus is ideal for examining small tissue samples 
such as fractionated murine bone. 
We recently published a method to examine gene expression in 
cortical and cancellous bone and demonstrated with qPCR that 
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centrifugation removed marrow more efficiently and increased the 
expression of bone-related genes [15]. Expanding on this method, we now 
ask how transcriptional profiles differ in cortical and cancellous bone at 
baseline and in response to mechanical loading. To date, use of RNA-seq to 
study murine bone has been limited and only focused on the cortical 
diaphysis, homogenized metaphysis or whole bones [16-20]. Transcriptional 
profiling with RNA-seq provides an opportunity to determine gene 
expression in cortical and cancellous tissues separately and to examine the 
molecular mechanisms responsible for mechanical loading-related 
anabolism. We hypothesized that basal gene expression would differ in 
cortical and cancellous bone and that the transcriptional response to 
mechanical loading would differ between the two tissues. To test this 
hypothesis, we applied compressive loading to the mouse tibia and 
performed RNA-seq in cortical and cancellous bone separately at two time 
points. 
 
3.2 Materials and methods 
3.2.1 Animals 
Fourteen 10-week-old female C57Bl/6 mice were subjected to a single 
session of in vivo mechanical loading of the left tibia (9N max load, 1200 
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cycles, 4Hz, triangle waveform) with the right tibia as contralateral control 
[9, 10, 21]. Three and twenty-four hours after a single loading session mice 
were euthanized (n=7/group), and their tibiae rapidly dissected for RNA 
isolation. The epiphysis, all soft tissues, periosteum, fibula, and the distal end 
were removed. Tibiae were centrifuged for 20s at 16,100g at room 
temperature in microcentrifuge tubes, as previously described [15] and then 
cut approximately 5 mm distal to the growth plate to isolate the metaphysis. 
The cancellous core of the metaphysis was separated from the cortical shell 
with a 1mm biopsy punch (Miltex, Integra LifeSciences Corp, Plainsboro, 
NJ). The IACUC of Cornell University approved all animal procedures.  
 
3.2.2 RNA isolation  
RNA isolation was performed using Trizol (Life Technologies, 
Carlsbad, CA) and RNeasy Mini kit (Qiagen, Germantown, MD) as 
described previously [13]. Briefly, individual cancellous and cortical samples 
were pulverized in liquid nitrogen-cooled flasks (Mikro-dismembrator S, 
Sartorius Stedim Biotech, Bohemia, NY, USA). Following pulverization, 
Trizol was added to the flasks and the powdered bone/Trizol mix was 
incubated at room temperature for 45 minutes. 300µL of chloroform was 
added to samples, vortexed for 15s, and decanted into phase lock gel tubes 
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(PLG, heavy, 5 Prime, Gaithersburg, MD). Samples were centrifuged for 15 
minutes at 4C and 11,500 rpm, to separate the nucleic acid phase (~600µL), 
which was removed and added to an equal volume of 70% ethanol. This 
mixture was applied to purification columns (RNeasy Mini kit, Qiagen) 
following the manufacturer’s instructions, including a DNase digestion 
(RNase free DNase kit, Qiagen). A final volume of 30µL of RNA was 
eluted.  
RNA purity and quantity were tested using a spectrophotometer 
(Nanodrop 1000, Thermo Scientific, Wilmington, DE) and RNA Quality 
Number (RQN) using a fragment analyzer (Advanced Analytical 
Technologies, Inc, Ames, IA). The mean (±SD) concentration of cortical 
samples was 92 (±40) ng/µL, and for cancellous samples was 30 (±17) 
ng/µL. The 260/280 ratio was within an acceptable range (1.8-2.1) for all 
samples. Cancellous samples were of higher quality than their cortical 
counterparts with a mean (±SD) RQN of 7.4 (± 0.9) and 5.3 (± 0.8), 
respectively. 
 
3.2.3 RNA-seq library preparation and analysis 
Total RNA from 8 animals (n=32 samples; 4 samples/animal from 
cortical and cancellous tissue of two tibiae) was processed to create RNA-
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seq libraries (Illumina TruSeq RNA Sample Preparation Kit v2, San Diego, 
CA) following the manufacturer’s instructions. mRNA was purified with 
polyA+ magnetic beads, chemically fragmented (120-200bp fragments), 
reverse transcribed using random hexamers, and ligated to bar-coded 
adapters. The resulting cDNA fragments were amplified to provide 
sufficient material for subsequent analysis. Finally, primer-dimers were 
removed by washing with AMPure XP beads (Agencourt AMPure XP, 
Beckman Coulter, Brea, CA). Final libraries were tested using a fragment 
analyzer to determine the distribution of fragment sizes. The thirty-two 
individually bar-coded libraries were normalized, pooled (maximum of 12 
libraries/lane), and sequenced (100-bp single-end reads, Illumina HiSeq 
2000).  
Sequences were aligned to the mouse genome (mm10) using TopHat 
followed by transcript assembly and gene counts with Cuffdiff [22]. On 
average, 77% of the 18 million reads/library were mapped to the mouse 
genome, 95% uniquely. Differential expression was determined with a paired 
design in edgeR [23]. The paired design consisted of an additive linear model 
with blocking for which the blocking factor was “tissue” when baseline 
cortical and cancellous tissue from the same bone were compared, and the 
blocking factor was “animal” when the loaded limb was compared to the 
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control contralateral limb in the same animal. Genes with low expression 
were filtered from each library by removing genes with counts per million 
less than one in at least four samples. Finally, differentially expressed genes 
were determined by fitting gene-wise generalized linear models and 
performing likelihood ratio tests. Genes were differentially expressed based 
on fold-change (FC) cut-off and 5% false discovery rate (FDR) cut-off. A 
more stringent fold change cut-off was applied for normal developmental 
changes (Ct to Cn baseline, >2-fold) than loading induced changes (>1.5-
fold).  
For the basal samples only, we identified contaminants from our 
RNA-seq data based on genes determined to be highly expressed in muscle, 
bone marrow, or blood compared to tibial bone by Ayturk et al. [16]. For the 
loaded samples all gene changes are reported including genes considered 
contaminants in the basal analysis.  
Lists of differentially expressed genes were imported into the 
Database for Annotation, Visualization and Integrated Discovery (DAVID, 
from the National Institute of Allergy and Infectious Diseases (NIAID), 
NIH - http://david.abcc.ncifcrf.gov/). Gene ontology (GO) for biological 
processes and enriched Kyoto Encyclopedia of Genes and Genomes 
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(KEGG) pathways were determined for each group using the functional 
annotation tool (p<0.05) [24, 25].  
 
3.2.4 Gene expression verification with qPCR 
Using qPCR, we verified differential gene expression obtained from 
RNAseq for 12 genes that were different between the two tissues or with 
loading: Gpr50, Grem1, Ostn, Ptgs2, Ptn, Sost, Timp1, Tnfrsf11b, Wnt1, Wnt10b, 
Wnt16, and Wnt7b (primer sequences in Table A.1). RNA from the 
remaining animals (n=3/per group) was reverse transcribed to cDNA 
following the manufacturer’s instructions (High Capacity cDNA Reverse 
Transcription kit, Life Technologies) and brought to 5ng/µL with RNase-
free water. A final volume of 20µL containing 2X SYBR Green (Perfecta 
SYBR Green Fastmix, with ROX, Quanta Biosciences, Gaithersburg, MD) 
was assayed by triplicate qPCR using 39 cycles of denaturing (95C, 5s) and 
annealing/elongation (60C, 30s) (CFX96 Real-Time PCR System, BioRad, 
Hercules, CA). Quantification cycle (Cq) was determined for each gene and 
compared to the reference gene Gapdh. All groups are presented as fold 
change with loading or tissue type (2−ΔΔCq). The log2 fold-change of RNA-seq 
versus qPCR was graphed to determine quality of correlation; a slope of one 
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would define perfect agreement. The strength of the relationship was 
quantified by Pearson correlation.   
3.3 Results 
3.3.1 Control cortical and cancellous bone exhibit different transcriptional profiles 
We first compared the transcription profiles of cortical and cancellous 
bone from control limbs (>2-fold). Cortical and cancellous bone samples 
from the contralateral control (non-loaded) limbs were analyzed 3 hours and 
24 hours after a single loading dose. A total of 178 genes were differentially 
expressed three hours after a single loading dose, with 110 genes more highly 
expressed in control cortical bone and 68 genes more highly expressed in 
control cancellous bone (Figure 3.1A, Table A.2). Genes known to be 
expressed in mesenchymal-derived bone cells included ostn (osteocrin; 29-
fold, Ct>Cn), wnt16 (wingless-related MMTV integration site 16; 12-fold, 
Ct>Cn), wnt7b (wingless-related MMTV integration site 7b; 7-fold, Ct>Cn), 
and sost (sclerostin; 4-fold, Ct>Cn).   
Three hundred and twenty six genes were differentially expressed 24 
hours after a single loading dose, with 287 genes more highly expressed in 
cortical bone and 39 genes more highly expressed in cancellous bone 
(Figure 3.1A, Table A.3). Ninety-three differentially expressed genes were 
shared at the two time points (77 Ct>Cn, 16 Cn>Ct) and included ostn (52-
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fold, 24h), wnt16 (43-fold, 24h), wnt7b (4-fold, 24h), and sost (4-fold, 24h) 
(Figure 3.1B). 
When cortical vs cancellous gene expression was examined in control 
tissue, five differentially-expressed genes from the 3-hour group and 84 
differentially-expressed genes from the 24-hour group were previously 
shown to be more highly expressed in skeletal muscle than bone and thus 
designated as “contaminants” by Ayturk et al. [16]. When we examined these 
genes in our data, all “contaminating” genes that were more highly expressed 
in cortical bone (n=83) were genes previously associated with muscle. Of 
those Ayturk-designated contaminant genes that were more highly expressed 
in cancellous bone in our data (n=4), one was from marrow, two from 
blood, and only one from muscle. Because the previously-identified 
contaminant genes in cortical bone were all from muscle and the cancellous 
genes from marrow and blood, we excluded these genes from the pathway 
analysis of the control tissue.  
Gene ontology (GO) was determined separately for genes that were more 
highly expressed in cancellous and cortical bone.  All genes from both time 
points were included, with the exception of the contaminating genes 
identified by Ayturk et al. The extracellular matrix-receptor interaction 
pathway was enriched in both cancellous and cortical bone, while 
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melanogenesis was enriched in cortical bone only and complement and 
coagulation cascades were enriched in cancellous bone only (Figure 3.1C). 
In cancellous bone, the top biological processes were regulation of body 
fluid levels, coagulation, and blood coagulation while in cortical bone cell 
adhesion, biological adhesion, and skeletal system development were the 
identified processes (Figure 3.1D).  
  
 
Figure 3.1 Control cortical and cancellous bone exhibit distinctly different 
transcriptional profiles. (A) Venn diagram showing the number of 
differentially expressed genes between control cortical and cancellous bone 
at 3 (left) and 24 (right) hours (FDR<5%, FC>2). Arrows (%) indicate 
proportion of genes that were more highly expressed in cortical (green) or 
cancellous (red) bone. A majority of genes were more highly expressed in 
cortical bone. (B) Top 10 genes (by 3h FC) out of 93 total differentially 
expressed in cortical versus cancellous bone that were shared at both time 
points. All genes shown are more highly expressed in cortical bone. 
DAVID analysis determined C) significantly enriched pathways and D) 
biological processes in cortical and cancellous bone (p<0.05).  
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3.3.2 The mechanical loading response at 3h is driven by Wnt signaling in cortical and 
cancellous bone 
Three hours after a single loading session 43 genes were differentially 
expressed >1.5-fold in cortical bone and 18 in cancellous bone. A majority 
of genes were upregulated by loading in both cortical and cancellous bone 
(Figure 3.2A). Eleven genes were shared and included Wnt1 (wingless-
related MMTV integration site 1; 6.2-fold Ct, 4.1-fold Cn), Wnt7b (3.2-fold 
Ct, 7.8-fold Cn), Timp1 (tissue inhibitor of metalloproteinase 1; 1.6-fold Ct, 
1.9-fold Cn), Ptgs2 (prostaglandin-endoperoxide synthase 2; 4.3-fold Ct, 3.9-
fold Cn), and Tnfrsf11b (tumor necrosis factor receptor superfamily, member 
11b (osteoprotegerin); 2.2-fold Ct, 1.9-fold Cn) (Figure 3.2B). Enriched 
signaling pathways included Wnt signaling in both cortical and cancellous 
bone and hedgehog signaling in cortical bone only (Figure 3.2C). Enriched 
biological processes included Wnt receptor signaling in cancellous and 
cortical bone, biomineral formation in cortical bone, and developmental 
maturation in cancellous bone (Figure 3.2D). Complete lists of differentially 
expressed genes with mechanical loading can be found in Table A.4 (cortical 
bone) and Table A.5 (cancellous bone). 
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Figure 3.2 Differential expression of Wnt signaling genes 3 h following a 
single loading session in cortical and cancellous bone. (A) Venn diagram 
showing the number of genes significantly altered by mechanical loading at 
3 h in cortical (left) and cancellous (right) bone (FDR<5%, FC>1.5). 
Arrows (%) indicate proportion of genes that were up- (green) or down- 
(red) regulated. A majority of genes were upregulated by loading. B) Genes 
differentially expressed due to mechanical loading common to both 
cortical and cancellous bone. DAVID analysis determined C) significantly 
enriched pathways and D) biological processes in cortical and cancellous 
bone following loading (p<0.05).  
 
3.3.3 The mechanical loading response at 24h includes changes in Wnt signaling in 
cortical bone and muscle-related genes in cancellous bone 
Twenty-four hours after a single loading session 58 genes were 
differentially expressed in cortical and 32 differentially expressed genes in 
cancellous bone (>1.5-fold). More genes were upregulated by loading in 
cortical bone (60%), while more genes were downregulated in cancellous 
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bone (66%) (Figure 3.3A). Both tissue types shared twelve genes, including 
Ptn (pleiotrophin; 2.7-fold Ct, 3.1-fold Cn), Vcan (versican; 1.8-fold Ct, 1.6-
fold Cn), and Tubb3 (tubulin beta 3; 2.5-fold Ct, 1.8-fold Cn) (Figure 3.3B). 
The only enriched signaling pathway in cortical bone was melanogenesis, 
while the only enriched pathway in cancellous bone was tight junction 
(Figure 3.3C). Biological processes included response to organic substance 
and response to toxin in cortical and muscle contraction and muscle system 
process in cancellous (Figure 3.3D). Notably, many highly downregulated 
muscle-related genes were identified in cancellous bone including Myh4 
(myosin, heavy polypeptide 4, skeletal muscle; −59.5-fold), Tnnc2 (troponin 
C2, fast; −41.6-fold), Smpx (small muscle protein, X-linked; −32.3-fold), 
Tnnt3 (troponin, T3, skeletal, fast; −36.6-fold), Mylk2 (myosin, light 
polypeptide kinase 2, skeletal muscle; −22.4-fold), Myoz1 (myozenin 1; 
−23.4-fold), Myom2 (myomesin 2; −21.5-fold), Actn3 (actinin alpha 3; −14.7-
fold), Myl1 (myosin, light polypeptide 1; −13.8-fold), Casq1 (calsequestrin 1; 
−12.4-fold), Mybpc2 (myosin binding protein C, fast-type; −12.1-fold), Myh2 
(myosin, heavy polypeptide 2, skeletal muscle, adult; −12.2-fold), Mylpf 
(myosin light chain, phosphorylatable, fast skeletal muscle; −12.9-fold), and 
Tnni2 (troponin I, skeletal, fast 2; −7.7-fold). Complete lists of differentially 
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expressed genes can be found in Table A.6 (cortical) and Table A.7 
(cancellous). 
 
Figure 3.3 Wnt signaling changes in cortical bone and muscle-related 
changes in cancellous bone 24 h following a single loading session. (A) 
Venn diagram showing the number of genes significantly altered by 
mechanical loading at 24 h in cortical (left) and cancellous (right) bone 
(FDR<5%, FC>1.5). Arrows (%) indicate proportion of genes that were 
up- (green) or down- (red) regulated. A majority of genes were upregulated 
by loading in cortical bone, while in cancellous bone, a majority of genes 
were downregulated. B) Genes differentially expressed due to mechanical 
loading common to both cortical and cancellous bone. Negative fold 
change values indicate downregulation in response to loading. DAVID 
analysis determined C) significantly enriched pathways and D) biological 
processes in cortical and cancellous bone following loading (p<0.05). 
 
3.3.4 Temporal comparison of differentially expressed genes with mechanical loading 
The gene expression response within cortical bone was grossly 
different at 3 and 24 hours following a single loading dose (Figure 3.4A). 
 73 
More genes were upregulated at 3 hours and to a greater magnitude than at 
24 hours, while at 24 hours more genes were highly downregulated than at 3 
hours. Four genes were differentially expressed in cortical bone at both 3 
and 24 hours following a single loading session: Wnt1, Wnt10b, Ptgs2, and 
Mt2 (metallothionein 2; upregulated at 3h, downregulated at 24h).  
In cancellous bone the upregulated genes at 3 hours and 24 hours had 
similar magnitudes of fold-change, but more genes were downregulated with 
higher magnitude fold-change at 24 hours (Figure 3.4B).  Only Timp1 was 
upregulated both 3h and 24h following a single loading dose in cancellous 
bone (1.9-fold 3h, 1.7-fold 24h).  
Finally, more genes were differentially expressed following loading at 
24 hours in both cortical and cancellous bone. At both 3 and 24 hours more 
genes were differentially expressed in cortical than cancellous bone. The 
magnitude of the fold change in upregulated genes at 3h in cortical bone was 
larger than in cancellous bone, while at 24h the magnitude of the fold change 
in downregulated genes was larger in cancellous bone than in cortical bone. 
 74 
 
Figure 3.4 More genes were differentially expressed in cortical bone and 
at 24 h. Ranged log2 fold change histograms of differentially expressed 
genes in A) cortical and B) cancellous bone at 3 h (gray bars) and 24 h 
(black bars) after a single loading session. The y-axis is aligned with the 
inflection between up- and down-regulated genes at 24 h to assist in 
visualization of trends in differentially expressed genes between time 
points and tissue types.  
 
3.3.5 RNA-seq verification with qPCR 
We found strong agreement between qPCR and RNA-seq for the 
twelve genes tested. When all differentially expressed genes were included 
(not only significant changes), the slope of the linear fit between RNA-seq 
and qPCR was close to one and the Pearson correlation was 0.89 (Figure 
3.5). 
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Figure 3.5 qPCR validated 12 differentially expressed genes. qPCR was 
performed for 12 genes identified as differentially expressed with RNA-
seq. Log2 fold change from RNA-seq vs qPCR. Gray dashed lines indicate 
2-fold up- and down-regulation, black dashed line is the identity line (1:1 
relationship), and the solid line is the linear regression.  
 
3.4 Discussion 
 We used RNA-seq to compare gene expression in cortical and 
cancellous bone of control and loaded limbs following a single bout of axial 
tibial compression in 10-week-old female mice.  Cortical and cancellous 
bone expressed different genes basally and in response to in vivo mechanical 
loading at two time points. At baseline, many genes were differentially 
regulated between cortical and cancellous bone, the majority of which were 
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more highly expressed in cortical bone. Genes expressed by osteoblasts and 
those mediating Wnt signaling dominated the response three hours after a 
single loading session. Cortical expression twenty-four hours after a single 
loading session was still enriched for upregulated bone-related and Wnt 
signaling genes, while the cancellous response involved downregulation of 
many muscle-related genes. More genes were differentially expressed at the 
twenty-four hour time point in both cortical and cancellous bone than three 
hours after loading.   
 The differential gene expression in baseline cortical and cancellous 
bone identified here is not surprising considering differences in growth and 
aging in these bone sites. Cortical and cancellous bone arise through 
different growth processes and have different age-related bone mass accrual 
and subsequent loss. For both tissues, hypertrophic chondrocytes can 
become osteoblasts and osteocytes that contribute to cancellous bone, the 
endosteum and mature bone [26, 27]. Cortical bone mass increases during 
development, stabilizes at skeletal maturity, and decreases during aging [28, 
29]. Cancellous bone mass also increases initially during growth but 
decreases immediately after reaching peak bone mass, without a stabilization 
phase [30]. These differences in development and age-related changes 
between cancellous and cortical bone suggest different regulatory 
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mechanisms driven by the differential transcription demonstrated in our 
study.  Furthermore, we confirmed that differences in gene expression did 
not reflect different proportions of bone cells in cortical and cancellous bone 
by determining the number of osteoblasts per bone surface and the number 
of osteocytes per bone area. These measures were not different in cortical 
and cancellous samples from six animals (data not shown).  
More genes were expressed differentially twenty-four hours after a 
single loading session in control bone, implying that mechanical loading is 
not a purely local response in terms of gene transcription.  Dynamic loading 
of the tibia causes adaptation in the loaded bone only and not in adjacent, 
contra-lateral or remote sites when measured at the tissue level with 
microcomputed tomography [31]. Future studies should examine 
transcription in cortical and cancellous bone of naïve (not externally loaded) 
animals to determine if loading causes systemic changes in gene expression.  
 Wnt signaling is vital for skeletal development and maintenance [32]. 
Recently, genetic variants in Wnt16 were linked to cortical bone thickness, 
bone mineral density and fracture risk in humans [33]. Mice lacking Wnt16 
have 27% thinner femoral cortices, bone strength reductions of 43%-61% 
and develop spontaneous fractures without changes in cancellous mass or 
architecture [33, 34]. Wnt16 is osteoblast-derived and inhibits 
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osteoclastogenesis by decreasing osteoclast progenitors and increasing 
osteoblast expression of osteoprotegerin [34]. In the current study Wnt16 
was 12- to 43-fold more highly expressed in cortical bone, in agreement with 
the cortical bone phenotype seen in humans and mice. Sost, a Wnt signaling 
inhibitor, was also more highly expressed in cortical bone (4-fold); however, 
a clear cortical-only bone phenotype is not seen in humans or rodents. Sost 
gene loss-of-function in humans causes Sclerosteosis and van Buchem’s 
diseases, characterized by drastically increased bone mass [35, 36]. 
Furthermore, sclerostin antibody increased bone mineral density by 3-12% at 
the lumbar spine, total hip and femoral neck after one year of treatment in a 
phase II clinical trial [37].  In addition, Sost deficient mice have high bone 
mass in both cortical and cancellous sites [38], and Sclerostin antibody 
increased bone formation in both cortical and cancellous bone in rats [39, 
40] and cynomolgus monkeys [41]. 
 Signaling pathways and genes regulating mechanoresponsiveness have 
been determined largely from studies of cortical bone, and the few studies 
that examine cancellous bone response have conflicting results. Osteocytes 
in the cancellous bone of the mouse vertebrae were examined six hours after 
a single loading dose. 287 genes were upregulated including Wnt5a, Aspn, 
and Igf1, while 52 genes were downregulated including Spock2 and Col19a1 
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[42]. Notably Sost did not change, while we saw a 2-fold downregulation of 
Sost 3 hours following loading in cancellous bone. Furthermore, our two 
studies shared few genes that were differentially expressed due to mechanical 
stimulation. This disparity may reflect the different time points examined 
following loading, different bones examined, or their use of collagenase 
digestion, which affects gene expression [16]. Three days of hindlimb 
unloading in rats decreased Sost expression in metaphyseal cancellous bone, 
had no effect on metaphyseal cortical bone, and caused upregulation in the 
cortical diaphysis [43]. Differences in cortical and cancellous expression and 
the lack of studies of mechanotransduction in cancellous bone highlight the 
need for site-specific determination of loading-induced changes in 
transcription. 
Canonical Wnt/β-catenin signaling is a major regulator of bone’s 
adaptive response to mechanical loading. In vivo tibial loading increased 
diaphyseal expression of Wnt pathway and Wnt/β-catenin target genes 
including Wnt10b, Sfrp1, Fzd2, Wisp2, Wnt2b, and Crebbp [11, 44] and 
decreased expression of the Wnt signaling inhibitor Sost [14]. We found 
increased expression of Wnt1, Wnt7b and Wnt10b 3 hours after a single 
loading session in cortical bone, while Crebbp (CREB binding protein) and 
Lrp5 (low density lipoprotein receptor-related protein 5) were modestly 
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decreased. Wnt1 and Wnt10b remained upregulated at 24 hours in cortical 
bone. Wnt1 and Wnt7b were also upregulated in cancellous bone at the 
earlier time point, while the Wnt inhibitors Sost and Dkk1 (dickkopf 
homolog 1) were downregulated. Furthermore, β-catenin activation by 
mechanical loading requires prostaglandin [45]. We saw loading-related 
upregulation of Ptgs2 (prostaglandin-endoperoxide synthase 2, aka COX-2) 
in cortical bone at 3 and 24 hours, and in cancellous bone at 3h only. Our 
data confirm the previously determined importance of Wnt signaling in the 
cortical response to mechanical loading and identifies the role of Wnt 
signaling in the early loading response in cancellous bone.   
Other skeletal genes were differentially expressed following 
mechanical loading. Tissue inhibitor of metalloproteinase (Timp1) was 
upregulated by loading in cortical bone at 3h (1.6-fold), and in cancellous 
bone at 3h (1.9-fold) and 24h (1.7-fold), in agreement with findings from 
homogenized tibial bone subjected to mechanical loading [14, 46]. 
Pleiotrophin (Ptn) was increased by 4.3-fold twenty-four hours after four 
sessions of 4-point bending of the mouse tibia [46], and was also upregulated 
in our study at 24 hours in both cortical (2.6-fold) and cancellous bone (3.1-
fold). Osteoprotegerin (Tnfrsf11b) is well known to inhibit osteoclast 
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differentiation [47] and was increased by loading at 3 hours in cortical (2.2-
fold) and cancellous (1.9-fold) bone.  
 Muscle genes were the largest group of downregulated genes twenty-
four hours following a single loading session in cancellous bone. A single 
loading session of the rat forearm (cortical site) also caused downregulation 
of muscle genes, seven of which were also identified in our study (Ampd1, 
Smpx, Tnnt3, Mylk2, Actn3, Mylpf, and Tnni2) [48]. In our experiment these 
gene changes are unlikely to reflect muscle contamination because muscle 
was carefully removed from the whole bone surface, and the cancellous core 
does not interface with muscle. Furthermore, calvarial-derived osteocytes 
express genes related to muscle function, development and differentiation, 
and to a greater extent than osteoblasts [49] as does young healthy articular 
cartilage [50]. Established expression of muscle-related genes in 
musculoskeletal tissues other than muscle suggests that their classification 
was based upon the first tissue in which they were identified or the tissue in 
which they are most abundant, but may not be muscle-specific. The exact 
cellular population in our samples has not been determined, but embedded 
osteocytes are a likely source; our centrifugation protocol removes marrow 
and non-adherent osteoblasts and osteoclasts. The role of muscle-related 
genes in bone biology and mechanotransduction is not well understood, and 
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elucidation of their functions in bone cells and the response to mechanical 
loading requires further study.   
Despite the removal of contaminating genes determined by Ayturk et 
al., pathways and biological processes were identified in cancellous bone that 
are related to coagulation. These results may reflect the presence of blood or 
serum within the tibial samples. 
 The current study is limited in its examination of the response to 
loading at the transcriptional level in young mice at two time points 
following a single loading session. Protein levels resulting from the 
transcriptional changes need to be confirmed, localized to the different cells, 
and ideally related to the strain field, to more accurately determine spatial 
and temporal responses to mechanical loading. The selection of appropriate 
time points for these studies will be critical to the experimental design. 
Future work could include adult mice, earlier time points to capture changes 
in transcription factors, later time points to examine matrix- and 
mineralization-related gene expression, and multiple loading sessions.  
The ability to examine cortical and cancellous bone separately and compare 
their baseline transcription and their response to mechanical loading is 
unique. Many gene knockout studies have demonstrated differential 
phenotypes in cortical and cancellous bone; some notable examples are the 
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primary effect in cancellous bone of absence of estrogen receptor alpha in 
bone cells [51-55], the previously mentioned cortical phenotype in mice 
lacking Wnt16 [33, 34], and the decrease in cortical but not cancellous bone 
volume when BMP2 is deleted from early-stage osteoblasts [56]. With in 
vivo compression of the mouse tibia, cancellous bone is often more 
responsive to mechanical loading than cortical bone [21, 57]; however, gene 
knockouts can modify this responsiveness in a site-specific manner [53, 58]. 
Future studies utilizing our methods to determine the baseline transcription 
and response to loading in cortical and cancellous bone in genetically 
modified mice will help unravel the complex molecular mechanisms 
responsible for in vivo bone homeostasis and mechanotransduction. 
 
3.4.1 Conclusions 
 In summary, we used RNA-seq to demonstrate differences in cortical 
and cancellous bone transcription separately at baseline and at two time 
points following a single loading session. The differences in transcription at 
baseline highlight the need to examine these bone tissue envelopes 
separately, particularly when cortical to cancellous phenotypic differences are 
observed. Furthermore, we discovered tissue-envelope-specific and time-
dependent differences in the response to mechanical loading. In particular, 
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further investigation into the large downregulation of muscle-related genes in 
cancellous bone is necessary. Next generation sequencing is a powerful tool 
to study bone transcription and identify future targets for treatment of 
osteoporosis. 
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CHAPTER 4 
FEMALE MICE LACKING ESTROGEN RECEPTOR ALPHA  
IN MATURE OSTEOBLASTS HAVE AN INCREASED 
TRANSCRIPTIONAL RESPONSE TO MECHANICAL LOADING  
IN CANCELLOUS BUT NOT CORTICAL BONE  
 
4.1 Introduction 
Postmenopausal osteoporosis is characterized by decreased bone mass and 
weaker skeletal structures caused in part by decreased bioavailable estrogen. 
Estrogen signaling in bone occurs through estrogen receptor alpha and beta (ERa 
and ERb). The importance of ERa was underscored by the discovery of a 
mutation in the ERa gene (ESR1) that resulted in unfused growth plates and low 
bone mass [1]. Human polymorphisms in ESR1 have since been linked to bone 
mineral density, fracture risk, and response to exercise [2-6]. Cancellous bone loss 
due to postmenopausal osteoporosis is more rapid than that occurring in cortical 
tissue, and fractures occur in corticocancellous sites [7, 8], suggesting that the 
effects of ERa may be distinct in cortical and cancellous bone tissue.  
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The role of estrogen in bone cells has been studied increasingly with cell-
specific ERa knockout (KO) mice. ERa has been removed at different 
osteoblastic cell lineages, with conflicting effects on cortical and cancellous bone 
mass in female mice. Deletion of ERa in osteoblast progenitors and precursors 
(Prx1- and Osx1-cre) decreased cortical bone mass while cancellous mass was 
unaffected [9]. In mature osteoblasts (OC-cre, pOC-ERaKO), ERa deletion 
decreased cortical and cancellous bone in females [10, 11], while deletion of ERa in 
committed osteoblasts (Col1a1-cre) failed to affect bone mass [9]. Finally, when 
ERa was removed from osteocytes (Dmp1-cre) cancellous bone volume decreased 
but cortical bone was unaffected in female mice [12]. Thus, estrogen is 
osteoprotective, and loss of estrogen reduces bone mass. Given estrogen’s 
pleiotropic role in regulation of bone mass and the fact that loading of bone is 
anabolic, estrogen may also play a role in bone mechanotransduction.  
Mechanical loading increases bone mass while disuse or reduced mechanical 
loading decreases bone mass in adult animals. Increased bone mass due to 
mechanical loading can be studied with rodent models of bone cyclic compression 
[13-15]. The response to mechanical loading in cortical bone of mice lacking ERa 
in osteoblast progenitors and precursors was decreased [16], while when ERa was 
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deleted in osteocytes the cortical response was similar to controls [17]. In contrast, 
adaptation to external mechanical loads was increased in mice lacking ERa in 
mature osteoblasts compared to littermate controls, particularly in cancellous bone 
[18]. The molecular mechanisms behind this site-specific increased anabolism are 
not well understood.  
Wnt/b-catenin signaling mediates the skeletal response to mechanical 
loading. Expression of Wnt agonists including Wnt10b, Wnt2b, Fzd2 (frizzled class 
receptor 2), and Wisp2 (Wnt1 inducible signaling pathway protein 2) was increased 
following loading in cortical bone [19, 20], while the Wnt antagonist Sost 
(sclerostin) was decreased [21-23]. Crosstalk between estrogen and Wnt/b-catenin 
signaling has been demonstrated. A single short period of dynamic mechanical 
strain increased nuclear accumulation of b-catenin, and this effect was blocked by 
an estrogen receptor inhibitor and was absent in osteoblasts from mice lacking 
ERa [19]. Three hours following tibial compression wild-type mice had differential 
expression of six genes involved in Wnt signaling but only retinoic acid receptor g 
(RARg) was differentially expressed in mice lacking ERa [19]. Although decreases 
in Wnt-related gene expression in response to mechanical loading have been 
demonstrated in cortical bone of mice lacking ERaKO, we saw increased tissue-
  95 
level response to loading in mice with osteoblast-specific knockout of ERa, 
particularly in the cancellous compartment [18]. Examination of the transcriptional 
differences in cortical versus cancellous bone of pOC-ERaKO mice following 
mechanical loading will add to our knowledge of ERa and Wnt signaling crosstalk 
and the transcriptome level changes in bone functional adaptation.      
We hypothesized that mechanical loading causes systemic changes in bone at 
the transcriptional level and that mice lacking ERa in bone cells have an increased 
response compared to littermate controls due to altered Wnt/b-catenin signaling, 
particularly in cancellous bone. We previously demonstrated that gene expression 
in response to mechanical loading differed in cortical versus cancellous marrow-
free murine bone [24, 25]. We now extend these techniques to further characterize 
the transcriptional response to mechanical loading in mice lacking ERa in mature 
osteoblasts. The left tibiae of 10-week-old female pOC-ERaKO and littermate 
control mice were subjected to a single session of axial tibial compression and the 
mice were euthanized 3 or 24 hours following loading. To determine baseline 
differences in cortical versus cancellous transcription and the possible systemic 
effects of loading, a third group of naïve (never loaded) littermate control animals 
was compared to contralateral control limbs of loaded animals (LC and pOC-
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ERaKO). We performed RNA-seq on marrow-free metaphyseal samples from the 
cortical shell and the cancellous core of the metaphysis to determine differential 
gene expression in response to load (versus contralateral control) and differential 
gene expression in naïve cortical and cancellous bone.  
 
4.2 Materials and Methods  
4.2.1 Animals  
Mice lacking ERa in mature osteoblasts (osteocalcin promoter, pOC-
ERaKO) along with their littermate controls (LC) were bred as previously 
described on a C57Bl/6 background [11, 18]. Ten-week-old female mice were 
subjected to a single session of in vivo mechanical loading of the left tibia (9N max 
load, 1200 cycles, 4Hz, triangle waveform) with the right tibia as contralateral 
control [14, 26, 27]. Three and twenty-four hours after a single loading session mice 
were euthanized (n=4-7/group). Another set of LC mice (n=4) was euthanized 
without external load application (naïve). Following euthanasia, tibiae were rapidly 
dissected for RNA isolation. The epiphysis, all soft tissues, periosteum, fibula, and 
the distal end were removed. Tibiae were centrifuged for 20s at 16,100 g at room 
temperature in microcentrifuge tubes, as previously described [24], and then cut 
approximately 5 mm distal to the growth plate to isolate the metaphysis. The 
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cancellous core of the metaphysis was separated from the cortical shell with a 1mm 
biopsy punch (Miltex, Integra LifeSciences Corp, Plainsboro, NJ). The IACUC of 
Cornell University approved all animal procedures.  
4.2.2 RNA isolation  
RNA isolation was performed using Trizol (Life Technologies, Carlsbad, 
CA) and RNeasy Mini kit (Qiagen, Germantown, MD) as described previously with 
a few important changes [24]. Individual cancellous and cortical samples were 
pulverized for 5 minutes in liquid-nitrogen-cooled 2mL tubes containing 2.8mm 
ceramic beads and Trizol (Mikro-dismembrator S, Sartorius Stedim Biotech, 
Bohemia, NY, USA), rather than dry pulverization with subsequent Trizol addition. 
Following pulverization the powdered bone/Trizol mix was incubated for 30 
minutes at room temperature and then stored at -80C overnight. Samples were 
thawed, transferred to new 1.5mL tubes, and centrifuged at 4C and 11,500 rpm for 
5 minutes, and then added to phase lock gel tubes (PLG, heavy, 5 Prime, 
Gaithersburg, MD) containing 300µL of chloroform. Samples were centrifuged for 
15 minutes at 4C and 11,500 rpm to separate the nucleic acid phase (~500µL), 
which was removed and added to an equal volume of 70% ethanol. This mixture 
was applied to purification columns (RNeasy Mini kit, Qiagen) following the 
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manufacturer’s instructions, including a DNase digestion (RNase free DNase kit, 
Qiagen). A final volume of 30µL of RNA was eluted.  
RNA purity and quantity were tested on all samples using a 
spectrophotometer (Nanodrop 1000, Thermo Scientific, Wilmington, DE). RNA 
Quality Number (RQN) was determined for a subset of samples (4-12/group) 
using a fragment analyzer (Advanced Analytical Technologies, Inc, Ames, IA). The 
mean (±SD) concentration of cortical samples was 108 (±29) ng/µL, and for 
cancellous samples was 35 (±15) ng/µL. The 260/280 ratio was within an 
acceptable range (1.5-2.1) for all samples. Cancellous and cortical samples were of 
high quality with mean (±SD) RQNs of 8.0 (± 1.0) and 8.6 (± 0.5), respectively. 
 
4.2.3 RNA-seq library preparation and analysis 
Total RNA from 20 animals (n=80 samples; 4 samples/animal from cortical 
and cancellous tissue of both tibiae) was processed following the manufacturer’s 
instructions to create RNA-seq libraries (Illumina TruSeq RNA Sample Preparation 
Kit v2, San Diego, CA). mRNA was purified with polyA+ magnetic beads, 
chemically fragmented (120-200bp fragments), reverse transcribed using random 
hexamers, and ligated to bar-coded adapters. The resulting cDNA fragments were 
amplified to provide sufficient material for subsequent analysis. Finally, primer-
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dimers were removed by washing with AMPure XP beads (Agencourt AMPure XP, 
Beckman Coulter, Brea, CA). Final libraries were tested using a fragment analyzer 
to determine the distribution of fragment sizes. The eighty individually bar-coded 
libraries were normalized, pooled (maximum of 20 libraries/lane), and sequenced 
(75-bp single-end reads, Illumina NextSeq 500).  
Sequences were aligned to the mouse genome (mm10) using TopHat 
followed by transcript assembly and gene counts with Cuffdiff [28]. On average, 
94% of the 27 million reads/library were mapped to the mouse genome, 95% 
uniquely. Differential expression was determined with a paired design in edgeR 
[29]. The paired design consisted of an additive linear model with blocking for 
which the blocking factor was “tissue” when baseline cortical and cancellous tissue 
from the same bone were compared, and the blocking factor was “animal” when 
the loaded limb was compared to the control contralateral limb in the same animal. 
Genes with low expression were filtered from each library by removing genes with 
counts per million less than one in at least four samples. Finally, differentially 
expressed genes were determined by fitting gene-wise generalized linear models and 
performing likelihood ratio tests. Differentially expressed genes were determined 
based on fold-change cut-off and 5% false discovery rate (FDR) cut-off. A more 
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stringent fold change cut-off was applied for normal developmental changes (Ct to 
Cn baseline, >2-fold) than for loading-induced changes (>1.5-fold).  
For the naïve LC and contralateral control samples only, we identified 
contaminants from our RNA-seq data based on genes determined to be highly 
expressed in muscle, bone marrow, or blood compared to tibial bone by Ayturk et 
al. [30]. For the loaded samples all gene changes were reported including genes 
considered contaminants in the control analysis.  
Lists of differentially expressed genes were imported into the Database for 
Annotation, Visualization and Integrated Discovery (DAVID, from the National 
Institute of Allergy and Infectious Diseases (NIAID), NIH - 
http://david.abcc.ncifcrf.gov/). Gene ontology (GO) for biological processes and 
enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were 
determined for each group using the functional annotation tool (p<0.05) [31, 32].  
 
4.2.4 Gene expression verification with qPCR 
Using qPCR, we verified differential gene expression obtained from RNAseq 
for 8 genes that were different between the two tissues or with loading: Ostn, 
Ptgs2, Ptn, Timp1, Tnfrsf11b, Wnt1, Wnt16, and Wnt7b (primer sequences in 
supplementary table S1). RNA from the 3-hour time point (n=3/per group) was 
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reverse transcribed to cDNA following the manufacturer’s instructions (High 
Capacity cDNA Reverse Transcription kit, Life Technologies) and brought to 
5ng/µL with RNase-free water. A final volume of 20µL containing 2X SYBR 
Green (Perfecta SYBR Green Fastmix, with ROX, Quanta Biosciences, 
Gaithersburg, MD) was assayed by triplicate qPCR using 39 cycles of denaturing 
(95C, 5s) and annealing/elongation (60C, 30s) (CFX96 Real-Time PCR System, 
BioRad, Hercules, CA). Quantification cycle (Cq) was determined for each gene 
and compared to the reference gene Gapdh. All groups are presented as fold 
change with loading or tissue type (2−∆∆Cq). The log2 fold-change of RNA-seq 
versus qPCR was graphed to determine quality of correlation; a slope of one would 
define perfect agreement. The strength of the relationship was quantified by 
Pearson correlation.   
 
4.3. Results 
4.3.1 Absence of ERa in mature osteoblasts resulted in markedly decreased differential gene 
expression in cortical bone following a single loading session 
A single session of in vivo mechanical loading caused differential expression 
of more genes in cortical bone of LC than pOC-ERaKO mice. Cortical samples 
from LC animals had differential expression of 772 genes (Table B2) three hours 
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following mechanical loading, while only 32 genes were differentially expressed in 
cortical bone from pOC-ERaKO animals (Table B3). For both groups, most 
affected genes were upregulated. Twenty-four hours following loading LC animals 
had 65 differentially expressed genes, of which a majority were downregulated 
(Table B4), while pOC-ERaKO animals had only 11 differentially expressed genes 
in cortical bone, which were mostly upregulated (Table B5) (Figure 4.1). 
 
Figure 4.1. Littermate control and ERa knockout animals respond 
differently to loading in cortical and cancellous bone. The number of genes 
differentially expressed in cortical and cancellous bone 3 and 24 hours after a 
single session of in vivo tibial loading of littermate control (solid) and pOC-
ERaKO animals (hashed) compared to their contralateral, non-loaded controls.  
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Thirteen genes were differentially expressed in both LC and pOC-ERaKO 
cortical bone three hours following a single loading session (Figure 4.2A). These 
genes included Ptgs2 (prostaglandin-endoperoxide synthase 2), Medag (mesenteric 
estrogen-dependent adipogenesis), Ngf (nerve growth factor), Lgr6 (leucine-rich 
repeat containing G protein-coupled receptor 6), Tnfrsf11b (tumor necrosis factor 
receptor superfamily member 11b, or osteoprotegerin), Adamts1 (a disintegrin-like 
and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 1), and 
Ccl7 (chemokine (C-C motif) ligand 7) (Figure 4.2A). Wnt7b was the only gene that 
was shared between the two time points in cortical bone, being upregulated at 3h 
and downregulated at 24h in LC.  
Six genes were differentially expressed in both LC and pOC-ERaKO 
cortical bone 24 hours following a single loading session. Gsg1l (germ cell 
associated 1-like) and Tubb3 (tubulin, beta 3 class III) were upregulated, while 
Wisp2 (Wnt1 inducible signaling pathway protein 2), Galnt6 (UDP-N-acetyl-alpha-
D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6), Ccr1 
(chemokine (C-C motif) receptor 1), and Cd83 (CD83 antigen) were downregulated 
(Figure 4.2A).  
Over 700 genes in LC mice at 3 hours and 58 genes at 24 hours were 
differentially expressed in cortical bone in only one genotype or time point 
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following loading. Those genes that were over 2-fold up or downregulated are 
shown (Figure 4.2B, 24 hours only. See Table B2 for 3-hour changes).  
 
Figure 4.2: More genes were differentially expressed in cortical bone of LC 
than pOC-ERaKO following mechanical loading Heat maps of differentially 
expressed (DE) genes in loaded cortical samples compared to contralateral 
controls 3 and 24 hours following a single loading session in LC and pOC-
ERaKO animals. Red indicates upregulation, blue downregulation, and gray no 
significant change. Genes in orange were highly upregulated. Gene names in bold 
were also DE in cancellous bone following a single loading session. A) 20 genes 
were DE in cortical bone of two or more groups following a single loading 
session. B) 65 genes were DE in cortical bone of only one group, mostly in LC 
cortical bone. ***LC Cortical bone at 3 hours had a total of 772 genes DE with 
loading, 220 which were downregulated. The full DE gene list for LC cortical 
bone at 3 hours can be found in Table B2, only those genes found in other 
groups are displayed in this figure. LC = littermate control, cKO = pOC-
ERaKO. 
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Notably, Sost (sclerostin), an important inhibitor of Wnt signaling, was 
downregulated only at 3h in LC animals. Amd1 (S-adenosylmethionine 
decarboxylase 1) was highly upregulated (226-fold) in cortical bone of LC animals 3 
hours following loading. Other genes with known musculoskeletal functions 
included Wnt1, Tnfrsf12a, Ank. At 24 hours following loading several genes with 
known osteoclast function were downregulated including Ctsk (cathepsin K), 
Dcstamp (dentrocyte expressed seven transmembrane protein), and Oscar (osteoclast 
associated receptor; see Table B9).   
In general, pOC-ERaKO mice had fewer genes that were differentially 
expressed following loading in cortical bone. However, 19 genes were differentially 
expressed in pOC-ERaKO cortical bone only 3 hours following loading. The most 
highly upregulated gene was Il6 (interleukin 6, 9.6-fold). Known bone-related genes 
included Dmp1 (dentin matrix protein 1), Notum, Timp1, and Fam20c. Five genes 
were differentially expressed only at 24 hours in pOC-ERaKO cortical bone, but 3 
of the 5 genes were very highly upregulated: Rspo4, R-spondin 4, 138-fold; Oprd1, 
opioid receptor, delta 1, 49-fold; and Serpina1a, serine (or cysteine) peptidase 
inhibitor, clade A, member 1A, 29-fold.  
Enriched signaling pathways and biological processes were determined for 
cortical bone from LC and pOC-ERaKO animals at 3 and 24 hours following a 
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single loading session. In LC cortical bone at 3 hours, signaling pathways included 
oxidative phosphorylation and ribosome. Enriched biological processes for LC 
cortical bone included muscle system process, myofibril assembly, and muscle 
contraction. After 24 hours of loading in LC cortical bone, enriched signaling 
pathways included osteoclast differentiation, glycosaminoglycan degradation, and 
cytokine-cytokine receptor interaction. pOC-ERaKO animals had few enriched 
signaling pathways and no enriched biological processes. The TNF signaling 
pathway and osteoclast differentiation were the only enriched pathways in pOC-
ERaKO cortical bone 3 hours following loading (Table 4.1)
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Table 4.1: Signaling pathways and biological processes significantly changed in cortical 
bone 3 and 24 hours following a single loading session in LC and pOC-ERaKO mice 
 3 hours 24 hours 
  LC pOC-ERaKO LC pOC-ERaKO 
Si
gn
al
in
g 
Pa
th
w
ay
s 
 
Oxidative 
phosphorylation 
TNF signaling 
pathway 
Osteoclast 
differentiation 
N.S. 
Ribosome Osteoclast 
differentiation 
Glycosaminoglycan 
degradation 
 
 
Huntington’s 
Disease 
 Cytokine-cytokine 
receptor interaction 
 
Parkinson’s 
Disease 
 Rheumatoid 
arthritis 
 
Alzheimer’s 
Disease 
   
Bi
ol
og
ic
al
 P
ro
ce
ss
es
 
Generation of 
precursor 
metabolites and 
energy 
 
N.S. Osteoclast 
differentiation 
N.S. 
Muscle system 
process 
 Cellular zinc ion 
homeostasis 
 
Myofibril assembly  Cell adhesion  
Muscle contraction  Positive regulation 
of gene expression 
 
Striated muscle cell 
development 
 Immune response  
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4.3.2 Absence of ERa in mature osteoblasts resulted in markedly increased differential gene 
expression in cancellous bone following a single loading session 
A single session of in vivo mechanical loading caused differential expression 
of more genes in cancellous bone of pOC-ERaKO than it did in LC mice. Three 
hours following a single loading session cancellous samples from pOC-ERaKO 
animals had differential expression of 40 genes (Table B7), while only 21 genes 
were differentially expressed in LC animals (Table B6). Twenty-four hours 
following a single loading session 147 genes were differentially expressed in 
cancellous bone of pOC-ERaKO animals (Table B9), while LC animals had only 
8 differentially expressed genes (Table B8). The majority of genes were 
upregulated in both genotypes and time points. (Figure 4.3). 
Seventeen genes were differentially expressed in both pOC-ERaKO and LC 
cancellous bone at 3 hours, and 2 genes at 24 hours (Figure 4.3A). The magnitude 
of the fold change was generally higher in pOC-ERaKO cancellous bone for genes 
that were shared. For example, 16 of the 17 genes differentially expressed three 
hours following a single loading session in cancellous bone of both genotypes were 
between 1.1 and 2.2 times more highly expressed in pOC-ERaKO compared to 
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LC (Figure 4.3B). Five genes were differentially expressed at 3 and 24 hours only 
in pOC-ERaKO cancellous bone, including Notum and Fam180a (Figure 4.3A). 
More genes were differentially expressed at only one time point in pOC-
ERaKO than in LC cancellous bone (Figure 4.3C). In pOC-ERaKO cancellous 
bone, 18 genes were differentially expressed at 3 hours including Amd1, which was 
highly upregulated (157-fold), Wnt7b (8.4-fold), Ank, and Fgf1. At 24 hours in 
pOC-ERaKO cancellous bone, 70 genes had greater than 2-fold differential 
expression. Six genes were highly upregulated including Rspo4 (537-fold), Ear12 
(292-fold), Myoz2 (51-fold), Oprd1 (43-fold), Serpina1a (24-fold), and Pax1 (23-fold).  
In LC cancellous bone, 4 genes were differentially expressed in each of the 3- and 
24-hour time points. 
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Figure 4.3: More genes are differentially expressed in cancellous bone of 
pOC-ERaKO than LC following mechanical loading with a higher fold 
change. A) Heat map of 24 differentially expressed (DE) genes in loaded 
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In cancellous bone, the only enriched signaling pathways were found in pOC-
ERaKO samples. The Hedgehog signaling pathway was enriched both 3 and 
24 hours following loading. Other enriched pathways three hours following 
loading included hippo signaling pathway, basal cell carcinoma, pathways in 
cancer, and melanogenesis. Twenty-four hours following loading the enriched 
pathways were mineral absorption, leishmaniasis, salivary secretion, and 
rheumatoid arthritis. Biological processes in cancellous bone of LC animals 
included cell-cell signaling, oxidation-reduction process, and hematopoietic 
stem cell proliferation at 3 hours and ion transport and cation transport at 24 
cancellous samples compared to contralateral controls that were shared by two or 
more groups in LC and pOC-ERaKO mice 3 and 24 hours following a single 
loading session. Upregulated genes in red, genes with no significant change in 
gray. Genes in orange and turquoise were highly up and down regulated, 
respectively. Gene names in bold were also DE in loaded cortical bone of at least 
one genotype/time point. B) 17 genes were upregulated 3 hours following a 
single loading session in LC and pOC-ERaKO cancellous bone and 16 of these 
DE genes were more highly upregulated in pOC-ERaKO mice. C) Heat maps of 
genes that were only differentially expressed in one genotype or time point in 
cancellous bone of LC and pOC-ERaKO cancellous bone (>2-fold). pOC-
ERaKO cancellous bone had more DE genes in response to load, particularly at 
24 hours. At 3 hours, Amd1 and Wnt7b were highly upregulated in pOC-
ERaKO cancellous bone only. At 24 hours, Rspo4, Ear12, Myoz2, Oprd1, 
Serpina1a and Pax1 were highly upregulated while Ear7 was highly 
downregulated in pOC-ERaKO cancellous bone only.  
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hours. pOC-ERaKO cancellous bone shared several biological processes at 3 
and 24 hours including positive regulation of cell proliferation, and (positive 
regulation of) osteoblast differentiation. Biological processes in pOC-ERaKO 
cancellous bone at 3 hours included only Wnt signaling pathway and 
angiogenesis, while at 24 hours skeletal system development, retinal rod cell 
differentiation, and cellular response to interleukin-1 processes were also 
enriched (Table 4.2).  
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Table 4.2: Signaling pathways and biological processes significantly changed in 
cancellous bone 3 and 24 hours following a single loading session in LC and pOC-
ERaKO mice 
 3 hours 24 hours 
  LC pOC-ERaKO LC pOC-ERaKO 
Si
gn
al
in
g 
Pa
th
w
ay
s 
 
N.S. Hedgehog 
signaling pathway 
N.S. Mineral 
absorption 
 
 Hippo signaling 
pathway 
 Hedgehog 
signaling pathway 
 Basal cell 
carcinoma 
 Leishmaniasis 
 Pathways in 
cancer 
 Salivary secretion 
 Melanogenesis  Rheumatoid 
arthritis 
Bi
ol
og
ic
al
 P
ro
ce
ss
es
 
Positive regulation 
of cell 
proliferation 
Positive regulation 
of cell 
proliferation 
Ion transport Skeletal system 
development 
Cell-cell signaling Multicellular 
organismal 
development 
Cation transport Positive regulation 
of cell 
proliferation 
Oxidation-
reduction process 
Positive regulation 
of osteoblast 
differentiation 
 Osteoblast 
differentiation 
Positive regulation 
of sequence-
specific DNA 
binding 
transcription 
factor activity 
 
Wnt signaling 
pathway 
 Retinal rod cell 
differentiation 
Hematopoietic 
stem cell 
proliferation 
Angiogenesis  Cellular response 
to interleukin-1 
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4.3.3 More Wnt signaling pathway genes were differentially regulated in LC versus pOC-
ERaKO mice 
To specifically examine differences in Wnt signaling between LC and pOC-
ERaKO mice, differentially expressed genes that were found within the gene 
ontology term “Wnt signaling pathway” (GO: 0016055), which contains a total of 
382 genes in the mouse, were determined for all groups and time points (Figure 
4.4). A total of 33 genes from the Wnt signaling pathway were differentially 
expressed in one or more groups. Differential expression of 25 of the 33 genes 
occurred in LC mice, while differential expression of 13 of the 33 genes occurred in 
pOC-ERaKO mice. Five genes were differentially expressed in both LC and pOC-
ERaKO mice: Wnt1, Wnt7b, Wnt10b, Wisp2, and Lgr6. These 5 genes positively 
regulate Wnt signaling, and were generally upregulated with loading in both LC and 
pOC-ERaKO mice. Wnt1 was upregulated in cortical and cancellous bone of LC 
animals, and, to a greater extent, in cancellous bone of pOC-ERaKO mice at 3 
hours. Lgr6 was upregulated in cortical and cancellous bone at 3 hours in both LC 
and pOC-ERaKO animals, but the upregulation was higher in pOC-ERaKO 
mice. Wnt10b was upregulated in cancellous bone 3 hours following loading in both 
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genotypes (LC: 2.0-fold, pOC-ERaKO: 2.6-fold). 24 hours following loading, 
Wnt7b was downregulated in cortical bone of LC mice, and Wisp2 was 
downregulated in both genotypes. Rspo4, as previously mentioned, was highly 
upregulated in cortical and cancellous bone at 24 hours in pOC-ERaKO mice 
only. Twenty Wnt signaling pathway genes were differentially expressed in cortical 
bone at 3 hours in LC animals only. Sost, previously shown to be an important 
inhibitor of Wnt signaling, was downregulated 2.3-fold. However, several positive 
regulators of Wnt signaling were also downregulated, including Lrp5 (low density 
lipoprotein receptor-related protein 5), Lef1 (lymphoid enhancer binding factor 1), 
Dlx5 (distal-less homeobox 5), and Dvl3 (dishevelled segment polarity protein 3). 
The Wnt signaling inhibitor Sfrp5 (secreted frizzled-related protein 5) was 
downregulated in cortical bone of pOC-ERaKO mice at 24 hours.
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Figure 4.4. More Wnt signaling pathway genes were differentially 
expressed in LC than pOC-ERaKO. Heat maps of differentially expressed 
(DE) genes that are involved in the Wnt signaling pathway (GO:0016055, 382 
genes total) in A) littermate control and B) pOC-ERaKO animals. Upregulated 
genes in red, downregulated in blue, and genes with no significant change in gray. 
Genes in orange were highly up regulated. Gene names in bold were DE in LC 
and pOC-ERaKO animals. A) Littermate control animals had DE of 25/33 
genes, while B) pOC-ERaKO animals had DE of 13/33 genes. Ct = cortical, Cn 
= cancellous, 3h = 3 hours following a single loading session, 24h = 24 hours 
following a single loading session. 
 
4.3.4 Cortical and cancellous bone exhibited different transcriptional profiles  
To determine transcriptional differences between cortical and cancellous 
bone, we compared expression in the right cortical versus right cancellous samples 
of four naïve animals. After removal of contaminants 285 genes were differentially 
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expressed (2-fold cut-off), with 73% being more highly expressed in cortical bone 
(208 genes Ct>Cn) (Table B10). By comparing differentially expressed genes 
between cortical and cancellous bone in naïve animals to those in the right limbs 
(contralateral control) of loaded LC and pOC-ERaKO animals, we identified genes 
that were consistently different in cortical versus cancellous bone, and genes 
associated with systemic effects of loading. At the 3-hour time point, 261 genes 
were differentially expressed in cortical versus cancellous bone of LC contralateral 
control limbs (Table B11) and 279 in pOC-ERaKO animals (Table B13). Eighty-
eight genes were shared between all three groups (Naïve, contralateral LC and 
contralateral pOC-ERaKO control tissues).  At the 24-hour time point 294 genes 
were differentially expressed in cortical versus cancellous bone of LC contralateral 
control limbs (Table B12), 172 in pOC-ERaKO contralateral control limbs 
(Table B14), and 69 genes were shared by the three groups (Figure 4.5). The top 
shared genes were all more highly expressed in cortical than cancellous bone. 
Highly expressed genes that were shared by the three groups at both 3 and 24 
hours included Cilp and Cilp2, Wnt16 (wingless-type MMTV integration site family, 
member 16), Ostn (osteocrin), Mfap4 (microfibrillar associated protein 4), Itgbl1 
(integrin, beta-like 1), Igfbp6 (insulin like growth factor binding protein 6), and Lrrn1 
(leucine rich repeat neuronal 1). These genes were consistently different in cortical 
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versus cancellous bone, and likely represent true transcriptional differences 
between bone tissues. 
 
4.3.5 Loading had systemic effects at the transcriptional level  
To address whether loading was purely local at the transcriptional level, we 
compared right and left limbs from 10-week-old female C57Bl/6 littermate control 
mice that were not externally loaded (naïve LC, n=4). Right and left cortical and 
cancellous samples had very similar gene expression within each bone envelope 
with only three genes differing for cortical right/left samples and 4 genes differing 
for cancellous right/left samples using a 2-fold cut-off. Overall, agreement was 
excellent between left and right limbs (R2=0.999 and R2=0.998 for cortical and 
cancellous samples, respectively) (Figure B1). 
Genes that were shared by contralateral control limbs of loaded animals but 
were not significantly different in the naïve (not loaded) animals may represent 
systemic changes following in vivo mechanical loading. At the 3-hour time point 26 
genes were more highly expressed in cortical bone and shared between the 
contralateral control limbs of LC and pOC-ERaKO animals (Figure 4.5C), while 
at 24 hours 21 genes were altered (Figure 4.5F). Of the top 10 shared genes only 
one gene overlapped between 3 and 24 hours in contralateral limbs: Sall1 (spalt-like 
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transcription factor 1: 8- to 9-fold). At 3 hours highly differentially expressed genes 
(>5-fold) included Myoc (myocilin), Igfn1 (immunoglobulin-like and fibronectin type 
III domain containing 1), Fgf14 and Fgf23 (fibroblast growth factors 14 and 23), 
and Bnc2 (basonuclin 2). At 24 hours highly differentially expressed genes (>5-fold) 
included Tigd4 (tigger transposable element derived 4), Jph4 (junctophilin 4), and 
Ear12 (eosinophil-associated, ribonuclease A family, member 12). Although not 
one of the top shared genes, Sost was more highly expressed in cortical bone of LC 
and pOC-ERaKO contralateral limbs (2.2-fold)
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Figure 4.5. Cortical and cancellous bone were transcriptionally distinct 
and loading had systemic effects that differed by genotype. Differential 
expression (DE) in non-loaded cortical vs cancellous bone of  naïve LC animals 
compared to control right limbs of  LC and pOC-ERaKO animals A,B,C) 3 
hours and D,E,F) 24 hours after a single loading session. A) 3 hours following a 
single loading session 261 to 285 genes were DE between non-loaded cortical 
and cancellous bone (after contaminant removal). Orange box indicates B) Top 
10 of  88 DE genes between cortical and cancellous bone and shared by all 
groups. Purple box indicates C) Top 10 of  26 DE genes in cortical vs cancellous 
bone and shared in the contralateral limbs of  LC and pOC-ERaKO animals. All 
top shared genes were more highly expressed in cortical than cancellous bone. D) 
24 hours following a single loading session 172 to 294 genes were DE between 
cortical and cancellous bone (after contaminant removal). Orange box indicates 
E) Top 10 of  69 genes that were DE between cortical and cancellous bone and 
shared by all groups. Purple box indicates F) Top 10 of  21 genes that were 
differentially expressed in cortical vs cancellous bone and shared in the 
contralateral limbs of  LC and pOC-ERaKO animals. All top shared genes were 
more highly expressed in cortical than cancellous bone. In A,D) black numbers 
indicate genes in only one group, white numbers are genes shared by two or three 
groups.  
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4.3.6 RNA-seq verification with qPCR 
We found strong agreement between qPCR and RNA-seq for the eight 
genes tested at the 3-hour time point. When all genes were included (not only those 
with significant differential expression), the slope of the linear fit between RNA-seq 
and qPCR Log2 fold change was close to 1.0 and the Pearson correlation was 0.80 
(Figure 4.6). 
 
Figure 4.6: qPCR validated 8 differentially expressed genes 3-hours 
following a single loading session. qPCR was performed for 8 genes identified 
as differentially expressed with RNA-seq. Log2 fold change from RNA-seq vs 
qPCR. Grey dashed lines indicate 2-fold up- and down-regulation, black dashed 
line is the identity line (1:1 relationship), and the solid line is the linear regression. 
Strong agreement was found with a Pearson correlation of 0.80. 
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4.4 Discussion 
Differential gene expression was determined in cortical and cancellous bone 
of control and loaded limbs following a single bout of axial tibial compression in 
10-week-old female mice lacking estrogen receptor alpha in mature osteoblasts 
(pOC-ERaKO) compared to their littermate controls (LC). More genes were 
differentially expressed in cortical bone of LC animals following a single session of 
mechanical loading than in cortical bone of pOC-ERaKO animals, particularly 
three hours following a single loading session. However, in cancellous bone, more 
genes were differentially expressed in pOC-ERaKO animals, particularly twenty-
four hours following a single loading session. More Wnt signaling pathway genes 
were differentially expressed in LC animals, while Wnt signaling pathway genes 
were generally more upregulated in pOC-ERaKO animals. We also compared 
expression in cortical versus cancellous bone of naïve (not externally loaded) 
littermate control animals and the control limbs of LC and pOC-ERaKO animals. 
We determined a set of genes that were more highly expressed in cortical bone, 
demonstrating that cortical versus cancellous bone are transcriptionally distinct. 
Additionally, genes that were shared in the contralateral limbs of LC and pOC-
ERaKO animals but were not differentially expressed in cortical versus cancellous 
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bone of naïve LC animals may represent genes that are systemically altered by 
loading.  
The molecular mechanisms of the skeletal response to mechanical loading 
have largely been studied in cortical or whole bone. In agreement with another 
study examining gene expression in response to tibial compression, we saw 6 to 24 
times fewer genes differentially regulated in cortical bone of ERa KO animals 
compared to littermate controls [33]. Cancellous bone response has not previously 
been examined at the transcriptional level in mice lacking ERa. 
Our laboratory showed previously that female mice lacking ERa in mature 
osteoblasts have decreased bone mass and strength but respond more to 
mechanical loading, particularly in cancellous bone [11, 18]. The current data show 
that pOC-ERaKO mice had 2 to 18 times the number of differentially expressed 
genes in cancellous bone following mechanical loading when compared to LC 
mice. Three hours following a single loading session pOC-ERaKO cancellous 
bone had larger differential expression of sixteen shared genes compared to LC. 
Wnt7b, an important regulator of osteoblast differentiation [34], was upregulated 
8.4-fold three hours following loading in pOC-ERaKO but not significantly 
different in LC mice. Notum, which suppresses Wnt signaling by deacylating Wnt 
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proteins [35],  was upregulated 3 hours following loading in cortical and cancellous 
bone and 24 hours after loading in cancellous bone of pOC-ERaKO animals. 
Twenty-four hours following a single loading session the number of differentially 
expressed genes in cancellous bone was markedly decreased in pOC-ERaKO and 
several genes were very highly upregulated. 
Genes that were highly upregulated in both cortical and cancellous bone of 
pOC-ERaKO, but not littermate control mice, included R-spondin 4 (Rspo4), 
opioid receptor delta 1 (Oprd1), and serine (or cysteine) peptidase inhibitor, clade A, 
member 1A (Serpina1a). The degree of upregulation ranged from 20- to 550-fold in 
cortical and cancellous bone 24 hours following mechanical loading. R-spondins 
interact with and enhance Wnt signaling, and R-spondin 1 (Rspo1) promoted 
vibration-induced bone formation in physiologically aged and telomere 
dysfunction-based mouse models of osteoporosis [36-39]. The drastic upregulation 
of Rspo4 in mice lacking estrogen receptor alpha may reflect an important 
compensatory mechanism for altered Wnt signaling and deserves further study. 
Oprd1 has been examined mostly in the context of the nervous system, but nerve 
growth factor (Ngf) induced expression of Oprd1 through PI3K/Akt signaling [40]. 
PI3K/Akt signaling is an important pathway in bone mechanotransduction [41]. 
Ngf was also upregulated with mechanical loading in our studies. Ngf may play a 
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role in the skeleton to stimulate osteoblast differentiation [42] and increase bone 
formation and quality during fracture repair [43, 44]. Neurotrophic factors such as 
Ngf and Oprd1 may play an important role in bone adaptation and should be further 
investigated. Finally, the Serpina1a gene encodes a protein called alpha-1 antitrypsin, 
which is a type of serine protease inhibitor (serpin) with anti-inflammatory 
properties [45]. Alpha-1 antitrypsin gene therapy was recently shown to ameliorate 
bone loss due to ovariectomy, possibly through inhibition of the pro-inflammatory 
cytokine IL-6 and RANK gene expression [46]. IL-6 was upregulated nearly 10-fold 
in cortical bone of pOC-ERaKO mice three hours after loading, and Ptgs2 (Cox2) 
was upregulated in several groups and time points, highlighting the need to 
understand the role of inflammatory cytokines in bone and the response to loading. 
Crosstalk between estrogen and canonical Wnt signaling has been reported 
but the exact mechanisms are not fully understood [19]. The hallmark of activated 
canonical Wnt signaling is b-catenin stabilization and translocation to the nucleus 
to enhance osteogenic gene transcription. The mechanisms of estrogen/Wnt 
crosstalk are not clear, but ERa and b-catenin physically interact [47]. Although we 
did not see changes in b-catenin gene transcription, we saw differential expression 
of 33 Wnt signaling pathway genes. More Wnt signaling pathway genes were 
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differentially expressed in LC mice (25/33 LC, 13/33 pOC-ERaKO), but effectors 
such as Wnt1, Wnt7b, and Wisp2 were differentially expressed even in pOC-
ERaKO mice. Furthermore, Rspo4 was highly upregulated in pOC-ERaKO mice. 
Distinguishing the exact effects of lack of ERa on Wnt signaling is difficult, but 
our data do not suggest that Wnt signaling was absent or deficient in pOC-
ERaKO mice. To examine differences in downstream Wnt signaling in the context 
of decreased estrogen signaling, we performed western blot for b-catenin 24 hours 
following loading in LC and pOC-ERaKO mice (data not shown). Total b-catenin 
protein levels were not different with loading or by genotype.   
Transcriptional differences in control cortical versus cancellous bone have 
been demonstrated previously and imply different regulatory mechanisms 
governing the two tissue types [25]. Wnt16 was found to be more highly expressed 
in cortical bone in naïve LC and contralateral control LC and pOC-ERaKO 
animals. Accumulating evidence shows that Wnt16 is an important regulator of 
cortical bone [48-50], and recent studies have demonstrated that overexpression of 
Wnt16 increases both cortical and cancellous bone mass [51, 52]. Osteocrin (Ostn) 
was also more highly expressed in control cortical bone from all groups and is a 
soluble osteoblast regulator that is localized to osteoblasts and young osteocytes 
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[53]. Overexpression of Ostn in transgenic mice caused elongated bones and a 
marked kyphosis associated with elevated bone cGMP levels [54].  
At the tissue level, evidence is conflicting regarding the systemic effects of 
loading, while the systemic effects on gene expression have not been examined. 
Tibial loading of mice was controlled locally and confined to the loaded bones [55]. 
Conversely, rat ulnar loading induced bone formation in distant skeletal sites that 
were not loaded [56, 57]. Our data indicate that loading may have systemic effects 
on transcription. Differential gene expression occurred in cortical versus cancellous 
bone in the contralateral limbs of LC and pOC-ERaKO limbs but not in naïve 
limbs. This finding implies that systemic gene expression changes should be taken 
into account when comparing loaded limb response to the contralateral control at 
the transcriptional level.  
Strengths of the current study include the unbiased examination of gene 
expression in cortical and cancellous bone separately in a biologically relevant 
bone-specific knockout mouse model. We were limited, however, to the 
examination of skeletally immature female mice at two time points following a 
single loading session. Our examination of female mice at 10 weeks of age was 
based on our previous data indicating differences in the response to mechanical 
loading in cancellous versus cortical bone of ERa KO female, but not male, mice 
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[18]. We are currently examining the tissue-level loading response in adult female 
and male mice lacking ERa in mature osteoblasts, and a future study to determine 
the differential gene expression in adult mice would complement this study. 
Examination of other time points following a single loading session, particularly 
immediate (30 minutes to 1 hour) and long-term (3 days to 1 week) time points 
would further characterize the time course of signaling events.  
 
4.4.1 Conclusions 
We used RNA-seq to demonstrate differences in cortical and cancellous 
bone transcription separately at two time points following a single loading session 
in mice lacking ERa in mature osteoblasts and their littermate controls. pOC-
ERaKO mice had markedly decreased gene expression in response to mechanical 
loading in cortical bone compared to littermate controls. In cancellous bone, 
however, pOC-ERaKO mice had increased gene expression corroborating the 
enhanced load-induced bone formation seen previously at the tissue level. R-
spondin 4 was highly upregulated in cortical and cancellous bone of pOC-ERaKO 
mice following loading, indicating this pathway may be an important compensatory 
mechanism when estrogen signaling is reduced. 
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CHAPTER 5 
CONCLUSIONS AND DISCUSSION 
 
5.1 Summary 
 
 The objective of this research was to elucidate the molecular mechanisms of 
bone adaptation to mechanical loading in cortical versus cancellous bone in the 
context of estrogen signaling. Mechanical loading is a potential anabolic therapy for 
bone loss due to postmenopausal osteoporosis. Following menopause, bone mass and 
circulating estrogen decrease. Estrogen also plays a role in mechanotransduction in 
bone. An increased understanding of estrogen signaling in the skeletal response to 
mechanical loading is critical in developing potential new therapies to combat 
postmenopausal bone loss. However, molecular mechanisms of mechanotransduction 
have been studied exclusively in cortical or whole bone with a candidate gene 
approach. Cortical and cancellous bone respond differently to mechanical loading at 
the tissue level, underscoring the importance of examining cellular responses in these 
two tissues separately. Whole transcriptome sequencing allows for the unbiased 
examination of the genes affected by mechanical loading. After developing a method 
to isolate high quality RNA from marrow-free mouse cortical and cancellous bone, 
differences in gene transcription were determined at baseline and following 
mechanical loading of wild-type mice, and osteoblast-specific ERa knockout (pOC-
ERaKO) compared to littermate control mice. Cortical and cancellous bone exhibited 
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different transcriptional profiles at baseline and in response to mechanical loading. 
The transcriptional profile in contralateral, unloaded limbs differed at both time 
points, indicating mechanical loading may have systemic effects at the gene level. 
pOC-ERaKO mice had a blunted response to mechanical loading in cortical bone 
compared to littermate controls, but had an increased response in cancellous bone.  
 
Aim 1 
 Our first aim was to develop a method to measure gene expression in marrow-
free cortical and cancellous bone. The high incidence of fragility fractures in cortico-
cancellous sites, plus the fact that individual skeletal sites exhibit different 
responsiveness to load and disease, reveals the need to document gene expression in 
cortical versus cancellous bone. The cellular and molecular mechanisms driving load-
induced bone anabolism have been examined using quantitative real-time polymerase 
chain reaction (qPCR) and microarray [1-4]. These studies have examined tissues from 
whole bones, homogenizing cortical and cancellous bone. Marrow cells were left in 
place [3], or removed by flushing [2] or centrifugation [1, 4]. However, failure to 
remove the highly cellular marrow component may result in contamination of RNA 
isolated from bone. Prior to the work presented here the relative efficacy of flushing 
to centrifugation had not been studied, nor had the effect of bone marrow 
contamination on apparent bone specific gene expression. More importantly, gene 
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expression had not been reported in minimally contaminated cortical versus 
cancellous bone, a challenging endeavor in murine models.  
This work describes a method to isolate high quality RNA from cortical and, 
separately, cancellous bone with minimal contamination from marrow cells. 
Centrifugation removed contaminating cells more efficiently that flushing, as indexed 
by histology, and decreased detection of a highly expressed erythroid gene. 
Furthermore, centrifuged cortical and cancellous bone had higher apparent relative 
expression of bone-related genes when compared to bone for which marrow was left 
intact. Lastly, cortical bone had higher expression of bone-related genes than 
cancellous bone. RNA isolated by this novel approach can reveal site-specific changes 
in gene expression in cortical and cancellous bone sites.  
 
Aim 2 
 Our second aim was to determine the transcriptional response to mechanical 
loading in cortical and cancellous bone separately. Mechanical loading is an anabolic 
stimulus that increases bone mass, and thus a promising method to counteract 
osteoporosis-related bone loss. The mechanism of this anabolism remains unclear, 
and needs to be established for both cortical and cancellous envelopes individually. 
Transcriptional profiling with RNA sequencing provides an opportunity to determine 
gene expression in cortical and cancellous tissues separately and to examine the 
molecular mechanisms responsible for mechanical loading-related anabolism. We 
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hypothesized that basal gene expression and the transcriptional response to 
mechanical loading would differ in cortical versus cancellous bone. To test this 
hypothesis, we applied compressive loading to the mouse tibia and performed RNA-
seq in cortical versus cancellous bone at two time points.  
Cortical and cancellous bone exhibited different transcriptional profiles basally 
and in response to mechanical loading. At baseline, more genes were expressed 
differentially 24 hours after a single loading session in control bone, implying that the 
response to mechanical loading is, at least partly, systemic. Enhanced Wnt signaling 
dominated the response to mechanical loading in cortical bone at 3 and 24 hours, but 
in cancellous bone only at 3 hours. In cancellous bone at 24 hours many muscle-
related genes were downregulated. These findings reveal key differences between 
cortical and cancellous genetic regulation in response to mechanical loading.  
 
Aim 3 
 Our third aim was to elucidate differences in the transcriptional response to 
mechanical loading in cortical versus cancellous bone with deficient estrogen 
signaling. Postmenopausal osteoporosis is characterized by reduced bone mass and 
estrogen signaling. Mechanical loading is an anabolic stimulus that increases bone 
mass. We recently showed that mice lacking ERa in osteoblasts and osteocytes (pOC-
ERaKO) had an increased adaptive response to mechanical loading, particularly in 
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cancellous bone [5]. The molecular mechanisms of functional adaptation to load in 
the context of decreased estrogen signaling are not fully elucidated, particularly in 
cortical versus cancellous sites. We examined transcription in cortical versus 
cancellous bone of tibiae from littermate control (LC) and pOC-ERaKO mice. 
Female mice were subjected to one session of mechanical loading with the 
contralateral tibia as control or euthanized without application of external loads 
(naïve). We performed RNA-seq on cortical versus cancellous bone to determine 
differential gene expression at two time points following a single loading session and 
at baseline (naïve animals and control limbs).  
Cortical bone responded more to a single session of mechanical loading in LC 
than pOC-ERaKO animals, particularly 3 hours following a single loading session. In 
cancellous bone, however, the transcriptional response to mechanical loading was 
greater in pOC-ERaKO than LC animals, particularly 24 hours following a single 
loading session. The increased gene expression in cancellous bone of pOC-ERaKO 
agrees with our previous tissue-level data showing enhanced response to loading.  
Wnt signaling is an important pathway for mechanotransduction and may 
require ERa. More Wnt signaling pathway genes were differentially expressed in LC 
mice, but effectors such as Wnt1, Wnt7b, and Wisp2 were differentially expressed 
even in pOC-ERaKO mice. Furthermore, Rspo4 was highly upregulated in pOC-
ERaKO mice. The exact effects of lack of ERa on Wnt signaling are difficult to 
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distinguish, but our data do not suggest that Wnt signaling was absent or deficient in 
pOC-ERaKO mice.  
A set of genes was more highly expressed in cortical bone, demonstrating that 
cortical and cancellous bone are transcriptionally distinct. Additionally, loading may 
cause systemic alterations in transcription. RNA-seq analysis of the in vivo mechanical 
loading response in cortical versus cancellous bone provides transcriptome level data 
to identify estrogen’s role in mechanotransduction and new targets for the treatment 
of osteoporosis. 
 Comparing across the wild-type/littermate control animals that were 
mechanically loaded in Aim 2 versus Aim 3, demonstrates some similarities and some 
differences in our results. Wnt signaling genes that were consistently affected by 
loading included Wnt1, Wnt7b, and Wnt10b. Other genes differentially expressed with 
loading in both experiments included Ptgs2, Tnfrsf11b, and Timp1. One major 
difference was the number of genes differentially expressed in cortical bone 3 hours 
following a single session of mechanical loading. In Aim 2, 43 genes were 
differentially expressed, while in Aim 3 772 genes were differentially expressed. 
Furthermore, more genes were differentially expressed 24 hours following a single 
loading session than at 3 hours in Aim 2, but not in Aim 3. Finally, we demonstrated a 
significant downregulation of muscle-related genes at 24 hours in cancellous bone in 
our second aim, but this response was not recapitulated in our third aim. The causes 
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for discrepancies in our data is not clear. Experimental differences included improved 
RNA isolation techniques that resulted in higher RNA quality in our third aim, 
particularly in cortical bone, and technical differences including different sequencing 
platforms, read lengths, sequencing depths, and read alignment metrics.  
 
5.2 Strengths 
 We are the first to establish a method for isolating high-quality RNA from 
mouse cortical and cancellous bone with minimal marrow contamination. Our 
technique was applied to examine transcriptomic differences in response to 
mechanical loading in cortical versus cancellous bone. Previous work has examined 
cancellous bone from mechanically loaded murine vertebrae, but expression was 
separately determined in cortical bone [6]. Furthermore, marrow was sequentially 
digested, a technique that has been shown to alter the expression of bone-related 
genes [7]. We determined that centrifugation efficiently removed marrow and 
increased the detection of bone-related genes.  
The tibial compression model used in this work is consistently osteogenic in 
both cortical and cancellous bone. Other loading models either cannot examine 
cancellous bone in the case of ulnar compression [8] or use a different waveform that 
decreases cancellous bone volume in the tibial metaphysis [9]. We have shown 
increased cortical and cancellous bone mass with our loading model in growing and 
adult male and female mice, and following gonadectomy or genetic modification [5, 
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10-13]. Anabolism in both cortical and cancellous bone allows for the separate 
quantification of the cellular mechanisms responsible for bone adaptation in these two 
tissues types. Cancellous bone tissue, however, is limited in the murine tibial 
metaphysis. Thus, gene expression measurement is challenging with standard 
techniques.    
RNA sequencing is an emerging technique that reveals the presence and 
quantity of the RNA transcriptome in small biological samples. The alternative 
methods to determine differential gene expression include quantitative polymerase 
chain reaction (qPCR) and microarray. qPCR is highly quantitative and sensitive but 
generally best for interrogating a relatively small number of transcripts in a large set of 
samples. Microarrays and RNA-seq offer genome-wide surveys of the transcriptome, 
but microarrays can only detect sequences homologous to known probes on the array. 
In contrast, RNA-seq is “unbiased,” and thus ideal for discovery. RNA-seq provides 
transcriptome level data from a very small quantity of input material, an important 
strength when examining the very small volumes of tissue in cancellous regions of 
mouse bone.  
The pOC-ERaKO mouse model, in which ERa is removed from mature 
osteoblasts and osteocytes, is another strength of this work. Global ERa knockout 
causes systemic changes which confound the determination of specific skeletal effects 
[14]. We had previously shown that female pOC-ERaKO mice had decreased bone 
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mass and strength, but responded more to mechanical loading than their littermate 
controls, particularly in cancellous bone [5, 15]. A logical next step was to determine 
the differential regulation occurring in cortical versus cancellous bone of pOC-
ERaKO mice following mechanical loading.  
 
5.3 Limitations 
 The central dogma of molecular biology is a framework to understand the 
transfer of genetic information within a biological system. It defines the dominant 
flow of biological information as replication (DNA can be copied to DNA), 
transcription (DNA information can be copied into mRNA), and translation (proteins 
are synthesized using the information in mRNA as a template) [16]. Our studies are 
limited to examining transcription, without determining the effect on translation.  
 At a more granular level, our studies were limited to examining a single age and 
gender of animal, at two time points following a single loading session. We chose to 
focus on adolescent (10 week old) females because we had previously shown a robust 
response to mechanical loading in cortical and cancellous bone of these animals, as 
well as an interesting differential response in female estrogen receptor alpha knockout 
mice [5, 12, 13]. It is important to determine the transcriptional response in older 
mice, however, as osteoporosis affects aged individuals and the skeleton becomes less 
responsive to mechanical loading with age [12]. Furthermore, NIH is developing 
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policies to balance the use of male and female animals in preclinical studies, so our 
examination of only females is an important limitation that should be addressed in the 
future [17]. Examination of the response at two time points following a single loading 
session was an important first step, but could be substantially expanded to include 
multiple time points and more loading sessions. Our early time point, three hours 
following a single loading session, may not capture transcription factor changes that 
occur within minutes of the stimulus. Additionally, later time points may provide 
important information on matrix production, which occurs three days to several 
weeks following mechanical loading in bone [18, 19].   
 The magnitude of controlled loads applied during in vivo tibial loading were 
determined based on strain measurements at the cortical diaphysis, but the 
corresponding tissue-level strains in the metaphysis are difficult to characterize, 
particularly in cancellous bone. A physiologic strain of +1200 microstrain (µe) at the 
mid-diaphysis has typically been used to study bone adaptation [12, 13, 20]. Bone 
stiffness was previously found to be similar between female pOC-ERaKO and LC 
mice, requiring a peak load of -9.0N to engender +1200 µe [5]. Therefore, peak loads 
of -9.0N were applied in the current studies. However, tissue measurements 
demonstrated that female pOC-ERaKO mice had decreased bone volume fraction at 
the tibial metaphysis compared to LC yet responded more to mechanical loading [5]. 
It is difficult to determine if the increased response in pOC-ERaKO mice is due to 
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differences in genotype, and thus intrinsic signaling factors, or differences in extrinsic 
cancellous bone strain application.  
An additional limitation is that we do not know the exact cellular makeup of 
our bone samples. Cortical versus cancellous samples could contain different 
proportions of osteoblasts and osteocytes. This limitation would only affect our 
examination of baseline cortical versus cancellous transcription differences. For 
loading-related changes we are comparing within tissue types, so cellular proportions 
should be similar. Embedded osteocytes are the most likely source of RNA in our 
samples. Osteocytes account for more than 90% of bone cells, and non-adherent 
osteoblasts and osteoclasts are likely removed with centrifugation. We counted 
osteoblasts and osteocytes per bone surface and area in cortical versus cancellous 
histological samples and did not find a difference in the proportions. This result is 
reassuring but does not rule out the possibility of differences in cellular makeup.     
 
5.4 Future Work 
The function and relative contributions of genes and pathways that were 
differentially expressed following mechanical loading in this work could be further 
elucidated. The methodology developed in this thesis can be easily extended to 
examine different ages, time points, and number of mechanical loading sessions. More 
importantly, the transcriptional differences need to be verified at the protein level, 
localized to different cells and ideally related to the strain field to more accurately 
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determine spatial and cell-specific responses to mechanical loading. Future studies 
could also examine changes in bone mass and transcription following targeted 
disruption of important mechanotransduction pathways such as Wnt signaling. 
 
Follow up studies of genes discovered  
 The goal of any large scale sequencing study is to discover genes of interest as 
potential targets of future studies. A few of the genes to emerge from the current 
work are Timp1, Ptgs2, Rspo4, Oprd1 and Serpin1a1. Tissue inhibitor of 
metalloproteinase (Timp1) and prostaglandin-endoperoxide synthase 2 (Ptgs2) were 
upregulated after loading in cortical and cancellous bone at several time points and 
across genotypes. Timp1 inhibits metalloproteinases, and thus degradation of 
extracellular matrix, and was previously found to be upregulated in homogenized tibial 
bone subjected to mechanical loading [4, 21]. Furthermore, Timp1 has been shown to 
be regulated by Wnt signaling [22]. Ptgs2, also known as Cox-2, produces 
prostaglandin, which is necessary for mechanical-loading induced b-catenin activation 
[23]. Another study demonstrated that Cox-2 activity is more important for 
endocortical bone adaptive response to mechanical loading than the periosteal 
response [24]. The molecular mechanisms responsible for such site-specific 
differences could be examined using our methodology.  
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 Several genes were found to be highly upregulated in both cortical and 
cancellous bone of pOC-ERaKO, but not littermate control mice. R-spondin 4 
(Rspo4), opioid receptor delta 1 (Oprd1), and serine (or cysteine) peptidase inhibitor, 
clade A, member 1A (Serpina1a) were upregulated 20- to 550-fold in cortical and 
cancellous bone 24 hours following mechanical loading. R-spondins have been shown 
to interact with and enhance Wnt signaling, and R-spondin 1 (Rspo1) promoted 
vibration-induced bone formation in physiologically aged and telomere-dysfunction 
based mouse models of osteoporosis [25-28]. The drastic upregulation of Rspo4 in 
mice lacking estrogen receptor alpha may reflect an important compensatory 
mechanism for altered Wnt signaling and deserves further study. Oprd1 has been 
examined mostly in the context of the nervous system, but nerve growth factor (Ngf) 
induced expression of Oprd1 through PI3K/Akt signaling [29]. PI3K/Akt signaling is 
an important pathway in bone mechanotransduction [30]. Ngf also was upregulated 
with mechanical loading in our studies. Ngf may play a role in the skeleton, as it can 
stimulate differentiation of an osteoblastic cell line [31] and can increase bone 
formation and quality of fracture repair [32, 33]. Neurotrophic factors such as Ngf and 
Oprd1 may play an important role in bone adaptation and could be further 
investigated.  Finally, the Serpina1a gene encodes a protein called alpha-1 antitrypsin, 
which is a type of serine protease inhibitor (serpin) with anti-inflammatory properties 
[34]. Alpha-1 antitrypsin gene therapy was recently shown to ameliorate bone loss due 
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to ovariectomy, possibly through inhibition of the proinflammatory cytokine IL-6 and 
RANK gene expression [35]. IL-6 was upregulated nearly 10-fold in cortical bone of 
pOC-ERaKO mice three hours after loading, highlighting the need to understand the 
role of inflammatory cytokines in bone loss and the response to loading. 
 Based on the results from Chapter 3, the role of muscle-related genes in bone 
mechanotransduction may be another area of interest. Muscle genes were the largest 
group of downregulated genes 24 hours following a single loading session in 
cancellous bone of wild-type mice. A single loading session of the rat forearm (cortical 
site) also caused downregulation of muscle genes [36] and calvarial-derived osteocytes 
[37] and young healthy articular cartilage [38] express genes related to muscle 
function, development, and differentiation. Elucidation of the function of muscle-
related genes in bone cells and the response to mechanical loading requires further 
study.  
 
Effects of age, gender, time point, and number of loading sessions 
 Differential gene expression can be determined using these methods for adult 
and aged mice, males, earlier and later time points and after multiple loading sessions. 
We have previously shown that adult (26-week-old) female mice are not as responsive 
to mechanical loading as young (10-week-old) mice [12]. A study comparing the 
transcriptomes of young, adult and aged mice subjected to mechanical loading could 
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determine the molecular mechanisms behind the reduced response with age. This data 
would have important clinical implications, as bone’s anabolic response to exercise 
declines with age [39] and osteoporosis mostly affects the elderly. As previously 
mentioned, there is a drive in the scientific community to perform preclinical studies 
in male and female animals, so our studies should also be performed on males. Finally, 
early and later time points following a single loading session as well as examining the 
response after multiple loading sessions would extend our knowledge of the time 
course of signaling events and effects of differing stimuli.  
 
Identification of translational changes 
 An important and logical next step would be to verify that the transcriptional 
changes we identified also result in differences in protein translation. The 
experimental design of these studies is complicated, as the selection of time point and 
proteins to verify is critical. We examined transcription three and twenty-four hours 
following mechanical loading, but translation may occur minutes to hours following 
transcription, depending on the gene size and post-transcriptional modifications. 
Furthermore, protein quantification methods including western blot and 
immunohistochemistry (IHC) can be functionally performed on only a small number 
of proteins. Protein isolation from bone is another challenge due to the relatively 
small amount of tissue and cells compared to matrix. It may be possible to use 
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proteomics to examine the entire set of proteins produced following mechanical 
loading [40].  
   
Spatial and cell-specific responses 
 We isolated RNA from the metaphyseal cortical shell and cancellous core of 
the mouse tibia, without quantification of the cellular population. Future studies could 
examine transcription at the tibial mid-diaphysis, where strains are typically measured. 
This is purely cortical, but transcriptional changes could be more directly linked to 
differing strain levels. Furthermore, the curvature of the mouse tibia results in regions 
of compression and tension on the cortical surface [41]. A recent study identified 
differences in teriparatide treatment on the compressive and tensile regions of the 
femoral neck in humans [42]. The transcriptional changes responsible for this 
differential effect could be determined for compressive and tensile regions of mouse 
cortical bone treated with teriparatide. Cell-specific responses could be determined by 
performing fluorescence-activated cell sorting (FACS) on bone samples from animals 
with GFP-labeled osteocytes [43], allowing for the specific determination of 
osteocyte-driven transcription in response to mechanical loading. Another approach 
to examine cell-specific transcription would be laser capture microdissection (LMD). 
This technique allows the study of individual cells or regions of cells [44]. RNA-seq 
can be performed on even a single cell, allowing for the quantification of the 
transcriptome at a very specific location [45]. Thus, performing RNA-seq on specific 
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regions of bone after LMD would provide a wealth of data on strain-dependent and 
even cell-specific transcription.   
 
Targeted disruption of the Wnt pathway 
 The current studies and many others have highlighted the importance of the 
Wnt signaling pathway in bone mechanotransduction. Recent genome-wide 
association studies have identified two SNPs that are strongly associated with 
decreased bone mass located within an intron of the human GPR177 gene [46, 47]. 
Wntless (Wls, also known as Gpr177) is required for normal secretion of Wnt ligands 
from cells and is highly specific [48, 49]. A recent study generated osteoblast-specific 
Wntless deficient mice (OC-Cre;Wls-flox) and found significantly reduced bone-mass 
accrual as early as 20 days of age, spontaneous fractures, and premature lethality at 
around 2 months of age [50]. An inducible Cre would allow for normal bone 
development and subsequent examination of Wnt deficiency, circumventing the 
drastic bone effects and premature death. A tamoxifen-inducible Cre fusion protein 
under the control of the type I collagen promoter (Col1-CreERTM) exists [51] and 
when crossed with the Wls-floxed mouse would allow for the controlled disruption of 
Wnt signaling after bone mass accrual. Tissue-level response to two weeks of 
mechanical loading would determine if bone adaptation requires Wnt ligands, and 
RNA-seq studies would determine any transcriptional response to counteract the loss 
of Wnt. Alternatively, the Porcupine gene (PORCN) encodes a protein that is the only 
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enzyme known to be required for Wnt ligand palmitoylation, which is essential for 
Wnt secretion [52]. Pharmaceutical companies have initiated clinical trials of a 
Porcupine inhibitor in patients with melanoma and some types of breast cancer [53, 
54]. Treatment of mice with Porcupine inhibitor would be another way to ablate Wnt 
signaling and examine the effects on bone mechanotransduction at the tissue and 
transcription level. Furthermore, crosstalk with estrogen signaling could be examined 
by administration of Porcupine inhibitor to pOC-ERaKO mice.  
 
5.5 Conclusions 
We developed a method of whole transcriptome analysis of cortical versus 
cancellous bone, an important contribution to the field that can be applied to many 
outstanding research questions in orthopaedics. We elucidated differences in the 
transcriptional response to mechanical load in cortical and cancellous bone with and 
without ERa. Wnt signaling is an important early response to mechanical loading that 
may be altered by decreased estrogen signaling. We have performed an important first 
step towards understanding the cellular responses to mechanical loading that 
ultimately result in increased bone mass on the organismal level. Developing new 
drugs that harness the fundamental differences in mechanotransduction in cancellous 
and cortical bone could revolutionize the treatment of osteoporosis-related bone loss 
in these sites. 
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Table A.1 List of primers for genes verified with qPCR. 
Accession # Gene Symbol Gene Name DE by Loading 
DE in Ct vs 
Cn Forward primer Reverse Primer 
NM_021279 Wnt1 
wingless-type MMTV 
integration site family, 
member 1 
3h Ct,  
3h Cn, 24h 
Ct 
N.S. GATTTTGGTCGCCTCTTTGG 
CGTGGCATTTGC
ACTCTTG 
NM_011718 Wnt10b 
wingless-type MMTV 
integration site family, 
member 10b 
3h Ct,  
24h Ct Ct>Cn 
GATCCTGCACCTG
AACCG 
TTAGAGCCCGACT
GAACAAAG 
NM_009528 Wnt7b 
wingless-type MMTV 
integration site family, 
member 7b 
3h Ct,  
3h Cn Ct>Cn 
AATGAGGCGGGC
AGAAAG 
TGCGTTGTACTTC
TCCTTGAG 
NM_011198 Ptgs2 prostaglandin-endoperoxide synthase 2 
3h Ct,  
3h Cn, 24h 
Ct 
N.S. CTCACGAAGGAACTCAGCAC 
GGATTGGAACAG
CAAGGATTTG 
NM_008973 Ptn Pleiotrophin 24h Ct, 24h Cn N.S. 
AACTGTCACCATC
TCCAAGC 
TCTCCTGTTTCTT
GCCTTCC 
NM_024449 Sost Sclerostin 3h Cn,  3h Ct Ct>Cn 
GAGAGAGCGTTT
GTAACAGAAG 
GGCTTTCAGTCTT
TGTGGATG 
NM_008764 Tnfrsf11b 
tumor necrosis factor 
receptor superfamily 
member 11B 
3h Ct,  
3h Cn, 24h 
Ct 
N.S. GAGAGGATAAAACGGAGACACAG 
CTGCTTTCACAGA
GGTCAATG 
NM_011593 Timp1 Tissue inhibitor of metalloproteinase 1 
3h Ct,  
3h Cn, 24h 
Cn 
N.S. CTCAAAGACCTATAGTGCTGGC 
CAAAGTGACGGC
TCTGGTAG 
NM_053116 Wnt16 
wingless-type MMTV 
integration site family, 
member 16 
N.S. Ct>Cn CGAGAGGTGGAACTGTATGG 
TGAATGCTGTCTC
CTTGGTG 
NM_010340 Gpr50 G-protein-coupled receptor 50 N.S. Cn>Ct 
GGAACTCCATGG
TCATTTTGG 
CATACAGCATCAA
AGGGTAGGG 
NM_011824 Grem1 Gremlin 1 N.S. Cn>Ct GCTCTCCTTCGTCTTCCTC 
AGTGTATGCGGT
GCGATTC 
NM_198112 Ostn Osteocrin N.S. Ct>Cn GGACTGGAGATTGGCAAGTAC 
CTTCTCTGGCTGT
GGGTG 
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Gene accession numbers (column A), gene symbols (column B), gene names (column C), time points and 
tissue if gene was differentially expressed with loading (column D) or at baseline (column E), forward 
primer (column F) and reverse primer (column G). N.S.: not significant, Ct: cortical, Cn: cancellous. 
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Table A.2: A complete list of genes that were differentially expressed at 3 hours in cortical vs 
cancellous bone at baseline in order of decreasing fold change that were: I. more highly expressed in 
cancellous bone and II. More highly expressed in cortical bone. Number of genes (column A), gene 
symbols (column B), gene names (column C), fold change (column D), control cortical (Ct) fragments 
per kilobase per million reads (FPKM) (column E), control cancellous (Cn) FPKM (column F), false 
discovery rate (FDR) (column G). * indicates contamination as determined by Ayturk et al. 
 
Table A.2, part I. List of genes more highly expressed in control Cancellous bone at 3 hours 
 Gene Symbol Gene Fold Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
1 Gpr50 G-protein-coupled receptor 50 5.02 0.26 1.31 0.0001 
2 Dclk3 doublecortin-like kinase 3 4.69 0.10 0.54 0.0009 
3 Cyp2f2 cytochrome P450, family 2, subfamily f, polypeptide 2 3.80 0.53 3.03 0.0028 
4 Havcr1 hepatitis A virus cellular receptor 1 3.52 0.22 0.84 0.0199 
5 Cyp2b10 cytochrome P450, family 2, subfamily b, polypeptide 10 3.34 0.16 0.63 0.0306 
6 Nlrp6 NLR family, pyrin domain containing 6 3.33 0.19 0.71 0.0016 
7 Lypd6 LY6/PLAUR domain containing 6 3.03 0.19 0.68 0.0224 
8 Fmo2 flavin containing monooxygenase 2 2.99 4.99 16.21 4.2E-10 
9 Hhip Hedgehog-interacting protein 2.91 0.70 2.02 0.0182 
10 Gm1968 predicted gene 1968 2.83 0.85 2.65 0.0224 
11 Efemp1 EGL nine homolog 3 (C. elegans) 2.62 2.11 6.02 4.4E-05 
12 Tubb1 tubulin, beta 1 2.57 33.59 90.13 2.0E-12 
13 Serpina3c serine (or cysteine) peptidase inhibitor, clade A, member 3C 2.55 1.50 4.07 0.0017 
14 Ccdc150 coiled-coil domain containing 150 2.49 0.35 0.96 0.0126 
15 Grem1 gremlin 1 2.49 4.26 12.18 0.0007 
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Table A.2, Part I. Continued 
 
 Gene Symbol Gene Fold Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
16 Cd226* CD226 antigen 2.37 5.78 14.41 2.3E-06 
17 Hal histidine ammonia lyase 2.37 0.32 0.80 0.0147 
18 Tesc tescalcin; similar to Tescalcin 2.34 5.38 13.32 0.0027 
19 Ppbp pro-platelet basic protein 2.34 484.60 1169.65 1.9E-08 
20 Ly6g6f lymphocyte antigen 6 complex, locus G6F 2.32 8.11 20.73 3.3E-05 
21 Gcsam germinal center associated, signaling and motility 2.31 3.72 8.91 1.7E-09 
22 Clec1b C-type lectin domain family 1, member b 2.29 25.18 60.24 5.1E-07 
23 F2rl2 coagulation factor II (thrombin) receptor-like 2 2.28 13.04 30.52 4.3E-11 
24 Gp6 glycoprotein 6 (platelet) 2.27 9.09 21.90 2.3E-07 
25 Adcyap1r1 adenylate cyclase activating polypeptide 1 receptor 1 2.27 0.26 0.70 0.0229 
26 Treml1 triggering receptor expressed on myeloid cells-like 1 2.26 24.78 58.56 1.7E-06 
27 Esm1 ets variant gene 4 (E1A enhancer binding protein, E1AF) 2.26 20.04 48.19 3.2E-06 
28 Pf4 platelet factor 4 2.26 265.90 632.00 5.8E-09 
29 Gp5 glycoprotein 5 (platelet) 2.25 18.45 44.06 1.5E-09 
30 Clec4b2 C-type lectin domain family 4, member b2 2.24 1.49 3.33 0.0478 
31 Slc24a5 solute carrier family 24, member 5 2.24 2.96 7.48 0.0010 
32 Serpinb2 serine (or cysteine) peptidase inhibitor, clade B, member 2 2.23 3.16 7.29 6.0E-05 
33 Itga2b integrin alpha 2b 2.22 32.63 76.59 5.5E-09 
34 Mmrn1 multimerin 1 2.20 9.31 21.20 1.7E-09 
35 AU023871 expressed sequence AU023871 2.20 10.24 23.55 3.3E-10 
36 Alox12 arachidonate 12-lipoxygenase 2.20 25.26 57.84 6.9E-09 
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Table A.2, Part I. Continued 
 
 Gene Symbol Gene Fold Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
37 Gpm6a glycoprotein m6a 2.20 4.67 10.06 1.9E-08 
38 Cd5l CD5 antigen-like 2.19 7.25 16.53 1.5E-06 
39 Slamf1 signaling lymphocytic activation molecule family member 1 2.19 3.94 9.03 8.7E-06 
40 Fcna ficolin A 2.19 33.63 79.88 1.4E-07 
41 Gp1ba 
glycoprotein 1b, alpha polypeptide; 
hypothetical protein LOC100048807 2.17 13.10 29.30 2.8E-09 
42 Kcnj5 potassium inwardly-rectifying channel, subfamily J, member 5 2.17 2.67 6.09 3.9E-07 
43 Vwf Von Willebrand factor homolog 2.16 8.79 20.07 1.9E-08 
44 Cass4 Cas scaffolding protein family member 4 2.16 1.83 4.21 1.9E-05 
45 Gp9* glycoprotein 9 (platelet) 2.16 32.87 74.68 9.0E-05 
46 Slc6a4 
solute carrier family 6 
(neurotransmitter transporter, 
serotonin), member 4 
2.15 8.94 20.05 1.5E-07 
47 Mpl myeloproliferative leukemia virus oncogene 2.15 8.13 18.09 3.8E-08 
48 Ttll11 tubulin tyrosine ligase-like family, member 11 2.15 1.39 3.07 0.0005 
49 Kcna2 
potassium voltage-gated channel, 
shaker-related subfamily, member 2 2.15 0.54 1.20 0.0003 
50 Ptger3 prostaglandin E receptor 3 (subtype EP3) 2.15 1.22 2.62 0.0098 
51 Tmem151b transmembrane protein 151B 2.14 0.41 0.87 0.0288 
52 Adipoq adiponectin, C1Q and collagen domain containing 2.13 67.20 152.58 5.9E-08 
53 Il1a interleukin 1 alpha 2.13 2.47 5.33 0.0038 
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Table A.2, Part I. Continued 
 
 Gene Symbol Gene Fold Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
54 2410076I21Rik RIKEN cDNA 2410076I21 gene 2.12 2.97 6.42 0.0106 
55 P2rx1 purinergic receptor P2X, ligand-gated ion channel, 1 2.12 8.49 18.78 1.8E-08 
56 Prkcq* protein kinase C, theta 2.11 4.95 10.73 2.1E-08 
57 Sele selectin, endothelial cell 2.11 3.23 6.90 1.5E-08 
58 C4b 
complement component 4B (Childo 
blood group) 2.10 9.10 20.03 1.3E-06 
59 Serpina3b serine (or cysteine) peptidase inhibitor, clade A, member 3B 2.09 1.98 4.40 0.0074 
60 Mrvi1 MRV integration site 1 2.08 7.64 16.49 6.4E-11 
61 Ubd ubiquitin D 2.07 4.64 9.77 0.0178 
62 Clca1 chloride channel calcium activated 1 2.06 6.52 13.55 1.2E-07 
63 BC147527 cDNA sequence BC147527 2.05 2.27 4.73 0.0049 
64 Plek pleckstrin 2.05 59.47 124.43 6.3E-08 
65 Sntb1 syntrophin, basic 1 2.04 1.72 3.82 0.0207 
66 Kng2 kininogen 2 2.04 10.49 22.07 1.2E-07 
67 Ubash3a ubiquitin associated and SH3 domain containing, A 2.00 2.36 4.84 6.2E-06 
68 Hpse heparanase 2.00 5.69 11.67 7.7E-07 
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Table A.2, Part II. List of genes more highly expressed in control Cortical bone at 3 hours 
 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
1 Ostn osteocrin 29.49 9.82 0.37 3.3E-16 
2 Myh4* myosin, heavy polypeptide 4, skeletal muscle 16.15 4.55 0.27 0.0120 
3 Itgbl1 integrin, beta-like 1 12.27 6.10 0.69 3.3E-05 
4 Wnt16 wingless-related MMTV integration site 16 11.76 2.55 0.27 0.0001 
5 Tnn tenascin N 7.78 30.23 5.39 1.1E-05 
6 Angptl7 angiopoietin-like 7 7.77 3.11 0.36 0.0098 
7 Col3a1 collagen, type III, alpha 1 7.11 355.74 65.55 6.3E-06 
8 Aspn asporin 7.08 56.72 9.28 1.4E-07 
9 Igfbp6 insulin-like growth factor binding protein 6 6.82 4.40 0.76 0.0002 
10 Wnt7b wingless-related MMTV integration site 7B 6.62 0.89 0.16 8.7E-06 
11 Col8a2 collagen, type VIII, alpha 2 6.50 5.00 1.06 0.0014 
12 Cilp2 cartilage intermediate layer protein 2 6.29 1.38 0.25 0.0023 
13 Krt75 keratin 75 6.10 0.28 0.04 0.0120 
14 Prrx2 paired related homeobox 2 5.84 3.09 0.65 0.0003 
15 Tbx4 T-box 4 5.82 0.57 0.10 0.0002 
16 Meox2 mesenchyme homeobox 2 5.81 0.98 0.16 0.0001 
17 Cdh6 cadherin 6 5.60 0.34 0.06 0.0087 
18 Dpysl4 dihydropyrimidinase-like 4 5.39 0.48 0.07 0.0010 
19 Lrrc15 leucine rich repeat containing 15 5.21 5.51 1.21 1.1E-07 
20 Olfr78 olfactory receptor 78 5.10 0.39 0.09 0.0029 
21 Lrrn1 leucine rich repeat protein 1, neuronal 4.94 0.68 0.15 0.0003 
22 Mfap4 microfibrillar-associated protein 4 4.47 1.23 0.33 0.0109 
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Table A.2, Part II. Continued 
 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
23 Spock1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 1 4.26 1.07 0.25 0.0082 
24 Foxp2 forkhead box P2 4.17 0.88 0.22 2.4E-05 
25 Rgs11 regulator of G-protein signaling 11 4.17 0.66 0.14 0.0440 
26 Nov nephroblastoma overexpressed gene 3.77 0.91 0.24 0.0102 
27 Slc6a17 solute carrier family 6 (neurotransmitter transporter), member 17 3.66 0.22 0.06 0.0150 
28 Sost sclerostin 3.65 351.06 101.32 1.3E-09 
29 Ptn pleiotrophin 3.65 8.73 2.93 0.0003 
30 1810041L15Rik 
RIKEN cDNA 1810041L15 gene 3.54 0.39 0.14 0.0197 
31 A330021E22Rik 
RIKEN cDNA A330021E22 gene 3.50 0.41 0.12 0.0237 
32 
Plekhg4 pleckstrin homology domain containing, 
family G (with RhoGef domain) member 4 3.26 2.42 0.73 1.2E-06 
33 Epha3 Eph receptor B3 3.23 3.93 1.21 5.9E-12 
34 Asic3 acid-sensing (proton-gated) ion channel 3 3.20 5.68 1.86 1.2E-06 
35 Chst8 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 3.18 0.61 0.20 0.0358 
36 Adamtsl5 ADAMTS-like 5 3.16 2.18 0.62 4.8E-05 
37 
Gcnt4 glucosaminyl (N-acetyl) transferase 4, core 2 
(beta-1,6-N-acetylglucosaminyltransferase) 3.15 0.61 0.20 0.0005 
38 Postn periostin, osteoblast specific factor 3.11 364.74 124.58 3.1E-08 
39 Col16a1 collagen, type XVI, alpha 1 2.92 38.12 13.22 1.0E-11 
40 Dpt dermatopontin 2.90 1.64 0.56 0.0159 
41 Galr2 galanin receptor 2 2.88 3.30 1.17 8.7E-06 
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Table A.2, Part II. Continued 
 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
42 
P4ha3 procollagen-proline, 2-oxoglutarate 4-
dioxygenase (proline 4-hydroxylase), alpha 
polypeptide III 
2.86 5.21 1.88 0.0001 
43 
Slc17a8 solute carrier family 17 (sodium-
dependent inorganic phosphate 
cotransporter), member 8 
2.82 0.27 0.10 0.0499 
44 Htra4 HtrA serine peptidase 4 2.82 2.75 1.05 0.0002 
45 Gm10635 predicted gene 10635 2.81 0.44 0.16 0.0235 
46 Akr1c18 aldo-keto reductase family 1, member C18 2.81 1.30 0.48 0.0452 
47 Piwil2 piwi-like homolog 2 (Drosophila) 2.81 0.53 0.18 0.0117 
48 Lrrc8e leucine rich repeat containing 8 family, member E 2.80 0.36 0.13 0.0237 
49 Car11 carbonic anhydrase 11 2.71 2.57 1.00 0.0326 
50 Fmod fibromodulin 2.68 92.51 48.37 0.0190 
51 Meox1 mesenchyme homeobox 1 2.63 2.26 0.86 0.0022 
52 Apln apelin 2.52 3.07 1.25 4.1E-06 
53 Ccdc3 coiled-coil domain containing 3 2.51 19.49 8.08 7.3E-09 
54 Mmp12 matrix metallopeptidase 12 2.51 0.44 0.19 0.0454 
55 
Kcnab1 potassium voltage-gated channel, shaker-
related subfamily, beta member 1 2.50 1.23 0.50 0.0051 
56 Tenm3 teneurin transmembrane protein 3 2.50 1.43 0.58 0.0227 
57 Adamtsl1 ADAMTS-like 1 2.50 0.70 0.28 0.0001 
58 Plat plasminogen activator, tissue 2.46 5.67 2.91 0.0026 
59 Prtg protogenin homolog (Gallus gallus) 2.45 0.47 0.18 0.0161 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
60 Grip2 glutamate receptor interacting protein 2 2.44 1.98 0.83 0.0309 
61 F3 coagulation factor III 2.43 4.96 2.09 0.0005 
62 Megf6 multiple EGF-like-domains 6 2.43 0.80 0.34 0.0013 
63 Tgfb2 transforming growth factor, beta 2 2.42 8.04 3.62 8.3E-06 
64 Adamtsl2 ADAMTS-like 2 2.39 6.69 3.25 0.0038 
65 Ebf4 enoyl Coenzyme A hydratase domain containing 2 2.36 1.40 0.58 0.0159 
66 Thbs2 thrombospondin 2 2.34 38.95 17.37 5.8E-08 
67 Aebp1 AE binding protein 1 2.33 26.29 11.63 9.9E-09 
68 Wnt10b wingless related MMTV integration site 10b 2.33 8.27 3.51 0.0030 
69 Col12a1 collagen, type XII, alpha 1 2.29 87.73 39.98 4.5E-05 
70 
C1qtnf5 C1q and tumor necrosis factor related 
protein 5; membrane-type frizzled-related 
protein 
2.28 19.35 8.66 8.5E-07 
71 Spock2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 2 2.28 2.51 1.13 0.0006 
72 Tnmd tenomodulin 2.26 2.40 1.11 0.0330 
73 Egr3 elastase 2, neutrophil 2.26 9.41 4.15 0.0005 
74 Fcrls Fc receptor-like S, scavenger receptor 2.26 6.12 2.89 0.0027 
75 Epcam Eph receptor A3 2.25 7.63 3.63 0.0002 
76 Glt8d2 glycosyltransferase 8 domain containing 2 2.24 2.08 0.90 0.0325 
77 Tppp3 tubulin polymerization-promoting protein family member 3 2.23 5.98 2.76 0.0076 
78 Fam69c RIKEN cDNA B230399E16 gene 2.23 1.58 0.69 0.0430 
79 Scn2b sodium channel, voltage-gated, type II, beta 2.23 0.52 0.22 0.0419 
80 Mustn1 musculoskeletal, embryonic nuclear protein 1 2.21 9.81 4.64 0.0074 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
81 Etv4 ets variant 4 2.20 1.38 0.61 0.0106 
82 Nmnat2 nicotinamide nucleotide adenylyltransferase 2 2.20 2.29 1.16 0.0181 
83 AU015836 expressed sequence AU015836 2.18 1.64 0.76 0.0230 
84 Arc activity regulated cytoskeletal-associated protein 2.18 2.48 1.20 0.0065 
85 Tg thyroglobulin 2.15 6.20 3.05 0.0001 
86 Shroom1 shroom family member 1 2.15 0.85 0.41 0.0335 
87 Cpeb1 cytoplasmic polyadenylation element binding protein 1 2.14 4.59 2.18 0.0252 
88 Asap3 ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 2.12 1.52 0.74 0.0076 
89 Cys1 cystin 1 2.12 2.88 1.39 0.0412 
90 Wfdc1* WAP four-disulfide core domain 1 2.11 5.95 2.97 0.0082 
91 Ccdc68 coiled-coil domain containing 68 2.11 5.10 2.52 0.0007 
92 Gpc3 glypican 3 2.10 1.73 0.86 0.0337 
93 Pcdhga12 protocadherin gamma subfamily A, 12 2.10 0.87 0.39 0.0468 
94 Lum lumican 2.09 748.03 381.13 0.0010 
95 Celf5 bruno-like 5, RNA binding protein (Drosophila) 2.09 1.27 0.62 0.0174 
96 Itm2a integral membrane protein 2A 2.08 36.55 18.11 0.0002 
97 Anxa8 annexin A8 2.08 31.39 17.50 0.0048 
98 Gabra3 gamma-aminobutyric acid (GABA) A receptor, subunit alpha 3 2.07 0.75 0.36 0.0288 
99 Lrrc17 leucine rich repeat containing 17 2.06 9.09 4.47 8.5E-07 
100 Prss23 protease, serine, 23 2.06 13.10 6.43 9.8E-07 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
101 
Edn1 epidermal growth factor-containing fibulin-
like extracellular matrix protein 1 2.04 1.25 0.63 0.0479 
102 Angptl2 angiopoietin-like 2 2.03 28.30 14.86 0.0005 
103 Echdc2 endothelin 1 2.02 6.53 3.32 0.0282 
104 
Tnfaip6 similar to TNF-stimulated gene 6 protein; 
tumor necrosis factor alpha induced protein 
6 
2.01 5.23 2.61 0.0019 
105 Dkk3 dickkopf homolog 3 (Xenopus laevis) 2.01 18.28 9.33 0.0001 
106 Sybu syntabulin (syntaxin-interacting) 2.01 4.98 2.59 0.0062 
107 Miat myocardial infarction associated transcript (non-protein coding) 2.00 1.07 0.56 0.0120 
108 Nbl1 neuroblastoma, suppression of tumorigenicity 1 2.00 85.84 46.25 0.0019 
109 Mepe matrix extracellular phosphoglycoprotein with ASARM motif (bone) 2.00 587.96 296.94 3.8E-09 
110 Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 2.00 12.70 7.11 0.0009 
 
 total 178    
 *indicates contaminant 5    
 total without contaminants 173    
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Table A.3: A complete list of genes that were differentially expressed at 24 hours in cortical vs 
cancellous bone at baseline in order of decreasing fold change that were: I. more highly expressed in 
cancellous bone and II. More highly expressed in cortical bone. Number of genes (column A), gene 
symbols (column B), gene names (column C), fold change (column D), control cortical (Ct) fragments 
per kilobase per million reads (FPKM) (column E), control cancellous (Cn) FPKM (column F), false 
discovery rate (FDR) (column G). * indicates contamination as determined by Ayturk et al. 
 
 
Table A.3, Part I. List of genes more highly expressed in control cancellous bone at 24 hours 
 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
1 Apoo-ps apolipoprotein O, pseudogene 42.97 1.53E-04 1.20 0.0020 
2 Epha8 Eph receptor A8 3.72 0.08 0.32 0.0230 
3 Gpr50 G-protein-coupled receptor 50 3.35 0.23 0.82 0.0467 
4 Cbln1 cerebellin 1 precursor protein; similar to 
precerebellin-1 
3.29 0.17 0.64 0.0459 
5 H2-L histocompatibility 2, D region; 
histocompatibility 2, D region locus 1 
3.29 4.79 15.61 6.2E-06 
6 Ltb4r2 leukotriene B4 receptor 2 3.02 0.35 1.03 0.0094 
7 Grem1 gremlin 1 2.74 3.66 10.29 4.2E-08 
8 Klrc1 killer cell lectin-like receptor subfamily C, 
member 1 
2.68 0.65 2.07 0.0370 
9 Abcc2 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 2 
2.55 0.11 0.32 0.0184 
10 Xylt1 xylosyltransferase 1 2.53 2.92 7.51 0.0334 
11 Akap5 A kinase (PRKA) anchor protein 5 2.48 0.49 1.22 0.0007 
12 Klk1 kallikrein 1 2.48 1.49 3.87 0.0181 
13 Htr2a 5-hydroxytryptamine (serotonin) receptor 
2A 
2.45 0.53 1.37 0.0009 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
14 Sele selectin, endothelial cell 2.40 2.55 6.46 0.0011 
15 Pkd1l3 polycystic kidney disease 1 like 3 2.37 0.81 1.96 0.0034 
16 Plin1 perilipin 2.36 1.24 2.76 0.0057 
17 Esm1 endothelial cell-specific molecule 1 2.33 21.71 51.71 3.5E-05 
18 Gpm6a glycoprotein m6a 2.32 4.08 9.72 0.0004 
19 Nlrp6 NLR family, pyrin domain containing 6 2.27 0.36 0.84 0.0174 
20 Lipg lipase, endothelial 2.26 1.69 3.85 2.7E-05 
21 Cd226* CD226 antigen 2.22 6.46 14.25 0.0020 
22 Gpr128 G protein-coupled receptor 128 2.22 0.41 0.95 0.0136 
23 Kcna2 potassium voltage-gated channel, shaker-
related subfamily, member 2 
2.21 0.49 1.14 0.0007 
24 Chl1 cell adhesion molecule with homology to 
L1CAM 
2.21 0.50 1.12 4.3E-05 
25 Pde3a phosphodiesterase 3A, cGMP inhibited 2.20 2.23 5.01 0.0006 
26 Kcnj5 potassium inwardly-rectifying channel, 
subfamily J, member 5 
2.19 2.81 6.22 0.0011 
27 Gm13139 predicted gene 13139 2.16 1.02 2.35 0.0010 
28 Gp6 glycoprotein 6 (platelet) 2.13 10.81 23.03 0.0013 
29 Mmrn1 multimerin 1 2.11 10.36 21.90 0.0004 
30 Tubb1 tubulin, beta 1 2.10 43.36 91.24 0.0016 
31 Kng1 kininogen 1 2.10 8.76 19.12 0.0002 
32 Ptch1 patched homolog 1 2.09 7.47 15.40 0.0439 
33 Plin4* plasma membrane associated protein, S3-12 2.09 1.23 2.99 0.0336 
34 Cass4 Cas scaffolding protein family member 4 2.07 2.27 4.77 0.0046 
35 Pls1 plastin 1 (I-isoform) 2.06 3.69 7.53 0.0026 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
36 C4b complement component 4B (Chido blood 
group) 
2.04 11.80 24.26 3.9E-07 
37 Ccr9 chemokine (C-C motif) receptor 9 2.04 0.63 1.41 0.0145 
38 Slc24a5 solute carrier family 24, member 5 2.02 3.33 6.83 0.0005 
39 Mpl myeloproliferative leukemia virus oncogene 2.00 9.51 18.97 0.0021 
36 C4b complement component 4B (Chido blood 
group) 
2.04 11.80 24.26 3.9E-07 
37 Ccr9 chemokine (C-C motif) receptor 9 2.04 0.63 1.41 0.0145 
38 Slc24a5 solute carrier family 24, member 5 2.02 3.33 6.83 0.0005 
39 Mpl myeloproliferative leukemia virus oncogene 2.00 9.51 18.97 0.0021 
 
 
 
Table A.3, Part II. List of genes more highly expressed in control Cortical bone at 24 hours 
 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
1 ChkbCpt1b Chkb-Cpt1b readthrough transcript (NMD candidate) 618.04 1.23 9.64E-05 7.0E-19 
2 Ccl21a chemokine (C-C motif) ligand 21A; predicted gene 1987 198.86 2.18 0.00 0.0002 
3 Myoc myocilin 134.79 5.56 0.05 2.5E-06 
4 Cilp cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 72.50 8.23 0.13 1.6E-09 
5 Mfap4 microfibrillar-associated protein 4 64.72 3.89 0.06 7.5E-09 
6 Itgbl1 integrin, beta-like 1 57.04 9.66 0.17 3.7E-09 
7 Igfbp6 insulin-like growth factor binding protein 6 56.47 16.46 0.25 2.9E-11 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
8 Ostn osteocrin 51.79 13.52 0.29 7.0E-19 
9 Wnt16 wingless-related MMTV integration site 16 42.82 3.18 0.09 8.4E-07 
10 Chodl chondrolectin 40.32 0.58 0.01 2.9E-05 
11 Mybpc1* myosin binding protein C, slow-type 37.16 8.85 0.30 3.9E-05 
12 Myh2* myosin, heavy polypeptide 2, skeletal muscle, adult 31.68 5.29 0.17 1.8E-14 
13 Mb* myoglobin 31.11 95.69 3.54 6.7E-05 
14 Angptl7 angiopoietin-like 7 29.70 10.19 0.28 7.4E-09 
15 Myh1* myosin, heavy polypeptide 1, skeletal muscle, adult 28.67 18.67 0.84 0.0066 
16 Meox2 mesenchyme homeobox 2 25.81 1.51 0.06 1.0E-11 
17 Thbs4 thrombospondin 4 22.40 24.21 1.02 1.0E-10 
18 Tnxb tenascin XB 19.83 0.95 0.04 1.5E-07 
19 Cilp2 cartilage intermediate layer protein 2 18.88 5.89 0.50 1.5E-05 
20 Smtnl1* smoothelin-like 1 17.26 1.83 0.11 0.0020 
21 Tpsb2 tryptase beta 2 17.05 1.01 0.05 2.0E-05 
22 Actn2* actinin alpha 2 14.86 3.52 0.24 6.2E-06 
23 Aspn asporin 14.62 62.09 4.03 1.7E-12 
24 Col8a2 collagen, type VIII, alpha 2 14.20 10.48 0.80 6.2E-06 
25 Slc17a8 
solute carrier family 17 (sodium-dependent 
inorganic phosphate cotransporter), 
member 8 
13.86 0.23 0.01 2.0E-05 
26 Mylk2* myosin, light polypeptide kinase 2, skeletal muscle 13.53 7.51 1.35 0.0090 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
27 Lrrn1 leucine rich repeat protein 1, neuronal 12.50 0.74 0.06 0.0001 
28 Ckmt2* creatine kinase, mitochondrial 2 11.84 8.25 1.22 0.0021 
29 Smpx* small muscle protein, X-linked 11.78 8.54 1.41 0.0054 
30 Tnn tenascin N 11.19 19.25 1.75 1.5E-40 
31 Tbx4 T-box 4 11.15 0.61 0.05 1.7E-08 
32 Lmod2* leiomodin 2 (cardiac) 11.08 2.01 0.16 3.3E-06 
33 Apobec2* apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2 10.59 14.37 1.93 0.0023 
34 Col3a1 collagen, type III, alpha 1 10.46 316.67 29.37 1.8E-13 
35 Pgm5 phosphoglucomutase 5 10.31 0.47 0.05 3.4E-08 
36 Prg4 proteoglycan 4 (megakaryocyte stimulating factor, articular superficial zone protein) 10.17 8.78 1.14 7.5E-05 
37 Ankrd1 ankyrin repeat domain 1 (cardiac muscle) 9.68 1.03 0.13 0.0001 
38 Asb15* ankyrin repeat and SOCS box-containing 15 9.66 0.35 0.03 0.0019 
39 Hhatl* hedgehog acyltransferase-like 9.49 1.35 0.23 0.0101 
40 Fitm1* fat storage-inducing transmembrane protein 1 9.38 5.39 0.76 0.0038 
41 Rgs11 regulator of G-protein signaling 11 9.32 1.14 0.10 3.6E-07 
42 Tigd4 tigger transposable element derived 4 9.04 0.80 0.08 0.0005 
43 Myl2* myosin, light polypeptide 2, regulatory, cardiac, slow 8.71 5.07 0.59 1.1E-06 
44 C1qtnf9 C1q and tumor necrosis factor related protein 9 8.61 1.38 0.15 1.3E-08 
45 Nov nephroblastoma overexpressed gene 8.57 2.05 0.26 6.0E-07 
46 Duoxa1 dual oxidase maturation factor 1 8.50 1.03 0.11 5.6E-06 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
47 Prrx2 paired related homeobox 2 7.94 6.12 0.84 7.2E-05 
48 Trim54* tripartite motif-containing 54 7.81 4.19 0.78 0.0500 
49 Eef1a2* eukaryotic translation elongation factor 1 alpha 2 7.73 8.44 1.94 0.0425 
50 Kcnc4* potassium voltage gated channel, Shaw-related subfamily, member 4 7.64 1.17 0.24 0.0309 
51 1810041L15Rik RIKEN cDNA 1810041L15 gene 7.52 0.70 0.09 0.0090 
52 Chst8 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 7.47 0.95 0.12 1.6E-07 
53 Nrap* nebulin-related anchoring protein 7.21 4.23 0.96 0.0019 
54 Sypl2* synaptophysin-like 2 7.20 2.03 0.62 0.0324 
55 Ano5* anoctamin 5 7.07 0.69 0.20 0.0301 
56 Sgcg* sarcoglycan, gamma (dystrophin-associated glycoprotein) 6.91 1.39 0.27 0.0129 
57 Csrp3 cysteine and glycine-rich protein 3 6.54 3.41 0.49 0.0007 
58 Myoz2* myozenin 2 6.50 2.88 0.40 0.0020 
59 Des* desmin 6.46 35.50 7.93 0.0042 
60 Rpl3l* ribosomal protein L3-like 6.40 8.78 1.56 0.0022 
61 Dhrs7c* dehydrogenase/reductase (SDR family) member 7C 6.22 3.79 0.98 0.0143 
62 Myoz3* myozenin 3 6.20 1.08 0.28 0.0312 
63 Cox8b* cytochrome c oxidase, subunit VIIIb 6.13 61.42 10.40 0.0079 
64 Snhg11 small nucleolar RNA host gene 11 (non-protein coding) 6.11 0.58 0.10 0.0001 
65 Ampd1* adenosine monophosphate deaminase 1 (isoform M) 6.11 4.97 2.17 0.0269 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
66 C1qtnf2 C1q and tumor necrosis factor related protein 2 6.10 2.07 0.31 5.7E-06 
67 Ugt1a6b UDP glucuronosyltransferase 1 family, polypeptide A6B 6.04 3.02 0.68 0.0236 
68 Murc* muscle-related coiled-coil protein 6.02 2.00 0.40 0.0106 
69 Kcna7* potassium voltage-gated channel, shaker-related subfamily, member 7 5.89 1.02 0.22 0.0083 
70 Cox7a1* cytochrome c oxidase, subunit VIIa 1 5.88 58.14 9.46 0.0002 
71 Ldb3* LIM domain binding 3 5.81 17.15 4.57 0.0269 
72 Adamts8 
a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin type 
1 motif, 8 
5.72 0.19 0.03 0.0155 
73 Cacna1s* calcium channel, voltage-dependent, L type, alpha 1S subunit 5.59 2.93 0.79 0.0108 
74 Neb* nebulin 5.52 3.33 1.02 0.0305 
75 Me3 malic enzyme 3, NADP(+)-dependent, mitochondrial 5.45 0.74 0.13 3.9E-06 
76 Xirp1* xin actin-binding repeat containing 1 5.42 0.41 0.08 0.0087 
77 Jsrp1* junctional sarcoplasmic reticulum protein 1 5.40 6.87 1.73 0.0411 
78 Htra4 HtrA serine peptidase 4 5.39 4.25 0.80 1.3E-10 
79 Dusp26 dual specificity phosphatase 26 (putative) 5.32 1.19 0.20 0.0077 
80 Scn4b* sodium channel, type IV, beta 5.32 2.04 0.46 0.0098 
81 Klhl41 kelch-like 41 5.30 5.70 1.41 0.0111 
82 Cacng1* calcium channel, voltage-dependent, gamma subunit 1 5.20 5.70 1.44 0.0163 
83 Sel1l3* RIKEN cDNA 2310045A20 gene 5.14 0.60 0.14 0.0118 
84 Lrrc15 leucine rich repeat containing 15 5.01 4.69 0.90 1.5E-13 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
85 Spock1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 1 4.99 0.61 0.12 0.0010 
86 Chrna10 cholinergic receptor, nicotinic, alpha polypeptide 10 4.84 0.70 0.15 0.0006 
87 Dpt dermatopontin 4.77 2.94 0.60 0.0001 
88 Clcn1* chloride channel 1 4.68 0.52 0.14 0.0411 
89 Mfap5 microfibrillar associated protein 5 4.64 0.99 0.21 0.0198 
90 Dpysl4 dihydropyrimidinase-like 4 4.61 0.51 0.10 0.0055 
91 Meg3 maternally expressed 3 4.58 3.70 0.78 3.5E-05 
92 2310002L09Rik* RIKEN cDNA 2310002L09 gene 4.53 1.82 0.51 0.0394 
93 Tnmd tenomodulin 4.52 3.45 0.74 1.4E-05 
94 H19* H19 fetal liver mRNA 4.50 9.36 3.07 0.0157 
95 Hspb8* heat shock protein 8 4.44 6.96 1.64 0.0007 
96 Trim72* tripartite motif-containing 72 4.38 2.18 0.50 0.0013 
97 Pgam2* phosphoglycerate mutase 2 4.35 39.56 13.10 0.0275 
98 Kcnj11 potassium inwardly rectifying channel, subfamily J, member 11 4.35 1.41 0.34 0.0064 
99 Hspb7* heat shock protein family, member 7 (cardiovascular) 4.34 5.63 1.27 9.1E-06 
100 Foxp2 forkhead box P2 4.33 0.70 0.17 3.6E-06 
101 Ttn* titin 4.32 1.56 0.56 0.0249 
102 Bnc2 basonuclin 2 4.28 0.21 0.05 0.0251 
103 Megf6 multiple EGF-like-domains 6 4.26 1.53 0.35 2.7E-06 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
104 3425401B19Rik* RIKEN cDNA 3425401B19 gene 4.18 1.42 0.43 0.0080 
105 Plekhg4 pleckstrin homology domain containing, family G (with RhoGef domain) member 4 4.17 3.17 0.73 4.6E-15 
106 Tppp3 tubulin polymerization-promoting protein family member 3 4.17 13.35 3.04 1.1E-06 
107 Apod apolipoprotein D 4.15 4.35 1.07 0.0020 
108 Pdlim3* PDZ and LIM domain 3 4.09 6.71 2.44 0.0283 
109 Coch coagulation factor C homolog (Limulus polyphemus) 4.09 0.44 0.09 0.0114 
110 Obscn* obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF 4.06 1.12 0.31 0.0062 
111 Rnf207 ring finger protein 207 3.93 0.47 0.11 0.0047 
112 Ephx3 epoxide hydrolase 3 3.88 0.43 0.11 0.0048 
113 Sost sclerostin 3.85 376.71 99.15 1.3E-16 
114 Trnp1 TMF1-regulated nuclear protein 1 3.74 3.17 0.80 1.7E-06 
115 Mustn1 musculoskeletal, embryonic nuclear protein 1 3.73 16.43 4.38 2.9E-13 
116 Higd1b HIG1 domain family, member 1B 3.71 3.37 0.79 0.0105 
117 Wnt7b wingless-related MMTV integration site 7B 3.71 0.54 0.14 0.0012 
118 2900041M22Rik RIKEN cDNA 2900041M22 gene 3.67 0.99 0.26 0.0036 
119 Fndc5* fibronectin type III domain containing 5 3.66 0.86 0.24 0.0396 
120 Txlnb* taxilin beta 3.66 2.61 0.82 0.0034 
121 Ptn pleiotrophin 3.66 6.05 1.66 2.4E-07 
122 Rtn2* reticulon 2 (Z-band associated protein) 3.63 21.81 6.52 0.0056 
123 Ryr1* ryanodine receptor 1, skeletal muscle 3.63 2.68 0.87 0.0400 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
124 Olfr78 olfactory receptor 78 3.61 0.49 0.14 0.0326 
125 Ankrd23* ankyrin repeat domain 23 3.61 28.51 9.06 0.0276 
126 Sh3bgr* SH3-binding domain glutamic acid-rich protein 3.60 9.91 3.32 0.0482 
127 Adamtsl5 ADAMTS-like 5 3.59 2.60 0.74 3.7E-06 
128 Rps27 ribosomal protein S27 3.59 37.74 3.34 0.0309 
129 Epcam epithelial cell adhesion molecule 3.55 10.24 2.90 9.1E-10 
130 Prss23 protease, serine, 23 3.54 14.98 4.14 4.0E-16 
131 Alpk3* alpha-kinase 3 3.50 0.93 0.25 0.0004 
132 9130019P16Rik RIKEN cDNA 9130019P16 gene 3.45 1.53 0.44 2.6E-09 
133 Pkia* protein kinase inhibitor, alpha 3.43 3.79 1.51 0.0220 
134 Asic3 acid-sensing (proton-gated) ion channel 3 3.43 5.70 1.60 3.7E-09 
135 Atp1a2* ATPase, Na+/K+ transporting, alpha 2 polypeptide 3.39 5.46 1.62 0.0177 
136 Wnt9a wingless-type MMTV integration site 9A 3.36 0.66 0.20 0.0008 
137 C130021I20Rik Riken cDNA C130021I20 gene 3.36 0.49 0.15 0.0023 
138 Wnk2 WNK lysine deficient protein kinase 2 3.34 0.46 0.15 0.0047 
139 Trpm6 transient receptor potential cation channel, subfamily M, member 6 3.34 0.24 0.07 0.0089 
140 Rab15 RAB15, member RAS oncogene family 3.30 0.89 0.25 0.0004 
141 Jph2* junctophilin 2 3.30 4.43 1.55 0.0073 
142 Cox6a2* cytochrome c oxidase, subunit VI a, polypeptide 2 3.29 39.66 12.60 0.0034 
143 Ablim3 actin binding LIM protein family, member 3 3.29 0.62 0.20 0.0007 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
144 Gpr115 G protein-coupled receptor 115 3.27 0.41 0.12 0.0141 
145 Ky* kyphoscoliosis peptidase 3.26 0.76 0.22 0.0116 
146 F3 coagulation factor III 3.24 3.51 1.10 4.2E-08 
147 P4ha3 
procollagen-proline, 2-oxoglutarate 4-
dioxygenase (proline 4-hydroxylase), alpha 
polypeptide III 
3.22 5.98 1.84 7.2E-09 
148 Tekt2 tektin 2 3.22 1.51 0.47 0.0019 
149 Medag mesenteric estrogen dependent adipogenesis 3.20 1.18 0.35 0.0067 
150 Tmem255b transmembrane protein 255B 3.20 1.57 0.49 0.0091 
151 A330021E22Rik RIKEN cDNA A330021E22 gene 3.19 0.45 0.13 0.0104 
152 Mss51 MSS51 mitochondrial translational activator 3.16 4.33 1.31 0.0001 
153 Sh3rf2 SH3 domain containing ring finger 2 3.15 0.42 0.13 0.0144 
154 Lrrc38 leucine rich repeat containing 38 3.14 1.04 0.33 0.0286 
155 Itm2a integral membrane protein 2A 3.12 55.11 18.14 6.5E-10 
156 Thpo thrombopoietin 3.12 0.64 0.20 0.0237 
157 Tmem38a* transmembrane protein 38A 3.12 14.20 4.43 0.0028 
158 Rian RNA imprinted and accumulated in nucleus 3.10 2.19 0.77 0.0010 
159 Grip2 glutamate receptor interacting protein 2 3.08 1.67 0.55 0.0006 
160 Rbp7 retinol binding protein 7, cellular 3.07 4.95 1.50 0.0093 
161 Hspb6* heat shock protein, alpha-crystallin-related, B6 3.05 19.76 6.56 0.0015 
162 Mrgprf MAS-related GPR, member F 3.03 1.11 0.35 0.0186 
163 Art1* ADP-ribosyltransferase 1 3.01 10.77 3.61 4.8E-05 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
164 Rbm24* RNA binding motif protein 24 3.00 1.40 0.44 0.0147 
165 Eno3* enolase 3, beta muscle 3.00 78.99 30.91 0.0091 
166 Mapt microtubule-associated protein tau 3.00 0.77 0.28 0.0074 
167 Tlx1 T-cell leukemia, homeobox 1 2.99 0.66 0.21 0.0164 
168 Car11 carbonic anhydrase 11 2.98 1.99 0.63 0.0056 
169 Fam131c family with sequence similarity 131, member C 2.97 1.31 0.42 0.0036 
170 Stac3* SH3 and cysteine rich domain 3 2.96 3.52 1.16 0.0065 
171 Mpp3 membrane protein, palmitoylated 3 (MAGUK p55 subfamily member 3) 2.89 0.52 0.18 0.0313 
172 Bai2 brain-specific angiogenesis inhibitor 2 2.88 0.41 0.14 0.0025 
173 Fam19a5 family with sequence similarity 19, member A5 2.86 1.21 0.44 0.0003 
174 Postn periostin, osteoblast specific factor 2.85 340.06 115.06 6.2E-08 
175 Plat plasminogen activator, tissue 2.78 7.30 2.67 1.5E-13 
176 Pcdhga2 protocadherin gamma subfamily A, 2 2.78 0.60 0.22 0.0165 
177 Tpm2* tropomyosin 2, beta 2.77 65.32 23.06 0.0002 
178 Sncg synuclein, gamma 2.76 5.89 2.08 0.0016 
179 Lrrn4cl LRRN4 C-terminal like 2.76 1.74 0.61 5.3E-05 
180 Fcrls Fc receptor-like S, scavenger receptor 2.75 7.56 2.59 1.5E-07 
181 Ccdc3 coiled-coil domain containing 3 2.74 17.98 6.40 1.8E-14 
182 Tagln transgelin 2.74 18.78 6.79 1.9E-07 
183 Sowahb trans-acting transcription factor 6 2.73 1.54 0.55 0.0001 
184 Prtg protogenin homolog (Gallus gallus) 2.70 0.59 0.22 0.0001 
185 Hbb-b2 hemoglobin, beta adult minor chain 2.69 81.01 27.88 0.0269 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
186 Adamtsl2 ADAMTS-like 2 2.69 7.15 2.42 0.0013 
187 Zfp185 zinc finger protein 185 2.67 0.31 0.11 0.0363 
188 Tfap2a transcription factor AP-2, alpha 2.67 0.84 0.30 0.0017 
189 Cyp46a1 cytochrome P450, family 46, subfamily a, polypeptide 1 2.66 1.01 0.37 0.0091 
190 Gpnmb glycoprotein (transmembrane) nmb 2.64 1.68 0.59 0.0048 
191 Hs3st5 heparan sulfate (glucosamine) 3-O-sulfotransferase 5 2.64 0.45 0.17 0.0364 
192 Ppp1r1a* protein phosphatase 1, regulatory (inhibitor) subunit 1A 2.63 1.90 0.69 0.0175 
193 Thbs2 thrombospondin 2 2.62 32.11 12.01 1.3E-11 
194 Pianp PILR alpha associated neural protein 2.61 2.25 0.87 0.0002 
195 Dkk3 dickkopf homolog 3 (Xenopus laevis) 2.61 19.52 7.44 1.9E-19 
196 Cpxm2 carboxypeptidase X 2 (M14 family) 2.60 5.51 2.11 0.0064 
197 Ndufa4l2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 2.60 17.98 6.91 2.1E-08 
198 Lrrc8e leucine rich repeat containing 8 family, member E 2.55 0.46 0.17 0.0208 
199 Mepe matrix extracellular phosphoglycoprotein with ASARM motif (bone) 2.54 460.56 184.38 1.6E-10 
200 Art5* ADP-ribosyltransferase 5 2.54 4.18 1.63 6.0E-05 
201 Gm996 predicted gene 996 2.53 0.61 0.24 0.0005 
202 Cys1 cystin 1 2.52 3.18 1.22 5.1E-05 
203 Ebf4 early B-cell factor 4 2.51 1.57 0.62 0.0003 
204 Pygm* muscle glycogen phosphorylase 2.51 32.38 14.74 0.0306 
205 Nbl1 neuroblastoma, suppression of tumorigenicity 1 2.51 81.12 32.02 4.9E-09 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
206 Sparcl1 SPARC-like 1 2.51 20.52 8.26 1.0E-11 
207 Hspb2* heat shock protein 2 2.50 25.97 10.47 0.0012 
208 Kcnc1 potassium voltage gated channel, Shaw-related subfamily, member 1 2.50 1.37 0.57 2.8E-06 
209 Nox4 NADPH oxidase 4 2.49 0.66 0.25 0.0189 
210 Hspa1a heat shock protein 1B; heat shock protein 1A; heat shock protein 1-like 2.48 0.59 0.23 0.0176 
211 Glrb glycine receptor, beta subunit 2.48 0.51 0.21 0.0375 
212 Cacng7 calcium channel, voltage-dependent, gamma subunit 7 2.48 2.40 1.00 0.0319 
213 Tg thyroglobulin 2.47 6.73 2.68 9.7E-10 
214 Galr2 galanin receptor 2 2.47 3.13 1.27 0.0010 
215 Etv4 ets variant gene 4 (E1A enhancer binding protein, E1AF) 2.47 1.41 0.55 0.0064 
216 Piwil2 piwi-like homolog 2 (Drosophila) 2.47 0.70 0.29 0.0014 
217 Lcat lecithin cholesterol acyltransferase 2.46 7.06 2.83 0.0002 
218 Arhgap22 Rho GTPase activating protein 22 2.45 1.24 0.50 0.0108 
219 Lrp2bp Lrp2 binding protein 2.44 0.37 0.15 0.0235 
220 Olfr1372-ps1 olfactory receptor 1372, pseudogene 1 2.44 0.84 0.37 0.0249 
221 Cabp1 calcium binding protein 1 2.42 1.27 0.51 0.0262 
222 Cacna1a calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 2.41 0.61 0.26 0.0015 
223 Gja3 gap junction protein, alpha 3 2.40 0.67 0.28 0.0281 
224 Tcea3* transcription elongation factor A (SII), 3 2.40 11.83 4.89 2.0E-05 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
225 Tnni3 troponin I, cardiac 3 2.40 3.04 1.20 0.0361 
226 Wnt10b wingless related MMTV integration site 10b 2.40 9.81 4.03 1.6E-07 
227 Adamtsl1 ADAMTS-like 1 2.38 0.70 0.29 0.0018 
228 Fndc1 fibronectin type III domain containing 1 2.36 5.50 2.13 5.5E-05 
229 Col16a1 collagen, type XVI, alpha 1 2.36 35.79 15.02 1.9E-05 
230 Gabra3 gamma-aminobutyric acid (GABA) A receptor, subunit alpha 3 2.36 0.87 0.36 0.0320 
231 Gcnt4 glucosaminyl (N-acetyl) transferase 4, core 2 (beta-1,6-N-acetylglucosaminyltransferase) 2.34 0.40 0.17 0.0129 
232 Aknad1 RIKEN cDNA 4921525H12 gene 2.34 0.66 0.28 0.0301 
233 Dmd dystrophin, muscular dystrophy 2.33 0.52 0.23 0.0032 
234 Acta2 actin, alpha 2, smooth muscle, aorta 2.33 15.20 6.39 0.0002 
235 Mamstr MEF2 activating motif and SAP domain containing transcriptional regulator 2.33 0.94 0.39 0.0139 
236 Slc6a7 solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 2.30 1.77 0.76 0.0002 
237 Tmod2 tropomodulin 2 2.30 0.35 0.15 0.0018 
238 Lor loricrin 2.29 0.77 0.32 0.0417 
239 Nmnat2 nicotinamide nucleotide adenylyltransferase 2 2.29 2.01 0.90 3.1E-05 
240 Wfdc1* WAP four-disulfide core domain 1 2.28 9.15 3.91 0.0011 
241 Coro6* coronin 6 2.28 3.46 1.52 0.0016 
242 Lrrc51 leucine rich repeat containing 51 2.27 3.94 1.63 0.0092 
243 Plekha4 
pleckstrin homology domain containing, 
family A (phosphoinositide binding specific) 
member 4 
2.25 1.26 0.53 0.0065 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
244 Mn1 meningioma 1 2.25 0.94 0.42 0.0066 
245 Rem1 rad and gem related GTP binding protein 1 2.24 1.19 0.52 0.0305 
246 Adam33 a disintegrin and metallopeptidase domain 33 2.22 1.47 0.68 0.0032 
247 A930006K02Rik RIKEN cDNA A930006K02 gene 2.21 4.10 1.80 0.0129 
248 Meox1 mesenchyme homeobox 1 2.21 2.65 1.18 0.0045 
249 Adam23 a disintegrin and metallopeptidase domain 23; similar to ADAM23 2.21 0.45 0.19 0.0123 
250 Cpeb1 cytoplasmic polyadenylation element binding protein 1 2.21 4.70 2.06 1.4E-07 
251 Trib3 tribbles homolog 3 (Drosophila) 2.20 1.12 0.48 0.0202 
252 Aox1 aldehyde oxidase 1 2.20 2.13 0.97 6.7E-05 
253 Slc47a1 solute carrier family 47, member 1 2.20 1.43 0.63 0.0356 
254 P2rx6 purinergic receptor P2X, ligand-gated ion channel, 6 2.20 1.27 0.56 0.0101 
255 C1qtnf5 C1q and tumor necrosis factor related protein 5 2.19 20.02 9.05 4.2E-05 
256 Bglap3 bone gamma-carboxyglutamate protein 3 2.19 9.46 4.21 0.0222 
257 Ssc5d scavenger receptor cysteine rich family, 5 domains 2.18 2.31 1.06 0.0005 
258 Egflam EGF-like, fibronectin type III and laminin G domains 2.18 0.39 0.17 0.0254 
259 Casq2 calsequestrin 2 2.17 1.63 0.72 0.0018 
260 Lum lumican 2.16 636.92 293.03 5.7E-06 
261 Tbx3 T-box 3 2.15 0.96 0.43 0.0052 
262 Aebp1 AE binding protein 1 2.14 25.21 11.75 3.3E-07 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
263 Best1 bestrophin 1; hypothetical protein LOC100046789 2.12 1.27 0.59 0.0163 
264 3000002C10Rik 
RIKEN cDNA 3000002C10 gene; predicted 
gene 7251 2.12 5.09 2.36 0.0005 
265 Prr15 proline rich 15 2.11 14.45 6.83 4.2E-05 
266 Pdlim4 PDZ and LIM domain 4 2.10 12.97 6.05 5.1E-06 
267 Shroom1 shroom family member 1 2.10 0.92 0.43 0.0182 
268 Myom3 myomesin family, member 3 2.08 0.81 0.39 0.0071 
269 4933436C20Rik RIKEN cDNA 4933436C20 gene 2.08 16.65 7.99 8.4E-06 
270 Tmeff1 transmembrane protein with EGF-like and two follistatin-like domains 1 2.07 1.27 0.60 0.0252 
271 Irx6 Iroquois related homeobox 6 (Drosophila) 2.07 3.54 1.66 0.0144 
272 Fgf9 fibroblast growth factor 9 2.06 0.75 0.36 0.0081 
273 Srl* sarcalumenin 2.06 7.56 3.77 0.0176 
274 Atp6v0e2* ATPase, H+ transporting, lysosomal V0 subunit E2 2.05 3.46 1.65 0.0056 
275 Cav3 caveolin 3 2.05 3.53 1.59 0.0333 
276 Stmn2 stathmin-like 2 2.05 2.09 1.05 0.0084 
277 Flnc* filamin C, gamma 2.05 2.06 1.00 0.0249 
278 Trim7 tripartite motif-containing 7 2.04 2.62 1.26 0.0053 
279 ORF63 open reading frame 63 2.03 2.19 0.99 0.0343 
280 Kcnab1 potassium voltage-gated channel, shaker-related subfamily, beta member 1 2.02 0.93 0.47 0.0196 
281 Ablim2 actin-binding LIM protein 2 2.02 2.05 0.99 0.0038 
282 Hr hairless 2.02 2.68 1.31 0.0006 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Control.Cn. 
fpkm FDR 
283 Eno2 enolase 2, gamma neuronal 2.01 1.40 0.70 0.0393 
284 Dok5 docking protein 5 2.00 4.56 2.25 0.0017 
285 Tgfb2 transforming growth factor, beta 2 2.00 7.81 4.21 0.0017 
286 Slc25a27 solute carrier family 25, member 27 2.00 1.85 0.93 0.0014 
287 Pacsin3* protein kinase C and casein kinase substrate in neurons 3 2.00 8.15 4.09 0.0032 
       
 total 326     
 *indicates contaminant 84     
 total without contaminants 242     
  190 
Table A.4: A complete list of genes that were differentially expressed 3 hours following a single 
loading session in cortical bone in order of decreasing fold change that were: I. upregulated by 
mechanical loading and II. downregulated by mechanical loading. Number of genes (column 
A), gene symbols (column B), gene names (column C), fold change (column D), control cortical 
(Ct) fragments per kilobase per million reads (FPKM) (column E), loaded cortical (Ct) FPKM 
(column F), false discovery rate (FDR) (column G). 
 
Table A.4, Part I. List of genes upregulated 3 hours after a single loading session in cortical 
bone 
 Gene Symbol Gene 
Fold 
Change 
Control.Ct.
fpkm 
Loaded.Ct.
fpkm FDR 
1 Gm5512 
required for meiotic nuclear division 1 
homolog (S. cerevisiae); predicted gene 
5512 459.83 0.32 8.66 0.0088 
2 Mb myoglobin 38.31 9.04 76.12 0.0334 
3 Csrp3 cysteine and glycine-rich protein 3 36.66 0.29 9.21 0.0342 
4 Klhl41 kelch-like 41 19.31 0.37 3.75 0.0064 
5 Acta1 actin, alpha 1, skeletal muscle 15.99 24.86 147.42 0.0387 
6 Rgs17 regulator of G-protein signaling 17 13.97 0.02 0.20 0.0253 
7 Rpl3l ribosomal protein L3-like 11.62 0.92 6.33 0.0230 
8 Mylpf 
myosin light chain, phosphorylatable, fast 
skeletal muscle 10.17 27.37 184.46 0.0387 
9 Murc muscle-related coiled-coil protein 7.04 0.28 1.93 0.0286 
10 Hspb7 
heat shock protein family, member 7 
(cardiovascular) 6.99 1.41 9.70 9.3E-06 
11 Ch25h cholesterol 25-hydroxylase 6.55 0.29 2.29 0.0030 
12 Mfap5 microfibrillar associated protein 5 6.34 0.22 1.49 0.0342 
13 Wnt1 wingless-related MMTV integration site 1 6.18 0.80 4.59 6.1E-13 
14 Gem 
GTP binding protein (gene overexpressed 
in skeletal muscle) 4.67 1.86 8.60 6.5E-16 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct.
fpkm 
Loaded.Ct.
fpkm FDR 
15 Medag 
mesenteric estrogen dependent 
adipogenesis 4.66 0.81 3.90 3.5E-07 
16 Ptgs2 prostaglandin-endoperoxide synthase 2 4.32 1.19 5.22 5.8E-09 
17 Ngf nerve growth factor 3.85 3.06 11.61 6.7E-07 
18 Ccl7 chemokine (C-C motif) ligand 7 3.76 1.37 4.85 0.0008 
19 Wnt7b 
wingless-related MMTV integration site 
7B 3.22 0.89 3.01 0.0251 
20 Ccl12 
chemokine (C-C motif) ligand 12; similar 
to monocyte chemoattractant protein-5 2.93 5.51 16.62 0.0064 
21 Tnfrsf12a 
tumor necrosis factor receptor 
superfamily, member 12a 2.82 10.22 29.78 2.4E-11 
22 Mustn1 
musculoskeletal, embryonic nuclear 
protein 1 2.51 9.81 27.38 0.0088 
23 Wnt10b 
wingless related MMTV integration site 
10b 2.39 8.27 20.11 0.0131 
24 Lmcd1 LIM and cysteine-rich domains 1 2.27 9.34 21.29 1.0E-07 
25 Tnfrsf11b 
tumor necrosis factor receptor 
superfamily, member 11b 
(osteoprotegerin) 2.17 18.91 41.62 3.5E-07 
26 Tfpi2 tissue factor pathway inhibitor 2 2.13 6.50 14.26 0.0002 
27 Epcam epithelial cell adhesion molecule 2.07 7.63 16.52 0.0064 
28 Hbegf heparin-binding EGF-like growth factor 2.06 2.44 5.20 0.0175 
29 Bmp2 bone morphogenetic protein 2 1.93 13.90 28.45 0.0029 
30 Srxn1 sulfiredoxin 1 homolog (S. cerevisiae) 1.91 12.97 25.15 1.2E-07 
31 Nt5e 5' nucleotidase, ecto 1.89 13.38 24.99 0.0230 
32 Mt2 metallothionein 2 1.77 353.79 647.46 0.0011 
33 Dmp1 dentin matrix protein 1 1.74 734.28 1283.10 0.0088 
34 Ugdh UDP-glucose dehydrogenase 1.68 39.39 66.19 5.4E-10 
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 Gene Symbol Gene 
Fold 
Change 
Control.Ct.
fpkm 
Loaded.Ct.
fpkm FDR 
35 Phlda1 
pleckstrin homology-like domain, family 
A, member 1 1.66 11.45 18.99 0.0002 
36 Glrx3 predicted gene 12669; glutaredoxin 3 1.64 21.98 35.44 0.0230 
37 Timp1 tissue inhibitor of metalloproteinase 1 1.63 197.17 330.52 0.0003 
38 S100a10 
S100 calcium binding protein A10 
(calpactin) 1.59 232.79 379.16 0.0006 
39 Rgcc regulator of cell cycle 1.57 44.65 69.46 0.0029 
40 Trib1 tribbles homolog 1 (Drosophila) 1.56 3.50 5.55 0.0029 
41 Fam20c 
family with sequence similarity 20, 
member C 1.52 48.29 72.66 0.0002 
 
 
 
 
Table A.4, Part II. List of genes downregulated 3 hours after a single loading session in cortical 
bone 
 Gene Symbol Gene 
Fold 
Change 
Control.Ct.
fpkm 
Loaded.Ct.
fpkm FDR 
1 Crebbp CREB binding protein -1.51 5.78 3.85 0.0230 
2 Lrp5 
low density lipoprotein receptor-related 
protein 5 -1.50 28.68 19.12 0.0251 
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Table A.5: A complete list of genes that were differentially expressed 3 hours following a single 
loading session in cancellous bone in order of decreasing fold change that were: I. upregulated by 
mechanical loading and II. downregulated by mechanical loading. Number of genes (column A), gene 
symbols (column B), gene names (column C), fold change (column D), control cancellous (Cn) 
fragments per kilobase per million reads (FPKM) (column E), loaded cancellous (Cn) FPKM (column 
F), false discovery rate (FDR) (column G). 
 
Table A.5, Part I. List of genes upregulated 3 hours after a single loading session in cancellous bone 
 Gene Symbol Gene 
Fold 
Change 
Control.Cn. 
fpkm 
Loaded.Cn. 
fpkm FDR 
1 Wnt7b 
wingless-related MMTV integration site 
7B 7.78 0.16 1.24 4.1E-06 
2 Wnt1 
wingless-related MMTV integration site 
1 4.08 0.45 1.85 2.8E-06 
3 Ptgs2 prostaglandin-endoperoxide synthase 2 3.90 0.81 3.01 4.1E-07 
4 Nt5e 5' nucleotidase, ecto 3.41 10.47 33.00 5.2E-10 
5 Tnfrsf12a 
tumor necrosis factor receptor 
superfamily, member 12a 3.10 7.19 21.84 6.8E-13 
6 Ngf nerve growth factor 2.36 2.89 6.80 0.0405 
7 Timp1 tissue inhibitor of metalloproteinase 1 1.90 112.05 211.16 1.6E-07 
8 Tnfrsf11b 
tumor necrosis factor receptor 
superfamily, member 11b 
(osteoprotegerin) 1.89 12.45 23.24 0.0003 
9 Tfpi2 tissue factor pathway inhibitor 2 1.83 6.77 12.67 0.0135 
10 Col6a3 collagen, type VI, alpha 3 1.65 32.00 51.05 0.0438 
11 Fam20c 
family with sequence similarity 20, 
member C 1.63 35.89 56.86 2.8E-06 
12 Srxn1 sulfiredoxin 1 homolog (S. cerevisiae) 1.51 13.19 19.92 0.0222 
13 Cspg4 chondroitin sulfate proteoglycan 4 1.50 11.35 16.49 0.0135 
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Table A.5, Part II. List of genes downregulated 3 hours after a single loading session in cancellous 
bone 
 
Gene  
Symbol Gene 
Fold 
Change 
Control.Cn. 
fpkm 
Loaded.Cn. 
fpkm FDR 
1 
9130019 
P16Rik RIKEN cDNA 9130019P16 gene -2.93 0.86 0.26 0.0406 
2 Sost sclerostin -2.27 101.32 42.60 0.0048 
3 Mepe 
matrix extracellular 
phosphoglycoprotein with ASARM 
motif (bone) -1.65 296.94 178.20 0.0008 
4 Dkk1 dickkopf homolog 1 (Xenopus laevis) -1.59 44.40 27.43 0.0011 
5 Fbln2 fibulin 2 -1.54 6.37 4.13 0.0243 
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Table A.6: A complete list of genes that were differentially expressed 24 hours following a single 
loading session in cortical bone in order of decreasing fold change that were: I. upregulated by 
mechanical loading and II. downregulated by mechanical loading. Number of genes (column A), gene 
symbols (column B), gene names (column C), fold change (column D), control cortical (Ct) fragments 
per kilobase per million reads (FPKM) (column E), loaded cortical (Ct) FPKM (column F), false 
discovery rate (FDR) (column G). 
 
Table A.6, Part I. List of genes upregulated 24 hours after a single loading session in cortical bone 
 
Gene  
Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Loaded.Ct. 
fpkm FDR 
1 Wnt1 
wingless-related MMTV integration site 
1 6.11 0.41 2.36 7.0E-07 
2 
Adamts8 a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin 
type 1 motif, 8 4.19 0.19 0.66 0.0082 
3 Ptn pleiotrophin 2.68 6.05 15.51 0.0006 
4 Tubb3 
tubulin, beta 3; tubulin, beta 3, 
pseudogene 1 2.48 4.97 11.73 7.0E-07 
5 Zfp365 zinc finger protein 365 2.32 0.50 1.14 0.0030 
6 Bcan brevican 2.24 2.98 6.08 0.0002 
7 Gabrb2 
gamma-aminobutyric acid (GABA) A 
receptor, subunit beta 2 2.01 0.31 0.65 0.0135 
8 Gsg1l GSG1-like 1.96 1.73 3.40 0.0025 
9 Nr4a2 
nuclear receptor subfamily 4, group A, 
member 2 1.96 5.30 10.29 0.0008 
10 Qpct 
glutaminyl-peptide cyclotransferase 
(glutaminyl cyclase) 1.93 5.25 9.89 0.0010 
11 Ptgs2 prostaglandin-endoperoxide synthase 2 1.88 0.90 1.66 0.0111 
12 Wnt10b 
wingless related MMTV integration site 
10b 1.81 9.81 17.33 0.0045 
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Gene  
Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Loaded.Ct. 
fpkm FDR 
13 Peg10 paternally expressed 10 1.80 1.48 2.70 0.0054 
14 Dclk1 doublecortin-like kinase 1 1.80 2.62 4.66 0.0002 
15 Lurap1l leucine rich adaptor protein 1-like 1.79 10.70 18.61 0.0006 
16 Brsk1 BR serine/threonine kinase 1 1.79 2.34 3.82 0.0242 
17 Hapln4 
hyaluronan and proteoglycan link 
protein 4 1.78 4.19 7.28 0.0063 
18 Pi15 peptidase inhibitor 15 1.77 4.65 7.75 0.0121 
19 Apcdd1 
adenomatosis polyposis coli down-
regulated 1 1.75 12.16 20.45 0.0010 
20 Cthrc1 collagen triple helix repeat containing 1 1.68 158.90 255.67 0.0031 
21 Vcan versican 1.68 10.63 18.69 9.1E-05 
22 Cdo1 cysteine dioxygenase 1, cytosolic 1.67 105.10 173.08 0.0019 
23 Dusp14 dual specificity phosphatase 14 1.62 7.34 12.04 0.0499 
24 Fkbp11 FK506 binding protein 11 1.62 50.85 78.72 0.0045 
25 Aldh1l2 
aldehyde dehydrogenase 1 family, 
member L2 1.61 12.49 19.68 0.0031 
26 Slc2a13 
solute carrier family 2 (facilitated 
glucose transporter), member 13 1.56 4.57 7.02 0.0202 
27 Pdzrn3 PDZ domain containing RING finger 3 1.55 5.51 8.46 0.0082 
28 Psd3 
pleckstrin and Sec7 domain containing 
3 1.53 8.17 12.61 0.0328 
29 Mamdc2 MAM domain containing 2 1.53 16.00 24.10 0.0180 
30 Gnai1 
guanine nucleotide binding protein (G 
protein), alpha inhibiting 1 1.53 26.75 40.45 0.0082 
31 Dcbld1 
discoidin, CUB and LCCL domain 
containing 1 1.52 4.42 6.49 0.0425 
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Gene  
Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Loaded.Ct. 
fpkm FDR 
32 
Sema3b 
sema domain, immunoglobulin domain 
(Ig), short basic domain, secreted, 
(semaphorin) 3B 1.51 15.76 23.05 0.0092 
33 
P4ha1 
procollagen-proline, 2-oxoglutarate 4-
dioxygenase (proline 4-hydroxylase), 
alpha 1 polypeptide 1.51 39.99 59.81 0.0095 
34 
1700066 
M21Rik RIKEN cDNA 1700066M21 gene 1.50 16.12 24.29 0.0082 
 
 
 
Table A.6, Part II. List of genes downregulated 24 hours after a single loading session in cortical 
bone 
 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Loaded.Ct. 
fpkm FDR 
1 Actc1 actin, alpha, cardiac muscle 1;  -18.55 3.44 0.58 0.0380 
2 Ampd1 
adenosine monophosphate deaminase 1 
(isoform M) -8.74 4.97 0.78 0.0215 
3 Dhrs7c 
dehydrogenase/reductase (SDR family) 
member 7C -8.34 3.79 0.54 0.0151 
4 Tnxb tenascin XB -7.03 0.95 0.11 0.0056 
5 Angptl7 angiopoietin-like 7 -6.10 10.19 1.39 0.0164 
6 F7 coagulation factor VII -2.66 1.08 0.40 0.0328 
7 Htra4 HtrA serine peptidase 4 -2.44 4.25 1.68 0.0082 
8 Tppp3 
tubulin polymerization-promoting 
protein family member 3 -2.39 13.35 5.13 0.0278 
9 Mt3 metallothionein 3 -2.07 191.75 95.64 0.0082 
10 Nmb neuromedin B -2.02 70.58 36.33 0.0031 
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Table A.6, Part II. Continued 
 Gene Symbol Gene 
Fold 
Change 
Control.Ct. 
fpkm 
Loaded.Ct. 
fpkm FDR 
11 Mt1 metallothionein 1 -1.93 323.04 176.08 0.0045 
12 Cxcr5 chemochine (C-X-C motif) receptor 5 -1.84 1.42 0.78 0.0270 
13 Mt2 metallothionein 2 -1.83 133.91 76.98 0.0111 
14 Wisp2 
WNT1 inducible signaling pathway 
protein 2 -1.81 42.71 23.77 0.0003 
15 Bdh2 
3-hydroxybutyrate dehydrogenase, type 
2 -1.77 9.21 5.14 0.0155 
16 Chchd10 
coiled-coil-helix-coiled-coil-helix 
domain containing 10 -1.76 36.81 20.42 0.0054 
17 Mst1r 
macrophage stimulating 1 receptor (c-
met-related tyrosine kinase) -1.66 16.83 10.02 0.0054 
18 Lif leukemia inhibitory factor -1.65 3.66 2.24 0.0351 
19 Smim5 small integral membrane protein 5 -1.64 22.22 12.80 0.0468 
20 
Galnt6 
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 6 -1.63 7.96 4.79 0.0006 
21 
Slc9b2 
solute carrier family 9, subfamily B 
(NHA2, cation proton antiporter 2), 
member 2 -1.60 74.27 46.61 0.0186 
22 Sgsm3 small G protein signaling modulator 3 -1.59 10.25 6.44 0.0103 
23 Adssl1 adenylosuccinate synthetase like 1 -1.51 38.10 24.61 0.0145 
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Table A.7: A complete list of genes that were differentially expressed 24 hours following a single 
loading session in cancellous bone in order of decreasing fold change that were: I. upregulated by 
mechanical loading and II. downregulated by mechanical loading. Number of genes (column A), gene 
symbols (column B), gene names (column C), fold change (column D), control cancellous (Cn) 
fragments per kilobase per million reads (FPKM) (column E), loaded cancellous (Cn) FPKM (column 
F), false discovery rate (FDR) (column G). 
 
Table A.7, Part I. List of genes upregulated 24 hours after a single loading session in cancellous bone 
 Gene Symbol Gene 
Fold 
Change 
Control.Cn. 
fpkm 
Loaded.Cn. 
fpkm FDR 
1 ChkbCpt1b 
Chkb-Cpt1b readthrough transcript 
(NMD candidate) 362.52 9.64E-05 0.66 8.5E-14 
2 Apoo-ps apolipoprotein O, pseudogene 7.59 1.20 5.41 0.0186 
3 Ptn pleiotrophin 3.08 1.66 5.47 0.0006 
4 Tubb3 
tubulin, beta 3; tubulin, beta 3, 
pseudogene 1 1.80 4.30 7.92 0.0205 
5 Lurap1l leucine rich adaptor protein 1-like 1.76 7.78 13.69 0.0035 
6 Timp1 tissue inhibitor of metalloproteinase 1 1.71 93.30 163.44 0.0082 
7 Peg10 paternally expressed 10 1.68 2.20 3.67 0.0365 
8 Hapln4 
hyaluronan and proteoglycan link 
protein 4 1.67 3.81 6.28 0.0442 
9 Vcan versican 1.63 5.99 9.80 0.0007 
10 Cthrc1 collagen triple helix repeat containing 1 1.62 124.37 197.56 0.0186 
11 Fkbp11 FK506 binding protein 11 1.56 47.11 73.82 0.0199 
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Table A.7, Part II. List of genes downregulated 24 hours after a single loading session in cancellous 
bone 
 
Gene  
Symbol Gene 
Fold 
Change 
Control.Cn. 
fpkm 
Loaded.Cn. 
fpkm FDR 
1 Myh4 
myosin, heavy polypeptide 4, skeletal 
muscle -59.48 32.30 0.51 0.0243 
2 Sypl2 synaptophysin-like 2 -49.05 0.62 4.06E-03 0.0031 
3 Tnnc2 troponin C2, fast -41.61 134.42 2.41 0.0434 
4 Ampd1 
adenosine monophosphate deaminase 
1 (isoform M) -31.88 2.17 0.03 0.0007 
5 Dhrs7c 
dehydrogenase/reductase (SDR family) 
member 7C -28.60 0.98 0.01 0.0074 
6 Smpx small muscle protein, X-linked -32.29 1.41 0.01 0.0160 
7 Tnnt3 troponin T3, skeletal, fast -36.62 150.70 2.74 0.0186 
8 Mylk2 
myosin, light polypeptide kinase 2, 
skeletal muscle -22.40 1.35 0.02 0.0432 
9 Myoz1 myozenin 1 -23.38 11.13 0.26 0.0421 
10 Myom2 myomesin 2 -21.54 1.35 0.03 0.0137 
11 
2310002 
L09Rik RIKEN cDNA 2310002L09 gene -14.99 0.51 0.01 0.0432 
12 Actn3 actinin alpha 3 -14.74 18.20 0.68 0.0063 
13 Myl1 myosin, light polypeptide 1 -13.81 108.90 3.66 0.0186 
14 Casq1 calsequestrin 1 -12.36 9.45 0.38 0.0434 
15 Mybpc2 myosin binding protein C, fast-type -12.09 6.85 0.34 0.0242 
16 Myh2 
myosin, heavy polypeptide 2, skeletal 
muscle, adult -12.17 0.17 0.01 0.0019 
17 Mylpf 
myosin light chain, phosphorylatable, 
fast skeletal muscle -12.85 122.42 5.10 0.0184 
18 Tnni2 troponin I, skeletal, fast 2 -7.69 116.33 11.62 0.0442 
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Table A.7, Part II. Continued 
 
Gene  
Symbol Gene 
Fold 
Change 
Control.Cn. 
fpkm 
Loaded.Cn. 
fpkm FDR 
19 Sh3bgr 
similar to putative SH3BGR protein; 
SH3-binding domain glutamic acid-rich 
protein -6.42 3.32 0.38 0.0492 
20 Nmb neuromedin B -1.94 69.75 36.90 0.0137 
21 Slc9b2 
solute carrier family 9, subfamily B 
(NHA2, cation proton antiporter 2), 
member 2 -1.66 72.66 44.47 0.0186 
 
  202 
APPENDIX B. CHAPTER 4 SUPPLEMENTARY FIGURES AND 
DATA 
 
TABLE OF CONTENTS 
 
Figure B.1 Right and Left limbs of naïve animals have similar 
transcriptional profiles ................................................................... 204 
Table B.1 List of primers for genes verified with qPCR ............................... 205 
Table B.2, Part I: List of genes upregulated 3 hours after a single loading 
session in cortical bone of littermate control animals ............... 206 
Table B.2, Part II: List of genes downregulated 3 hours after a single 
loading session in cortical bone of littermate control animals 228 
Table B.3, Part I: List of genes upregulated 3 hours after a single loading 
session in cortical bone of pOC-ERaKO animals .................... 238 
Table B.4, Part I: List of genes upregulated 24 hours after a single loading 
session in cortical bone of littermate control animals ............... 240 
Table B.4, Part II: List of genes downregulated 24 hours after a single 
loading session in cortical bone of littermate control animals . 240 
Table B.5, Part I: List of genes upregulated 24 hours after a single loading 
session in cortical bone of pOC-ERaKO animals .................... 243 
Table B.5, Part II: List of genes downregulated 24 hours after a single 
loading session in cortical bone of pOC-ERaKO animals ....... 243 
Table B.6, Part I: List of genes upregulated 3 hours after a single loading 
session in cancellous bone of littermate control animals .......... 244 
Table B.7, Part I: List of genes upregulated 3 hours after a single loading 
session in cancellous bone of pOC-ERaKO animals .............. 246 
Table B.7, Part II: List of genes downregulated 3 hours after a single 
loading session in cancellous bone of pOC-ERaKO animals 247 
Table B.8, Part I: List of genes upregulated 24 hours after a single loading 
session in cancellous bone of littermate control animals .......... 248 
Table B.8, Part II: List of genes downregulated 24 hours after a single 
loading session in cancellous bone of littermate control 
animals .............................................................................................. 248 
Table B.9, Part I: List of genes upregulated 24 hours after a single loading 
session in cancellous bone of pOC-ERaKO animals .............. 249 
Table B.9, Part II: List of genes downregulated 24 hours after a single 
loading session in cancellous bone of pOC-ERaKO animals 253 
Table B.10, Part I: List of genes more highly expressed in naïve control 
cortical bone .................................................................................... 256 
  203 
Table B.10, Part II: List of genes more highly expressed in naïve control 
cancellous bone ............................................................................... 267 
Table B.11, Part I: List of genes more highly expressed in control cortical 
bone of littermate control animals at 3 hours ............................ 271 
Table B.11, Part II: List of genes more highly expressed in control 
cancellous bone of littermate control animals at 3 hours ......... 281 
Table B.12, Part I: List of genes more highly expressed in control cortical 
bone of littermate control animals at 24 hours .......................... 285 
Table B.12, Part II: List of genes more highly expressed in control 
cancellous bone of littermate control animals at 24 hours ....... 296 
Table B.13, Part I: List of genes more highly expressed in control cortical 
bone of pOC-ERaKO animals at 3 hours ................................. 301 
Table B.13, Part II: List of genes more highly expressed in control 
cancellous bone of pOC-ERaKO animals at 3 hours .............. 312 
Table B.14, Part I: List of genes more highly expressed in control cortical 
bone of pOC-ERaKO animals at 24 hours ............................... 318 
Table B.14, Part II: List of genes more highly expressed in control 
cancellous bone of pOC-ERaKO animals at 24 hours ............ 328 
 
  204 
 
 
Figure B.1 Right and Left limbs of naïve animals have similar 
transcriptional profiles. A) Scatter plot of gene counts between right and 
left cortical bone were very similar with B) only three genes that were 
differentially expressed. Right versus left cancellous samples were also very 
similar in their C) scatter plot of gene counts and D) only four 
differentially expressed genes. Hbb-b2 (hemoglobin, beta adult minor 
chain) was 112-fold higher in right cancellous samples, but this is likely due 
to contamination as it is a major component of blood. Cilp2 (cartilage 
intermediate layer protein-2) was 5-fold higher in right cancellous bone 
and Col10a1 (collagen type X alpha 1) was 13-fold higher in left cancellous 
samples, but both of these may be due to slight variations in preparation 
and amount of the hypertrophic chondrocytes and cartilage that were 
removed proximally from the sample. 
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Table B.1 List of primers for genes verified with qPCR. 
Accession # Gene Symbol Gene Name Forward primer Reverse Primer 
NM_021279 Wnt1 
wingless-type MMTV 
integration site family, member 
1 
GATTTTGGTCGCCTCTTTG
G CGTGGCATTTGCACTCTTG 
NM_009528 Wnt7b 
wingless-type MMTV 
integration site family, member 
7b 
AATGAGGCGGGCAGAAAG TGCGTTGTACTTCTCCTTGAG 
NM_011198 Ptgs2 prostaglandin-endoperoxide synthase 2 
CTCACGAAGGAACTCAGCA
C 
GGATTGGAACAGCAAGGA
TTTG 
NM_008973 Ptn Pleiotrophin AACTGTCACCATCTCCAAGC TCTCCTGTTTCTTGCCTTCC 
NM_008764 Tnfrsf11b tumor necrosis factor receptor superfamily member 11B 
GAGAGGATAAAACGGAGA
CACAG 
CTGCTTTCACAGAGGTCAA
TG 
NM_011593 Timp1 Tissue inhibitor of metalloproteinase 1 
CTCAAAGACCTATAGTGCT
GGC 
CAAAGTGACGGCTCTGGTA
G 
NM_053116 Wnt16 
wingless-type MMTV 
integration site family, member 
16 
CGAGAGGTGGAACTGTAT
GG 
TGAATGCTGTCTCCTTGGT
G 
NM_198112 Ostn Osteocrin GGACTGGAGATTGGCAAGTAC CTTCTCTGGCTGTGGGTG 
Gene accession numbers (column A), gene symbols (column B), gene names (column C), forward primer 
(column D) and reverse primer (column D). 
 
  206 
Table B.2: A complete list of genes that were differentially expressed 3 hours following a single 
loading session in littermate control cortical bone in order of decreasing fold change that were: I. 
upregulated by mechanical loading and II. downregulated by mechanical loading. Number of genes 
(column A), gene symbols (column B), gene names (column C), fold change (column D), false 
discovery rate (FDR) (column E). 
 
Table B.2, Part I. Upregulated 3 hours after a single loading session in cortical bone of littermate 
control animals 
 Gene Symbol Gene Fold 
Change 
FDR 
1 Amd1 S-adenosylmethionine decarboxylase 1 225.88 2.2E-04 
2 Gm20594 predicted gene, 20594 22.12 1.6E-02 
3 Sypl2 synaptophysin-like 2 16.71 8.8E-04 
4 Sgcg sarcoglycan, gamma (dystrophin-associated glycoprotein) 16.00 2.1E-03 
5 Smpx small muscle protein, X-linked 15.88 2.9E-03 
6 Hfe2 hemochromatosis type 2 (juvenile) (human homolog) 15.30 1.8E-02 
7 Trim63 tripartite motif-containing 63 15.24 1.2E-03 
8 Xirp1 xin actin-binding repeat containing 1 15.10 1.8E-03 
9 Myot myotilin 14.48 1.7E-02 
10 Mylk4 myosin light chain kinase family, member 4 14.17 2.6E-04 
11 Murc muscle-related coiled-coil protein 13.75 8.0E-05 
12 Myom2 myomesin 2 13.66 8.8E-03 
13 Actn2 actinin alpha 2 11.99 3.4E-04 
14 Cilp cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 11.98 8.1E-03 
15 Mylk2 myosin, light polypeptide kinase 2, skeletal muscle 11.25 1.2E-02 
16 Atp2a1 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 11.23 2.3E-03 
17 Klhl41 kelch-like 41 11.07 8.0E-05 
18 Eef1a2 eukaryotic translation elongation factor 1 alpha 2 11.07 7.4E-03 
19 Myl1 myosin, light polypeptide 1 11.04 1.2E-03 
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Table B.2, Part I. Continued 
 Gene Symbol Gene Fold 
Change 
FDR 
20 Mybpc1 myosin binding protein C, slow-type 10.94 8.1E-03 
21 Neb nebulin 10.72 5.9E-04 
22 Lmod2 leiomodin 2 (cardiac) 10.66 8.8E-03 
23 A930016O22Rik RIKEN cDNA A930016O22 gene 10.23 1.7E-03 
24 Ucp3 uncoupling protein 3 (mitochondrial, proton carrier) 10.17 4.3E-05 
25 Ckmt2 creatine kinase, mitochondrial 2 9.93 7.4E-03 
26 Myoz1 myozenin 1 9.90 3.3E-02 
27 Apobec2 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2 9.82 4.3E-04 
28 Smyd1 SET and MYND domain containing 1 9.77 1.4E-02 
29 Mylpf myosin light chain, phosphorylatable, fast skeletal muscle 9.65 1.2E-03 
30 Acta1 actin, alpha 1, skeletal muscle 9.20 3.0E-02 
31 Casq1 calsequestrin 1 9.16 8.0E-03 
32 Nrap nebulin-related anchoring protein 9.07 9.4E-04 
33 Ttn titin 9.03 7.9E-04 
34 Ryr1 ryanodine receptor 1, skeletal muscle 8.98 2.2E-04 
35 Myoz3 myozenin 3 8.98 2.6E-02 
36 Mypn myopalladin 8.92 1.1E-02 
37 Mb myoglobin 8.85 1.5E-02 
38 Mybpc2 myosin binding protein C, fast-type 8.57 2.7E-03 
39 Myh1 myosin, heavy polypeptide 1, skeletal muscle, adult 8.56 3.3E-02 
40 Gm12505 predicted gene 12505 8.50 1.9E-05 
41 Actc1 actin, alpha, cardiac muscle 1 8.47 2.3E-02 
42 Ldb3 LIM domain binding 3 8.37 5.7E-04 
43 Tnnt3 troponin T3, skeletal, fast 8.23 2.2E-02 
44 Trim54 tripartite motif-containing 54 8.11 1.5E-02 
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Table B.2, Part I. Continued 
 Gene Symbol Gene Fold 
Change 
FDR 
45 Rsc1a1 regulatory solute carrier protein, family 1, member 1 8.02 3.8E-02 
46 Tnni2 troponin I, skeletal, fast 2 7.81 7.2E-03 
47 Cacna1s calcium channel, voltage-dependent, L type, alpha 1S subunit 7.77 2.7E-03 
48 Sh3bgr SH3-binding domain glutamic acid-rich protein 7.73 2.4E-03 
49 Tnnc2 troponin C2, fast 7.72 1.6E-02 
50 Scn4b sodium channel, type IV, beta 7.32 3.4E-04 
51 Prg4 proteoglycan 4 (megakaryocyte stimulating factor, articular superficial 
zone protein) 
7.18 1.4E-07 
52 Trim72 tripartite motif-containing 72 7.00 1.3E-04 
53 Atp1a2 ATPase, Na+/K+ transporting, alpha 2 polypeptide 6.97 8.7E-05 
54 Tmod4 tropomodulin 4 6.95 6.4E-04 
55 Angptl7 angiopoietin-like 7 6.90 1.2E-03 
56 Actn3 actinin alpha 3 6.83 2.8E-03 
57 Myoz2 myozenin 2 6.81 1.3E-03 
58 Mir703 microRNA 703 6.80 3.0E-02 
59 Trdn triadin 6.73 3.3E-02 
60 Rpl3l ribosomal protein L3-like 6.56 3.1E-03 
61 Cpt1b carnitine palmitoyltransferase 1b, muscle 6.49 3.2E-03 
62 Obscn obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF 6.48 1.6E-04 
63 Des desmin 6.41 3.9E-04 
64 Hspb7 heat shock protein family, member 7 (cardiovascular) 6.38 3.6E-05 
65 Pgam2 phosphoglycerate mutase 2 6.15 3.5E-04 
66 Pkia protein kinase inhibitor, alpha 5.99 1.0E-03 
67 Tcap titin-cap 5.95 3.8E-02 
68 Medag mesenteric estrogen dependent adipogenesis 5.65 2.2E-08 
69 Mlf1 myeloid leukemia factor 1 5.39 1.5E-04 
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Table B.2, Part I. Continued 
 Gene Symbol Gene Fold 
Change 
FDR 
70 Txlnb taxilin beta 5.37 2.7E-03 
71 Hspb8 heat shock protein 8 5.25 4.5E-05 
72 Phkg1 phosphorylase kinase gamma 1 5.21 1.9E-04 
73 Eno3 enolase 3, beta muscle 5.01 8.0E-05 
74 Synpo2l synaptopodin 2-like 4.86 1.0E-02 
75 Myo18b myosin XVIIIb 4.78 2.4E-03 
76 Ccdc175 coiled-coil domain containing 175 4.72 4.0E-02 
77 Cox7a1 cytochrome c oxidase, subunit VIIa 1 4.45 2.0E-03 
78 Itgb1bp2 integrin beta 1 binding protein 2 4.38 5.5E-03 
79 Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N 4.31 4.0E-05 
80 Myl2 myosin, light polypeptide 2, regulatory, cardiac, slow 4.29 2.9E-02 
81 Srl sarcalumenin 4.27 3.5E-04 
82 Ptgs2 prostaglandin-endoperoxide synthase 2 4.24 1.2E-08 
83 Ankrd23 ankyrin repeat domain 23 4.23 8.2E-04 
84 Flnc filamin C, gamma 4.18 5.2E-04 
85 Jsrp1 junctional sarcoplasmic reticulum protein 1 4.17 4.3E-02 
86 Lrrc2 leucine rich repeat containing 2 4.16 6.4E-04 
87 Pygm muscle glycogen phosphorylase 4.12 4.3E-04 
88 Tmem38a transmembrane protein 38A 4.01 3.0E-04 
89 Pdlim3 PDZ and LIM domain 3 3.99 5.1E-03 
90 Thbs4 thrombospondin 4 3.86 1.6E-03 
91 Scn4a sodium channel, voltage-gated, type IV, alpha 3.82 1.3E-03 
92 Ccl2 chemokine (C-C motif) ligand 2 3.75 1.2E-05 
93 Glrx3 predicted gene 12669; glutaredoxin 3 3.68 1.1E-04 
94 Cox6a2 cytochrome c oxidase, subunit VI a, polypeptide 2 3.67 4.9E-03 
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Table B.2, Part I. Continued 
 Gene Symbol Gene Fold 
Change 
FDR 
95 Ccl7 chemokine (C-C motif) ligand 7 3.65 3.0E-05 
96 Wnt7b wingless-related MMTV integration site 7B 3.63 1.8E-02 
97 Alpk3 alpha-kinase 3 3.59 2.8E-03 
98 Tnxb tenascin XB 3.56 8.9E-04 
99 Rpl22l1 ribosomal protein L22 like 1 3.52 2.7E-03 
100 Ppp1r3c protein phosphatase 1, regulatory (inhibitor) subunit 3C 3.50 5.2E-03 
101 Wnt1 wingless-related MMTV integration site 1 3.42 1.3E-05 
102 Tnfrsf12a tumor necrosis factor receptor superfamily, member 12a 3.41 2.2E-08 
103 Olfr1033 olfactory receptor 1033 3.36 4.2E-04 
104 Pm20d2 peptidase M20 domain containing 2 3.32 6.3E-03 
105 Tmsb15l thymosin beta 15b like 3.31 1.4E-02 
106 Rbm20 RNA binding motif protein 20 3.28 2.3E-03 
107 Asb2 ankyrin repeat and SOCS box-containing 2 3.26 1.2E-03 
108 Ndufc1 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1 3.25 4.7E-04 
109 Rtn2 reticulon 2 (Z-band associated protein) 3.21 4.9E-03 
110 1700063D05Rik RIKEN cDNA 1700063D05 gene 3.20 1.9E-02 
111 Gm6402 predicted pseudogene 6402 3.14 2.6E-02 
112 Smtnl2 smoothelin-like 2 3.13 3.3E-03 
113 1700007J10Rik RIKEN cDNA 1700007J10 gene 2.98 2.7E-03 
114 Jph2 junctophilin 2 2.94 4.8E-03 
115 2310040G24Rik RIKEN cDNA 2310040G24 gene 2.92 6.0E-03 
116 Rpl39 ribosomal protein L39 2.90 4.8E-03 
117 Myadml2 myeloid-associated differentiation marker-like 2 2.90 2.4E-02 
118 Fsd2 fibronectin type III and SPRY domain containing 2 2.89 1.2E-02 
119 Plin4 perilipin 4 2.88 1.8E-03 
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Table B.2, Part I. Continued 
 Gene Symbol Gene Fold 
Change 
FDR 
120 Gm561 predicted gene 561 2.87 7.2E-03 
121 Snrpe small nuclear ribonucleoprotein E; predicted gene 6487 2.87 1.8E-03 
122 Mt2 metallothionein 2 2.86 1.1E-04 
123 Nkx6-2 NK6 homeobox 2 2.83 2.2E-02 
124 Cmya5 cardiomyopathy associated 5 2.82 2.6E-03 
125 Hspb6 heat shock protein, alpha-crystallin-related, B6 2.78 3.5E-02 
126 Il20ra interleukin 20 receptor, alpha 2.76 7.3E-03 
127 Rragd Ras-related GTP binding D 2.75 3.1E-04 
128 Pgm5 phosphoglucomutase 5 2.74 4.6E-03 
129 Dpt dermatopontin 2.72 5.2E-04 
130 Acyp2 acylphosphatase 2, muscle type 2.72 4.0E-04 
131 Ch25h cholesterol 25-hydroxylase 2.65 5.8E-03 
132 Mlxipl MLX interacting protein-like 2.57 1.0E-02 
133 Snrpg predicted gene 8186; small nuclear ribonucleoprotein polypeptide G 2.56 5.9E-04 
134 Gm6634 predicted gene 6634 2.55 4.6E-03 
135 LOC100038947 signal-regulatory protein beta 1 2.54 2.7E-03 
136 2010107E04Rik RIKEN cDNA 2010107E04 gene 2.54 2.2E-04 
137 Shisa2 shisa homolog 2 (Xenopus laevis) 2.53 1.5E-02 
138 Nt5e 5' nucleotidase, ecto 2.53 1.9E-04 
139 Nov nephroblastoma overexpressed gene 2.52 2.8E-02 
140 Gm4980 predicted gene 4980 2.52 3.4E-04 
141 Cap2 CAP, adenylate cyclase-associated protein, 2 (yeast) 2.49 1.1E-02 
142 Zdhhc2 zinc finger, DHHC domain containing 2 2.46 1.4E-02 
143 Prkaa2 protein kinase, AMP-activated, alpha 2 catalytic subunit 2.45 2.7E-03 
144 Gt(ROSA)26Sor gene trap ROSA 26, Philippe Soriano 2.44 1.1E-02 
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Table B.2, Part I. Continued 
 Gene Symbol Gene Fold 
Change 
FDR 
145 0610009L18Rik RIKEN cDNA 0610009L18 gene 2.44 7.3E-03 
146 Nup62-il4i1 predicted gene, 21948 2.42 3.2E-04 
147 Snhg6 small nucleolar RNA host gene (non-protein coding) 6 2.40 8.5E-04 
148 Rian RNA imprinted and accumulated in nucleus 2.40 1.6E-03 
149 Mrps14 mitochondrial ribosomal protein S14 2.40 1.7E-03 
150 Tfpi2 tissue factor pathway inhibitor 2 2.40 1.1E-07 
151 Mustn1 musculoskeletal, embryonic nuclear protein 1 2.39 1.7E-03 
152 Cyp2r1 cytochrome P450, family 2, subfamily r, polypeptide 1 2.39 3.4E-02 
153 Ankrd2 ankyrin repeat domain 2 (stretch responsive muscle) 2.38 2.3E-02 
154 Steap1 six transmembrane epithelial antigen of the prostate 1 2.37 3.5E-02 
155 3425401B19Rik RIKEN cDNA 3425401B19 gene 2.37 2.0E-02 
156 Gm20939 predicted gene, 20939 2.37 4.3E-02 
157 Dmd dystrophin, muscular dystrophy 2.36 1.2E-02 
158 Gprc5a G protein-coupled receptor, family C, group 5, member A 2.36 1.3E-02 
159 Hist2h3c2 histone cluster 2, H3c2 2.35 4.5E-02 
160 2310010M20Rik RIKEN cDNA 2310010M20 gene 2.32 1.1E-02 
161 Ncs1 neuronal calcium sensor 1 2.32 1.1E-04 
162 5730408K05Rik RIKEN cDNA 5730408K05 gene 2.31 4.1E-03 
163 Sema3c sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3C 
2.30 3.1E-03 
164 Fhl1 four and a half LIM domains 1 2.30 1.6E-03 
165 Nxpe5 neurexophilin and PC-esterase domain family, member 5 2.30 7.2E-04 
166 0610039K10Rik RIKEN cDNA 0610039K10 gene 2.29 2.2E-03 
167 Ociad2 OCIA domain containing 2 2.29 1.5E-02 
168 Fam69c family with sequence similarity 69, member C 2.27 1.4E-02 
169 Pfkm phosphofructokinase, muscle 2.26 4.0E-03 
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170 Pp2d1 protein phosphatase 2C-like domain containing 1 2.26 1.9E-02 
171 Mapt microtubule-associated protein tau 2.24 4.0E-02 
172 H2afz H2A histone family, member Z; predicted gene 6722; predicted gene 8203 2.24 3.0E-03 
173 Igfbp6 insulin-like growth factor binding protein 6 2.24 3.4E-02 
174 Cox5a cytochrome c oxidase, subunit Va 2.23 3.6E-05 
175 Hint3 histidine triad nucleotide binding protein 3 2.23 1.5E-02 
176 Stard3nl STARD3 N-terminal like 2.22 5.3E-03 
177 AU041133 expressed sequence AU041133 2.22 2.4E-02 
178 Cib2 calcium and integrin binding family member 2 2.22 1.2E-04 
179 0610010B08Rik RIKEN cDNA 0610010B08 gene 2.21 1.5E-02 
180 Ndrg2 N-myc downstream regulated gene 2 2.20 3.2E-03 
181 Cd53 CD53 antigen 2.19 2.1E-03 
182 Stac3 SH3 and cysteine rich domain 3 2.18 1.6E-02 
183 Lyz1 lysozyme 1 2.17 1.1E-02 
184 Ccl12 chemokine (C-C motif) ligand 12 2.16 1.2E-03 
185 Rpl39l ribosomal protein L39-like 2.16 1.4E-02 
186 Tpm2 tropomyosin 2, beta 2.14 3.7E-02 
187 Slirp SRA stem-loop interacting RNA binding protein 2.14 6.4E-04 
188 1110058L19Rik RIKEN cDNA 1110058L19 gene 2.14 1.1E-02 
189 Tacc2 transforming, acidic coiled-coil containing protein 2 2.14 8.3E-04 
190 Tm4sf1 transmembrane 4 superfamily member 1 2.13 5.9E-04 
191 Pvt1 plasmacytoma variant translocation 1 2.13 1.4E-03 
192 Eda2r ectodysplasin A2 isoform receptor 2.11 2.4E-02 
193 Rfc4 replication factor C (activator 1) 4 2.11 2.0E-03 
194 Ddn dendrin 2.10 4.6E-02 
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195 2010003O02Rik RIKEN cDNA 2010003O02 gene 2.10 6.8E-03 
196 Scn7a sodium channel, voltage-gated, type VII, alpha 2.10 1.8E-02 
197 Slc4a4 solute carrier family 4 (anion exchanger), member 4 2.09 1.7E-03 
198 Ms4a6d membrane-spanning 4-domains, subfamily A, member 6D 2.08 3.7E-07 
199 Baalc brain and acute leukemia, cytoplasmic 2.08 3.6E-02 
200 Churc1 churchill domain containing 1 2.08 1.2E-03 
201 Ptp4a1 protein tyrosine phosphatase 4a1 2.07 1.6E-03 
202 Egf epidermal growth factor 2.07 2.2E-02 
203 Ly6a lymphocyte antigen 6 complex, locus A 2.07 8.0E-05 
204 Timm9 translocase of inner mitochondrial membrane 9 homolog (yeast) 2.06 5.9E-04 
205 Sar1b SAR1 gene homolog B (S. cerevisiae) 2.06 3.0E-04 
206 Pigp phosphatidylinositol glycan anchor biosynthesis, class P 2.05 9.8E-03 
207 Rps27rt ribosomal protein S27, retrogene 2.04 4.0E-03 
208 Cfl2 cofilin 2, muscle 2.04 4.0E-04 
209 Pdzd9 PDZ domain containing 9 2.04 3.7E-02 
210 Ndufb6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 2.03 3.8E-04 
211 Zxdb zinc finger, X-linked, duplicated B 2.03 2.4E-02 
212 Uqcc2 ubiquinol-cytochrome c reductase complex assembly factor 2 2.02 1.6E-04 
213 Cav2 caveolin 2 2.02 2.4E-03 
214 Cisd1 CDGSH iron sulfur domain 1 2.02 8.0E-05 
215 Zfp938 zinc finger protein 938 2.02 2.0E-02 
216 Ppap2c phosphatidic acid phosphatase type 2C 2.02 1.6E-03 
217 Lars2 leucyl-tRNA synthetase, mitochondrial 2.01 7.3E-04 
218 Ngf nerve growth factor 2.01 1.7E-03 
219 Slc25a33 solute carrier family 25, member 33 2.00 5.2E-03 
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220 Clec4b1 C-type lectin domain family 4, member b1 2.00 3.8E-02 
221 Fdx1 ferredoxin 1 2.00 1.9E-03 
222 Gm16596 predicted gene, 16596 1.98 2.5E-02 
223 Ccl8 chemokine (C-C motif) ligand 8 1.98 4.3E-02 
224 Tnfrsf11b tumor necrosis factor receptor superfamily, member 11b 
(osteoprotegerin) 
1.98 2.6E-04 
225 Lmcd1 LIM and cysteine-rich domains 1 1.97 2.0E-03 
226 B3gat2 beta-1,3-glucuronyltransferase 2 (glucuronosyltransferase S) 1.97 1.2E-02 
227 Acn9 ACN9 homolog (S. cerevisiae) 1.96 2.1E-02 
228 Mir22hg Mir22 host gene (non-protein coding) 1.95 1.2E-03 
229 Rps27a ribosomal protein S27A 1.95 4.6E-03 
230 Art1 ADP-ribosyltransferase 1 1.95 3.3E-02 
231 Dmkn dermokine 1.94 1.1E-02 
232 Gng10 guanine nucleotide binding protein (G protein), gamma 10 1.94 2.0E-03 
233 5830428M24Rik RIKEN cDNA 5830428M24 gene 1.93 4.8E-02 
234 Mrps18c mitochondrial ribosomal protein S18C 1.93 1.8E-03 
235 Kbtbd3 kelch repeat and BTB (POZ) domain containing 3 1.93 4.8E-02 
236 Ndufs4 NADH dehydrogenase (ubiquinone) Fe-S protein 4 1.92 4.8E-04 
237 Cntf ciliary neurotrophic factor 1.92 4.3E-02 
238 Kcne4 potassium voltage-gated channel, Isk-related subfamily, gene 4 1.92 2.5E-02 
239 Myom3 myomesin family, member 3 1.92 2.6E-02 
240 A730017L22Rik RIKEN cDNA A730017L22 gene 1.92 9.9E-03 
241 Smim4 small integral membrane protein 4 1.92 2.8E-02 
242 Mss51 MSS51 mitochondrial translational activator 1.92 3.2E-02 
243 Popdc2 popeye domain containing 2 1.92 4.1E-02 
244 3110007F17Rik RIKEN cDNA 3110007F17 gene 1.91 2.3E-02 
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245 Unc45b unc-45 homolog B (C. elegans) 1.90 1.2E-03 
246 Cenpw centromere protein W 1.89 2.9E-02 
247 Eif1 eukaryotic translation initiation factor 1 1.89 1.8E-03 
248 Zfp825 zinc finger protein 825 1.89 1.4E-02 
249 Rpl10 ribosomal protein L10 1.89 9.6E-03 
250 Tatdn1 TatD DNase domain containing 1 1.88 6.4E-03 
251 1110001J03Rik RIKEN cDNA 1110001J03 gene 1.88 4.3E-03 
252 Vbp1 von Hippel-Lindau binding protein 1 1.88 4.0E-03 
253 Tmem128 transmembrane protein 128 1.88 5.9E-03 
254 Usp13 ubiquitin specific peptidase 13 (isopeptidase T-3) 1.88 2.4E-02 
255 Rps14 ribosomal protein S14 1.87 6.4E-03 
256 Rps19 ribosomal protein S19 1.87 4.0E-03 
257 Rgs16 regulator of G-protein signaling 16 1.87 1.4E-02 
258 1110046J04Rik RIKEN cDNA 1110046J04 gene 1.87 4.5E-02 
259 1810032O08Rik RIKEN cDNA 1810032O08 gene 1.87 2.7E-03 
260 Plat plasminogen activator, tissue 1.86 2.8E-02 
261 Mcts1 malignant T cell amplified sequence 1 1.86 9.2E-03 
262 Vmp1 vacuole membrane protein 1 1.86 2.2E-04 
263 Glmn glomulin, FKBP associated protein 1.86 2.1E-02 
264 Rpl34 ribosomal protein L34 1.86 4.1E-02 
265 Eef1e1 eukaryotic translation elongation factor 1 epsilon 1 1.86 1.1E-03 
266 1500015O10Rik RIKEN cDNA 1500015O10 gene 1.86 1.4E-02 
267 Klhl30 kelch-like 30 (Drosophila) 1.85 1.0E-02 
268 Art3 ADP-ribosyltransferase 3 1.85 4.0E-02 
269 Gpd1 glycerol-3-phosphate dehydrogenase 1 (soluble) 1.85 4.5E-03 
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270 Tceanc transcription elongation factor A (SII) N-terminal and central domain 
containing 
1.85 1.4E-02 
271 Fam108b family with sequence similarity 108, member B 1.84 1.1E-02 
272 Cox16 cytochrome c oxidase assembly protein 16 1.84 7.6E-03 
273 Inhba inhibin beta-A 1.84 6.2E-03 
274 Myeov2 myeloma overexpressed 2 1.83 2.4E-03 
275 Ndufb2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2 1.83 8.4E-03 
276 2410076I21Rik RIKEN cDNA 2410076I21 gene 1.83 4.7E-02 
277 Ak4 adenylate kinase 4 1.83 1.8E-03 
278 Tbca tubulin cofactor A 1.83 1.2E-02 
279 Tspan4 tetraspanin 4 1.82 1.2E-03 
280 Hbegf heparin-binding EGF-like growth factor 1.82 1.3E-03 
281 Mettl23 methyltransferase like 23 1.82 2.0E-02 
282 Pole4 polymerase (DNA-directed), epsilon 4 (p12 subunit) 1.82 2.4E-03 
283 Zfp593 zinc finger protein 593 1.81 9.5E-04 
284 Zfp930 zinc finger protein 930 1.81 8.9E-03 
285 Pcgf6 polycomb group ring finger 6 1.81 7.4E-03 
286 Gls glutaminase 1.80 3.0E-03 
287 B630005N14Rik RIKEN cDNA B630005N14 gene 1.80 8.8E-03 
288 Hgh1 HGH1 homolog 1.80 5.0E-03 
289 Zfp932 zinc finger protein 932 1.80 4.1E-03 
290 Atf3 activating transcription factor 3 1.80 4.3E-02 
291 Slpi secretory leukocyte peptidase inhibitor 1.80 7.5E-03 
292 Synm synemin, intermediate filament protein 1.80 3.0E-04 
293 Lgr6 leucine-rich repeat-containing G protein-coupled receptor 6 1.79 4.1E-02 
294 Zfp119a zinc finger protein 119a 1.79 1.1E-02 
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295 Cox11 COX11 homolog, cytochrome c oxidase assembly protein (yeast) 1.79 9.7E-04 
296 Hspb1 heat shock protein 1 1.79 4.3E-03 
297 Fam96a family with sequence similarity 96, member A 1.78 2.0E-03 
298 Slc2a4 solute carrier family 2 (facilitated glucose transporter), member 4 1.78 2.4E-02 
299 2310001H17Rik RIKEN cDNA 2310001H17 gene 1.78 3.4E-02 
300 Sdcbp syndecan binding protein 1.78 1.2E-03 
301 2010315B03Rik RIKEN cDNA 2010315B03 gene 1.78 7.0E-03 
302 Ndufab1 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1 1.78 2.7E-03 
303 Ap4s1 adaptor-related protein complex AP-4, sigma 1 1.78 3.7E-03 
304 Got1 glutamate oxaloacetate transaminase 1, soluble 1.78 6.4E-04 
305 Stbd1 starch binding domain 1 1.78 1.9E-02 
306 1700113A16Rik RIKEN cDNA 1700113A16 gene 1.77 1.7E-02 
307 Tmed5 transmembrane emp24 protein transport domain containing 5 1.77 2.8E-03 
308 Chac2 ChaC, cation transport regulator homolog 2 (E. coli) 1.77 1.6E-02 
309 Crip1 cysteine-rich protein 1 (intestinal) 1.76 8.7E-04 
310 Pfkfb1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 1.76 2.6E-02 
311 Tmsb4x thymosin, beta 4, X chromosome 1.76 7.5E-03 
312 0610009B22Rik RIKEN cDNA 0610009B22 gene 1.76 2.6E-02 
313 2210013O21Rik RIKEN cDNA 2210013O21 gene 1.76 9.1E-03 
314 Snhg3 small nucleolar RNA host gene (non-protein coding) 3 1.76 2.0E-03 
315 Ms4a7 membrane-spanning 4-domains, subfamily A, member 7 1.75 9.7E-05 
316 Tmem256 transmembrane protein 256 1.75 2.1E-03 
317 Ugdh UDP-glucose dehydrogenase 1.75 8.0E-05 
318 Car14 carbonic anhydrase 14 1.75 2.1E-02 
319 Mdh1 malate dehydrogenase 1, NAD (soluble) 1.74 9.9E-04 
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320 Chchd2 coiled-coil-helix-coiled-coil-helix domain containing 2 1.74 3.8E-04 
321 Gstp1 glutathione S-transferase, pi 1 1.74 4.1E-03 
322 Dancr differentiation antagonizing non-protein coding RNA 1.74 9.1E-03 
323 Slc35a1 solute carrier family 35 (CMP-sialic acid transporter), member 1 1.74 3.8E-03 
324 Ndufaf5 NADH dehydrogenase (ubiquinone) complex I, assembly factor 5 1.74 9.8E-03 
325 Aldh3a1 aldehyde dehydrogenase family 3, subfamily A1 1.74 4.9E-04 
326 Clec4a2 C-type lectin domain family 4, member a2 1.73 4.9E-03 
327 Atp5g3 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c 
(subunit 9), isoform 3 
1.73 9.9E-04 
328 Il1b interleukin 1 beta 1.73 1.7E-03 
329 Ndufa4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4 1.73 5.9E-04 
330 Cept1 choline/ethanolaminephosphotransferase 1 1.72 3.8E-03 
331 Gabarapl2 gamma-aminobutyric acid (GABA) A receptor-associated protein-like 2 1.72 4.6E-03 
332 Smim7 small integral membrane protein 7 1.72 4.6E-03 
333 Tmem60 transmembrane protein 60 1.72 3.7E-02 
334 Coq10b coenzyme Q10 homolog B (S. cerevisiae) 1.71 5.2E-03 
335 Cklf chemokine-like factor 1.71 1.5E-02 
336 Actr6 ARP6 actin-related protein 6 homolog (yeast) 1.71 1.9E-02 
337 Lipt2 lipoyl(octanoyl) transferase 2 (putative) 1.71 1.4E-02 
338 Pdrg1 p53 and DNA damage regulated 1 1.71 8.0E-05 
339 Cox14 cytochrome c oxidase assembly protein 14 1.71 9.2E-03 
340 Fsd1l fibronectin type III and SPRY domain containing 1-like 1.70 3.1E-02 
341 Srxn1 sulfiredoxin 1 homolog (S. cerevisiae) 1.70 8.0E-05 
342 Hist1h4i histone cluster 1, H4i 1.70 2.2E-02 
343 1810043H04Rik RIKEN cDNA 1810043H04 gene 1.70 1.1E-02 
344 Cript cysteine-rich PDZ-binding protein 1.69 5.1E-03 
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345 Stard7 START domain containing 7 1.69 1.7E-03 
346 C1d C1D nuclear receptor co-repressor 1.69 1.3E-02 
347 Usp2 ubiquitin specific peptidase 2 1.69 9.8E-03 
348 Tmod1 tropomodulin 1 1.69 2.1E-02 
349 Atp5e ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon 
subunit 
1.69 3.5E-04 
350 Kbtbd8 kelch repeat and BTB (POZ) domain containing 8 1.69 3.3E-02 
351 Wdr92 WD repeat domain 92 1.69 2.6E-04 
352 Igj immunoglobulin joining chain 1.69 1.2E-02 
353 Clec2d C-type lectin domain family 2, member d 1.68 2.0E-03 
354 Cnbp cellular nucleic acid binding protein 1.68 8.0E-04 
355 Tmem126a transmembrane protein 126A 1.68 3.2E-03 
356 Mettl5 methyltransferase like 5 1.68 1.2E-02 
357 Cops5 COP9 (constitutive photomorphogenic) homolog, subunit 5 (Arabidopsis 
thaliana) 
1.68 2.6E-03 
358 Amn1 antagonist of mitotic exit network 1 homolog (S. cerevisiae) 1.68 3.4E-02 
359 Tcp11l2 t-complex 11 (mouse) like 2 1.68 6.2E-03 
360 Psma3 proteasome (prosome, macropain) subunit, alpha type 3; predicted gene 
5406 
1.68 1.1E-03 
361 Nipa2 non imprinted in Prader-Willi/Angelman syndrome 2 homolog (human) 1.68 6.5E-03 
362 Fam213b family with sequence similarity 213, member B 1.67 9.5E-04 
363 Pgk1 phosphoglycerate kinase 1 1.67 1.0E-04 
364 Tnfsf11 tumor necrosis factor (ligand) superfamily, member 11 1.67 3.1E-03 
365 Qrsl1 glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1 1.67 2.4E-02 
366 Pdp1 protein phosphatase 2C, magnesium dependent, catalytic subunit 1.67 4.2E-03 
367 Pde4b phosphodiesterase 4B, cAMP specific 1.67 5.5E-04 
368 Gyk glycerol kinase 1.67 4.0E-03 
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369 Gp49a glycoprotein 49 A; leukocyte immunoglobulin-like receptor, subfamily B, 
member 4 
1.67 4.8E-04 
370 Tefm transcription elongation factor, mitochondrial 1.66 1.3E-02 
371 Ndufa3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3 1.66 2.3E-03 
372 1600020E01Rik RIKEN cDNA 1600020E01 gene 1.66 2.4E-02 
373 Fundc2 FUN14 domain containing 2 1.66 7.2E-03 
374 S100a9 S100 calcium binding protein A9 (calgranulin B) 1.66 1.9E-02 
375 Scn1b sodium channel, voltage-gated, type I, beta 1.65 5.6E-04 
376 Hnrnpa1 heterogeneous nuclear ribonucleoprotein A1 1.65 2.1E-03 
377 Gcsh glycine cleavage system protein H (aminomethyl carrier) 1.65 6.9E-04 
378 Slc25a3 solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 
3 
1.65 2.7E-03 
379 Bbs12 Bardet-Biedl syndrome 12 (human) 1.65 2.8E-02 
380 Styx serine/threonine/tyrosine interaction protein 1.65 1.4E-02 
381 Acacb acetyl-Coenzyme A carboxylase beta 1.65 4.9E-02 
382 Eny2 enhancer of yellow 2 homolog (Drosophila); predicted gene 16373 1.64 5.2E-03 
383 Ildr2 immunoglobulin-like domain containing receptor 2 1.64 1.9E-02 
384 Zfp711 zinc finger protein 711 1.64 3.4E-02 
385 Tspan8 tetraspanin 8 1.64 1.6E-02 
386 Gnl3 guanine nucleotide binding protein-like 3 (nucleolar) 1.64 1.2E-04 
387 Rchy1 ring finger and CHY zinc finger domain containing 1 1.64 7.2E-04 
388 Chchd4 coiled-coil-helix-coiled-coil-helix domain containing 4 1.64 1.8E-03 
389 Aldoa aldolase A, fructose-bisphosphate 1.63 1.1E-02 
390 Tm2d1 TM2 domain containing 1 1.63 2.1E-02 
391 Ctps cytidine 5'-triphosphate synthase 1.63 8.4E-06 
392 Soat2 sterol O-acyltransferase 2 1.63 3.7E-02 
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393 Chi3l3 chitinase 3-like 3 1.63 2.2E-02 
394 Fyttd1 forty-two-three domain containing 1 1.63 4.6E-03 
395 S100a6 S100 calcium binding protein A6 (calcyclin) 1.62 8.3E-04 
396 Chuk conserved helix-loop-helix ubiquitous kinase 1.62 1.1E-02 
397 L2hgdh L-2-hydroxyglutarate dehydrogenase 1.62 1.0E-02 
398 Prdx3 peroxiredoxin 3 1.62 7.4E-03 
399 Hdgfrp3 hepatoma-derived growth factor, related protein 3 1.62 2.5E-02 
400 Bcap29 B-cell receptor-associated protein 29 1.62 1.4E-02 
401 Zfp472 zinc finger protein 472 1.62 1.4E-02 
402 Idh3a isocitrate dehydrogenase 3 (NAD+) alpha 1.62 1.7E-03 
403 Polr2l polymerase (RNA) II (DNA directed) polypeptide L 1.61 8.6E-04 
404 2900076A07Rik RIKEN cDNA 2900076A07 gene 1.61 3.7E-02 
405 Capza2 capping protein (actin filament) muscle Z-line, alpha 2 1.61 7.1E-03 
406 Mrpl13 mitochondrial ribosomal protein L13 1.61 8.0E-05 
407 Slc35b3 solute carrier family 35, member B3 1.61 2.5E-02 
408 Cd320 CD320 antigen 1.61 3.4E-02 
409 Pla2g16 phospholipase A2, group XVI 1.61 4.3E-03 
410 Eif3m eukaryotic translation initiation factor 3, subunit M 1.61 9.2E-04 
411 Zfp52 zinc finger protein 52 1.61 3.8E-03 
412 Paip2b poly(A) binding protein interacting protein 2B 1.61 2.8E-03 
413 Gem GTP binding protein (gene overexpressed in skeletal muscle) 1.61 3.3E-02 
414 Bvht braveheart long non-coding RNA 1.61 1.6E-02 
415 Ccnb1 cyclin B1 1.61 1.9E-02 
416 Acat3 acetyl-Coenzyme A acetyltransferase 3 1.60 1.7E-02 
417 2610001J05Rik RIKEN cDNA 2610001J05 gene 1.60 2.8E-03 
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418 Ccr3 chemokine (C-C motif) receptor 3 1.60 3.1E-02 
419 Prdx4 peroxiredoxin 4 1.60 5.1E-03 
420 Tmem70 transmembrane protein 70 1.60 4.8E-03 
421 Fam26e family with sequence similarity 26, member E 1.60 4.7E-02 
422 Pnp purine-nucleoside phosphorylase 1.60 3.7E-03 
423 BC017612 cDNA sequence BC017612 1.60 1.7E-02 
424 Wdr12 WD repeat domain 12 1.60 3.4E-04 
425 Psmg4 proteasome (prosome, macropain) assembly chaperone 4 1.60 5.0E-02 
426 Calcrl calcitonin receptor-like 1.60 9.9E-03 
427 Cyb561 cytochrome b-561 1.59 2.3E-02 
428 Polr3k polymerase (RNA) III (DNA directed) polypeptide K 1.59 5.1E-03 
429 Mtcp1 mature T-cell proliferation 1 1.59 8.8E-03 
430 Gm17066 predicted gene 17066 1.59 2.1E-02 
431 Gnb4 guanine nucleotide binding protein (G protein), beta 4 1.59 3.8E-03 
432 Rps21 ribosomal protein S21 1.59 9.2E-03 
433 Zfand5 zinc finger, AN1-type domain 5 1.59 7.2E-03 
434 Rps15a ribosomal protein S15A 1.59 3.3E-03 
435 Ube2e3 ubiquitin-conjugating enzyme E2E 3, UBC4/5 homolog (yeast) 1.59 1.3E-02 
436 Apold1 apolipoprotein L domain containing 1 1.59 4.4E-03 
437 Ran RAN, member RAS oncogene family 1.58 1.1E-03 
438 Msr1 macrophage scavenger receptor 1 1.58 3.5E-04 
439 Cnep1r1 CTD nuclear envelope phosphatase 1 regulatory subunit 1 1.58 1.1E-02 
440 Timm8a1 translocase of inner mitochondrial membrane 8 homolog a1 (yeast) 1.58 7.9E-04 
441 Ccr5 chemokine (C-C motif) receptor 5 1.58 4.0E-03 
442 Mir17hg Mir17 host gene (non-protein coding) 1.58 1.2E-02 
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443 2700097O09Rik RIKEN cDNA 2700097O09 gene 1.58 4.4E-02 
444 Tceb1 transcription elongation factor B (SIII), polypeptide 1 1.58 9.6E-03 
445 Phka1 phosphorylase kinase alpha 1 1.58 8.9E-03 
446 Uqcr10 RIKEN cDNA 1110020P15 gene; predicted gene 6293 1.58 8.3E-04 
447 Tmem126b transmembrane protein 126B 1.58 3.6E-02 
448 Cmc1 COX assembly mitochondrial protein homolog (S. cerevisiae) 1.58 4.1E-02 
449 Tex30 testis expressed 30 1.58 3.9E-02 
450 Ifi47 interferon gamma inducible protein 47 1.58 9.8E-03 
451 Psmd6 proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 1.58 7.4E-03 
452 1110038B12Rik RIKEN cDNA 1110038B12 gene 1.57 1.3E-02 
453 Itga7 integrin alpha 7 1.57 9.6E-03 
454 Mmadhc methylmalonic aciduria (cobalamin deficiency) cblD type, with 
homocystinuria 
1.57 5.2E-03 
455 Suz12 suppressor of zeste 12 homolog (Drosophila) 1.57 1.2E-02 
456 Rab28 RAB28, member RAS oncogene family 1.57 1.7E-02 
457 Mbip MAP3K12 binding inhibitory protein 1 1.57 2.6E-02 
458 Tomm20 translocase of outer mitochondrial membrane 20 homolog (yeast) 1.57 2.5E-03 
459 Qtrtd1 queuine tRNA-ribosyltransferase domain containing 1 1.57 9.3E-04 
460 Orc4 origin recognition complex, subunit 4 1.56 1.3E-02 
461 Hspa1l heat shock protein 1B; heat shock protein 1A; heat shock protein 1-like 1.56 3.6E-02 
462 Vmn1r58 vomeronasal 1 receptor 58 1.56 3.4E-02 
463 Drg1 developmentally regulated GTP binding protein 1 1.56 5.1E-03 
464 Trim59 tripartite motif-containing 59 1.56 2.2E-02 
465 Timm8b translocase of inner mitochondrial membrane 8 homolog b (yeast) 1.56 2.7E-03 
466 Sft2d1 SFT2 domain containing 1 1.56 7.4E-03 
467 Uqcrfs1 ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 1.56 1.4E-03 
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468 Wdyhv1 WDYHV motif containing 1 1.56 1.7E-02 
469 Rangrf RAN guanine nucleotide release factor 1.56 1.5E-02 
470 Unc50 unc-50 homolog (C. elegans) 1.56 1.2E-02 
471 Eif1a eukaryotic translation initiation factor 1A 1.56 3.8E-04 
472 Wfdc17 WAP four-disulfide core domain 17 1.56 1.0E-02 
473 Hilpda hypoxia inducible lipid droplet associated 1.56 2.7E-02 
474 Atp5j2 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F2 1.56 6.9E-04 
475 Pcmt1 protein-L-isoaspartate (D-aspartate) O-methyltransferase 1 1.55 5.2E-03 
476 Atp6v0e ATPase, H+ transporting, lysosomal V0 subunit E 1.55 1.3E-02 
477 Ufc1 ubiquitin-fold modifier conjugating enzyme 1 1.55 2.8E-02 
478 Egln3 EGL nine homolog 3 (C. elegans) 1.55 4.0E-02 
479 Mkks McKusick-Kaufman syndrome protein 1.55 1.2E-02 
480 Rbbp4 retinoblastoma binding protein 4 1.55 7.8E-03 
481 Ube2v2 ubiquitin-conjugating enzyme E2 variant 2 1.55 1.4E-02 
482 Mff mitochondrial fission factor; hypothetical protein LOC637796 1.55 1.1E-02 
483 Emp1 epithelial membrane protein 1 1.55 2.3E-03 
484 Cd209a CD209a antigen 1.55 1.3E-02 
485 Tmem147 transmembrane protein 147 1.55 4.3E-03 
486 Cops8 COP9 (constitutive photomorphogenic) homolog, subunit 8 (Arabidopsis 
thaliana) 
1.55 8.3E-04 
487 Tmem167 transmembrane protein 167 1.55 2.4E-02 
488 Epdr1 ependymin related protein 1 (zebrafish) 1.55 4.4E-03 
489 Aasdhppt aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl 
transferase; hypothetical protein LOC100044211 
1.55 1.4E-02 
490 Mrps17 mitochondrial ribosomal protein S17 1.55 2.9E-03 
491 Skp1a S-phase kinase-associated protein 1A 1.55 5.2E-03 
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492 Tmem59 transmembrane protein 59 1.54 3.4E-02 
493 Jtb jumping translocation breakpoint 1.54 9.2E-03 
494 Cd36 CD36 antigen 1.54 9.2E-03 
495 Ank progressive ankylosis 1.54 1.6E-02 
496 Ndufa2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2 1.54 1.8E-03 
497 Fgl2 fibrinogen-like protein 2 1.54 1.2E-03 
498 Adamts1 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 1 
1.54 1.4E-03 
499 Tmem62 transmembrane protein 62 1.54 9.2E-03 
500 Med6 mediator of RNA polymerase II transcription, subunit 6 homolog (yeast) 1.54 1.4E-02 
501 Fdxacb1 ferredoxin-fold anticodon binding domain containing 1 1.54 2.2E-02 
502 Sgk1 serum/glucocorticoid regulated kinase 1 1.54 1.2E-04 
503 Pex2 peroxisomal biogenesis factor 2 1.54 7.4E-03 
504 Nudt16 nudix (nucleoside diphosphate linked moiety X)-type motif 16 1.54 2.9E-02 
505 2700094K13Rik RIKEN cDNA 2700094K13 gene 1.54 3.1E-02 
506 Ldha lactate dehydrogenase A 1.53 3.0E-04 
507 Mmp19 matrix metallopeptidase 19 1.53 2.7E-03 
508 Heatr1 HEAT repeat containing 1 1.53 1.3E-03 
509 Etfa electron transferring flavoprotein, alpha polypeptide 1.53 5.2E-03 
510 Rps18 ribosomal protein S18 1.53 1.5E-02 
511 Cldn25 predicted gene 16492 1.53 9.7E-03 
512 Zfx zinc finger protein X-linked 1.53 2.4E-02 
513 Nrep neuronal regeneration related protein 1.53 1.1E-02 
514 Gpr171 G protein-coupled receptor 171 1.53 4.6E-02 
515 Slc4a7 solute carrier family 4, sodium bicarbonate cotransporter, member 7 1.53 1.6E-02 
516 Anxa1 annexin A1 1.53 8.0E-03 
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517 Slc22a5 solute carrier family 22 (organic cation transporter), member 5 1.53 1.4E-02 
518 Atp5l ATP synthase, H+ transporting, mitochondrial F0 complex, subunit G 1.53 4.9E-04 
519 Cox17 cytochrome c oxidase assembly protein 17 1.53 1.3E-02 
520 Reep1 receptor accessory protein 1 1.53 2.0E-02 
521 Fau Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously 
expressed (fox derived) 
1.52 3.5E-02 
522 Tmem64 transmembrane protein 64 1.52 2.9E-02 
523 1810026B05Rik RIKEN cDNA 1810026B05 gene 1.52 1.5E-02 
524 Arrdc3 arrestin domain containing 3 1.52 6.4E-04 
525 Naa50 N(alpha)-acetyltransferase 50, NatE catalytic subunit 1.52 4.6E-03 
526 Mrps6 mitochondrial ribosomal protein S6 1.52 1.1E-02 
527 Ddit4l DNA-damage-inducible transcript 4-like 1.52 2.8E-03 
528 Rtn4 reticulon 4 1.52 1.7E-03 
529 Fam126b family with sequence similarity 126, member B 1.52 2.6E-02 
530 Prdx1 peroxiredoxin 1 1.52 3.1E-03 
531 Srsf7 serine/arginine-rich splicing factor 7 1.52 6.6E-03 
532 Aif1 allograft inflammatory factor 1 1.51 2.0E-02 
533 Gyg glycogenin 1.51 1.2E-02 
534 Zfp383 zinc finger protein 383 1.51 4.1E-02 
535 Rnf138 ring finger protein 138 1.51 3.0E-02 
536 Fastkd3 FAST kinase domains 3 1.51 1.6E-02 
537 Slc30a4 solute carrier family 30 (zinc transporter), member 4 1.51 2.0E-02 
538 Immp1l IMP1 inner mitochondrial membrane peptidase-like (S. cerevisiae) 1.51 3.1E-02 
539 Tubgcp5 tubulin, gamma complex associated protein 5 1.51 1.6E-02 
540 Mpp7 membrane protein, palmitoylated 7 (MAGUK p55 subfamily member 7) 1.51 1.2E-02 
541 Gm11974 predicted gene 11974 1.51 4.7E-02 
  228 
Table B.2, Part I. Continued 
 Gene Symbol Gene Fold 
Change 
FDR 
542 Desi2 desumoylating isopeptidase 2 1.51 1.4E-02 
543 Echs1 enoyl Coenzyme A hydratase, short chain, 1, mitochondrial 1.51 7.4E-03 
544 Vamp3 vesicle-associated membrane protein 3 1.51 1.0E-02 
545 Mat2a methionine adenosyltransferase II, alpha 1.51 9.2E-03 
546 Olfr613 olfactory receptor 613 1.51 4.1E-02 
547 Actr2 ARP2 actin-related protein 2 homolog (yeast); predicted gene 6828 1.50 1.2E-02 
548 Hemk1 HemK methyltransferase family member 1 1.50 3.1E-02 
549 2410015M20Rik RIKEN cDNA 2410015M20 gene 1.50 4.1E-03 
550 Ndufb8 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8 1.50 1.0E-03 
551 Smcr7 Smith-Magenis syndrome chromosome region, candidate 7 homolog 
(human) 
1.50 3.9E-03 
552 Dynll2 dynein light chain LC8-type 2 1.50 5.5E-03 
 
 
Table B.2, Part II. List of genes downregulated 3 hours after a single loading session in cortical bone 
of littermate control animals 
 Gene Symbol Gene Fold Change FDR 
1 Gm5512 
required for meiotic nuclear division 1 homolog (S. cerevisiae); predicted 
gene 5512 -239.27 4.0E-03 
2 Ear12 eosinophil-associated, ribonuclease A family, member 12 -78.20 2.3E-02 
3 Ppp1r1b protein phosphatase 1, regulatory (inhibitor) subunit 1B -7.23 2.3E-02 
4 Ihh Indian hedgehog -3.55 1.9E-02 
5 2810055G20Rik RIKEN cDNA 2810055G20 gene -3.16 3.4E-04 
6 Oaz1 ornithine decarboxylase antizyme 1 -3.07 1.9E-03 
7 Tgoln2 trans-golgi network protein 2; trans-golgi network protein -2.67 4.3E-04 
8 Map3k19 mitogen-activated protein kinase kinase kinase 19 -2.59 1.8E-02 
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9 Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 -2.58 2.9E-02 
10 Muc5b mucin 5, subtype B, tracheobronchial -2.51 3.6E-02 
11 Il4i1 interleukin 4 induced 1 -2.34 9.1E-03 
12 Sost sclerostin -2.33 2.2E-08 
13 Aox4 aldehyde oxidase 4 -2.30 1.5E-02 
14 Amer2 APC membrane recruitment 2 -2.23 3.1E-02 
15 Pfdn5 prefoldin 5 -2.11 3.9E-03 
16 Reep6 receptor accessory protein 6 -2.06 3.4E-02 
17 Fam71b family with sequence similarity 71, member B -2.05 2.0E-02 
18 Ccdc170 coiled-coil domain containing 170 -2.05 2.2E-03 
19 Stc2 stanniocalcin 2 -2.04 8.6E-03 
20 Eomes eomesodermin homolog (Xenopus laevis) -2.03 1.5E-02 
21 A730008H23Rik RIKEN cDNA A730008H23 gene -2.02 1.8E-03 
22 4930526I15Rik RIKEN cDNA 4930526I15 gene -2.01 1.5E-02 
23 Gm10532 predicted gene 10532 -1.99 5.4E-03 
24 Crebbp CREB binding protein -1.97 5.9E-04 
25 Ciz1 CDKN1A interacting zinc finger protein 1 -1.91 8.2E-04 
26 Ccdc15 coiled-coil domain containing 15 -1.90 2.7E-02 
27 Nabp2 nucleic acid binding protein 2 -1.89 2.0E-03 
28 Adarb2 adenosine deaminase, RNA-specific, B2 -1.89 3.6E-02 
29 Gp1bb glycoprotein Ib, beta polypeptide -1.86 9.2E-03 
30 Irx6 Iroquois related homeobox 6 (Drosophila) -1.84 6.5E-03 
31 Klf5 Kruppel-like factor 5 -1.84 2.0E-02 
32 BC090627 predicted readthrough transcript (NMD candidate), 44502 -1.83 3.7E-02 
33 Pram1 PML-RAR alpha-regulated adaptor molecule 1 -1.83 5.9E-03 
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34 Bglap bone gamma carboxyglutamate protein 1 -1.81 1.1E-02 
35 Cby1 chibby homolog 1 (Drosophila) -1.80 7.2E-04 
36 Tmem108 transmembrane protein 108 -1.80 3.4E-02 
37 Hnrnpul1 heterogeneous nuclear ribonucleoprotein U-like 1 -1.80 2.3E-03 
38 Atn1 atrophin 1 -1.77 8.6E-04 
39 Gm10684 predicted gene 10684 -1.77 2.8E-02 
40 Prrt2 proline-rich transmembrane protein 2 -1.76 1.2E-03 
41 Nat6 N-acetyltransferase 6 -1.76 4.1E-03 
42 Fkbp2 FK506 binding protein 2 -1.76 2.1E-02 
43 Tcf7l1 transcription factor 3 -1.75 2.1E-04 
44 Otud3 OTU domain containing 3 -1.75 2.4E-03 
45 Ankrd24 ankyrin repeat domain 24 -1.75 5.9E-03 
46 Cnot3 CCR4-NOT transcription complex, subunit 3 -1.74 1.2E-03 
47 Hspb11 heat shock protein family B (small), member 11 -1.74 6.5E-03 
48 Gps2 G protein pathway suppressor 2 -1.74 1.1E-02 
49 Dlx5 distal-less homeobox 5 -1.74 1.8E-03 
50 Lef1 lymphoid enhancer binding factor 1 -1.74 5.0E-03 
51 Slc25a23 
solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 
23 -1.73 3.4E-04 
52 Cdc42ep5 CDC42 effector protein (Rho GTPase binding) 5 -1.73 2.5E-02 
53 Zfp362 zinc finger protein 362 -1.73 8.3E-04 
54 Tnfrsf13b tumor necrosis factor receptor superfamily, member 13b -1.72 2.2E-02 
55 1700026D08Rik RIKEN cDNA 1700026D08 gene -1.72 1.1E-02 
56 Mepe matrix extracellular phosphoglycoprotein with ASARM motif (bone) -1.72 2.7E-03 
57 Batf2 basic leucine zipper transcription factor, ATF-like 2 -1.72 2.8E-02 
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58 Camsap3 calmodulin regulated spectrin-associated protein family, member 3 -1.72 5.2E-03 
59 Baiap2l2 BAI1-associated protein 2-like 2 -1.72 3.2E-03 
60 Rora RAR-related orphan receptor alpha -1.72 3.6E-02 
61 Fam81a family with sequence similarity 81, member A -1.72 2.5E-02 
62 Lyar Ly1 antibody reactive clone -1.71 2.1E-02 
63 Zfp69 zinc finger protein 69 -1.71 2.6E-02 
64 Ccdc55 coiled-coil domain containing 55 -1.70 1.1E-02 
65 Amt aminomethyltransferase -1.70 7.2E-03 
66 Cd68 CD68 antigen -1.70 1.6E-02 
67 Plagl1 pleiomorphic adenoma gene-like 1 -1.70 1.2E-04 
68 Mef2d myocyte enhancer factor 2D -1.70 2.7E-03 
69 Pax5 paired box gene 5 -1.69 4.5E-02 
70 Card11 caspase recruitment domain family, member 11 -1.69 4.0E-03 
71 Faim3 Fas apoptotic inhibitory molecule 3 -1.69 1.6E-02 
72 Celf5 bruno-like 5, RNA binding protein (Drosophila) -1.69 7.8E-03 
73 Alyref2 Aly/REF export factor 2 -1.68 1.2E-02 
74 Pacsin1 protein kinase C and casein kinase substrate in neurons 1 -1.68 1.2E-04 
75 Gltscr1 glioma tumor suppressor candidate region gene 1 -1.68 2.4E-03 
76 Prrt1 proline-rich transmembrane protein 1 -1.67 1.7E-02 
77 Jakmip1 janus kinase and microtubule interacting protein 1 -1.67 3.7E-02 
78 Shank1 SH3/ankyrin domain gene 1 -1.67 4.9E-03 
79 Pin4 protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting, 4 (parvulin) -1.66 3.3E-02 
80 Cd247 CD247 antigen -1.66 4.9E-02 
81 Crocc ciliary rootlet coiled-coil, rootletin -1.66 4.6E-03 
82 Pcgf2 polycomb group ring finger 2 -1.66 9.1E-04 
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83 Sp100 nuclear antigen Sp100 -1.66 9.6E-03 
84 Srp54c signal recognition particle 54C -1.65 3.1E-02 
85 Fkbpl FK506 binding protein-like -1.65 2.3E-02 
86 Ubxn1 UBX domain protein 1 -1.65 1.3E-02 
87 Chst12 carbohydrate sulfotransferase 12 -1.65 2.2E-03 
88 C1qa complement component 1, q subcomponent, alpha polypeptide -1.64 3.0E-03 
89 Col13a1 collagen, type XIII, alpha 1 -1.64 2.1E-03 
90 Clta clathrin, light polypeptide (Lca) -1.64 2.8E-03 
91 Sap25 sin3A-binding protein, SAP25 -1.64 4.1E-02 
92 S100a1 S100 calcium binding protein A1 -1.63 5.1E-03 
93 Cd27 CD27 antigen -1.63 4.7E-02 
94 Dvl3 dishevelled 3, dsh homolog (Drosophila) -1.63 1.7E-03 
95 Helz helicase with zinc finger domain -1.63 2.6E-03 
96 Fli1 Friend leukemia integration 1 -1.63 9.0E-03 
97 4922501C03Rik RIKEN cDNA 4922501C03 gene -1.63 5.1E-03 
98 Azi1 5-azacytidine induced gene 1 -1.63 7.2E-03 
99 Kcnab3 potassium voltage-gated channel, shaker-related subfamily, beta member 3 -1.63 2.1E-02 
100 Gatad2b GATA zinc finger domain containing 2B -1.62 6.9E-04 
101 Zscan2 zinc finger and SCAN domain containing 2 -1.62 4.1E-02 
102 Sdk2 sidekick homolog 2 (chicken) -1.62 5.1E-03 
103 Leng9 leukocyte receptor cluster (LRC) member 9 -1.61 1.1E-02 
104 Mettl21b methyltransferase like 21B -1.61 3.1E-02 
105 Safb scaffold attachment factor B -1.61 1.2E-02 
106 Hoxa9 homeo box A9 -1.61 7.8E-03 
107 Tmem191c transmembrane protein 191C -1.61 7.0E-03 
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108 Rassf9 Ras association (RalGDS/AF-6) domain family (N-terminal) member 9 -1.61 4.7E-02 
109 Mta3 metastasis associated 3 -1.61 1.1E-02 
110 Gpr182 G protein-coupled receptor 182 -1.61 1.5E-02 
111 Hlx H2.0-like homeobox -1.60 9.9E-03 
112 Foxo3 forkhead box O3 -1.60 4.7E-04 
113 Tmie transmembrane inner ear -1.60 4.1E-03 
114 Zfr2 zinc finger RNA binding protein 2 -1.60 4.0E-03 
115 Creb3l1 cAMP responsive element binding protein 3-like 1 -1.60 5.9E-03 
116 Pqbp1 polyglutamine binding protein 1 -1.60 3.1E-03 
117 Grasp GRP1 (general receptor for phosphoinositides 1)-associated scaffold protein -1.60 1.4E-02 
118 Spen SPEN homolog, transcriptional regulator (Drosophila) -1.60 1.6E-03 
119 Gm5918 predicted gene 5918 -1.59 3.6E-02 
120 Ddrgk1 DDRGK domain containing 1 -1.59 1.3E-02 
121 Gem GTP binding protein (gene overexpressed in skeletal muscle) -1.59 3.9E-02 
122 Safb2 scaffold attachment factor B2 -1.59 2.6E-02 
123 Nfix nuclear factor I/X -1.59 1.4E-03 
124 Myl12b myosin, light chain 12B, regulatory -1.59 6.0E-03 
125 Ccdc88c coiled-coil domain containing 88C -1.59 1.1E-02 
126 Ybx1 Y box protein 1 -1.59 1.5E-02 
127 Rassf8 Ras association (RalGDS/AF-6) domain family (N-terminal) member 8 -1.59 2.4E-02 
128 Sh3bgrl3 SH3 domain binding glutamic acid-rich protein-like 3 -1.59 1.8E-02 
129 Trerf1 transcriptional regulating factor 1 -1.59 1.1E-02 
130 Slc8a3 solute carrier family 8 (sodium/calcium exchanger), member 3 -1.59 5.9E-04 
131 Gli2 GLI-Kruppel family member GLI2 -1.59 1.1E-02 
132 Pmvk phosphomevalonate kinase -1.59 2.9E-02 
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133 Maml3 mastermind like 3 (Drosophila) -1.59 4.3E-04 
134 9930111J21Rik1 RIKEN cDNA 9930111J21 gene -1.59 2.2E-03 
135 Cic capicua homolog (Drosophila) -1.58 2.8E-03 
136 A630007B06Rik RIKEN cDNA A630007B06 gene -1.58 2.0E-03 
137 Bfsp1 beaded filament structural protein 1, in lens-CP94 -1.58 2.4E-02 
138 Sipa1l3 signal-induced proliferation-associated 1 like 3 -1.58 7.4E-03 
139 Acy3 aspartoacylase (aminoacylase) 3 -1.58 2.7E-02 
140 Cep250 centrosomal protein 250 -1.58 1.1E-02 
141 Taok3 TAO kinase 3 -1.58 1.4E-02 
142 Setd1b SET domain containing 1B -1.58 2.2E-03 
143 Zfhx2 zinc finger homeobox 2; similar to Zinc finger protein 409 -1.58 1.4E-02 
144 Bmp7 bone morphogenetic protein 7 -1.58 9.8E-03 
145 Prr12 proline rich 12 -1.57 2.0E-03 
146 St14 suppression of tumorigenicity 14 (colon carcinoma) -1.57 4.9E-02 
147 Rps26 ribosomal protein S26 -1.57 1.7E-02 
148 Mark4 MAP/microtubule affinity-regulating kinase 4 -1.56 1.2E-03 
149 Fxyd5 FXYD domain-containing ion transport regulator 5 -1.56 2.6E-02 
150 Pou2f2 POU domain, class 2, transcription factor 2 -1.56 1.4E-02 
151 Ift57 intraflagellar transport 57 homolog (Chlamydomonas) -1.56 1.4E-02 
152 Zfp618 zinc fingerprotein 618 -1.56 4.4E-02 
153 Cnbd2 cyclic nucleotide binding domain containing 2 -1.56 4.7E-02 
154 Kank4 KN motif and ankyrin repeat domains 4 -1.56 2.1E-03 
155 Hcfc1r1 host cell factor C1 regulator 1 (XPO1-dependent) -1.56 7.4E-03 
156 Ranbp1 RAN binding protein 1 -1.55 2.0E-02 
157 Tspyl2 TSPY-like 2 -1.55 1.1E-02 
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158 Ogfod3 2-oxoglutarate and iron-dependent oxygenase domain containing 3 -1.55 9.2E-03 
159 Ebf3 early B-cell factor 3 -1.55 7.3E-03 
160 Scaf4 SR-related CTD-associated factor 4 -1.55 4.9E-03 
161 Ccdc88b coiled-coil domain containing 88B -1.55 2.0E-02 
162 Mll5 myeloid/lymphoid or mixed-lineage leukemia 5 -1.55 3.1E-03 
163 Foxp4 forkhead box P4 -1.55 4.9E-03 
164 Ebf1 early B-cell factor 1 -1.55 1.7E-03 
165 Bmp4 bone morphogenetic protein 4 -1.55 2.0E-03 
166 Dtd1 D-tyrosyl-tRNA deacylase 1 homolog (S. cerevisiae) -1.55 3.1E-02 
167 Ldoc1l leucine zipper, down-regulated in cancer 1-like -1.55 5.9E-03 
168 Mospd3 motile sperm domain containing 3 -1.54 3.9E-03 
169 Treml4 triggering receptor expressed on myeloid cells-like 4 -1.54 1.5E-02 
170 Lrp5 low density lipoprotein receptor-related protein 5 -1.54 1.2E-03 
171 Kifc2 kinesin family member C2 -1.54 2.7E-03 
172 Nucb2 nucleobindin 2 -1.54 9.1E-03 
173 Atxn2 ataxin 2 -1.54 4.8E-03 
174 Polr2j polymerase (RNA) II (DNA directed) polypeptide J -1.54 1.3E-02 
175 Apobr apolipoprotein B receptor -1.54 1.8E-02 
176 Ncoa6 nuclear receptor coactivator 6 -1.53 1.1E-03 
177 Fads2 fatty acid desaturase 2 -1.53 4.0E-03 
178 Pura purine rich element binding protein A -1.53 9.6E-03 
179 Hoxa7 homeo box A7 -1.53 4.2E-03 
180 Rufy4 RUN and FYVE domain containing 4 -1.53 2.8E-02 
181 Praf2 PRA1 domain family 2; predicted gene 4168 -1.53 3.1E-03 
182 Gripap1 GRIP1 associated protein 1 -1.53 1.1E-02 
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183 2310045N01Rik RIKEN cDNA 2310045N01 gene -1.53 8.9E-03 
184 Fip1l1 FIP1 like 1 (S. cerevisiae) -1.53 1.1E-02 
185 Prrc2a proline-rich coiled-coil 2A -1.53 7.2E-03 
186 Rp9 retinitis pigmentosa 9 (human) -1.53 3.6E-02 
187 Tle2 transducin-like enhancer of split 2, homolog of Drosophila E(spl) -1.53 1.7E-03 
188 Map2k6 mitogen-activated protein kinase kinase 6 -1.52 2.7E-03 
189 Usp53 ubiquitin specific peptidase 53 -1.52 2.7E-02 
190 Brd4 bromodomain containing 4 -1.52 6.6E-03 
191 Nfatc1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 -1.52 2.1E-02 
192 1700034P13Rik RIKEN cDNA 1700034P13 gene -1.52 4.9E-02 
193 Bcl9l B-cell CLL/lymphoma 9-like -1.52 3.1E-03 
194 Fam193a cDNA sequence BC037112 -1.52 2.8E-03 
195 2210018M11Rik RIKEN cDNA 2210018M11 gene -1.52 2.7E-03 
196 Sugp1 SURP and G patch domain containing 1 -1.52 1.2E-02 
197 Jdp2 Jun dimerization protein 2 -1.52 9.8E-03 
198 Dlx3 distal-less homeobox 3 -1.52 8.4E-03 
199 Ubap2l ubiquitin associated protein 2-like -1.52 8.9E-03 
200 Dbp D site albumin promoter binding protein -1.52 1.1E-03 
201 Hoxc6 homeo box C6 -1.52 1.9E-02 
202 Ttll5 tubulin tyrosine ligase-like family, member 5 -1.52 5.8E-03 
203 Ttc28 tetratricopeptide repeat domain 28 -1.52 3.1E-03 
204 Shroom3 shroom family member 3 -1.52 3.8E-03 
205 Calcoco1 calcium binding and coiled coil domain 1 -1.51 2.8E-03 
206 Polr3gl polymerase (RNA) III (DNA directed) polypeptide G like -1.51 1.5E-02 
207 Ncor1 nuclear receptor co-repressor 1 -1.51 3.3E-03 
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208 Ankrd11 ankyrin repeat domain 11 -1.51 1.1E-02 
209 Afap1l2 actin filament associated protein 1-like 2 -1.51 4.8E-03 
210 Mrps5 predicted gene 13328; mitochondrial ribosomal protein S5 -1.51 3.0E-02 
211 Zfp579 zinc finger protein 579 -1.51 1.6E-02 
212 Evl Ena-vasodilator stimulated phosphoprotein -1.51 1.8E-03 
213 Tmsb10 thymosin, beta 10 -1.51 2.9E-02 
214 Samd1 sterile alpha motif domain containing 1 -1.51 5.2E-03 
215 Hspa2 heat shock protein 2 -1.51 3.7E-03 
216 Fam13c family with sequence similarity 13, member C -1.50 6.1E-03 
217 Prpf38b 
PRP38 pre-mRNA processing factor 38 (yeast) domain containing B; similar 
to PRP38 pre-mRNA processing factor 38 (yeast) domain containing B -1.50 3.0E-02 
218 Ncor2 nuclear receptor co-repressor 2 -1.50 1.2E-02 
219 Mad1l1 mitotic arrest deficient 1-like 1 -1.50 1.5E-02 
220 Serpinf1 serine (or cysteine) peptidase inhibitor, clade F, member 1 -1.50 1.6E-02 
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loading session in pOC-ERaKO cortical bone in order of decreasing fold change that were: I. 
upregulated by mechanical loading. There were no downregulated genes. Number of genes (column 
A), gene symbols (column B), gene names (column C), fold change (column D), false discovery rate 
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Table B.3, Part I. List of genes upregulated 3 hours after a single loading session in cortical bone of 
pOC-ERaKO animals 
 Gene Symbol Gene Fold Change FDR 
1 Il6 interleukin 6 9.57 2.3E-04 
2 Ptgs2 prostaglandin-endoperoxide synthase 2 6.21 3.8E-08 
3 Ngf nerve growth factor 3.74 3.0E-09 
4 Ccl7 chemokine (C-C motif) ligand 7 3.51 1.0E-02 
5 Medag mesenteric estrogen dependent adipogenesis 3.32 1.1E-03 
6 Dmp1 dentin matrix protein 1 3.13 1.2E-04 
7 Inhba inhibin beta-A 3.11 2.4E-07 
8 Lgr6 leucine-rich repeat-containing G protein-coupled receptor 6 2.58 5.4E-05 
9 Tfpi2 tissue factor pathway inhibitor 2 2.55 5.3E-05 
10 Hbegf heparin-binding EGF-like growth factor 2.32 2.8E-05 
11 Notum notum pectinacetylesterase homolog (Drosophila) 2.23 2.1E-02 
12 Glis3 GLIS family zinc finger 3 2.21 1.6E-05 
13 Tnfrsf11b tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) 2.17 1.5E-02 
14 Hivep3 human immunodeficiency virus type I enhancer binding protein 3 2.15 1.0E-07 
15 Timp1 tissue inhibitor of metalloproteinase 1 2.01 2.3E-02 
16 Srxn1 sulfiredoxin 1 homolog (S. cerevisiae) 1.99 8.3E-05 
17 Fam20c family with sequence similarity 20, member C 1.93 2.1E-03 
18 Gem GTP binding protein (gene overexpressed in skeletal muscle) 1.90 2.1E-02 
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Table B.3, Part I. Continued 
 Gene Symbol Gene Fold Change FDR 
19 Adamts1 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 1 
1.74 2.0E-02 
20 Socs3 suppressor of cytokine signaling 3 1.74 3.4E-05 
21 Ugdh UDP-glucose dehydrogenase 1.72 3.6E-02 
22 Fgf1 fibroblast growth factor 1 1.70 1.5E-02 
23 Il1rn interleukin 1 receptor antagonist 1.69 2.0E-02 
24 Heyl hairy/enhancer-of-split related with YRPW motif-like 1.65 1.8E-06 
25 Cd244 CD244 natural killer cell receptor 2B4 1.65 6.4E-03 
26 Phlda1 pleckstrin homology-like domain, family A, member 1 1.64 4.0E-03 
27 Bcl3 B-cell leukemia/lymphoma 3 1.63 1.7E-02 
28 Uck2 uridine-cytidine kinase 2 1.63 3.9E-02 
29 Gpatch4 G patch domain containing 4 1.57 3.1E-02 
30 Map3k6 mitogen-activated protein kinase kinase kinase 6 1.52 4.3E-03 
31 Junb Jun-B oncogene 1.51 5.2E-03 
32 Rrp12 ribosomal RNA processing 12 homolog (S. cerevisiae) 1.51 2.9E-03 
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Table B.4: A complete list of genes that were differentially expressed 24 hours following a single 
loading session in littermate control cortical bone in order of decreasing fold change that were: I. 
upregulated by mechanical loading and II. downregulated by mechanical loading. Number of genes 
(column A), gene symbols (column B), gene names (column C), fold change (column D), false 
discovery rate (FDR) (column E). 
 
Table B.4, Part I. List of genes upregulated 24 hours after a single loading session in cortical bone of 
littermate control animals 
 Gene Symbol Gene Fold Change FDR 
1 Ptn pleiotrophin 2.18 1.7E-02 
2 Tubb3 tubulin, beta 3; tubulin, beta 3, pseudogene 1 1.85 5.6E-03 
3 Bcan brevican 1.83 8.6E-04 
4 Gsg1l GSG1-like 1.78 1.1E-02 
5 Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 1.74 3.1E-02 
6 Smpdl3b sphingomyelin phosphodiesterase, acid-like 3B 1.69 2.5E-02 
7 Fkbp11 FK506 binding protein 11 1.63 7.5E-05 
8 Hapln4 hyaluronan and proteoglycan link protein 4 1.62 3.4E-02 
 
 
Table B.4, Part II. List of genes downregulated 24 hours after a single loading session in cortical 
bone of littermate control animals 
 Gene Symbol Gene Fold Change FDR 
1 Adrb3 adrenergic receptor, beta 3 -3.90 6.5E-03 
2 Wnt7b wingless-related MMTV integration site 7B -3.38 4.4E-04 
3 Lamc2 laminin, gamma 2 -3.02 7.8E-03 
4 Msln mesothelin -2.98 4.0E-05 
5 Prss46 RIKEN cDNA 1700112C13 gene -2.83 7.9E-03 
6 Htra4 HtrA serine peptidase 4 -2.83 2.7E-03 
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Table B4, Part II. Continued 
 Gene Symbol Gene Fold Change FDR 
7 A630023A22Rik RIKEN cDNA A630023A22 gene -2.82 3.1E-02 
8 Lctl lactase-like -2.80 4.4E-04 
9 F7 coagulation factor VII -2.77 1.2E-02 
10 Mt2 metallothionein 2 -2.50 4.4E-04 
11 Mt1 metallothionein 1 -2.39 4.0E-05 
12 Mt3 metallothionein 3 -2.38 1.0E-02 
13 Nmb neuromedin B -2.33 1.2E-03 
14 Tnfrsf9 tumor necrosis factor receptor superfamily, member 9 -2.32 8.4E-04 
15 Calcr calcitonin receptor -2.31 9.3E-05 
16 Rgs9 regulator of G-protein signaling 9 -2.27 3.7E-02 
17 Pamr1 peptidase domain containing associated with muscle regeneration 1 -2.15 8.6E-04 
18 Ret ret proto-oncogene -2.14 1.6E-02 
19 Spp1 secreted phosphoprotein 1 -2.12 4.4E-04 
20 Mst1r macrophage stimulating 1 receptor (c-met-related tyrosine kinase) -2.08 1.2E-03 
21 Slc9b2 solute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), 
member 2 
-2.06 5.6E-03 
22 Lif leukemia inhibitory factor -2.05 3.0E-04 
23 Ctsk cathepsin K -2.04 7.7E-03 
24 Galnt6 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 6 
-2.03 4.0E-05 
25 Wisp2 WNT1 inducible signaling pathway protein 2 -2.01 5.4E-05 
26 Kcnj15 potassium inwardly-rectifying channel, subfamily J, member 15 -2.00 6.0E-03 
27 Dcstamp dentrocyte expressed seven transmembrane protein -2.00 1.9E-03 
28 Gm6377 predicted gene 6377 -1.99 1.9E-02 
29 Slc37a2 solute carrier family 37 (glycerol-3-phosphate transporter), member 2 -1.95 1.4E-02 
30 Sfrp4 secreted frizzled-related protein 4 -1.89 4.3E-06 
31 Smoc1 SPARC related modular calcium binding 1 -1.89 1.8E-05 
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Table B4, Part II. Continued 
 Gene Symbol Gene Fold Change FDR 
32 Oscar osteoclast associated receptor -1.83 3.6E-02 
33 Hyal1 hyaluronoglucosaminidase 1 -1.80 1.6E-02 
34 Oit3 oncoprotein induced transcript 3 -1.78 7.7E-03 
35 Tnfrsf11a tumor necrosis factor receptor superfamily, member 11a -1.75 5.1E-03 
36 Uchl1 ubiquitin carboxy-terminal hydrolase L1 -1.70 2.4E-02 
37 Snx10 sorting nexin 10 -1.70 7.9E-03 
38 Tfrc transferrin receptor -1.69 2.3E-02 
39 Rcan1 regulator of calcineurin 1 -1.69 3.9E-02 
40 Fos FBJ osteosarcoma oncogene -1.68 1.1E-02 
41 Tppp3 tubulin polymerization-promoting protein family member 3 -1.67 4.8E-02 
42 Gpr137b similar to Gpr137b protein; G protein-coupled receptor 137B -1.65 2.5E-02 
43 Fam198b RIKEN cDNA 1110032E23 gene -1.65 1.6E-02 
44 Amz1 archaelysin family metallopeptidase 1 -1.63 7.8E-03 
45 Ccr1 chemokine (C-C motif) receptor 1 -1.63 1.0E-02 
46 Cyp4v3 cytochrome P450, family 4, subfamily v, polypeptide 3 -1.62 5.1E-03 
47 Bcl2a1b B-cell leukemia/lymphoma 2 related protein A1b -1.62 6.9E-03 
48 Gpr137b-ps G protein-coupled receptor 137B, pseudogene -1.62 1.4E-02 
49 Prdm1 PR domain containing 1, with ZNF domain -1.58 7.7E-03 
50 Glb1 galactosidase, beta 1 -1.56 4.0E-02 
51 Hexb hexosaminidase B -1.56 4.9E-02 
52 Met met proto-oncogene -1.55 6.0E-03 
53 Ank progressive ankylosis -1.55 5.1E-03 
54 Megf10 multiple EGF-like-domains 10 -1.55 1.6E-02 
55 Cd83 CD83 antigen -1.54 8.9E-04 
56 Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 -1.54 7.9E-03 
57 Capg capping protein (actin filament), gelsolin-like -1.53 4.8E-02 
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Table B.5: A complete list of genes that were differentially expressed 24 hours following a single 
loading session in pOC-ERaKO cortical bone in order of decreasing fold change that were: I. 
upregulated by mechanical loading and II. downregulated by mechanical loading. Number of genes 
(column A), gene symbols (column B), gene names (column C), fold change (column D), false 
discovery rate (FDR) (column E). 
 
Table B.5, Part I. List of genes upregulated 24 hours after a single loading session in cortical bone of 
pOC-ERaKO animals 
 Gene Symbol Gene Fold Change FDR 
1 Rspo4 R-spondin family, member 4 137.71 3.1E-18 
2 Oprd1 opioid receptor, delta 1 49.46 5.9E-05 
3 Serpina1a serine (or cysteine) peptidase inhibitor, clade A, member 1A 29.46 1.1E-02 
4 Prg4 
proteoglycan 4 (megakaryocyte stimulating factor, articular superficial 
zone protein) 5.82 4.8E-02 
5 Gsg1l GSG1-like 1.92 3.1E-03 
6 Tubb3 tubulin, beta 3; tubulin, beta 3, pseudogene 1 1.62 4.9E-02 
 
 
Table B.5, Part II. List of genes downregulated 24 hours after a single loading session in cortical 
bone of pOC-ERaKO animals 
 Gene Symbol Gene Fold Change FDR 
1 Wisp2 WNT1 inducible signaling pathway protein 2 -2.15 9.6E-10 
2 Sfrp2 secreted frizzled-related protein 2 -2.00 5.3E-02 
3 Galnt6 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 6 -1.68 1.1E-02 
4 Cd83 CD83 antigen -1.51 2.7E-02 
5 Ccr1 chemokine (C-C motif) receptor 1 -1.51 2.7E-02 
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Table B.6: A complete list of genes that were differentially expressed 3 hours following a single 
loading session in littermate control cancellous bone in order of decreasing fold change that were: I. 
upregulated by mechanical loading. There were no downregulated genes. Number of genes (column 
A), gene symbols (column B), gene names (column C), fold change (column D), false discovery rate 
(FDR) (column E). 
 
Table B.6, Part I. List of genes upregulated 3 hours after a single loading session in cancellous bone 
of littermate control animals 
 Gene Symbol Gene Fold Change FDR 
1 Wnt1 wingless-related MMTV integration site 1 6.55 8.2E-12 
2 Hspb7 heat shock protein family, member 7 (cardiovascular) 3.90 3.5E-02 
3 Medag mesenteric estrogen dependent adipogenesis 3.86 6.4E-04 
4 Ch25h cholesterol 25-hydroxylase 3.23 4.1E-02 
5 Tnfrsf12a tumor necrosis factor receptor superfamily, member 12a 3.14 1.7E-06 
6 Baalc brain and acute leukemia, cytoplasmic 3.11 2.0E-02 
7 Ptgs2 prostaglandin-endoperoxide synthase 2 3.09 1.7E-04 
8 Nt5e 5' nucleotidase, ecto 2.75 1.7E-04 
9 Tnfrsf11b tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) 2.69 2.1E-08 
10 Arc activity regulated cytoskeletal-associated protein 2.59 1.8E-02 
11 Mustn1 musculoskeletal, embryonic nuclear protein 1 2.49 1.8E-02 
12 Lgr6 leucine-rich repeat-containing G protein-coupled receptor 6 2.42 2.0E-02 
13 Ngf nerve growth factor 2.40 8.1E-04 
14 Ncs1 neuronal calcium sensor 1 2.34 1.7E-03 
15 Dmp1 dentin matrix protein 1 2.26 1.5E-02 
16 Timp1 tissue inhibitor of metalloproteinase 1 2.14 1.5E-02 
17 Wnt10b wingless related MMTV integration site 10b 2.03 2.9E-03 
18 Fam20c family with sequence similarity 20, member C 1.93 7.6E-03 
19 Aldh3a1 aldehyde dehydrogenase family 3, subfamily A1 1.77 4.2E-03 
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Table B.6, Part I. Continued 
 Gene Symbol Gene Fold Change FDR 
20 Ugdh UDP-glucose dehydrogenase 1.59 1.4E-02 
21 Srxn1 sulfiredoxin 1 homolog (S. cerevisiae) 1.52 2.0E-02 
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Table B.7: A complete list of genes that were differentially expressed 3 hours following a single 
loading session in pOC-ERaKO cancellous bone in order of decreasing fold change that were: I. 
upregulated by mechanical loading and II. downregulated by mechanical loading. Number of genes 
(column A), gene symbols (column B), gene names (column C), fold change (column D), false 
discovery rate (FDR) (column E). 
 
Table B.7, Part I. List of genes upregulated 3 hours after a single loading session in cancellous bone 
of pOC-ERaKO animals 
 Gene Symbol Gene Fold Change FDR 
1 Amd1 S-adenosylmethionine decarboxylase 1 156.89 1.3E-02 
2 Wnt7b wingless-related MMTV integration site 7B 8.42 5.9E-06 
3 Wnt1 wingless-related MMTV integration site 1 7.41 8.2E-06 
4 Ptgs2 prostaglandin-endoperoxide synthase 2 6.85 3.7E-08 
5 Fam180a cDNA sequence BC064033 5.25 4.7E-02 
6 Hspb7 heat shock protein family, member 7 (cardiovascular) 5.03 6.3E-04 
7 Medag mesenteric estrogen dependent adipogenesis 4.42 7.9E-05 
8 Lgr6 leucine-rich repeat-containing G protein-coupled receptor 6 3.74 1.5E-08 
9 Baalc brain and acute leukemia, cytoplasmic 3.72 2.3E-03 
10 Tnfrsf12a tumor necrosis factor receptor superfamily, member 12a 3.66 3.1E-06 
11 Mustn1 musculoskeletal, embryonic nuclear protein 1 3.53 3.2E-04 
12 Dmp1 dentin matrix protein 1 3.46 1.7E-05 
13 Nt5e 5' nucleotidase, ecto 3.36 2.0E-03 
14 Notum notum pectinacetylesterase homolog (Drosophila) 3.19 3.1E-05 
15 Miat myocardial infarction associated transcript (non-protein coding) 3.16 9.7E-04 
16 Timp1 tissue inhibitor of metalloproteinase 1 2.89 6.4E-06 
17 Tfpi2 tissue factor pathway inhibitor 2 2.87 2.5E-06 
18 Ngf nerve growth factor 2.65 2.3E-04 
19 Wnt10b wingless related MMTV integration site 10b 2.61 4.5E-04 
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Table B.7, Part I. Continued 
 Gene Symbol Gene Fold Change FDR 
20 Tnfrsf11b tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) 2.60 4.6E-04 
21 Fam20c family with sequence similarity 20, member C 2.48 4.9E-07 
22 Ngef neuronal guanine nucleotide exchange factor 2.18 8.4E-03 
23 Cspg4 chondroitin sulfate proteoglycan 4 2.14 1.7E-04 
24 Hivep3 human immunodeficiency virus type I enhancer binding protein 3 1.96 1.5E-05 
25 Fgf1 fibroblast growth factor 1 1.89 6.3E-04 
26 Ank progressive ankylosis 1.86 3.7E-03 
27 Cd276 CD276 antigen 1.81 7.3E-03 
28 Gas1 growth arrest specific 1 1.81 4.6E-04 
29 Ugdh UDP-glucose dehydrogenase 1.79 1.5E-02 
30 Srxn1 sulfiredoxin 1 homolog (S. cerevisiae) 1.78 3.5E-03 
31 Heyl hairy/enhancer-of-split related with YRPW motif-like 1.74 1.7E-07 
32 Snai1 snail homolog 1 (Drosophila) 1.71 2.0E-03 
33 Adamtsl4 ADAMTS-like 4 1.66 4.7E-02 
34 Mical2 microtubule associated monoxygenase, calponin and LIM domain 
containing 2 
1.62 2.9E-02 
35 Map3k6 mitogen-activated protein kinase kinase kinase 6 1.56 2.0E-03 
36 Fam129b family with sequence similarity 129, member B 1.55 4.5E-03 
37 S100a10 S100 calcium binding protein A10 (calpactin) 1.52 3.7E-02 
38 Smyd5 SET and MYND domain containing 5 1.51 2.2E-02 
 
Table B.7, Part II. List of genes downregulated 3 hours after a single loading session in cancellous 
bone of pOC-ERaKO animals 
 Gene Symbol Gene Fold Change FDR 
1 Serpina3c serine (or cysteine) peptidase inhibitor, clade A, member 3C -2.14 3.1E-03 
2 Gm4951 predicted gene 4951 -1.55 4.9E-02 
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Table B.8: A complete list of genes that were differentially expressed 24 hours following a single 
loading session in littermate control cancellous bone in order of decreasing fold change that were: I. 
upregulated by mechanical loading and II. downregulated by mechanical loading. Number of genes 
(column A), gene symbols (column B), gene names (column C), fold change (column D), false 
discovery rate (FDR) (column E). 
 
Table B.8, Part I. List of genes upregulated 24 hours after a single loading session in cancellous bone 
of littermate control animals 
 Gene Symbol Gene Fold Change FDR 
1 Zim1 zinc finger, imprinted 1 10.91 1.7E-02 
2 Lrrn1 leucine rich repeat protein 1, neuronal 9.59 1.6E-03 
3 Mfap4 microfibrillar-associated protein 4 8.16 3.2E-02 
4 Trpm6 transient receptor potential cation channel, subfamily M, member 6 4.34 3.2E-02 
5 Panx3 pannexin 3 2.34 1.6E-03 
6 Ddit4l DNA-damage-inducible transcript 4-like 1.58 3.2E-02 
 
 
Table B.8, Part II. List of genes downregulated 24 hours after a single loading session in cancellous 
bone of littermate control animals 
 Gene Symbol Gene Fold Change FDR 
1 Atp6v0e2 ATPase, H+ transporting, lysosomal V0 subunit E2 -2.22 3.2E-02 
2 Fcer2a Fc receptor, IgE, low affinity II, alpha polypeptide -1.64 3.2E-02 
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Table B.9: A complete list of genes that were differentially expressed 24 hours following a single 
loading session in pOC-ERaKO cancellous bone in order of decreasing fold change that were: I. 
upregulated by mechanical loading and II. downregulated by mechanical loading. Number of genes 
(column A), gene symbols (column B), gene names (column C), fold change (column D), false 
discovery rate (FDR) (column E). 
 
Table B.9, Part I. List of genes upregulated 24 hours after a single loading session in cancellous bone 
of pOC-ERaKO animals 
 Gene Symbol Gene Fold Change FDR 
1 Rspo4 R-spondin family, member 4 537.25 3.4E-29 
2 Ear12 eosinophil-associated, ribonuclease A family, member 12 292.22 1.0E-02 
3 Myoz2 myozenin 2 51.42 2.3E-02 
4 Oprd1 opioid receptor, delta 1 43.32 5.4E-06 
5 Serpina1a serine (or cysteine) peptidase inhibitor, clade A, member 1A 24.00 7.4E-03 
6 Pax1 paired box gene 1 22.96 1.2E-02 
7 Slc38a3 solute carrier family 38, member 3 17.19 1.4E-02 
8 Chad chondroadherin 16.49 5.0E-02 
9 Syt8 synaptotagmin VIII 14.15 5.3E-02 
10 Fxyd2 FXYD domain-containing ion transport regulator 2 14.06 2.5E-02 
11 Hapln1 hyaluronan and proteoglycan link protein 1 11.54 3.7E-02 
12 Ncmap noncompact myelin associated protein 11.21 1.0E-02 
13 Ihh Indian hedgehog 11.10 3.4E-02 
14 Zcchc5 zinc finger, CCHC domain containing 5 9.28 9.5E-03 
15 Pcolce2 procollagen C-endopeptidase enhancer 2 8.78 2.3E-02 
16 Zim1 zinc finger, imprinted 1 8.23 6.2E-03 
17 Acan aggrecan 8.15 1.0E-02 
18 Prkg2 protein kinase, cGMP-dependent, type II 8.09 3.0E-02 
19 Fam180a cDNA sequence BC064033 7.71 2.5E-02 
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Table B.9, Part I. Continued 
 Gene Symbol Gene Fold Change FDR 
20 Nrk Nik related kinase 7.51 7.1E-03 
21 H19 H19 fetal liver mRNA 6.95 8.5E-03 
22 Plekhb1 pleckstrin homology domain containing, family B (evectins) member 1 6.91 1.2E-02 
23 Tcfl5 transcription factor-like 5 (basic helix-loop-helix) 6.53 1.1E-02 
24 Col4a5 collagen, type IV, alpha 5 4.98 1.2E-02 
25 B230206H07Rik RIKEN cDNA B230206H07 gene 4.85 2.2E-02 
26 Tpd52l1 tumor protein D52-like 1 4.55 2.3E-02 
27 Sstr2 somatostatin receptor 2 4.36 3.6E-02 
28 Extl1 exostoses (multiple)-like 1 3.99 3.4E-02 
29 Eps8l2 EPS8-like 2 3.89 1.1E-02 
30 Crispld1 cysteine-rich secretory protein LCCL domain containing 1 3.84 2.3E-02 
31 Mgp matrix Gla protein 3.59 7.5E-03 
32 Steap1 six transmembrane epithelial antigen of the prostate 1 3.53 7.4E-03 
33 Scube1 signal peptide, CUB domain, EGF-like 1 3.53 1.6E-04 
34 Sox8 SRY-box containing gene 8 3.50 1.1E-02 
35 Panx3 pannexin 3 3.32 7.4E-03 
36 Sox9 SRY-box containing gene 9 3.21 1.0E-02 
37 Wscd2 WSC domain containing 2 3.05 9.7E-03 
38 Gfpt2 glutamine fructose-6-phosphate transaminase 2 3.02 5.2E-02 
39 Gli1 GLI-Kruppel family member GLI1 2.93 8.9E-04 
40 Ppa1 pyrophosphatase (inorganic) 1 2.89 2.7E-02 
41 Thbs3 thrombospondin 3 2.85 1.0E-02 
42 Stc2 stanniocalcin 2 2.79 5.0E-02 
43 Capn6 calpain 6 2.76 3.4E-02 
44 Cpa6 carboxypeptidase A6 2.74 5.5E-03 
45 Notum notum pectinacetylesterase homolog (Drosophila) 2.72 7.4E-03 
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Table B.9, Part I. Continued 
 Gene Symbol Gene Fold Change FDR 
46 Glt25d2 glycosyltransferase 25 domain containing 2 2.71 2.4E-02 
47 Ptgs2 prostaglandin-endoperoxide synthase 2 2.70 4.6E-03 
48 Slc38a4 solute carrier family 38, member 4 2.65 2.5E-02 
49 Aldh1a3 aldehyde dehydrogenase family 1, subfamily A3 2.61 1.7E-04 
50 Kif26b kinesin family member 26B 2.56 5.0E-02 
51 Arsi arylsulfatase i 2.54 4.5E-02 
52 Ntrk2 neurotrophic tyrosine kinase, receptor, type 2 2.53 6.1E-02 
53 Ptch1 patched homolog 1 2.50 1.9E-03 
54 Fmod fibromodulin 2.41 1.1E-02 
55 Prkcz protein kinase C, zeta 2.40 5.2E-02 
56 Kcnc3 potassium voltage gated channel, Shaw-related subfamily, member 3 2.35 1.0E-02 
57 Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 2.32 4.1E-04 
58 Ephb2 Eph receptor B2 2.24 1.7E-04 
59 Cdkn1c cyclin-dependent kinase inhibitor 1C (P57) 2.18 1.6E-03 
60 Peg3 paternally expressed 3; antisense transcript gene of Peg3 2.18 2.4E-03 
61 Ptn pleiotrophin 2.18 2.3E-02 
62 Miat myocardial infarction associated transcript (non-protein coding) 2.02 2.5E-02 
63 Peg3as Peg3 opposite strand 2.02 6.1E-02 
64 Fn1 fibronectin 1 1.97 1.6E-02 
65 Gli2 GLI-Kruppel family member GLI2 1.95 4.6E-06 
66 Car12 carbonic anyhydrase 12 1.93 1.4E-02 
67 Nog noggin 1.93 5.2E-02 
68 Ntn1 netrin 1 1.93 6.9E-03 
69 Papss2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 1.93 2.4E-03 
70 Nphp4 nephronophthisis 4 (juvenile) homolog (human) 1.87 1.1E-02 
71 Zfp13 zinc finger protein 13 1.85 3.9E-02 
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Table B.9, Part I. Continued 
 Gene Symbol Gene Fold Change FDR 
72 Nid2 nidogen 2 1.82 1.1E-03 
73 Smpdl3b sphingomyelin phosphodiesterase, acid-like 3B 1.79 2.7E-02 
74 Cobll1 Cobl-like 1 1.79 2.7E-02 
75 Shisa4 shisa homolog 4 (Xenopus laevis) 1.73 3.3E-02 
76 Plagl1 pleiomorphic adenoma gene-like 1 1.73 2.6E-03 
77 Col6a3 collagen, type VI, alpha 3 1.73 1.1E-02 
78 Tgfb2 transforming growth factor, beta 2 1.72 5.2E-02 
79 Foxc2 forkhead box C2 1.71 5.2E-02 
80 Mcc mutated in colorectal cancers 1.70 4.5E-02 
81 Lrig3 leucine-rich repeats and immunoglobulin-like domains 3 1.70 2.2E-02 
82 Frzb frizzled-related protein 1.69 5.1E-02 
83 Tubb3 tubulin, beta 3; tubulin, beta 3, pseudogene 1 1.67 7.4E-03 
84 Ccdc80 coiled-coil domain containing 80 1.65 1.1E-02 
85 Fads2 fatty acid desaturase 2 1.64 1.9E-03 
86 Gsg1l GSG1-like 1.64 2.5E-02 
87 Trpv4 transient receptor potential cation channel, subfamily V, member 4 1.64 4.1E-02 
88 Pcdh17 protocadherin 17 1.64 6.1E-02 
89 Cspg4 chondroitin sulfate proteoglycan 4 1.59 3.5E-02 
90 Snai1 snail homolog 1 (Drosophila) 1.58 5.9E-02 
91 Sox12 SRY-box containing gene 12 1.57 5.3E-02 
92 Adamts12 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 12 
1.56 1.7E-02 
93 Lrrc16a leucine rich repeat containing 16A 1.56 1.0E-02 
94 Scd2 stearoyl-Coenzyme A desaturase 2 1.55 7.4E-03 
95 A730008H23Rik RIKEN cDNA A730008H23 gene 1.53 2.4E-02 
96 Gdf10 growth differentiation factor 10 1.53 4.1E-02 
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Table B.9, Part II. List of genes downregulated 24 hours after a single loading session in cancellous 
bone of pOC-ERaKO animals 
 Gene Symbol Gene Fold Change FDR 
1 Ear7 eosinophil-associated, ribonuclease A family, member 7 -45.51 3.3E-02 
2 Klre1 killer cell lectin-like receptor family E member 1 -3.12 5.0E-02 
3 Klrd1 killer cell lectin-like receptor, subfamily D, member 1 -2.64 2.3E-02 
4 Gm4841 predicted gene 4841 -2.34 4.8E-02 
5 Lyz1 lysozyme 1 -2.20 4.6E-02 
6 Pdzd3 PDZ domain containing 3 -2.16 6.3E-02 
7 Mt2 metallothionein 2 -2.15 4.8E-03 
8 P2ry10 purinergic receptor P2Y, G-protein coupled 10 -2.00 2.4E-02 
9 Amica1 adhesion molecule, interacts with CXADR antigen 1 -1.87 2.4E-03 
10 Siglech sialic acid binding Ig-like lectin H -1.87 4.1E-04 
11 Lpl lipoprotein lipase; similar to Lipoprotein lipase precursor (LPL) -1.87 1.7E-04 
12 Ms4a1 membrane-spanning 4-domains, subfamily A, member 1 -1.87 1.0E-02 
13 AU021092 expressed sequence AU021092 -1.81 4.1E-02 
14 Il1b interleukin 1 beta -1.81 1.0E-02 
15 Klrk1 killer cell lectin-like receptor subfamily K, member 1 -1.81 7.8E-03 
16 Rspo2 R-spondin 2 homolog (Xenopus laevis) -1.80 3.0E-02 
17 Cd53 CD53 antigen -1.78 2.3E-02 
18 Slpi secretory leukocyte peptidase inhibitor -1.77 5.0E-02 
19 Ifi27l2a interferon, alpha-inducible protein 27 like 2A -1.76 2.4E-03 
20 Ifi47 interferon gamma inducible protein 47 -1.76 3.5E-02 
21 Esm1 endothelial cell-specific molecule 1 -1.74 6.2E-03 
22 Klra2 killer cell lectin-like receptor, subfamily A, member 2 -1.73 3.1E-02 
23 Ccl5 chemokine (C-C motif) ligand 5 -1.71 2.4E-02 
24 Serpina3f serine (or cysteine) peptidase inhibitor, clade A, member 3F -1.71 2.4E-02 
25 Ccl6 chemokine (C-C motif) ligand 6 -1.70 1.7E-04 
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26 AW112010 expressed sequence AW112010 -1.69 5.1E-03 
27 Ubd ubiquitin D -1.68 3.3E-02 
28 Retnlg resistin like gamma -1.68 2.4E-03 
29 Ddx60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 -1.67 1.4E-02 
30 H2-Ob histocompatibility 2, O region beta locus -1.67 1.0E-02 
31 Cd209a CD209a antigen -1.65 1.0E-02 
32 Fpr1 formyl peptide receptor 1 -1.64 1.5E-02 
33 Slfn4 schlafen 4 -1.63 1.1E-02 
34 Bst1 bone marrow stromal cell antigen 1 -1.62 1.1E-02 
35 Ear1 eosinophil-associated, ribonuclease A family, member 1 -1.62 5.1E-02 
36 Znf41-ps ZNF41, pseudogene -1.61 4.5E-02 
37 Ccr3 chemokine (C-C motif) receptor 3 -1.60 2.5E-02 
38 F630028O10Rik RIKEN cDNA F630028O10 gene -1.60 1.0E-02 
39 Il2rb interleukin 2 receptor, beta chain -1.59 4.0E-02 
40 Emr4 
EGF-like module containing, mucin-like, hormone receptor-like sequence 
4 -1.59 7.4E-03 
41 Gimap3 
similar to immunity-associated nucleotide 4; GTPase, IMAP family 
member 3 -1.58 2.7E-02 
42 Trim30d tripartite motif-containing 30D -1.57 5.5E-02 
43 Ccl9 chemokine (C-C motif) ligand 9 -1.57 1.1E-02 
44 Cyp4b1 
predicted gene 12839; cytochrome P450, family 4, subfamily b, polypeptide 
1 -1.57 2.3E-02 
45 Kmo kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) -1.56 4.8E-02 
46 Pyhin1 pyrin and HIN domain family, member 1 -1.55 1.6E-02 
47 Kitl kit ligand -1.54 3.1E-03 
48 Il1f9 interleukin 1 family, member 9 -1.52 6.1E-02 
49 Slc40a1 solute carrier family 40 (iron-regulated transporter), member 1 -1.52 2.4E-02 
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50 Fgl2 fibrinogen-like protein 2 -1.51 2.3E-02 
51 Bst2 bone marrow stromal cell antigen 2 -1.51 7.4E-03 
 
 
 
 
  256 
Table B.10: A complete list of genes that were differentially expressed in naïve control cortical vs 
cancellous bone in order of decreasing fold change that were: I. more highly expressed in cortical bone 
and II. More highly expressed in cancellous bone. Number of genes (column A), gene symbols (column 
B), gene names (column C), fold change (column D), false discovery rate (FDR) (column E). * indicates 
contamination as determined by Ayturk et al. 
 
Table B.10, Part I. List of genes more highly expressed in naïve control cortical bone 
 Gene Symbol Gene Fold Change FDR 
1 Myh2* myosin, heavy polypeptide 2, skeletal muscle, adult; myosin, heavy 
polypeptide 1, skeletal muscle, adult 
1849.60 1.2E-08 
2 Myot* myotilin 482.93 4.2E-06 
3 Myh1* myosin, heavy polypeptide 2, skeletal muscle, adult; myosin, heavy 
polypeptide 1, skeletal muscle, adult 
456.18 2.3E-07 
4 Myh4* myosin, heavy polypeptide 4, skeletal muscle 250.02 2.5E-05 
5 Eef1a2* eukaryotic translation elongation factor 1 alpha 2 165.88 9.3E-05 
6 Acta1* actin, alpha 1, skeletal muscle 130.00 3.2E-05 
7 Mb* myoglobin 125.87 2.8E-07 
8 Pvalb* parvalbumin 112.12 1.3E-04 
9 Ano5* anoctamin 5 109.16 9.3E-04 
10 Ckm* creatine kinase, muscle 97.41 2.3E-05 
11 Ppp1r3a* protein phosphatase 1, regulatory (inhibitor) subunit 3A 96.41 6.1E-04 
12 Trdn* triadin 92.65 2.5E-06 
13 Myoz1* myozenin 1 88.05 1.7E-05 
14 Dhrs7c* dehydrogenase/reductase (SDR family) member 7C 77.10 5.3E-04 
15 Tnnc2* troponin C2, fast 56.75 4.3E-05 
16 Mylk2* myosin, light polypeptide kinase 2, skeletal muscle 47.09 2.2E-04 
17 Xirp2* xin actin-binding repeat containing 2 46.79 1.1E-03 
18 Ckmt2* creatine kinase, mitochondrial 2 40.80 5.5E-06 
19 Sgcg* sarcoglycan, gamma (dystrophin-associated glycoprotein) 39.12 7.8E-04 
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20 Mfap4 microfibrillar-associated protein 4 38.49 2.7E-11 
21 Mybpc1* myosin binding protein C, slow-type 35.12 4.6E-04 
22 Wnt16 wingless-related MMTV integration site 16 32.60 2.2E-11 
23 Lmod2* leiomodin 2 (cardiac) 30.70 1.0E-03 
24 Ostn osteocrin 28.67 4.4E-07 
25 Cilp2 cartilage intermediate layer protein 2 27.08 6.9E-12 
26 Kcna7* potassium voltage-gated channel, shaker-related subfamily, member 
7 
27.07 1.9E-04 
27 Tnnt3* troponin T3, skeletal, fast 26.93 8.0E-04 
28 Tcap* titin-cap 26.22 4.1E-05 
29 Hbb-b2 hemoglobin, beta adult major chain; hemoglobin, beta adult minor 
chain 
24.85 1.8E-02 
30 Cilp cartilage intermediate layer protein, nucleotide 
pyrophosphohydrolase 
23.41 9.8E-05 
31 Kcnc4* potassium voltage gated channel, Shaw-related subfamily, member 4 20.79 4.4E-03 
32 Smtnl1* smoothelin-like 1 20.00 8.9E-04 
33 A930016O22Rik* RIKEN cDNA A930016O22 gene 19.67 8.4E-05 
34 Myom2* myomesin 2 19.58 8.0E-04 
35 Actn2* actinin alpha 2 17.37 3.7E-03 
36 Itgbl1 integrin, beta-like 1 17.34 5.0E-05 
37 Casq1* calsequestrin 1 16.33 3.8E-04 
38 Atp2a1* ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 16.28 3.9E-04 
39 Smpx* small muscle protein, X-linked 15.11 1.3E-02 
40 Lrrn1 leucine rich repeat protein 1, neuronal 14.90 9.3E-05 
41 Hfe2* hemochromatosis type 2 (juvenile) (human homolog) 14.75 3.6E-03 
42 H19* H19 fetal liver mRNA 13.83 3.3E-07 
43 Igfbp6 insulin-like growth factor binding protein 6 12.89 6.7E-08 
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44 Smyd1* SET and MYND domain containing 1 12.58 3.2E-03 
45 Myl1* myosin, light polypeptide 1 11.15 1.9E-04 
46 Ampd1* adenosine monophosphate deaminase 1 (isoform M) 10.48 4.0E-02 
47 C1qtnf3 C1q and tumor necrosis factor related protein 3 10.43 1.4E-05 
48 Fam180a cDNA sequence BC064033 9.58 7.3E-07 
49 Tnn tenascin N 9.57 1.4E-06 
50 Tbx4 T-box 4 9.51 1.4E-09 
51 Tnni2* troponin I, skeletal, fast 2 9.32 6.9E-04 
52 Aspn asporin 8.99 1.4E-06 
53 1810041L15Rik RIKEN cDNA 1810041L15 gene 8.93 3.0E-03 
54 Fmod fibromodulin 8.60 3.3E-12 
55 Cacna1s* calcium channel, voltage-dependent, L type, alpha 1S subunit 8.42 1.7E-03 
56 Dner delta/notch-like EGF-related receptor 8.41 3.3E-05 
57 Col3a1 collagen, type III, alpha 1 8.27 4.8E-07 
58 3110079O15Rik RIKEN cDNA 3110079O15 gene 7.93 3.9E-03 
59 Jsrp1* junctional sarcoplasmic reticulum protein 1 7.72 1.5E-02 
60 Col8a2 collagen, type VIII, alpha 2 7.44 8.9E-05 
61 Wnt7b wingless-related MMTV integration site 7B 7.20 2.5E-07 
62 Myoz3* myozenin 3 6.72 1.8E-02 
63 Clec3a C-type lectin domain family 3, member a 6.69 9.6E-03 
64 Meox2 mesenchyme homeobox 2 6.55 1.6E-06 
65 Pgm5 phosphoglucomutase 5 6.48 9.7E-06 
66 Lrrc15 leucine rich repeat containing 15 6.44 7.5E-08 
67 Actn3* actinin alpha 3 6.37 1.3E-04 
68 Slc38a3* solute carrier family 38, member 3 6.32 2.1E-04 
69 Ldb3* LIM domain binding 3 6.22 2.1E-03 
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70 C130021I20Rik Riken cDNA C130021I20 gene 6.05 1.8E-07 
71 Mylpf* myosin light chain, phosphorylatable, fast skeletal muscle 6.02 5.1E-03 
72 Cntfr ciliary neurotrophic factor receptor 5.91 3.6E-05 
73 Spock1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 1 5.89 1.6E-02 
74 Chst8 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 5.89 1.1E-05 
75 Col10a1 collagen, type X, alpha 1 5.88 2.1E-02 
76 3632451O06Rik RIKEN cDNA 3632451O06 gene 5.87 5.0E-13 
77 Fitm1* fat storage-inducing transmembrane protein 1 5.82 3.3E-02 
78 Scube2 similar to signal peptide, CUB domain, EGF-like 2; signal peptide, 
CUB domain, EGF-like 2 
5.72 1.2E-07 
79 Slc17a8 solute carrier family 17 (sodium-dependent inorganic phosphate 
cotransporter), member 8 
5.70 8.0E-06 
80 Klhl41 kelch-like 41 5.68 2.8E-03 
81 Prrx2 paired related homeobox 2 5.61 2.6E-09 
82 Thbs4 thrombospondin 4 5.48 4.7E-04 
83 Nrap* nebulin-related anchoring protein 5.39 4.4E-03 
84 Megf6 multiple EGF-like-domains 6 5.26 2.5E-07 
85 Nov nephroblastoma overexpressed gene 5.19 1.4E-04 
86 Plekhg4 pleckstrin homology domain containing, family G (with RhoGef 
domain) member 4 
5.00 7.4E-08 
87 Cytl1 cytokine-like 1 4.98 1.9E-02 
88 Kcnj11 potassium inwardly rectifying channel, subfamily J, member 11 4.97 9.5E-03 
89 Akr1c18 aldo-keto reductase family 1, member C18 4.95 5.2E-03 
90 Lect1 leukocyte cell derived chemotaxin 1 4.84 4.4E-02 
91 Slc6a17 solute carrier family 6 (neurotransmitter transporter), member 17 4.71 4.6E-06 
92 Ttn* titin 4.65 6.7E-03 
93 Tnxb tenascin XB 4.33 1.3E-03 
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94 Neb* nebulin 4.24 2.8E-02 
95 Dpysl4 dihydropyrimidinase-like 4 4.23 1.3E-05 
96 Cox7a1* cytochrome c oxidase, subunit VIIa 1 4.18 1.1E-02 
97 Des* desmin 4.17 2.0E-03 
98 Sh3bgr* similar to putative SH3BGR protein; SH3-binding domain glutamic 
acid-rich protein 
4.10 3.4E-02 
99 Tenm3 teneurin transmembrane protein 3 4.01 5.2E-04 
100 Snhg11 small nucleolar RNA host gene 11 (non-protein coding) 4.00 5.5E-05 
101 Htra4 HtrA serine peptidase 4 3.96 3.3E-03 
102 Sema3c sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3C 
3.83 1.3E-05 
103 Anxa8 annexin A8 3.80 1.2E-05 
104 Col16a1 collagen, type XVI, alpha 1 3.78 3.5E-09 
105 Col9a3 collagen, type IX, alpha 3 3.70 2.5E-02 
106 Hspb7* heat shock protein family, member 7 (cardiovascular) 3.67 2.2E-03 
107 Adamtsl1 ADAMTS-like 1 3.65 1.5E-07 
108 Mybpc2* myosin binding protein C, fast-type 3.63 3.1E-02 
109 Wnt9a wingless-type MMTV integration site 9A 3.62 1.1E-06 
110 Thbs2 thrombospondin 2 3.62 2.5E-07 
111 A330021E22Rik RIKEN cDNA A330021E22 gene 3.60 5.9E-05 
112 Chad chondroadherin 3.55 2.8E-03 
113 Olfr78 olfactory receptor 78 3.54 1.9E-04 
114 Galr2 galanin receptor 2 3.50 1.8E-07 
115 Hhipl1 hedgehog interacting protein-like 1 3.47 3.2E-03 
116 Miat myocardial infarction associated transcript (non-protein coding) 3.46 1.2E-07 
117 Postn periostin, osteoblast specific factor 3.44 4.6E-07 
118 Prtg protogenin homolog (Gallus gallus) 3.41 2.2E-04 
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119 Col9a1 collagen, type IX, alpha 1 3.40 4.4E-02 
120 Ptn pleiotrophin 3.38 3.3E-03 
121 Medag mesenteric estrogen dependent adipogenesis 3.33 2.5E-03 
122 Cacng7 calcium channel, voltage-dependent, gamma subunit 7 3.31 1.5E-04 
123 Tnmd tenomodulin 3.27 4.5E-03 
124 C1qtnf9 C1q and tumor necrosis factor related protein 9 3.27 1.8E-03 
125 Lrrc55 leucine rich repeat containing 55 3.26 5.6E-04 
126 Itm2a integral membrane protein 2A 3.25 3.2E-13 
127 Gabra3 gamma-aminobutyric acid (GABA) A receptor, subunit alpha 3 3.20 8.0E-06 
128 Plat plasminogen activator, tissue 3.18 2.8E-07 
129 Epha3 Eph receptor A3 3.12 8.6E-12 
130 Pcdh9 protocadherin 9 3.11 7.4E-04 
131 AI593442 expressed sequence AI593442 3.08 5.9E-04 
132 Peg3 paternally expressed 3; antisense transcript gene of Peg3 3.06 1.1E-06 
133 Meg3 maternally expressed 3 3.05 3.3E-04 
134 Hs3st5 heparan sulfate (glucosamine) 3-O-sulfotransferase 5 3.05 5.4E-05 
135 Thbs3 thrombospondin 3 3.04 4.5E-06 
136 Scn4b* sodium channel, type IV, beta 3.03 4.7E-02 
137 Mia melanoma inhibitory activity 3.01 3.1E-02 
138 Fam69c RIKEN cDNA B230399E16 gene 2.98 1.1E-06 
139 Matn4 matrilin 4 2.97 2.4E-08 
140 Col12a1 collagen, type XII, alpha 1 2.96 1.1E-06 
141 Prnd prion protein dublet 2.95 8.2E-06 
142 Fosb FBJ osteosarcoma oncogene B 2.95 1.4E-04 
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143 P4ha3 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-
hydroxylase), alpha polypeptide III 
2.94 6.3E-06 
144 Angptl2 angiopoietin-like 2 2.93 2.1E-06 
145 Rab15 RAB15, member RAS oncogene family 2.93 4.2E-03 
146 Susd5 sushi domain containing 5 2.92 1.2E-11 
147 Emilin3 elastin microfibril interfacer 3 2.91 2.2E-03 
148 Dpt dermatopontin 2.91 1.7E-03 
149 Bai2 brain-specific angiogenesis inhibitor 2 2.87 1.6E-04 
150 Pnmal2 PNMA-like 2 2.87 1.4E-05 
151 Prkg2 protein kinase, cGMP-dependent, type II 2.85 1.3E-02 
152 Tmem200c predicted gene 6338 2.83 2.3E-04 
153 Peg3as Peg3 opposite strand 2.82 4.6E-04 
154 Rian RNA imprinted and accumulated in nucleus 2.82 3.6E-05 
155 Gucy1a2 hypothetical protein LOC100044212; guanylate cyclase 1, soluble, 
alpha 2 
2.82 1.4E-03 
156 Gpnmb glycoprotein (transmembrane) nmb 2.82 7.3E-05 
157 Sox8 SRY-box containing gene 8 2.81 1.7E-03 
158 Higd1b HIG1 domain family, member 1B 2.80 5.3E-03 
159 Foxp2 forkhead box P2 2.80 7.2E-04 
160 Clmn calmin 2.80 1.1E-03 
161 Piwil2 piwi-like homolog 2 (Drosophila) 2.77 1.4E-04 
162 Asic3 acid-sensing (proton-gated) ion channel 3 2.76 1.7E-04 
163 Pgam2* phosphoglycerate mutase 2 2.75 2.2E-02 
164 Crabp2 cellular retinoic acid binding protein II 2.75 2.8E-03 
165 Dkk3 dickkopf homolog 3 (Xenopus laevis) 2.73 1.1E-09 
166 Cdh13 cadherin 13 2.72 1.8E-05 
167 Gpc3 glypican 3 2.70 4.5E-05 
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168 Capn6 calpain 6 2.69 6.9E-12 
169 Radil Ras association and DIL domains 2.69 1.3E-03 
170 Rxrg retinoid X receptor gamma 2.67 1.1E-03 
171 Msln mesothelin 2.66 8.0E-06 
172 Acan aggrecan 2.65 1.0E-03 
173 Shisa2* shisa homolog 2 (Xenopus laevis) 2.65 6.3E-05 
174 B9d1 B9 protein domain 1 2.63 1.5E-05 
175 Hr hairless 2.63 3.2E-06 
176 Hrasls* HRAS-like suppressor 2.61 3.7E-03 
177 1500015O10Rik RIKEN cDNA 1500015O10 gene 2.58 2.5E-10 
178 Nox4 NADPH oxidase 4 2.58 3.5E-04 
179 Comp cartilage oligomeric matrix protein 2.54 4.9E-10 
180 Sparcl1 SPARC-like 1 2.54 1.4E-06 
181 Ccdc3 coiled-coil domain containing 3 2.53 1.7E-11 
182 Lum lumican 2.53 1.2E-08 
183 Jph2* junctophilin 2 2.53 6.0E-03 
184 Cav3* caveolin 3 2.53 6.9E-03 
185 Islr2 immunoglobulin superfamily containing leucine-rich repeat 2 2.53 2.5E-02 
186 Wnt10b wingless related MMTV integration site 10b 2.52 1.4E-06 
187 3425401B19Rik* RIKEN cDNA 3425401B19 gene 2.50 2.8E-02 
188 Gm8300 predicted gene 8300 2.50 1.4E-02 
189 Angptl7 angiopoietin-like 7 2.49 3.7E-02 
190 Pkia* protein kinase inhibitor, alpha 2.49 3.4E-03 
191 Hapln1 hyaluronan and proteoglycan link protein 1 2.48 2.8E-02 
192 Fcrls Fc receptor-like S, scavenger receptor 2.47 2.6E-08 
193 Igsf1 immunoglobulin superfamily, member 1 2.47 1.4E-07 
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194 Ambn ameloblastin 2.47 2.0E-02 
195 Hspb8* heat shock protein 8 2.46 2.7E-02 
196 Prss23 protease, serine, 23 2.46 9.4E-07 
197 Spock2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 2 2.45 7.7E-03 
198 Tmem255b transmembrane protein 255B 2.44 1.1E-02 
199 Dnahc7b dynein, axonemal, heavy chain 7B; dynein, axonemal, heavy chain 
7A 
2.43 2.1E-02 
200 Lman1l lectin, mannose-binding 1 like 2.43 5.5E-03 
201 Eno2 enolase 2, gamma neuronal 2.43 1.4E-05 
202 Nbl1 neuroblastoma, suppression of tumorigenicity 1 2.42 8.6E-12 
203 Lamc2 laminin, gamma 2 2.40 7.9E-05 
204 Aldh1a3 aldehyde dehydrogenase family 1, subfamily A3 2.40 7.2E-03 
205 Rgs11 regulator of G-protein signaling 11; similar to regulator of G-
protein signaling 11 
2.40 3.5E-03 
206 Apod apolipoprotein D 2.39 2.8E-02 
207 Mt2 metallothionein 2 2.38 1.6E-07 
208 Gm10635 predicted gene 10635 2.38 4.9E-02 
209 Aebp1 AE binding protein 1 2.36 3.6E-05 
210 Fam19a5 family with sequence similarity 19, member A5 2.33 2.1E-02 
211 Mab21l1 mab-21-like 1 (C. elegans) 2.32 2.6E-03 
212 Dok5 docking protein 5 2.32 2.3E-05 
213 Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 2.31 1.1E-06 
214 Gfpt2 glutamine fructose-6-phosphate transaminase 2 2.30 5.0E-04 
215 Flnc* filamin C, gamma 2.30 2.6E-03 
216 Ssc5d scavenger receptor cysteine rich family, 5 domains 2.29 3.7E-04 
217 Rpl39l ribosomal protein L39-like 2.28 1.1E-05 
218 Ptprv protein tyrosine phosphatase, receptor type, V 2.28 2.8E-07 
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219 Sdk1 sidekick homolog 1 (chicken) 2.28 4.8E-03 
220 Spp1 secreted phosphoprotein 1 2.27 1.1E-05 
221 Ephb3 Eph receptor B3 2.26 5.8E-11 
222 P2rx6 purinergic receptor P2X, ligand-gated ion channel, 6 2.26 7.7E-04 
223 C1qtnf2 C1q and tumor necrosis factor related protein 2 2.25 5.0E-02 
224 Ogdhl oxoglutarate dehydrogenase-like 2.25 1.2E-02 
225 Aspg asparaginase homolog (S. cerevisiae) 2.24 2.6E-05 
226 F3 coagulation factor III 2.23 3.0E-03 
227 Gabrb3 gamma-aminobutyric acid (GABA) A receptor, subunit beta 3 2.23 1.4E-04 
228 Edil3 EGF-like repeats and discoidin I-like domains 3 2.21 7.0E-09 
229 Adra2b adrenergic receptor, alpha 2b 2.20 4.6E-02 
230 Ablim3 actin binding LIM protein family, member 3 2.19 2.8E-02 
231 Meox1 mesenchyme homeobox 1 2.19 9.9E-03 
232 Mlph melanophilin 2.19 6.4E-04 
233 Ky* kyphoscoliosis peptidase 2.18 3.4E-02 
234 Gprasp2 G protein-coupled receptor associated sorting protein 2 2.18 3.7E-02 
235 Kcnmb4 potassium large conductance calcium-activated channel, subfamily 
M, beta member 4 
2.17 1.2E-02 
236 Amhr2 anti-Mullerian hormone type 2 receptor 2.17 6.8E-03 
237 Begain brain-enriched guanylate kinase-associated 2.17 1.1E-02 
238 C1qtnf5 C1q and tumor necrosis factor related protein 5; membrane-type 
frizzled-related protein 
2.17 3.5E-07 
239 Lrrc17 leucine rich repeat containing 17 2.16 3.7E-08 
240 D630003M21Rik RIKEN cDNA D630003M21 gene 2.16 3.2E-03 
241 Casq2 calsequestrin 2 2.16 4.4E-04 
242 Ebf4 early B-cell factor 4 2.15 5.1E-03 
243 Sulf1 sulfatase 1 2.14 1.0E-05 
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244 Htra1 HtrA serine peptidase 1 2.14 1.4E-04 
245 Wnt5b wingless-related MMTV integration site 5B 2.14 1.4E-06 
246 Lrrc8e similar to Leucine rich repeat containing 8 family, member E; 
leucine rich repeat containing 8 family, member E 
2.14 4.3E-02 
247 Grip2 glutamate receptor interacting protein 2 2.12 6.5E-04 
248 Epha4 Eph receptor A4 2.11 6.9E-04 
249 Gstp2* glutathione S-transferase, pi 2; glutathione S-transferase, pi 1; 
similar to glutathione S-transferase pi class A; predicted gene 3934 
2.10 1.8E-03 
250 Smoc2 SPARC related modular calcium binding 2 2.09 4.1E-05 
251 Etv4 ets variant gene 4 (E1A enhancer binding protein, E1AF) 2.09 1.7E-02 
252 Gpx3 glutathione peroxidase 3 2.09 1.9E-06 
253 Hspb2* heat shock protein 2 2.09 4.2E-05 
254 Ednrb endothelin receptor type B 2.08 1.8E-04 
255 Mgp matrix Gla protein 2.08 1.9E-05 
256 Vipr2 vasoactive intestinal peptide receptor 2 2.08 4.5E-03 
257 Ecm2 extracellular matrix protein 2, female organ and adipocyte specific 2.07 7.4E-07 
258 Timp1 tissue inhibitor of metalloproteinase 1 2.07 5.0E-03 
259 2310010J17Rik RIKEN cDNA 2310010J17 gene 2.06 3.1E-02 
260 Camk4 calcium/calmodulin-dependent protein kinase IV 2.06 2.1E-03 
261 Nos2 nitric oxide synthase 2, inducible 2.04 8.1E-03 
262 2310069G16Rik RIKEN cDNA 2310069G16 gene 2.04 2.0E-02 
263 Peli3 pellino 3 2.03 1.1E-02 
264 4930429F24Rik* RIKEN cDNA 4930429F24 gene 2.03 4.3E-02 
265 Rnf207 ring finger protein 207 2.03 1.6E-02 
266 Zfp811 zinc finger protein 811 2.02 2.1E-02 
267 Col6a3 collagen, type VI, alpha 3 2.02 2.2E-04 
268 Samd5 sterile alpha motif domain containing 5 2.02 4.3E-04 
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269 Fam198a RIKEN cDNA C730027P07 gene 2.02 2.8E-07 
270 2700069I18Rik RIKEN cDNA 2700069I18 gene 2.01 8.6E-03 
271 Fgfr3 fibroblast growth factor receptor 3 2.01 3.2E-12 
272 Aplp1 amyloid beta (A4) precursor-like protein 1 2.00 1.6E-04 
273 Slc6a7 solute carrier family 6 (neurotransmitter transporter, L-proline), 
member 7 
2.00 1.7E-03 
274 Fam26e family with sequence similarity 26, member E 2.00 8.7E-06 
275 Cpxm2 carboxypeptidase X 2 (M14 family) 2.00 3.1E-02 
276 Fzd2 frizzled homolog 2 (Drosophila) 2.00 2.8E-03 
 
 
 
Table B.10, Part II. List of genes more highly expressed in naïve control cancellous bone 
 Gene Symbol Gene Fold Change FDR 
1 Cbln1 cerebellin 1 precursor protein; similar to precerebellin-1 3.56 1.3E-03 
2 Slco1a4 solute carrier organic anion transporter family, member 1a4 3.43 5.4E-05 
3 Ly6g6c lymphocyte antigen 6 complex, locus G6C 3.34 7.1E-04 
4 Hist1h4m histone cluster 1, H4m 3.21 2.3E-05 
5 Havcr1 hepatitis A virus cellular receptor 1 3.00 3.8E-06 
6 Klra18 killer cell lectin-like receptor, subfamily A, member 18 3.00 1.8E-03 
7 Gpr50 G-protein-coupled receptor 50 2.48 9.0E-05 
8 Adrb3 adrenergic receptor, beta 3 2.43 1.2E-02 
9 Acvr1c activin A receptor, type IC 2.41 2.5E-02 
10 Pira7 paired-Ig-like receptor A7 2.40 1.0E-02 
11 Efemp1 epidermal growth factor-containing fibulin-like extracellular matrix 
protein 1 
2.39 2.4E-06 
  268 
Table B.10, Part II. Continued 
 Gene Symbol Gene Fold Change FDR 
12 Irg1 immunoresponsive gene 1 2.36 2.4E-03 
13 Ptger3 prostaglandin E receptor 3 (subtype EP3) 2.32 3.3E-07 
14 Clec4g C-type lectin domain family 4, member g 2.32 5.0E-05 
15 Grem1 gremlin 1 2.30 1.5E-09 
16 Klk1 kallikrein 1 2.28 3.0E-05 
17 F2rl2 coagulation factor II (thrombin) receptor-like 2 2.27 6.3E-10 
18 Gp1ba glycoprotein 1b, alpha polypeptide; hypothetical protein 
LOC100048807 
2.27 9.7E-10 
19 Mmrn1 multimerin 1 2.25 1.3E-13 
20 Eomes eomesodermin homolog (Xenopus laevis) 2.24 1.3E-03 
21 Gm1968 predicted gene 1968 2.24 6.5E-05 
22 Syt13 synaptotagmin XIII 2.23 6.6E-03 
23 Ubd ubiquitin D 2.22 7.6E-10 
24 Arhgap6 Rho GTPase activating protein 6 2.22 4.0E-09 
25 Akap5 A kinase (PRKA) anchor protein 5 2.22 4.2E-08 
26 Clca1 chloride channel calcium activated 1 2.22 3.0E-12 
27 Sycp2 synaptonemal complex protein 2 2.20 8.4E-06 
28 Bicd1 bicaudal D homolog 1 (Drosophila) 2.20 8.4E-05 
29 B3galt5 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 2.19 1.9E-02 
30 Gcsam germinal center associated, signaling and motility 2.17 2.0E-10 
31 Mpl myeloproliferative leukemia virus oncogene 2.17 3.5E-11 
32 Slco1a5 solute carrier organic anion transporter family, member 1a5 2.17 4.5E-02 
33 Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N 2.15 1.7E-02 
34 Gnaz guanine nucleotide binding protein, alpha z subunit 2.15 6.9E-08 
35 Gp1bb glycoprotein Ib, beta polypeptide 2.15 3.1E-06 
36 Ccdc150 coiled-coil domain containing 150 2.14 1.8E-04 
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 Gene Symbol Gene Fold Change FDR 
37 Marco macrophage receptor with collagenous structure 2.14 1.5E-02 
38 AU023871 expressed sequence AU023871 2.14 1.8E-11 
39 6330409D20Rik RIKEN cDNA 6330409D20 gene 2.14 2.5E-02 
40 Rnf165 ring finger protein 165 2.13 1.3E-03 
41 Slc35d3 solute carrier family 35, member D3 2.12 8.1E-09 
42 Cxcl9 chemokine (C-X-C motif) ligand 9 2.12 8.2E-06 
43 Mro maestro 2.12 1.2E-02 
44 E230029C05Rik RIKEN cDNA E230029C05 gene 2.12 2.8E-02 
45 Nlrp6 NLR family, pyrin domain containing 6 2.12 4.7E-05 
46 Sgk2 serum/glucocorticoid regulated kinase 2 2.12 1.6E-02 
47 Rspo2 R-spondin 2 homolog (Xenopus laevis) 2.10 9.6E-10 
48 Btnl6 butyrophilin-like 6 2.10 1.3E-03 
49 Gbx2 gastrulation brain homeobox 2 2.10 3.4E-03 
50 Cxcl13 chemokine (C-X-C motif) ligand 13 2.09 5.0E-02 
51 Treml1 triggering receptor expressed on myeloid cells-like 1 2.07 6.7E-11 
52 Slamf1 signaling lymphocytic activation molecule family member 1 2.07 4.4E-08 
53 Bex4 predicted gene 4322; brain expressed gene 4 2.07 1.8E-03 
54 Chrdl1 chordin-like 1 2.07 2.8E-07 
55 Tac2 tachykinin 2 2.06 3.8E-03 
56 4931440F15Rik RIKEN cDNA 4931440F15 gene 2.06 3.7E-02 
57 Serpina3b serine (or cysteine) peptidase inhibitor, clade A, member 3B 2.06 9.1E-07 
58 P2ry12 purinergic receptor P2Y, G-protein coupled 12 2.06 1.0E-08 
59 Serpinb2 serine (or cysteine) peptidase inhibitor, clade B, member 2 2.06 8.3E-07 
60 Tubb1 tubulin, beta 1 2.06 1.0E-09 
61 G6b G6B protein 2.05 4.6E-03 
62 Mc2r melanocortin 2 receptor 2.05 1.7E-02 
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 Gene Symbol Gene Fold Change FDR 
63 Esm1 endothelial cell-specific molecule 1 2.04 1.1E-10 
64 Alox12 arachidonate 12-lipoxygenase 2.03 8.1E-09 
65 Pde3a phosphodiesterase 3A, cGMP inhibited 2.03 1.6E-06 
66 Ccr9 chemokine (C-C motif) receptor 9 2.03 2.4E-06 
67 Gpm6a glycoprotein m6a 2.02 2.8E-10 
68 Clec1b C-type lectin domain family 1, member b 2.02 1.5E-10 
69 Lipg lipase, endothelial 2.02 2.0E-08 
70 Ifi205 interferon activated gene 205 2.02 2.3E-03 
71 Npas4 neuronal PAS domain protein 4 2.01 1.6E-07 
72 Kcnj16 potassium inwardly-rectifying channel, subfamily J, member 16 2.01 4.6E-02 
73 Kcnj5 potassium inwardly-rectifying channel, subfamily J, member 5 2.01 3.9E-07 
74 Csmd1 CUB and Sushi multiple domains 1 2.01 8.3E-07 
75 Gp6 glycoprotein 6 (platelet) 2.00 1.3E-07 
76 Nrgn neurogranin 2.00 1.8E-07 
77 D830046C22Rik RIKEN cDNA D830046C22 gene 2.00 3.1E-05 
     
  total 353  
  *indicates contaminant 68  
  total without contaminants 285  
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Table B.11: A complete list of genes that were differentially expressed in littermate control animals at 
3 hours in cortical vs cancellous bone at baseline in order of decreasing fold change that were: I. more 
highly expressed in cortical bone and II. More highly expressed in cancellous bone. Number of genes 
(column A), gene symbols (column B), gene names (column C), fold change (column D), false discovery 
rate (FDR) (column E). * indicates contamination as determined by Ayturk et al. 
 
Table B.11, Part I. List of genes more highly expressed in control cortical bone of littermate control 
animals at 3 hours 
 Gene Symbol Gene Fold Change FDR 
1 Myh4* myosin, heavy polypeptide 4, skeletal muscle 168.63 3.2E-05 
2 Ckm* creatine kinase, muscle 110.72 4.2E-06 
3 Myoc myocilin 98.57 1.9E-04 
4 Myot* myotilin 93.59 1.4E-05 
5 Myh2* myosin, heavy polypeptide 2, skeletal muscle, adult; myosin, heavy 
polypeptide 1, skeletal muscle, adult 
88.56 7.0E-05 
6 Pvalb* parvalbumin 84.80 9.1E-05 
7 Mb* myoglobin 83.19 5.9E-08 
8 Mylk2* myosin, light polypeptide kinase 2, skeletal muscle 78.36 2.9E-06 
9 Eef1a2 eukaryotic translation elongation factor 1 alpha 2 71.88 4.3E-06 
10 Acta1* actin, alpha 1, skeletal muscle 59.29 4.9E-06 
11 Xirp2* xin actin-binding repeat containing 2 54.35 2.0E-05 
12 Igfn1 immunoglobulin-like and fibronectin type III domain containing 1 52.92 1.3E-03 
13 Tcap* titin-cap 50.75 1.2E-06 
14 Myh1* myosin, heavy polypeptide 2, skeletal muscle, adult; myosin, heavy 
polypeptide 1, skeletal muscle, adult 
48.21 6.8E-06 
15 Tnnt3* troponin T3, skeletal, fast 45.78 3.2E-06 
16 Ckmt2* creatine kinase, mitochondrial 2 43.50 2.5E-05 
17 Tnnc2* troponin C2, fast 42.17 1.7E-06 
18 Mybpc1* myosin binding protein C, slow-type 41.27 4.2E-06 
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 Gene Symbol Gene Fold Change FDR 
19 Ampd1* adenosine monophosphate deaminase 1 (isoform M) 37.82 1.2E-03 
20 Smpx* small muscle protein, X-linked 33.25 8.9E-04 
21 Myoz1* myozenin 1 32.01 9.8E-05 
22 Trdn* triadin 26.02 5.9E-05 
23 Myom2* myomesin 2 24.23 9.9E-04 
24 Ppp1r3a* protein phosphatase 1, regulatory (inhibitor) subunit 3A 21.85 1.0E-02 
25 Atp2a1* ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 21.12 1.4E-05 
26 Wnt16 wingless-related MMTV integration site 16 20.18 5.8E-03 
27 Ostn osteocrin 19.27 1.4E-03 
28 Jsrp1* junctional sarcoplasmic reticulum protein 1 17.21 5.3E-05 
29 Casq1* calsequestrin 1 16.75 9.9E-05 
30 Ucma upper zone of growth plate and cartilage matrix associated 16.20 8.6E-04 
31 Cilp cartilage intermediate layer protein, nucleotide 
pyrophosphohydrolase 
15.89 1.4E-03 
32 Col10a1 collagen, type X, alpha 1 14.29 5.1E-04 
33 Trim54* tripartite motif-containing 54 13.15 3.9E-03 
34 Foxa2 forkhead box A2 13.12 1.4E-03 
35 Actc1* actin, alpha, cardiac muscle 1; similar to alpha-actin (AA 27-375) 12.89 6.1E-03 
36 1810041L15Rik RIKEN cDNA 1810041L15 gene 12.59 1.6E-02 
37 Myl1* myosin, light polypeptide 1 12.48 9.8E-05 
38 A930016O22Rik* RIKEN cDNA A930016O22 gene 12.03 1.9E-04 
39 Smyd1* SET and MYND domain containing 1 11.84 3.1E-03 
40 Krt75 keratin 75 11.76 8.5E-06 
41 Lrrn1 leucine rich repeat protein 1, neuronal 11.30 6.8E-03 
42 Myoz2* myozenin 2 11.26 2.3E-03 
43 Tnni2* troponin I, skeletal, fast 2 11.21 4.3E-04 
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 Gene Symbol Gene Fold Change FDR 
44 Itgbl1 integrin, beta-like 1 10.91 1.8E-03 
45 Hfe2* hemochromatosis type 2 (juvenile) (human homolog) 10.68 1.6E-02 
46 Mfap4 microfibrillar-associated protein 4 9.73 8.6E-03 
47 Tnn tenascin N 9.20 5.0E-08 
48 Sall1 sal-like 1 (Drosophila) 9.00 4.7E-06 
49 Meox2 mesenchyme homeobox 2 8.40 9.8E-09 
50 H19* H19 fetal liver mRNA 8.12 9.8E-05 
51 Col9a3 collagen, type IX, alpha 3 8.05 3.1E-03 
52 Myl2* myosin, light polypeptide 2, regulatory, cardiac, slow 7.94 3.5E-03 
53 Col9a1 collagen, type IX, alpha 1 7.53 5.8E-03 
54 Aspn asporin 7.47 6.2E-05 
55 Actn2* actinin alpha 2 7.45 2.0E-03 
56 Mylpf* myosin light chain, phosphorylatable, fast skeletal muscle 7.39 1.1E-03 
57 Col9a2 collagen, type IX, alpha 2 7.11 2.4E-03 
58 Igfbp6 insulin-like growth factor binding protein 6 7.07 3.3E-07 
59 Actn3* actinin alpha 3 6.96 1.1E-03 
60 Col8a2 collagen, type VIII, alpha 2 6.93 1.0E-02 
61 Spock1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 1 6.58 3.1E-03 
62 Trim63* similar to tripartite motif-containing 63; tripartite motif-containing 
63 
6.51 2.9E-02 
63 Fgf14 fibroblast growth factor 14 6.46 9.4E-04 
64 Col3a1 collagen, type III, alpha 1 6.40 1.2E-04 
65 Lect1 leukocyte cell derived chemotaxin 1 6.34 1.4E-02 
66 Clec3a C-type lectin domain family 3, member a 6.28 1.6E-02 
67 Cacna1s* calcium channel, voltage-dependent, L type, alpha 1S subunit 6.23 4.1E-03 
68 Cilp2 cartilage intermediate layer protein 2 6.19 1.2E-03 
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 Gene Symbol Gene Fold Change FDR 
69 Fgf23 similar to FGF23; fibroblast growth factor 23 6.02 1.0E-02 
70 Cntfr ciliary neurotrophic factor receptor 5.99 6.3E-07 
71 Bnc2 basonuclin 2 5.92 2.3E-03 
72 Ldb3* LIM domain binding 3 5.75 2.0E-03 
73 Acan aggrecan 5.72 2.3E-03 
74 Ttn* titin 5.67 2.9E-03 
75 Mfi2 antigen p97 (melanoma associated) identified by monoclonal 
antibodies 133.2 and 96.5 
5.67 2.7E-02 
76 3110079O15Rik RIKEN cDNA 3110079O15 gene 5.60 2.7E-02 
77 Slc17a8 solute carrier family 17 (sodium-dependent inorganic phosphate 
cotransporter), member 8 
5.48 1.0E-03 
78 Nrap* nebulin-related anchoring protein 5.39 4.6E-03 
79 Chad chondroadherin 5.38 1.5E-02 
80 Klhl41 kelch-like 41 5.24 4.4E-03 
81 Chst8 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 5.20 9.2E-06 
82 Lrrc15 leucine rich repeat containing 15 5.16 8.3E-07 
83 Fmod fibromodulin 5.15 5.7E-07 
84 Matn3 matrilin 3 5.06 2.6E-02 
85 Mybpc2* myosin binding protein C, fast-type 4.96 1.0E-02 
86 Rpl3l* ribosomal protein L3-like 4.92 9.3E-03 
87 C1qtnf3 C1q and tumor necrosis factor related protein 3 4.79 4.7E-04 
88 Trpm6 transient receptor potential cation channel, subfamily M, member 6 4.78 1.5E-04 
89 Hapln1 hyaluronan and proteoglycan link protein 1 4.72 6.1E-03 
90 Des* desmin 4.64 1.2E-03 
91 3632451O06Rik RIKEN cDNA 3632451O06 gene 4.63 3.1E-07 
92 Neb* nebulin 4.42 1.4E-02 
93 Thbs4 thrombospondin 4 4.38 1.2E-04 
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 Gene Symbol Gene Fold Change FDR 
94 Sh3bgr* similar to putative SH3BGR protein; SH3-binding domain glutamic 
acid-rich protein 
4.19 2.4E-02 
95 Foxp2 forkhead box P2 4.19 1.0E-04 
96 Tbx4 T-box 4 4.04 7.8E-04 
97 Syt8 synaptotagmin VIII 3.98 1.7E-02 
98 Fam180a cDNA sequence BC064033 3.84 2.1E-03 
99 Tcfl5 transcription factor-like 5 (basic helix-loop-helix) 3.81 2.0E-02 
100 Nr1h4 nuclear receptor subfamily 1, group H, member 4 3.76 4.4E-03 
101 Fxyd2 FXYD domain-containing ion transport regulator 2 3.74 4.4E-02 
102 Dner delta/notch-like EGF-related receptor 3.74 1.9E-02 
103 Fosb FBJ osteosarcoma oncogene B 3.70 2.7E-05 
104 Cox7a1* cytochrome c oxidase, subunit VIIa 1 3.67 8.1E-03 
105 Col16a1 collagen, type XVI, alpha 1 3.60 4.6E-08 
106 Slc6a17 solute carrier family 6 (neurotransmitter transporter), member 17 3.56 1.5E-04 
107 Ablim3 actin binding LIM protein family, member 3 3.55 9.4E-05 
108 Anxa8 annexin A8 3.55 2.6E-07 
109 Prrx2 paired related homeobox 2 3.53 4.4E-04 
110 Scube2 similar to signal peptide, CUB domain, EGF-like 2; signal peptide, 
CUB domain, EGF-like 2 
3.49 2.4E-04 
111 Comp cartilage oligomeric matrix protein 3.46 1.8E-04 
112 Crabp2 cellular retinoic acid binding protein II 3.45 1.9E-02 
113 Spock2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 2 3.44 1.1E-05 
114 Postn periostin, osteoblast specific factor 3.44 1.7E-05 
115 Htra4 HtrA serine peptidase 4 3.43 5.5E-04 
116 Jph2* junctophilin 2 3.40 8.6E-04 
117 Meg3 maternally expressed 3 3.38 1.3E-06 
118 Angptl2 angiopoietin-like 2 3.37 5.3E-11 
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 Gene Symbol Gene Fold Change FDR 
119 Miat myocardial infarction associated transcript (non-protein coding) 3.35 4.0E-05 
120 Plekhg4 pleckstrin homology domain containing, family G (with RhoGef 
domain) member 4 
3.33 1.1E-04 
121 Hspb7* heat shock protein family, member 7 (cardiovascular) 3.33 5.4E-03 
122 Hhipl1 hedgehog interacting protein-like 1 3.30 5.2E-04 
123 R3hdml R3H domain containing-like 3.30 8.1E-03 
124 Thbs2 thrombospondin 2 3.26 2.6E-07 
125 Tenm3 teneurin transmembrane protein 3 3.22 4.1E-05 
126 Peg3 paternally expressed 3 3.20 1.7E-06 
127 Tceal3 transcription elongation factor A (SII)-like 3 3.16 7.2E-05 
128 Thbs3 thrombospondin 3 3.16 2.8E-08 
129 Epha3 Eph receptor A3 3.09 1.3E-07 
130 Ihh Indian hedgehog 3.09 3.6E-02 
131 Bai2 brain-specific angiogenesis inhibitor 2 3.08 5.4E-05 
132 Prkg2 protein kinase, cGMP-dependent, type II 3.06 2.3E-02 
133 Pgam2* phosphoglycerate mutase 2 3.06 1.6E-02 
134 Ptn pleiotrophin 3.05 1.5E-04 
135 Cacng7 calcium channel, voltage-dependent, gamma subunit 7 3.04 6.7E-04 
136 3425401B19Rik* RIKEN cDNA 3425401B19 gene 3.03 2.3E-03 
137 Rab15 RAB15, member RAS oncogene family 2.97 4.5E-04 
138 Ppp1r1a* protein phosphatase 1, regulatory (inhibitor) subunit 1A 2.97 4.9E-03 
139 Gm10635 predicted gene 10635 2.96 6.2E-03 
140 Wfdc6a WAP four-disulfide core domain 6A 2.96 2.0E-03 
141 Kcns1 K+ voltage-gated channel, subfamily S, 1 2.94 6.0E-03 
142 C1qtnf9 C1q and tumor necrosis factor related protein 9 2.94 8.9E-03 
143 Sema3c sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3C 
2.92 2.9E-04 
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 Gene Symbol Gene Fold Change FDR 
144 P4ha3 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-
hydroxylase), alpha polypeptide III 
2.89 4.1E-05 
145 Fez1 fasciculation and elongation protein zeta 1 (zygin I) 2.80 4.0E-03 
146 Megf6 multiple EGF-like-domains 6 2.78 1.3E-04 
147 Hr hairless 2.78 4.3E-07 
148 Pgm5 phosphoglucomutase 5 2.77 7.9E-03 
149 Wnt9a wingless-type MMTV integration site 9A 2.75 4.0E-03 
150 Sox9 SRY-box containing gene 9 2.74 3.1E-03 
151 Sema3e sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3E 
2.74 4.0E-02 
152 Col12a1 collagen, type XII, alpha 1 2.73 5.7E-06 
153 Penk preproenkephalin 2.71 4.1E-04 
154 Bglap3 bone gamma-carboxyglutamate protein 3 2.66 1.7E-03 
155 Gcnt4 predicted gene 73 2.65 2.6E-03 
156 Ambn ameloblastin 2.64 2.2E-02 
157 Dpysl4 dihydropyrimidinase-like 4 2.64 6.3E-03 
158 Piwil2 piwi-like homolog 2 (Drosophila) 2.62 3.2E-05 
159 Arsi arylsulfatase i 2.61 4.5E-03 
160 Tnmd tenomodulin 2.58 5.9E-03 
161 Susd5 sushi domain containing 5 2.58 7.8E-07 
162 Raver2 ribonucleoprotein, PTB-binding 2 2.57 1.1E-03 
163 Sparcl1 SPARC-like 1 2.56 3.2E-05 
164 Adamtsl1 ADAMTS-like 1 2.55 1.4E-03 
165 Has2 hyaluronan synthase 2 2.54 1.6E-02 
166 Wfdc1* WAP four-disulfide core domain 1 2.53 4.9E-05 
167 Aldh1a3 aldehyde dehydrogenase family 1, subfamily A3 2.48 4.5E-03 
168 Asic3 acid-sensing (proton-gated) ion channel 3 2.47 6.9E-05 
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 Gene Symbol Gene Fold Change FDR 
169 Kcnmb4 potassium large conductance calcium-activated channel, subfamily 
M, beta member 4 
2.47 3.5E-04 
170 Timp1 tissue inhibitor of metalloproteinase 1 2.45 4.6E-05 
171 Bglap bone gamma carboxyglutamate protein 1 2.45 3.0E-05 
172 Lrp2bp Lrp2 binding protein 2.43 6.9E-03 
173 Shisa2* shisa homolog 2 (Xenopus laevis) 2.43 2.1E-02 
174 Mab21l2 mab-21-like 2 (C. elegans) 2.43 2.1E-09 
175 Peg3as Peg3 opposite strand 2.42 4.4E-03 
176 Mapt microtubule-associated protein tau 2.41 3.8E-02 
177 Efcc1 EF hand and coiled-coil domain containing 1 2.41 3.9E-04 
178 Dpt dermatopontin 2.40 6.4E-03 
179 Oaz1 predicted gene 9786; ornithine decarboxylase antizyme 1 2.40 1.2E-02 
180 Gm3893 predicted gene 3893 2.40 2.0E-05 
181 Zcchc5 zinc finger, CCHC domain containing 5 2.40 2.5E-02 
182 C130021I20Rik Riken cDNA C130021I20 gene 2.39 2.3E-02 
183 Dkk3 dickkopf homolog 3 (Xenopus laevis) 2.39 4.8E-04 
184 Nox4 NADPH oxidase 4 2.37 3.3E-02 
185 Prtg protogenin homolog (Gallus gallus) 2.35 2.6E-02 
186 Kcnab1 potassium voltage-gated channel, shaker-related subfamily, beta 
member 1 
2.34 4.2E-02 
187 Galr2 galanin receptor 2 2.33 1.5E-03 
188 Sncg synuclein, gamma 2.33 2.9E-03 
189 Sytl5 synaptotagmin-like 5 2.33 4.2E-03 
190 Ssc5d scavenger receptor cysteine rich family, 5 domains 2.32 4.6E-05 
191 Akr1c18 aldo-keto reductase family 1, member C18 2.32 4.5E-02 
192 Tgfb2 transforming growth factor, beta 2 2.31 2.7E-05 
193 Gm5124 predicted gene 5124 2.31 1.2E-03 
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 Gene Symbol Gene Fold Change FDR 
194 Pcdh9 protocadherin 9 2.31 1.3E-02 
195 Stc2 stanniocalcin 2 2.30 1.1E-03 
196 F3 coagulation factor III 2.29 4.1E-05 
197 Cdh13 cadherin 13 2.29 1.3E-04 
198 Arhgap22 Rho GTPase activating protein 22 2.29 1.3E-04 
199 Pnmal2 PNMA-like 2 2.29 7.6E-03 
200 Baalc brain and acute leukemia, cytoplasmic 2.27 2.1E-02 
201 Tnxb tenascin XB 2.27 4.3E-02 
202 Cpxm2 carboxypeptidase X 2 (M14 family) 2.27 4.4E-03 
203 Aebp1 AE binding protein 1 2.26 8.3E-07 
204 Itm2a integral membrane protein 2A 2.25 2.0E-02 
205 Wscd2 WSC domain containing 2 2.25 1.6E-03 
206 Lrrc17 leucine rich repeat containing 17 2.25 3.2E-05 
207 Car11 carbonic anhydrase 11 2.23 6.5E-03 
208 Fstl4 follistatin-like 4 2.23 2.3E-02 
209 Arc activity regulated cytoskeletal-associated protein 2.22 5.0E-03 
210 Tbx3 T-box 3 2.21 1.3E-04 
211 Fndc1 fibronectin type III domain containing 1 2.21 2.9E-06 
212 Tmeff1 transmembrane protein with EGF-like and two follistatin-like 
domains 1;  
2.21 2.1E-02 
213 Camk4 calcium/calmodulin-dependent protein kinase IV 2.20 1.6E-03 
214 Emilin3 elastin microfibril interfacer 3 2.20 3.2E-02 
215 LOC100504703 Mus musculus uncharacterized LOC100504703, non-coding RNA 2.20 4.0E-02 
216 Lonrf2 LON peptidase N-terminal domain and ring finger 2 2.19 3.3E-03 
217 Egr3 early growth response 3 2.19 2.1E-03 
218 Clec2l C-type lectin domain family, member l 2.17 8.1E-03 
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 Gene Symbol Gene Fold Change FDR 
219 Gabra3 gamma-aminobutyric acid (GABA) A receptor, subunit alpha 3 2.17 3.1E-02 
220 Col6a5 collagen, type VI, alpha 5 2.17 1.8E-03 
221 Ccdc68 coiled-coil domain containing 68 2.16 2.0E-04 
222 Scube1 signal peptide, CUB domain, EGF-like 1 2.15 2.1E-04 
223 Mrgprf MAS-related GPR, member F 2.15 7.3E-03 
224 2810055G20Rik RIKEN cDNA 2810055G20 gene 2.15 1.0E-02 
225 Myo16 myosin XVI 2.15 2.0E-02 
226 Sost sclerostin 2.15 4.3E-07 
227 Ccdc3 coiled-coil domain containing 3 2.13 4.2E-06 
228 Col6a3 collagen, type VI, alpha 3 2.13 7.2E-05 
229 Nxph4 neurexophilin 4 2.12 4.9E-02 
230 Gpc3 glypican 3 2.12 5.8E-04 
231 Rtn4r reticulon 4 receptor 2.12 4.3E-04 
232 Htra1 HtrA serine peptidase 1 2.12 4.2E-06 
233 Rgs11 regulator of G-protein signaling 11 2.10 1.4E-02 
234 Prrt2 proline-rich transmembrane protein 2 2.10 7.3E-06 
235 Ube2ql1 RIKEN cDNA 3110006E14 gene 2.10 2.3E-04 
236 Clip3 CAP-GLY domain containing linker protein 3 2.10 6.7E-07 
237 Etv4 ets variant gene 4 (E1A enhancer binding protein, E1AF) 2.09 1.7E-02 
238 Dlgap3 discs, large (Drosophila) homolog-associated protein 3 2.09 3.1E-02 
239 Fam131c family with sequence similarity 131, member C 2.09 1.8E-02 
240 Col6a2 collagen, type VI, alpha 2 2.08 4.3E-06 
241 Wnt10b wingless related MMTV integration site 10b 2.08 7.6E-05 
242 Islr2 immunoglobulin superfamily containing leucine-rich repeat 2 2.07 4.3E-02 
243 Tfcp2l1 transcription factor CP2-like 1 2.07 7.4E-03 
244 Celf5 bruno-like 5, RNA binding protein (Drosophila) 2.07 9.1E-05 
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245 Col2a1 collagen, type II, alpha 1 2.07 9.4E-03 
246 Mab21l1 mab-21-like 1 (C. elegans) 2.05 1.1E-02 
247 Fetub fetuin beta 2.04 1.5E-03 
248 Rora RAR-related orphan receptor alpha 2.04 3.9E-03 
249 Tcea3* transcription elongation factor A (SII), 3 2.03 2.0E-03 
250 Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 2.03 1.2E-06 
251 Dnahc7b dynein, axonemal, heavy chain 7B; dynein, axonemal, heavy chain 
7A 
2.02 4.0E-02 
252 Fbln1 fibulin 1 2.02 1.8E-04 
253 A330021E22Rik RIKEN cDNA A330021E22 gene 2.01 4.2E-02 
254 Dlx5 distal-less homeobox 5 2.00 2.5E-05 
255 Shank1 SH3/ankyrin domain gene 1 2.00 4.3E-05 
 
 
Table B.11, Part II. List of genes more highly expressed in control cancellous bone of littermate control 
animals at 3 hours 
 Gene Symbol Gene Fold Change FDR 
1 Amd1* S-adenosylmethionine decarboxylase 1 76.76 2.8E-03 
2 Hbb-b2 
hemoglobin, beta adult major chain; hemoglobin, beta adult minor 
chain 32.33 3.9E-02 
3 Gm20594 predicted gene, 20594 10.37 5.0E-02 
4 Rsc1a1 
regulatory solute carrier protein, family 1, member 1; DNA-damage 
inducible protein 2 7.09 4.5E-02 
5 Pira7 paired-Ig-like receptor A7 3.93 1.6E-02 
6 Gm12505 predicted gene 12505 3.02 3.8E-02 
7 Cd300c CD300C antigen 2.89 1.1E-03 
8 A730036I17Rik RIKEN cDNA A730036I17 gene 2.75 1.1E-03 
9 Adamdec1 ADAM-like, decysin 1 2.71 3.4E-03 
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10 Clec4g C-type lectin domain family 4, member g 2.71 2.1E-05 
11 Ly6i lymphocyte antigen 6 complex, locus I 2.66 3.3E-03 
12 Cd209d CD209d antigen 2.61 1.7E-02 
13 Gm5483 predicted gene 5483 2.58 8.1E-03 
14 Dclk3 doublecortin-like kinase 3 2.57 6.2E-04 
15 Cxcl5 chemokine (C-X-C motif) ligand 5 2.54 8.0E-06 
16 1700027J07Rik RIKEN cDNA 1700027J07 gene 2.49 1.0E-02 
17 0610009L18Rik* RIKEN cDNA 0610009L18 gene 2.46 4.5E-03 
18 LOC100038947 signal-regulatory protein beta 1  2.44 2.5E-03 
19 Gm1968 predicted gene 1968 2.39 3.5E-04 
20 Glrx3 glutaredoxin 3 2.38 7.6E-03 
21 Pdzd3 PDZ domain containing 3 2.38 7.0E-04 
22 Lyz1 lysozyme 1 2.38 2.6E-03 
23 Ubd ubiquitin D 2.37 8.9E-04 
24 Gm20939 predicted gene, 20939 2.33 4.0E-02 
25 Acmsd amino carboxymuconate semialdehyde decarboxylase 2.32 5.4E-03 
26 5830428M24Rik RIKEN cDNA 5830428M24 gene 2.28 7.6E-03 
27 Slc6a3 
solute carrier family 6 (neurotransmitter transporter, dopamine), 
member 3 2.24 2.6E-04 
28 Sgk2 serum/glucocorticoid regulated kinase 2 2.24 8.4E-03 
29 Efemp1 
epidermal growth factor-containing fibulin-like extracellular matrix 
protein 1 2.24 3.2E-05 
30 Fam110c family with sequence similarity 110, member C 2.22 1.0E-02 
31 Ear6 eosinophil-associated, ribonuclease A family, member 7 2.22 5.7E-08 
32 Cd53 CD53 antigen 2.22 8.9E-04 
33 Gad1 glutamic acid decarboxylase 1 2.20 3.1E-02 
34 0610010B08Rik RIKEN cDNA 0610010B08 gene 2.19 1.2E-02 
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35 Ear1 eosinophil-associated, ribonuclease A family, member 1 2.18 2.1E-09 
36 Slpi secretory leukocyte peptidase inhibitor 2.17 1.3E-04 
37 2410076I21Rik RIKEN cDNA 2410076I21 gene 2.17 6.2E-03 
38 Gm14085 predicted gene 1968 2.16 4.6E-03 
39 Gm6634 predicted gene 6634 2.16 1.7E-02 
40 Ccr3 chemokine (C-C motif) receptor 3 2.15 1.0E-04 
41 Snrpe small nuclear ribonucleoprotein E; predicted gene 6487 2.15 1.7E-02 
42 Cd5l CD5 antigen-like 2.14 5.1E-05 
43 Ear2 eosinophil-associated, ribonuclease A family, member 2 2.14 9.8E-09 
44 Xlr3b X-linked lymphocyte-regulated 3B 2.13 2.2E-02 
45 Klrd1 killer cell lectin-like receptor, subfamily D, member 1 2.12 2.0E-02 
46 Cntf 
Zfp91-Cntf readthrough transcript; zinc finger protein 91; ciliary 
neurotrophic factor 2.12 1.4E-02 
47 Rfc4 replication factor C (activator 1) 4 2.11 1.0E-03 
48 Cdkl1 cyclin-dependent kinase-like 1 (CDC2-related kinase) 2.11 1.3E-03 
49 Ltb4r2 leukotriene B4 receptor 2 2.10 4.7E-03 
50 Zpbp zona pellucida binding protein 2.10 2.2E-02 
51 Ly6g6f lymphocyte antigen 6 complex, locus G6F 2.09 4.9E-05 
52 AA467197 expressed sequence AA467197 2.08 1.1E-02 
53 Kcnj9 potassium inwardly-rectifying channel, subfamily J, member 9 2.07 1.5E-02 
54 Ms4a1 membrane-spanning 4-domains, subfamily A, member 1 2.06 5.1E-04 
55 Snrpg small nuclear ribonucleoprotein polypeptide G 2.06 6.1E-03 
56 4931431B13Rik RIKEN cDNA 4931431B13 gene 2.05 1.4E-02 
57 Ppbp pro-platelet basic protein 2.05 7.4E-05 
58 Gm10658 predicted gene 10658 2.05 3.0E-02 
59 Cenpw centromere protein W 2.05 9.0E-03 
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60 Retnlg resistin like gamma 2.05 1.2E-05 
61 Hist1h4i histone cluster 1, H4i 2.04 8.1E-04 
62 Kcna2 
potassium voltage-gated channel, shaker-related subfamily, member 
2 2.04 4.0E-04 
63 Gm16548 predicted gene 5483 2.04 3.3E-04 
64 Cldn13 claudin 13 2.03 1.5E-04 
65 Rhag Rhesus blood group-associated A glycoprotein 2.02 2.1E-05 
     
  total 320  
  *indicates contaminant 59  
  total without contaminants 261  
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Table B.12: A complete list of genes that were differentially expressed in littermate control animals at 
24 hours in cortical vs cancellous bone at baseline in order of decreasing fold change that were: I. 
more highly expressed in cortical bone and II. More highly expressed in cancellous bone. Number of 
genes (column A), gene symbols (column B), gene names (column C), fold change (column D), false 
discovery rate (FDR) (column E). * indicates contamination as determined by Ayturk et al. 
 
Table B.12, Part I. List of genes more highly expressed in control cortical bone of littermate control 
animals at 24 hours 
 Gene Symbol Gene Fold Change FDR 
1 Myh4* myosin, heavy polypeptide 4, skeletal muscle 416.27 2.3E-08 
2 Pvalb* parvalbumin 348.05 3.0E-10 
3 Xirp2* xin actin-binding repeat containing 2 330.58 3.2E-08 
4 Myh2* myosin, heavy polypeptide 2, skeletal muscle, adult 310.00 6.6E-12 
5 Mb* myoglobin 254.97 9.9E-12 
6 Eef1a2* eukaryotic translation elongation factor 1 alpha 2 250.03 3.1E-11 
7 Myot* myotilin 247.13 2.4E-10 
8 Acta1* actin, alpha 1, skeletal muscle 222.17 2.0E-13 
9 Ampd1* adenosine monophosphate deaminase 1 (isoform M) 175.50 1.8E-10 
10 Ckm* creatine kinase, muscle 166.89 2.9E-10 
11 Myh1* myosin, heavy polypeptide 1, skeletal muscle, adult 162.35 3.1E-08 
12 Mylk2* myosin, light polypeptide kinase 2, skeletal muscle 146.28 6.5E-11 
13 Mybpc1* myosin binding protein C, slow-type 141.88 3.5E-14 
14 A930016O22Rik* RIKEN cDNA A930016O22 gene 141.77 2.4E-14 
15 Trdn* triadin 132.14 6.6E-11 
16 Myom2* myomesin 2 100.69 2.9E-07 
17 Smpx* small muscle protein, X-linked 86.30 6.5E-08 
18 Myoz1* myozenin 1 84.02 3.5E-14 
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19 Tnnt3* troponin T3, skeletal, fast 83.42 2.4E-14 
20 Hfe2* hemochromatosis type 2 (juvenile) (human homolog) 78.69 4.4E-09 
21 Tnnc2* troponin C2, fast 64.64 2.3E-08 
22 Clec3a C-type lectin domain family 3, member a 53.60 8.9E-04 
23 1810041L15Rik RIKEN cDNA 1810041L15 gene 50.24 7.6E-14 
24 Atp2a1* ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 43.43 9.4E-13 
25 Ano5* anoctamin 5 42.99 2.7E-06 
26 Tcap* titin-cap 41.03 1.4E-09 
27 Mfap4 microfibrillar-associated protein 4 25.11 2.7E-09 
28 Lrrn1 leucine rich repeat protein 1, neuronal 24.74 3.4E-11 
29 Casq1* calsequestrin 1 21.33 5.1E-08 
30 Cytl1 cytokine-like 1 20.88 1.7E-03 
31 Cilp2 cartilage intermediate layer protein 2 19.84 1.9E-09 
32 Myoz3* myozenin 3 19.73 2.0E-05 
33 Myl1* myosin, light polypeptide 1 18.78 3.3E-13 
34 Jsrp1* junctional sarcoplasmic reticulum protein 1 18.51 1.5E-08 
35 Smyd1* SET and MYND domain containing 1 15.71 1.0E-05 
36 Ostn osteocrin 15.31 1.3E-05 
37 Tnni2* troponin I, skeletal, fast 2 14.55 1.8E-07 
38 Sall1 sal-like 1 (Drosophila) 14.43 2.3E-09 
39 Actn2* actinin alpha 2 14.17 2.0E-06 
40 Itgbl1 integrin, beta-like 1 13.65 1.2E-05 
41 3110079O15Rik RIKEN cDNA 3110079O15 gene 13.52 9.4E-03 
42 Actn3* actinin alpha 3 13.49 3.5E-11 
43 Mylpf* myosin light chain, phosphorylatable, fast skeletal muscle 13.43 3.3E-09 
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44 Col10a1 collagen, type X, alpha 1 13.31 1.9E-02 
45 H19* H19 fetal liver mRNA 13.22 3.3E-05 
46 Igfbp6 insulin-like growth factor binding protein 6 12.28 3.9E-11 
47 Zim1 zinc finger, imprinted 1 11.61 4.0E-05 
48 Jph4 junctophilin 4 11.51 3.1E-08 
49 Lect1 leukocyte cell derived chemotaxin 1 10.67 3.9E-03 
50 Ckmt2* creatine kinase, mitochondrial 2 10.64 3.6E-04 
51 Klhl41 kelch-like 41 10.49 2.7E-08 
52 Cacna1s* calcium channel, voltage-dependent, L type, alpha 1S subunit 10.46 1.1E-06 
53 Neb* nebulin 10.46 7.5E-07 
54 Mypn* myopalladin 10.46 2.6E-03 
55 Apobec2* apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2 9.68 5.5E-05 
56 Cilp 
cartilage intermediate layer protein, nucleotide 
pyrophosphohydrolase 9.39 6.4E-03 
57 Ttn* titin 9.33 2.0E-08 
58 Wnt16 wingless-related MMTV integration site 16 9.31 3.4E-06 
59 Cacng1* calcium channel, voltage-dependent, gamma subunit 1 9.17 6.0E-04 
60 Snhg11 small nucleolar RNA host gene 11 (non-protein coding) 9.01 3.6E-07 
61 Col8a2 collagen, type VIII, alpha 2 8.46 5.8E-07 
62 Mybpc2* myosin binding protein C, fast-type 8.40 3.9E-07 
63 Dner delta/notch-like EGF-related receptor 8.39 1.8E-09 
64 Rpl3l* ribosomal protein L3-like 8.30 1.8E-04 
65 Wnt7b wingless-related MMTV integration site 7B 8.10 1.3E-11 
66 Ldb3* LIM domain binding 3 8.08 1.2E-05 
67 Aspn asporin 8.01 6.1E-08 
68 Trpm6 transient receptor potential cation channel, subfamily M, member 6 7.94 3.7E-09 
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69 Ucma upper zone of growth plate and cartilage matrix associated 7.83 5.4E-03 
70 Cox8b* cytochrome c oxidase, subunit VIIIb 7.48 1.4E-05 
71 Des* desmin 7.38 1.8E-08 
72 Slc38a3* solute carrier family 38, member 3 7.14 1.1E-02 
73 C1qtnf3 C1q and tumor necrosis factor related protein 3 7.07 4.3E-06 
74 Spock1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 1 6.73 2.0E-06 
75 Nrap* nebulin-related anchoring protein 6.62 3.7E-05 
76 Col3a1 collagen, type III, alpha 1 6.36 8.4E-07 
77 Tmem215 transmembrane protein 215 6.24 2.2E-05 
78 Thbs4 thrombospondin 4 6.08 1.3E-06 
79 Tnn tenascin N 6.01 1.1E-08 
80 Tbx4 T-box 4 5.98 1.7E-06 
81 Pgm5 phosphoglucomutase 5 5.88 4.7E-08 
82 Foxp2 forkhead box P2 5.82 8.7E-12 
83 Htra4 HtrA serine peptidase 4 5.80 2.0E-10 
84 Sh3bgr* SH3-binding domain glutamic acid-rich protein 5.60 1.0E-03 
85 Tigd4 tigger transposable element derived 4 5.51 8.5E-03 
86 Mylk4* myosin light chain kinase family, member 4 5.47 5.3E-03 
87 Plekhg4 
pleckstrin homology domain containing, family G (with RhoGef 
domain) member 4 5.42 4.5E-09 
88 Chad chondroadherin 5.41 1.6E-02 
89 Meox2 mesenchyme homeobox 2 5.39 1.1E-04 
90 Nov nephroblastoma overexpressed gene 5.38 2.4E-05 
91 Fmod fibromodulin 5.37 4.7E-09 
92 Prrx2 paired related homeobox 2 5.32 3.3E-09 
93 Cox7a1* cytochrome c oxidase, subunit VIIa 1 5.00 6.2E-04 
  289 
Table B.12, Part I. Continued 
 Gene Symbol Gene Fold Change FDR 
94 Sema3c 
sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3C 4.98 3.0E-06 
95 Hspb7* heat shock protein family, member 7 (cardiovascular) 4.91 1.1E-06 
96 Fam180a cDNA sequence BC064033 4.85 1.9E-03 
97 Matn3 matrilin 3 4.77 2.7E-02 
98 Ryr1* ryanodine receptor 1, skeletal muscle 4.74 2.0E-04 
99 Scube2 signal peptide, CUB domain, EGF-like 2 4.61 8.9E-06 
100 Chst8 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 4.54 6.4E-05 
101 Cntfr ciliary neurotrophic factor receptor 4.50 4.9E-05 
102 Lrrc15 leucine rich repeat containing 15 4.44 2.8E-10 
103 Postn periostin, osteoblast specific factor 4.37 1.2E-09 
104 Miat myocardial infarction associated transcript (non-protein coding) 4.33 9.4E-06 
105 Kcnab1 
potassium voltage-gated channel, shaker-related subfamily, beta 
member 1 4.25 1.6E-06 
106 Pkia* protein kinase inhibitor, alpha 4.24 6.1E-05 
107 Pgam2* phosphoglycerate mutase 2 4.22 3.0E-04 
108 Nrk Nik related kinase 3.97 2.0E-02 
109 Megf6 multiple EGF-like-domains 6 3.92 1.5E-03 
110 Slc17a8 
solute carrier family 17 (sodium-dependent inorganic phosphate 
cotransporter), member 8 3.87 5.1E-05 
111 Meg3 maternally expressed 3 3.79 1.1E-10 
112 Rian RNA imprinted and accumulated in nucleus 3.75 5.7E-08 
113 C130021I20Rik Riken cDNA C130021I20 gene 3.74 1.5E-05 
114 Shisa2* shisa homolog 2 (Xenopus laevis) 3.74 1.9E-04 
115 Adamtsl1 ADAMTS-like 1 3.72 8.2E-05 
116 P4ha3 
procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-
hydroxylase), alpha polypeptide III 3.67 2.9E-06 
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117 Ncmap noncompact myelin associated protein 3.64 2.1E-02 
118 Col16a1 collagen, type XVI, alpha 1 3.62 7.7E-12 
119 Msln mesothelin 3.60 1.4E-08 
120 A330021E22Rik RIKEN cDNA A330021E22 gene 3.58 2.2E-04 
121 Mmp12 matrix metallopeptidase 12 3.57 8.4E-03 
122 Tnmd tenomodulin 3.55 4.7E-04 
123 Gcnt4 predicted gene 73 3.54 4.1E-05 
124 Scn4b* sodium channel, type IV, beta 3.50 6.6E-03 
125 Fam69c RIKEN cDNA B230399E16 gene 3.47 4.0E-07 
126 C1qtnf9 C1q and tumor necrosis factor related protein 9 3.47 1.2E-02 
127 Slc6a17 solute carrier family 6 (neurotransmitter transporter), member 17 3.39 2.6E-04 
128 Tmod4* tropomodulin 4 3.37 1.2E-02 
129 Gabra3 gamma-aminobutyric acid (GABA) A receptor, subunit alpha 3 3.35 1.7E-06 
130 Anxa8 annexin A8 3.30 7.8E-04 
131 Dpysl4 dihydropyrimidinase-like 4 3.29 9.3E-06 
132 Spock2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 2 3.26 6.2E-09 
133 Mrgprf MAS-related GPR, member F 3.24 3.3E-05 
134 Thbs2 thrombospondin 2 3.22 6.0E-09 
135 Ptn pleiotrophin 3.20 9.9E-07 
136 Zfp185 zinc finger protein 185 3.19 6.7E-03 
137 Piwil2 piwi-like homolog 2 (Drosophila) 3.16 2.0E-07 
138 Tenm3 teneurin transmembrane protein 3 3.15 4.5E-07 
139 Medag mesenteric estrogen dependent adipogenesis 3.13 3.3E-05 
140 C1qtnf2 C1q and tumor necrosis factor related protein 2 3.12 9.5E-04 
141 Crabp2 cellular retinoic acid binding protein II 3.11 1.6E-03 
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142 Itm2a integral membrane protein 2A 3.11 9.9E-12 
143 Bai2 brain-specific angiogenesis inhibitor 2 3.11 1.0E-03 
144 Emilin3 elastin microfibril interfacer 3 3.10 3.8E-04 
145 Flnc* filamin C, gamma 3.09 5.0E-06 
146 Ablim3 actin binding LIM protein family, member 3 3.08 1.8E-04 
147 Fosb FBJ osteosarcoma oncogene B 3.05 5.3E-03 
148 Mia melanoma inhibitory activity 3.05 5.0E-02 
149 Prtg protogenin homolog (Gallus gallus) 3.03 5.0E-05 
150 Aspg asparaginase homolog (S. cerevisiae) 2.99 9.1E-06 
151 Prss23 protease, serine, 23 2.97 4.3E-06 
152 Peg3as Peg3 opposite strand 2.97 2.8E-06 
153 Rgs11 regulator of G-protein signaling 11 2.96 1.1E-04 
154 Pnmal2 PNMA-like 2 2.96 3.4E-04 
155 Rnf207 ring finger protein 207 2.95 3.7E-04 
156 3632451O06Rik RIKEN cDNA 3632451O06 gene 2.93 9.7E-07 
157 Epha3 Eph receptor A3 2.92 1.5E-09 
158 Col12a1 collagen, type XII, alpha 1 2.91 2.0E-08 
159 B230206H07Rik RIKEN cDNA B230206H07 gene 2.91 1.1E-03 
160 Olfr78 olfactory receptor 78 2.91 1.2E-03 
161 Asic3 acid-sensing (proton-gated) ion channel 3 2.90 4.6E-05 
162 Jph2* junctophilin 2 2.90 1.1E-04 
163 Trim72* tripartite motif-containing 72 2.90 2.2E-02 
164 Angptl2 angiopoietin-like 2 2.89 3.8E-08 
165 4930429F24Rik* RIKEN cDNA 4930429F24 gene 2.88 9.1E-03 
166 Sparcl1 SPARC-like 1 2.88 5.4E-08 
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167 Slmo1 slowmo homolog 1 (Drosophila) 2.88 6.8E-03 
168 Susd5 sushi domain containing 5 2.87 1.1E-04 
169 Gng8 guanine nucleotide binding protein (G protein), gamma 8 2.86 2.3E-03 
170 Obscn* obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF 2.85 1.1E-02 
171 Plat plasminogen activator, tissue 2.81 6.1E-09 
172 Lrrc17 leucine rich repeat containing 17 2.81 4.5E-09 
173 Wnt10b wingless related MMTV integration site 10b 2.78 1.6E-09 
174 Alpk3* alpha-kinase 3 2.78 5.3E-03 
175 Gm10635 predicted gene 10635 2.77 1.6E-03 
176 Ogdhl oxoglutarate dehydrogenase-like 2.77 1.0E-02 
177 Kcp kielin/chordin-like protein 2.70 1.0E-03 
178 Ngfr nerve growth factor receptor (TNFR superfamily, member 16) 2.70 3.1E-04 
179 Ccl12 chemokine (C-C motif) ligand 12 2.67 8.3E-03 
180 Wnt9a wingless-type MMTV integration site 9A 2.65 6.8E-06 
181 Thbs3 thrombospondin 3 2.64 3.1E-05 
182 Wnt2b wingless related MMTV integration site 2b 2.64 4.2E-08 
183 1500015O10Rik RIKEN cDNA 1500015O10 gene 2.62 2.5E-08 
184 F3 coagulation factor III 2.60 4.5E-06 
185 Edil3 EGF-like repeats and discoidin I-like domains 3 2.60 1.0E-06 
186 Prnd prion protein dublet 2.60 2.2E-06 
187 Ptprv protein tyrosine phosphatase, receptor type, V 2.59 1.1E-07 
188 Galr2 galanin receptor 2 2.59 2.0E-06 
189 Peg3 paternally expressed 3 2.54 2.3E-05 
190 Txlnb* taxilin beta 2.51 4.7E-02 
191 Camk4 calcium/calmodulin-dependent protein kinase IV 2.49 2.9E-06 
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192 Rab15 RAB15, member RAS oncogene family 2.49 6.7E-03 
193 Eif3j1 eukaryotic translation initiation factor 3, subunit J1 2.46 4.3E-02 
194 Best1 bestrophin 1; hypothetical protein LOC100046789 2.44 1.6E-04 
195 Lrrc55 leucine rich repeat containing 55 2.44 3.8E-02 
196 Aldh1a3 aldehyde dehydrogenase family 1, subfamily A3 2.44 2.2E-02 
197 Dkk3 dickkopf homolog 3 (Xenopus laevis) 2.41 2.5E-09 
198 Epha4 Eph receptor A4 2.41 6.2E-06 
199 Hspb8* heat shock protein 8 2.40 5.8E-03 
200 Ccdc3 coiled-coil domain containing 3 2.40 1.7E-08 
201 Comp cartilage oligomeric matrix protein 2.39 2.4E-02 
202 Gpnmb glycoprotein (transmembrane) nmb 2.39 2.7E-07 
203 Tnxb tenascin XB 2.38 1.0E-02 
204 Rbp7 retinol binding protein 7, cellular 2.37 1.2E-02 
205 Sulf1 sulfatase 1 2.37 3.3E-13 
206 Mall mal, T-cell differentiation protein-like 2.35 3.4E-03 
207 Igsf1 immunoglobulin superfamily, member 1 2.35 1.7E-05 
208 Rarres1 retinoic acid receptor responder (tazarotene induced) 1 2.34 2.8E-04 
209 Dnahc1 dynein, axonemal, heavy chain 1 2.34 6.2E-06 
210 Col6a3 collagen, type VI, alpha 3 2.32 5.2E-07 
211 Dpt dermatopontin 2.32 4.9E-03 
212 Snap91 synaptosomal-associated protein 91 2.32 3.9E-02 
213 Fcrls Fc receptor-like S, scavenger receptor 2.32 9.7E-06 
214 Sost sclerostin 2.32 2.4E-04 
215 Slc6a7 
solute carrier family 6 (neurotransmitter transporter, L-proline), 
member 7 2.30 3.8E-06 
216 Gabrb3 gamma-aminobutyric acid (GABA) A receptor, subunit beta 3 2.30 1.3E-04 
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217 Spp1 secreted phosphoprotein 1 2.28 2.4E-06 
218 Hr hairless 2.28 6.9E-06 
219 Capn6 calpain 6 2.27 1.5E-02 
220 Meox1 mesenchyme homeobox 1 2.27 8.1E-05 
221 Rtn2* reticulon 2 (Z-band associated protein) 2.26 2.9E-02 
222 A730090H04Rik RIKEN cDNA A730090H04 gene 2.26 1.5E-03 
223 Lgi3 leucine-rich repeat LGI family, member 3 2.25 3.3E-03 
224 Asphd2 aspartate beta-hydroxylase domain containing 2 2.25 3.4E-04 
225 Etv4 ets variant gene 4 (E1A enhancer binding protein, E1AF) 2.25 1.7E-03 
226 Radil Ras association and DIL domains 2.25 4.5E-02 
227 Nptxr neuronal pentraxin receptor 2.24 4.6E-02 
228 Pamr1 peptidase domain containing associated with muscle regeneration 1 2.24 1.4E-05 
229 Chd5 chromodomain helicase DNA binding protein 5 2.22 1.2E-02 
230 Col6a5 collagen, type VI, alpha 5 2.22 3.3E-06 
231 AI593442 expressed sequence AI593442 2.22 1.2E-02 
232 Gpr115 G protein-coupled receptor 115 2.22 4.5E-02 
233 Htra1 HtrA serine peptidase 1 2.22 1.7E-06 
234 Tgfb2 transforming growth factor, beta 2 2.21 3.7E-04 
235 Cacng7 calcium channel, voltage-dependent, gamma subunit 7 2.21 4.0E-02 
236 Mlph melanophilin 2.21 1.3E-04 
237 Eps8l2 EPS8-like 2 2.19 3.9E-03 
238 Pygm* muscle glycogen phosphorylase 2.18 4.4E-03 
239 Tppp3 tubulin polymerization-promoting protein family member 3 2.17 6.7E-06 
240 Islr2 immunoglobulin superfamily containing leucine-rich repeat 2 2.17 4.7E-02 
241 Kcne4 potassium voltage-gated channel, Isk-related subfamily, gene 4 2.16 7.9E-04 
  295 
Table B.12, Part I. Continued 
 Gene Symbol Gene Fold Change FDR 
242 Mt2 metallothionein 2 2.16 5.4E-04 
243 Srl* sarcalumenin 2.15 2.8E-03 
244 Sox5 SRY-box containing gene 5 2.15 1.2E-02 
245 Mgp matrix Gla protein 2.15 6.1E-05 
246 Fbln1 fibulin 1 2.14 3.3E-08 
247 Clmn calmin 2.14 8.6E-03 
248 Cdh13 cadherin 13 2.14 1.4E-03 
249 Cmya5* cardiomyopathy associated 5 2.14 1.4E-03 
250 Tub cDNA sequence BC049265; tubby candidate gene 2.14 3.1E-06 
251 Gprasp2 G protein-coupled receptor associated sorting protein 2 2.13 1.8E-02 
252 1700007J10Rik RIKEN cDNA 1700007J10 gene 2.13 3.1E-02 
253 Eno3* enolase 3, beta muscle 2.12 4.2E-03 
254 Matn2 matrilin 2 2.12 4.0E-06 
255 Mmp13 matrix metallopeptidase 13 2.12 3.6E-03 
256 Lum lumican 2.10 3.9E-05 
257 Serpind1 serine (or cysteine) peptidase inhibitor, clade D, member 1 2.10 2.1E-02 
258 Mustn1 musculoskeletal, embryonic nuclear protein 1 2.10 6.4E-05 
259 Arntl2 aryl hydrocarbon receptor nuclear translocator-like 2;  2.10 3.9E-02 
260 Ulk4 unc-51-like kinase 4 (C. elegans) 2.09 3.2E-02 
261 Abhd3 abhydrolase domain containing 3 2.09 6.0E-03 
262 Eno2 enolase 2, gamma neuronal 2.08 5.7E-05 
263 Higd1b HIG1 domain family, member 1B 2.07 3.6E-02 
264 Ssc5d scavenger receptor cysteine rich family, 5 domains 2.07 2.1E-02 
265 Rpl39l ribosomal protein L39-like 2.07 1.7E-03 
266 Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 2.07 7.2E-10 
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 Gene Symbol Gene Fold Change FDR 
267 Ecm2 extracellular matrix protein 2, female organ and adipocyte specific 2.06 1.3E-05 
268 Lamc2 laminin, gamma 2 2.06 3.7E-02 
269 Nox4 NADPH oxidase 4 2.05 1.6E-02 
270 Tmod2 tropomodulin 2 2.05 4.1E-03 
271 C1qtnf5 
C1q and tumor necrosis factor related protein 5; membrane-type 
frizzled-related protein 2.05 2.9E-07 
272 Ogn osteoglycin 2.04 2.4E-04 
273 Gpx3 glutathione peroxidase 3 2.03 7.3E-06 
274 Cav1 caveolin 1, caveolae protein 2.03 1.0E-07 
275 Tnfaip6 tumor necrosis factor alpha induced protein 6 2.02 5.4E-03 
276 Megf10 multiple EGF-like-domains 10 2.02 3.8E-08 
277 Asap3 ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 2.02 6.2E-06 
278 Cys1 cystin 1 2.01 4.3E-03 
279 Arhgap44  Rho GTPase activating protein 44 2.01 6.5E-03 
280 Dnahc7b dynein, axonemal, heavy chain 7B 2.00 4.2E-02 
 
 
 
Table B.12, Part II. List of genes more highly expressed in control cancellous bone of littermate 
control animals at 24 hours 
 Gene Symbol Gene Fold Change FDR 
1 Ear12 eosinophil-associated, ribonuclease A family, member 12 439.55 4.2E-03 
2 Cbln1 cerebellin 1 precursor protein 5.14 1.3E-06 
3 Ly6g6c lymphocyte antigen 6 complex, locus G6C 3.54 3.7E-03 
4 Hist1h4m histone cluster 1, H4m 2.79 7.0E-04 
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 Gene Symbol Gene Fold Change FDR 
5 Btnl6 butyrophilin-like 6 2.65 1.4E-03 
6 Serpinb2 serine (or cysteine) peptidase inhibitor, clade B, member 2 2.61 6.6E-11 
7 Ubd ubiquitin D 2.55 2.0E-10 
8 AU023871 expressed sequence AU023871 2.50 2.6E-13 
9 Gp1ba 
glycoprotein 1b, alpha polypeptide; hypothetical protein 
LOC100048807 2.48 3.2E-12 
10 Alox12 arachidonate 12-lipoxygenase 2.48 5.3E-13 
11 Treml1 triggering receptor expressed on myeloid cells-like 1 2.45 5.2E-14 
12 Gpr50 G-protein-coupled receptor 50 2.42 2.9E-03 
13 Tubb1 tubulin, beta 1 2.42 1.4E-14 
14 Marco macrophage receptor with collagenous structure 2.42 1.4E-02 
15 Cxcl5 
similar to LPS-induced CXC chemokine; chemokine (C-X-C motif) 
ligand 5 2.40 1.7E-03 
16 Slamf1 signaling lymphocytic activation molecule family member 1 2.38 4.9E-10 
17 Ccdc37 coiled-coil domain containing 37 2.37 1.3E-02 
18 Gp6 glycoprotein 6 (platelet) 2.36 4.0E-12 
19 Lipg lipase, endothelial 2.35 2.4E-14 
20 Spatc1 spermatogenesis and centriole associated 1 2.35 8.3E-03 
21 Mpl myeloproliferative leukemia virus oncogene 2.35 1.1E-12 
22 Efemp1 
epidermal growth factor-containing fibulin-like extracellular matrix 
protein 1 2.35 2.0E-08 
23 Nrgn neurogranin 2.34 1.1E-12 
24 Ccdc92 coiled-coil domain containing 92 2.33 1.9E-08 
25 Syt13 synaptotagmin XIII 2.33 8.5E-03 
26 Clca1 chloride channel calcium activated 1 2.32 9.0E-13 
27 Gnaz guanine nucleotide binding protein, alpha z subunit 2.32 7.7E-13 
28 Ccdc150 coiled-coil domain containing 150 2.31 4.9E-06 
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 Gene Symbol Gene Fold Change FDR 
29 Clec1b C-type lectin domain family 1, member b 2.29 1.7E-10 
30 Cd5l CD5 antigen-like 2.29 2.3E-07 
31 Slc6a4 
solute carrier family 6 (neurotransmitter transporter, serotonin), 
member 4 2.27 1.9E-07 
32 Gp5 glycoprotein 5 (platelet) 2.27 4.9E-10 
33 Nlrp6 NLR family, pyrin domain containing 6 2.26 9.9E-05 
34 Npas4 neuronal PAS domain protein 4 2.25 2.6E-07 
35 Ly6g6f lymphocyte antigen 6 complex, locus G6F 2.24 7.0E-04 
36 Ppbp pro-platelet basic protein 2.24 1.0E-06 
37 Clec4g C-type lectin domain family 4, member g 2.22 4.2E-04 
38 Hmga2-ps1 high mobility group AT-hook 2, pseudogene 1 2.21 1.8E-10 
39 Gramd1c GRAM domain containing 1C 2.20 3.1E-05 
40 Aldob aldolase B, fructose-bisphosphate 2.20 3.4E-05 
41 Lypd6 LY6/PLAUR domain containing 6 2.19 4.5E-02 
42 Gp1bb glycoprotein Ib, beta polypeptide 2.18 1.2E-07 
43 Sec14l5* SEC14-like 5 (S. cerevisiae) 2.17 1.0E-04 
44 Gpm6a glycoprotein m6a 2.17 4.9E-07 
45 Tesc tescalcin 2.16 1.7E-06 
46 Itga2b integrin alpha 2b 2.16 2.3E-08 
47 Ufsp1 UFM1-specific peptidase 1 2.14 1.0E-07 
48 Kcna2 
potassium voltage-gated channel, shaker-related subfamily, member 
2 2.14 2.9E-07 
49 F2rl2 coagulation factor II (thrombin) receptor-like 2 2.14 4.5E-11 
50 Cd226* CD226 antigen 2.13 1.9E-04 
51 Tnfsf14 tumor necrosis factor (ligand) superfamily, member 14 2.13 2.4E-14 
52 Spic Spi-C transcription factor (Spi-1/PU.1 related) 2.13 2.9E-09 
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 Gene Symbol Gene Fold Change FDR 
53 Gcsam germinal center associated, signaling and motility 2.12 7.6E-08 
54 Mfsd2b predicted gene 1964 2.12 2.4E-10 
55 Gad1 glutamic acid decarboxylase 1 2.12 1.1E-02 
56 Cass4 Cas scaffolding protein family member 4 2.12 1.5E-07 
57 Mmrn1 multimerin 1 2.12 4.4E-13 
58 Reep2 receptor accessory protein 2 2.11 6.9E-08 
59 2010204K13Rik RIKEN cDNA 2010204K13 gene 2.10 2.1E-02 
60 Hoxb8 homeo box B8 2.10 3.4E-03 
61 Slc24a5 solute carrier family 24, member 5 2.09 1.0E-07 
62 Grap2* GRB2-related adaptor protein 2 2.09 1.5E-10 
63 Itgad integrin, alpha D 2.09 1.9E-06 
64 Fcna ficolin A 2.09 2.5E-10 
65 Stab2 similar to FEX2; stabilin 2 2.08 2.4E-14 
66 Slc35d3 solute carrier family 35, member D3 2.07 4.6E-07 
67 Treml4 triggering receptor expressed on myeloid cells-like 4 2.07 1.9E-07 
68 Slc6a3 
solute carrier family 6 (neurotransmitter transporter, dopamine), 
member 3 2.06 4.4E-04 
69 Cited4 
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-
terminal domain, 4 2.06 3.8E-04 
70 Ptger3 prostaglandin E receptor 3 (subtype EP3) 2.05 4.7E-04 
71 Ccdc67 coiled-coil domain containing 67 2.05 3.5E-02 
72 Rbpms2 predicted gene 3470; RNA binding protein with multiple splicing 2 2.05 4.7E-09 
73 Esm1 endothelial cell-specific molecule 1 2.05 2.4E-14 
74 Gbx2 gastrulation brain homeobox 2 2.05 4.9E-03 
75 Cdh1 cadherin 1 2.04 2.6E-03 
76 BC016579 cDNA sequence, BC016579 2.04 3.0E-02 
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 Gene Symbol Gene Fold Change FDR 
77 Fmo2 flavin containing monooxygenase 2 2.03 1.3E-07 
78 Kcna3 
potassium voltage-gated channel, shaker-related subfamily, member 
3 2.03 1.5E-04 
79 Pls1 plastin 1 (I-isoform) 2.03 4.4E-05 
80 Bin2 bridging integrator 2 2.03 2.9E-11 
81 Guca1b guanylate cyclase activator 1B 2.03 2.4E-02 
82 P2rx1 purinergic receptor P2X, ligand-gated ion channel, 1 2.03 6.6E-05 
83 Grem1 gremlin 1 2.03 1.2E-09 
84 Ache* acetylcholinesterase 2.02 1.5E-08 
85 Akap5 A kinase (PRKA) anchor protein 5 2.01 2.1E-04 
86 Hal histidine ammonia lyase 2.01 2.2E-02 
87 Serpina3f serine (or cysteine) peptidase inhibitor, clade A, member 3F 2.00 3.9E-05 
88 Vwf Von Willebrand factor homolog 2.00 1.1E-09 
89 Kcnj9 potassium inwardly-rectifying channel, subfamily J, member 9 2.00 6.0E-03 
     
  total 369  
  *indicates contaminant 75  
  total without contaminants 294  
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Table B.13: A complete list of genes that were differentially expressed in pOC-ERaKO animals at 3 hours 
in cortical vs cancellous bone at baseline in order of decreasing fold change that were: I. More highly 
expressed in cortical bone and II. More highly expressed in cancellous bone. Number of genes (column A), 
gene symbols (column B), gene names (column C), fold change (column D), false discovery rate (FDR) 
(column E). * indicates contamination as determined by Ayturk et al. 
 
Table B.13, Part I. List of genes more highly expressed in control cortical bone of pOC-ERaKO animals 
at 3 hours 
 Gene Symbol Gene Fold Change FDR 
1 Xirp2* xin actin-binding repeat containing 2 2016.93 2.3E-11 
2 Myh1* 
myosin, heavy polypeptide 2, skeletal muscle, adult; myosin, heavy 
polypeptide 1, skeletal muscle, adult 1950.34 3.4E-17 
3 Myh4* myosin, heavy polypeptide 4, skeletal muscle 957.03 2.3E-06 
4 Myh2* 
myosin, heavy polypeptide 2, skeletal muscle, adult; myosin, heavy 
polypeptide 1, skeletal muscle, adult 540.45 2.7E-09 
5 Trim54* tripartite motif-containing 54 425.80 4.4E-10 
6 Smpx* small muscle protein, X-linked 420.56 8.9E-10 
7 Myot* myotilin 347.39 1.0E-09 
8 Ppp1r3a* protein phosphatase 1, regulatory (inhibitor) subunit 3A 338.57 9.8E-08 
9 Sgcg* sarcoglycan, gamma (dystrophin-associated glycoprotein) 296.14 1.2E-08 
10 Smtnl1* smoothelin-like 1 293.08 2.8E-08 
11 Eef1a2* eukaryotic translation elongation factor 1 alpha 2 278.59 4.7E-09 
12 Dhrs7c* dehydrogenase/reductase (SDR family) member 7C 277.31 1.0E-07 
13 Mylk2* myosin, light polypeptide kinase 2, skeletal muscle 257.82 7.5E-16 
14 Ankrd1 ankyrin repeat domain 1 (cardiac muscle) 253.96 1.0E-08 
15 Acta1* actin, alpha 1, skeletal muscle 248.33 8.9E-08 
16 Mybpc1* myosin binding protein C, slow-type 226.90 1.4E-09 
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 Gene Symbol Gene Fold Change FDR 
17 Pvalb* parvalbumin 223.09 8.2E-07 
18 Klhl40 kelch-like 40 208.31 1.6E-08 
19 Trdn* triadin 206.14 2.0E-11 
20 Mb* myoglobin 198.04 2.1E-09 
21 Myom2* myomesin 2 169.25 1.2E-09 
22 Tnnt3* troponin T3, skeletal, fast 153.94 8.9E-10 
23 Ampd1* adenosine monophosphate deaminase 1 (isoform M) 138.98 5.3E-08 
24 Ckm* creatine kinase, muscle 125.67 9.8E-07 
25 Tcap* titin-cap 122.05 2.1E-09 
26 Myoz3* myozenin 3 116.10 1.0E-07 
27 Myoc myocilin 108.53 2.2E-06 
28 Cilp cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 105.27 3.3E-06 
29 Tnnc2* troponin C2, fast 97.68 1.2E-06 
30 Sypl2* synaptophysin-like 2 78.78 3.1E-08 
31 Myoz1* myozenin 1 78.42 9.2E-05 
32 A930016O22Rik* RIKEN cDNA A930016O22 gene 76.07 1.6E-08 
33 Igfn1 immunoglobulin-like and fibronectin type III domain containing 1 72.72 1.7E-05 
34 Hfe2* hemochromatosis type 2 (juvenile) (human homolog) 71.06 1.6E-08 
35 Abra* actin-binding Rho activating protein 68.31 3.3E-08 
36 Ano5* anoctamin 5 63.14 5.4E-07 
37 Atp2a1* ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 55.51 5.9E-06 
38 Klhl31* kelch-like 31 (Drosophila) 46.09 3.6E-05 
39 Smyd1* SET and MYND domain containing 1 42.61 6.7E-05 
40 Casq1* calsequestrin 1 39.54 2.0E-05 
41 Lmod2* leiomodin 2 (cardiac) 37.21 2.9E-07 
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42 Ostn osteocrin 35.26 2.0E-07 
43 Trim63* similar to tripartite motif-containing 63; tripartite motif-containing 63 33.44 1.4E-06 
44 Myl1* myosin, light polypeptide 1 29.98 2.7E-07 
45 Tnni2* troponin I, skeletal, fast 2 29.94 6.8E-05 
46 Cacna1s* calcium channel, voltage-dependent, L type, alpha 1S subunit 29.87 2.2E-07 
47 Kcnc4* potassium voltage gated channel, Shaw-related subfamily, member 4 26.72 3.8E-03 
48 Thbs4 thrombospondin 4 24.56 1.9E-13 
49 Kcna7* potassium voltage-gated channel, shaker-related subfamily, member 7 23.77 7.2E-07 
50 Cilp2 cartilage intermediate layer protein 2 23.54 5.7E-08 
51 Actn3* actinin alpha 3 22.40 1.2E-04 
52 Mylpf* myosin light chain, phosphorylatable, fast skeletal muscle 22.29 3.0E-05 
53 Xirp1* xin actin-binding repeat containing 1 21.94 7.7E-04 
54 Jsrp1* junctional sarcoplasmic reticulum protein 1 18.76 9.2E-05 
55 Ldb3* LIM domain binding 3 17.68 3.2E-04 
56 Mybpc2* myosin binding protein C, fast-type 17.45 3.5E-04 
57 Apobec2* 
apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2; similar to 
APOBEC-2 protein 17.25 1.9E-04 
58 Ttn* titin 16.41 8.9E-05 
59 Actn2* actinin alpha 2 16.12 8.9E-05 
60 Mypn* myopalladin 15.79 1.5E-02 
61 Mfap4 microfibrillar-associated protein 4 15.65 2.5E-03 
62 Kcnj11 potassium inwardly rectifying channel, subfamily J, member 11 15.33 3.2E-05 
63 Lrrn1 leucine rich repeat protein 1, neuronal 14.85 2.4E-04 
64 Fitm1* fat storage-inducing transmembrane protein 1 14.56 7.0E-04 
65 Nrap* nebulin-related anchoring protein 14.53 2.8E-04 
66 Ckmt2* creatine kinase, mitochondrial 2 14.22 1.4E-03 
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67 Lmod3* leiomodin 3 (fetal) 13.29 2.2E-04 
68 Cacng1* calcium channel, voltage-dependent, gamma subunit 1 11.62 3.9E-03 
69 Igfbp6 insulin-like growth factor binding protein 6 11.47 2.1E-09 
70 Des* desmin 10.90 3.4E-04 
71 Sh3bgr* 
similar to putative SH3BGR protein; SH3-binding domain glutamic acid-
rich protein 10.68 6.1E-04 
72 Neb* nebulin 10.52 1.1E-03 
73 Angptl7 angiopoietin-like 7 10.41 1.7E-05 
74 Rpl3l* ribosomal protein L3-like 10.33 2.0E-03 
75 Mylk4* myosin light chain kinase family, member 4 10.18 3.6E-03 
76 Murc* muscle-related coiled-coil protein 9.93 6.3E-03 
77 Wnt16 wingless-related MMTV integration site 16 9.85 1.9E-03 
78 Itgbl1 integrin, beta-like 1 9.72 3.4E-03 
79 Klhl41 kelch-like 41 9.70 1.5E-04 
80 Fgf14 fibroblast growth factor 14 9.54 1.7E-05 
81 C1qtnf3 C1q and tumor necrosis factor related protein 3 9.47 2.7E-03 
82 Cox8b* cytochrome c oxidase, subunit VIIIb 9.22 4.2E-03 
83 Synpo2l* synaptopodin 2-like 9.05 1.9E-03 
84 H19* H19 fetal liver mRNA 8.96 2.6E-04 
85 Asb14* ankyrin repeat and SOCS box-containing 14 8.84 1.5E-03 
86 Aspn asporin 8.82 4.5E-06 
87 Tigd4 tigger transposable element derived 4 8.78 1.4E-03 
88 Tbx4 T-box 4 8.15 1.0E-09 
89 Atp1a2* ATPase, Na+/K+ transporting, alpha 2 polypeptide 7.71 5.0E-03 
90 1810041L15Rik RIKEN cDNA 1810041L15 gene 7.70 7.5E-03 
91 Pdlim3* PDZ and LIM domain 3 7.64 2.3E-03 
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92 Lrrc15 leucine rich repeat containing 15 7.44 2.1E-07 
93 Meox2 mesenchyme homeobox 2 7.28 1.0E-07 
94 Slc17a8 
solute carrier family 17 (sodium-dependent inorganic phosphate 
cotransporter), member 8 7.25 1.5E-02 
95 Dusp13* dual specificity phosphatase 13 7.13 1.7E-02 
96 Fam180a cDNA sequence BC064033 7.10 1.9E-04 
97 Myh14 myosin, heavy polypeptide 14 6.80 4.2E-02 
98 Cntfr ciliary neurotrophic factor receptor 6.68 2.7E-04 
99 Tnn tenascin N 6.57 2.1E-06 
100 Pgam2* phosphoglycerate mutase 2 6.43 4.4E-03 
101 Tmod4* tropomodulin 4 6.38 1.0E-03 
102 Ryr1* ryanodine receptor 1, skeletal muscle 6.37 1.8E-02 
103 Cox7a1* cytochrome c oxidase, subunit VIIa 1 6.30 7.2E-03 
104 Sall1 sal-like 1 (Drosophila) 6.20 3.0E-04 
105 Hspb7* heat shock protein family, member 7 (cardiovascular) 6.06 4.9E-06 
106 Sema3c 
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3C 5.72 6.5E-05 
107 Scube2 
similar to signal peptide, CUB domain, EGF-like 2; signal peptide, CUB 
domain, EGF-like 2 5.50 2.1E-05 
108 Col3a1 collagen, type III, alpha 1 5.48 3.5E-04 
109 Clcn1* chloride channel 1 5.38 4.2E-02 
110 Islr2 immunoglobulin superfamily containing leucine-rich repeat 2 5.36 1.2E-03 
111 Fmod fibromodulin 5.11 5.6E-06 
112 Wnt7b wingless-related MMTV integration site 7B 5.02 2.9E-04 
113 Angptl1 angiopoietin-like 1 4.78 2.3E-03 
114 Fndc1 
fibronectin type III domain containing 1; similar to fibronectin type III 
domain containing 1 4.76 1.1E-06 
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115 Obscn* obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF 4.76 4.9E-03 
116 Tnxb tenascin XB 4.74 1.8E-02 
117 Col8a2 collagen, type VIII, alpha 2 4.59 2.1E-02 
118 Pgm5 phosphoglucomutase 5 4.58 1.7E-04 
119 Jph2* junctophilin 2 4.48 2.0E-02 
120 Scn4b* sodium channel, type IV, beta 4.46 4.0E-02 
121 Postn periostin, osteoblast specific factor 4.35 4.8E-05 
122 Nov nephroblastoma overexpressed gene 4.29 1.3E-02 
123 Duoxa1 dual oxidase maturation factor 1 4.29 5.9E-04 
124 Txlnb* taxilin beta 4.28 8.6E-03 
125 Bnc2 basonuclin 2 4.15 2.4E-03 
126 Miat myocardial infarction associated transcript (non-protein coding) 3.98 1.0E-06 
127 Angptl2 angiopoietin-like 2 3.97 8.9E-10 
128 Flnc* filamin C, gamma 3.97 4.9E-05 
129 Trpm6 transient receptor potential cation channel, subfamily M, member 6 3.89 1.2E-03 
130 P4ha3 
procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), 
alpha polypeptide III 3.84 1.5E-03 
131 Prrx2 paired related homeobox 2 3.79 1.6E-03 
132 Plekhg4 
pleckstrin homology domain containing, family G (with RhoGef domain) 
member 4 3.76 1.1E-04 
133 Snhg11 small nucleolar RNA host gene 11 (non-protein coding) 3.74 5.8E-03 
134 Srl* sarcalumenin 3.68 1.7E-03 
135 C130021I20Rik Riken cDNA C130021I20 gene 3.68 4.9E-03 
136 Rtn2* reticulon 2 (Z-band associated protein) 3.68 1.3E-02 
137 Pkia* protein kinase inhibitor, alpha 3.61 1.7E-02 
138 Htra4 HtrA serine peptidase 4 3.59 2.7E-02 
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139 C1qtnf9 C1q and tumor necrosis factor related protein 9 3.59 7.9E-03 
140 Pygm* muscle glycogen phosphorylase 3.57 1.9E-02 
141 Apod apolipoprotein D 3.54 1.5E-03 
142 Thbs2 thrombospondin 2 3.53 4.3E-06 
143 3425401B19Rik* RIKEN cDNA 3425401B19 gene 3.51 1.9E-02 
144 Col16a1 collagen, type XVI, alpha 1 3.49 1.1E-07 
145 Nox4 NADPH oxidase 4 3.49 7.9E-05 
146 Ablim3 actin binding LIM protein family, member 3 3.48 4.2E-04 
147 Tenm3 teneurin transmembrane protein 3 3.39 2.6E-04 
148 Chst8 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 3.38 4.0E-03 
149 Zfp185 zinc finger protein 185 3.33 1.9E-02 
150 Fgf23 similar to FGF23; fibroblast growth factor 23 3.31 3.0E-02 
151 Ptn pleiotrophin 3.29 2.5E-03 
152 Ankrd23* ankyrin repeat domain 23 3.28 1.6E-02 
153 Col12a1 collagen, type XII, alpha 1 3.28 5.3E-06 
154 Penk preproenkephalin 3.26 3.5E-02 
155 Gabra3 gamma-aminobutyric acid (GABA) A receptor, subunit alpha 3 3.23 1.9E-02 
156 Dkk3 dickkopf homolog 3 (Xenopus laevis) 3.19 3.5E-04 
157 Shisa2* shisa homolog 2 (Xenopus laevis) 3.13 3.9E-02 
158 Eno3* enolase 3, beta muscle 3.13 2.3E-02 
159 Meg3 maternally expressed 3 3.12 1.9E-07 
160 Lrrc17 leucine rich repeat containing 17 3.08 1.4E-06 
161 Hhipl1 hedgehog interacting protein-like 1 3.05 1.1E-02 
162 Kcnab1 potassium voltage-gated channel, shaker-related subfamily, beta member 1 3.05 2.2E-04 
163 3632451O06Rik RIKEN cDNA 3632451O06 gene 3.02 6.9E-03 
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164 Anxa8 annexin A8 3.02 4.3E-04 
165 Ppp1r3c* protein phosphatase 1, regulatory (inhibitor) subunit 3C 3.00 2.7E-02 
166 Rian RNA imprinted and accumulated in nucleus 2.97 3.0E-04 
167 Gpnmb glycoprotein (transmembrane) nmb 2.97 1.8E-05 
168 Cmya5* cardiomyopathy associated 5 2.97 1.0E-02 
169 Itm2a integral membrane protein 2A 2.93 3.7E-04 
170 Foxp2 forkhead box P2 2.90 1.1E-02 
171 Tppp3 tubulin polymerization-promoting protein family member 3 2.90 2.4E-04 
172 Spock2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 2 2.88 2.6E-04 
173 Gpc3 glypican 3 2.87 2.1E-05 
174 Spock1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 1 2.84 3.6E-02 
175 Myo16 myosin XVI 2.83 1.4E-03 
176 Hspb8* heat shock protein 8 2.76 3.5E-02 
177 Tmem38a* transmembrane protein 38A 2.76 4.4E-02 
178 Thbs3 thrombospondin 3 2.76 4.7E-03 
179 Epha3 Eph receptor A3 2.74 2.5E-06 
180 Cacng7 calcium channel, voltage-dependent, gamma subunit 7 2.71 1.0E-03 
181 Rgs11 
regulator of G-protein signaling 11; similar to regulator of G-protein 
signaling 11 2.70 1.9E-02 
182 Dnahc1 dynein, axonemal, heavy chain 1 2.63 6.7E-04 
183 Camk4 calcium/calmodulin-dependent protein kinase IV 2.61 1.5E-03 
184 Medag mesenteric estrogen dependent adipogenesis 2.61 1.1E-02 
185 Rab15 RAB15, member RAS oncogene family 2.59 2.6E-03 
186 Best1 bestrophin 1; hypothetical protein LOC100046789 2.59 7.0E-03 
187 Art5* ADP-ribosyltransferase 5 2.58 3.8E-03 
188 Glrb glycine receptor, beta subunit 2.57 9.6E-03 
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189 Prtg protogenin homolog (Gallus gallus) 2.57 4.8E-03 
190 Tceal3 transcription elongation factor A (SII)-like 3 2.56 4.4E-04 
191 Ccdc3 coiled-coil domain containing 3 2.55 8.1E-12 
192 Higd1b HIG1 domain family, member 1B 2.54 3.8E-02 
193 Glt8d2 glycosyltransferase 8 domain containing 2 2.53 1.7E-04 
194 Tnmd tenomodulin 2.52 8.2E-03 
195 C1qtnf2 C1q and tumor necrosis factor related protein 2 2.51 4.3E-02 
196 Sparcl1 SPARC-like 1 2.48 3.2E-06 
197 Slc6a17 solute carrier family 6 (neurotransmitter transporter), member 17 2.47 9.7E-03 
198 Mustn1 musculoskeletal, embryonic nuclear protein 1 2.45 5.5E-03 
199 Tgfb2 transforming growth factor, beta 2 2.45 1.0E-03 
200 Dpysl4 dihydropyrimidinase-like 4 2.44 1.7E-02 
201 Clmn calmin 2.44 4.5E-02 
202 Ccdc141 RIKEN cDNA 2610301F02 gene 2.44 2.9E-03 
203 Matn2 matrilin 2 2.43 6.6E-05 
204 Msln mesothelin 2.42 1.5E-04 
205 Piwil2 piwi-like homolog 2 (Drosophila) 2.41 1.9E-03 
206 Aebp1 AE binding protein 1 2.41 4.7E-06 
207 Cdh13 cadherin 13 2.40 3.3E-05 
208 Col6a3 collagen, type VI, alpha 3 2.39 2.9E-05 
209 Arhgap22 Rho GTPase activating protein 22 2.38 2.2E-02 
210 Peg3 paternally expressed 3; antisense transcript gene of Peg3 2.35 2.1E-02 
211 Adamtsl1 ADAMTS-like 1 2.34 2.8E-02 
212 Asic3 acid-sensing (proton-gated) ion channel 3 2.34 2.6E-04 
213 Scn2b sodium channel, voltage-gated, type II, beta 2.32 1.8E-03 
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214 Radil Ras association and DIL domains 2.31 1.1E-02 
215 Galr2 galanin receptor 2 2.31 5.5E-03 
216 Cys1 cystin 1 2.31 1.9E-02 
217 Lum lumican 2.29 3.0E-02 
218 Plat plasminogen activator, tissue 2.29 4.3E-02 
219 Sost sclerostin 2.29 4.3E-02 
220 Wnt10b wingless related MMTV integration site 10b 2.29 5.4E-04 
221 Tmeff1 transmembrane protein with EGF-like and two follistatin-like domains 1 2.29 3.1E-02 
222 Cobl cordon-bleu 2.28 4.3E-02 
223 Baalc brain and acute leukemia, cytoplasmic 2.28 3.9E-02 
224 Ecm2 extracellular matrix protein 2, female organ and adipocyte specific 2.27 1.4E-06 
225 Slc6a7 solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 2.27 1.0E-04 
226 Mall mal, T-cell differentiation protein-like 2.24 4.2E-02 
227 Usp13* ubiquitin specific peptidase 13 (isopeptidase T-3) 2.24 1.5E-02 
228 Rnf207 ring finger protein 207 2.24 3.1E-02 
229 Hr hairless 2.24 1.3E-02 
230 Hrc* histidine rich calcium binding protein 2.24 2.8E-02 
231 Adamts17 
a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 17 2.24 1.4E-04 
232 Pamr1 peptidase domain containing associated with muscle regeneration 1 2.22 8.0E-06 
233 Sulf1 sulfatase 1 2.21 3.2E-07 
234 Peg3as Peg3 opposite strand 2.21 2.1E-02 
235 Prnd prion protein dublet 2.20 2.3E-03 
236 Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 2.19 8.2E-04 
237 Cyb5r2 cytochrome b5 reductase 2 2.19 1.7E-02 
238 Edil3 EGF-like repeats and discoidin I-like domains 3 2.18 5.7E-06 
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239 Adcy1 adenylate cyclase 1 2.17 1.6E-03 
240 Nbl1 neuroblastoma, suppression of tumorigenicity 1 2.17 3.0E-02 
241 Dnahc7b dynein, axonemal, heavy chain 7B 2.17 2.5E-02 
242 D630003M21Rik RIKEN cDNA D630003M21 gene 2.16 1.2E-02 
243 Ssc5d scavenger receptor cysteine rich family, 5 domains 2.16 1.3E-05 
244 Htra1 HtrA serine peptidase 1 2.15 2.2E-05 
245 Mn1 meningioma 1 2.14 3.2E-02 
246 Gabrb3 gamma-aminobutyric acid (GABA) A receptor, subunit beta 3 2.13 1.7E-02 
247 P2rx6 purinergic receptor P2X, ligand-gated ion channel, 6 2.12 4.4E-02 
248 Gpx3 glutathione peroxidase 3 2.10 6.8E-05 
249 Magix MAGI family member, X-linked 2.10 1.6E-02 
250 Pdgfrl platelet-derived growth factor receptor-like 2.09 1.4E-02 
251 Jph1* junctophilin 1 2.09 4.0E-02 
252 Epha4 Eph receptor A4 2.08 1.3E-04 
253 Hmcn1 hemicentin 1 2.08 8.3E-03 
254 Meox1 mesenchyme homeobox 1 2.08 6.6E-03 
255 Wfdc1* WAP four-disulfide core domain 1 2.07 3.4E-02 
256 Lama2 laminin, alpha 2 2.06 1.3E-02 
257 Efcc1 EF hand and coiled-coil domain containing 1 2.06 1.3E-02 
258 Ankrd29 ankyrin repeat domain 29 2.03 4.7E-03 
259 Npy neuropeptide Y 2.03 2.9E-03 
260 Ube2ql1 RIKEN cDNA 3110006E14 gene 2.03 1.1E-03 
261 Timp1 tissue inhibitor of metalloproteinase 1 2.03 1.9E-03 
262 Smoc2 SPARC related modular calcium binding 2 2.03 1.7E-02 
263 Rassf9 Ras association (RalGDS/AF-6) domain family (N-terminal) member 9 2.03 5.0E-03 
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264 Lonrf2 LON peptidase N-terminal domain and ring finger 2 2.02 2.0E-02 
265 Ptprv protein tyrosine phosphatase, receptor type, V 2.01 7.5E-06 
 
 
 
Table B.13, Part II. List of genes more highly expressed in control cancellous bone of pOC-ERaKO 
animals at 3 hours 
 Gene Symbol Gene Fold Change FDR 
1 Ly6g6c lymphocyte antigen 6 complex, locus G6C 3.42 6.0E-03 
2 Clec4g C-type lectin domain family 4, member g 3.40 1.1E-04 
3 G6b G6B protein 3.11 3.9E-04 
4 Ccdc150 coiled-coil domain containing 150 2.82 3.0E-06 
5 Kcnj5 potassium inwardly-rectifying channel, subfamily J, member 5 2.81 2.4E-06 
6 Slamf1 signaling lymphocytic activation molecule family member 1 2.73 1.0E-09 
7 Reep2 receptor accessory protein 2 2.72 2.2E-05 
8 Gp6 glycoprotein 6 (platelet) 2.69 1.4E-06 
9 Serpinb2 serine (or cysteine) peptidase inhibitor, clade B, member 2 2.69 2.1E-07 
10 AU023871 expressed sequence AU023871 2.69 2.3E-06 
11 Gp1ba glycoprotein 1b, alpha polypeptide 2.65 8.2E-06 
12 Akap5 A kinase (PRKA) anchor protein 5 2.63 1.2E-03 
13 Cd226* CD226 antigen 2.60 1.1E-07 
14 Lypd6 LY6/PLAUR domain containing 6 2.60 1.8E-02 
15 Gm13710 predicted gene 13710 2.60 3.4E-02 
16 Ppbp pro-platelet basic protein 2.56 9.2E-07 
17 F2rl2 coagulation factor II (thrombin) receptor-like 2 2.54 1.8E-06 
  313 
Table B.13, Part II. Continued 
 Gene Symbol Gene Fold Change FDR 
18 Gp5 glycoprotein 5 (platelet) 2.52 2.8E-05 
19 Mmrn1 multimerin 1 2.49 4.9E-06 
20 Slc16a9 solute carrier family 16 (monocarboxylic acid transporters), member 9 2.48 1.7E-06 
21 Clec1b C-type lectin domain family 1, member b 2.48 4.9E-07 
22 Cxcl5 chemokine (C-X-C motif) ligand 5 2.47 2.8E-04 
23 Ly6g6f lymphocyte antigen 6 complex, locus G6F 2.47 6.5E-05 
24 Gcsam germinal center associated, signaling and motility 2.47 1.5E-05 
25 Tubb1 tubulin, beta 1 2.46 2.5E-06 
26 Ptprn protein tyrosine phosphatase, receptor type, N 2.45 4.6E-03 
27 Mpl myeloproliferative leukemia virus oncogene 2.45 1.9E-05 
28 Gm1968 predicted gene 1968 2.44 3.3E-04 
29 Nlrp6 NLR family, pyrin domain containing 6 2.43 6.7E-03 
30 Treml1 triggering receptor expressed on myeloid cells-like 1 2.43 1.1E-05 
31 Alox12 arachidonate 12-lipoxygenase 2.43 8.6E-06 
32 Gnaz guanine nucleotide binding protein, alpha z subunit 2.41 6.7E-04 
33 Dclk3 doublecortin-like kinase 3 2.41 3.4E-02 
34 Slc14a1 solute carrier family 14 (urea transporter), member 1 2.41 3.8E-05 
35 Elovl7 ELOVL family member 7, elongation of long chain fatty acids (yeast) 2.40 7.2E-05 
36 Tnfsf15 tumor necrosis factor (ligand) superfamily, member 15 2.40 3.4E-02 
37 Itga2b integrin alpha 2b 2.40 1.3E-04 
38 Clca1 chloride channel calcium activated 1 2.39 2.3E-06 
39 Pf4 platelet factor 4 2.37 2.5E-05 
40 Pls1 plastin 1 (I-isoform) 2.37 4.1E-05 
41 Igfbp2 insulin-like growth factor binding protein 2 2.36 2.2E-04 
42 Ache* acetylcholinesterase 2.36 6.5E-05 
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43 Slc6a4 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 2.36 1.3E-06 
44 Pkd1l3 polycystic kidney disease 1 like 3 2.35 2.5E-03 
45 E230029C05Rik RIKEN cDNA E230029C05 gene 2.34 3.7E-02 
46 Aldob aldolase B, fructose-bisphosphate 2.32 1.4E-02 
47 Ltb4r2 leukotriene B4 receptor 2 2.32 4.1E-02 
48 Kng2 kininogen 2 2.32 1.4E-06 
49 Mrvi1 MRV integration site 1 2.31 4.4E-05 
50 Ufsp1 UFM1-specific peptidase 1 2.30 3.2E-05 
51 Gramd1c GRAM domain containing 1C 2.30 8.0E-06 
52 Gp9* glycoprotein 9 (platelet) 2.30 2.3E-04 
53 Gp1bb glycoprotein Ib, beta polypeptide 2.29 2.6E-04 
54 C530008M17Rik RIKEN cDNA C530008M17 gene 2.28 3.5E-05 
55 Mfsd2b predicted gene 1964 2.28 4.5E-05 
56 Nrgn neurogranin 2.28 2.2E-05 
57 Slc6a20a solute carrier family 6 (neurotransmitter transporter), member 20A 2.27 1.7E-02 
58 Rbpms2 RNA binding protein with multiple splicing 2 2.27 5.6E-06 
59 Ppp1r14a protein phosphatase 1, regulatory (inhibitor) subunit 14A 2.27 4.6E-02 
60 Il1a interleukin 1 alpha 2.27 3.1E-06 
61 P2rx1 purinergic receptor P2X, ligand-gated ion channel, 1 2.26 2.2E-05 
62 Rgs18 regulator of G-protein signaling 18 2.26 3.7E-07 
63 Slc24a5 solute carrier family 24, member 5 2.25 2.2E-04 
64 Dok2 docking protein 2 2.25 1.4E-06 
65 Tesc tescalcin; similar to Tescalcin 2.25 3.6E-03 
66 Plek pleckstrin 2.23 4.9E-06 
67 Vwf Von Willebrand factor homolog 2.23 9.5E-04 
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68 Slc35d3 solute carrier family 35, member D3 2.21 1.0E-03 
69 Kng1 kininogen 1 2.21 1.8E-06 
70 Selp selectin, platelet 2.20 7.6E-06 
71 Hist1h1d histone cluster 1, H1d 2.19 2.3E-02 
72 Slc6a3 solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 2.18 1.8E-03 
73 Ubd ubiquitin D 2.18 1.8E-04 
74 C6 complement component 6 2.17 4.0E-04 
75 Ptger3 prostaglandin E receptor 3 (subtype EP3) 2.17 2.7E-04 
76 Lipg lipase, endothelial 2.16 2.0E-04 
77 Serpina3b serine (or cysteine) peptidase inhibitor, clade A, member 3B 2.16 1.2E-02 
78 Cd5l CD5 antigen-like 2.16 7.1E-04 
79 F5 coagulation factor V 2.16 4.5E-05 
80 Robo3 roundabout homolog 3 (Drosophila) 2.15 1.6E-03 
81 Trpc6 transient receptor potential cation channel, subfamily C, member 6 2.15 1.4E-05 
82 D830046C22Rik RIKEN cDNA D830046C22 gene 2.15 2.4E-03 
83 Kcna2 potassium voltage-gated channel, shaker-related subfamily, member 2 2.15 5.1E-05 
84 AI504432 expressed sequence AI504432 2.14 1.4E-07 
85 Angpt1 angiopoietin 1 2.14 4.9E-06 
86 Prkar2b protein kinase, cAMP dependent regulatory, type II beta 2.13 6.2E-06 
87 Grem1 gremlin 1 2.13 2.0E-03 
88 Cass4 Cas scaffolding protein family member 4 2.12 9.9E-05 
89 Dhcr24 24-dehydrocholesterol reductase 2.12 1.5E-04 
90 Pde3a phosphodiesterase 3A, cGMP inhibited 2.11 9.9E-05 
91 Cited4 
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal 
domain, 4 2.11 7.2E-03 
92 Arhgap6 Rho GTPase activating protein 6 2.09 6.7E-04 
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93 Fcna ficolin A 2.09 1.8E-04 
94 Hist1h4m histone cluster 1, H4m 2.09 4.0E-02 
95 Chrdl1 chordin-like 1 2.09 2.5E-06 
96 Sdpr serum deprivation response 2.08 1.2E-05 
97 Npas4 neuronal PAS domain protein 4 2.08 6.3E-04 
98 Esm1 endothelial cell-specific molecule 1 2.07 6.3E-05 
99 Kcnj9 potassium inwardly-rectifying channel, subfamily J, member 9 2.07 3.5E-02 
100 Susd2 sushi domain containing 2 2.07 1.7E-04 
101 Gpm6a glycoprotein m6a 2.06 4.2E-04 
102 Tmem40 transmembrane protein 40 2.06 6.1E-05 
103 Fmo2 flavin containing monooxygenase 2 2.06 7.2E-05 
104 Gm16548 predicted gene 16548 2.05 5.4E-03 
105 Scimp SLP adaptor and CSK interacting membrane protein 2.04 2.4E-02 
106 Sec14l5* SEC14-like 5 (S. cerevisiae) 2.04 6.2E-03 
107 Gfi1b growth factor independent 1B 2.04 1.0E-03 
108 Serpinb10 serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 10 2.03 6.0E-04 
109 Tmem178 transmembrane protein 178 2.02 1.9E-03 
110 I830077J02Rik RIKEN cDNA I830077J02 gene 2.02 3.5E-04 
111 Darc Duffy blood group, chemokine receptor 2.02 7.6E-04 
112 F2rl3 coagulation factor II (thrombin) receptor-like 3 2.02 4.9E-03 
113 Slc30a10 solute carrier family 30, member 10 2.01 2.9E-02 
114 Lat linker for activation of T cells 2.01 2.4E-03 
115 Gata1 GATA binding protein 1 2.01 7.9E-04 
116 Ubash3b ubiquitin associated and SH3 domain containing, B 2.00 2.7E-06 
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  total 381  
  *indicates contaminant 102  
  total without contaminants 279  
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Table B.14 A complete list of genes that were differentially expressed in pOC-ERaKO animals at 
24 hours in cortical vs cancellous bone at baseline in order of decreasing fold change that were: I. more 
highly expressed in cortical bone and II. more highly expressed in cancellous bone. Number of genes 
(column A), gene symbols (column B), gene names (column C), fold change (column D), false discovery 
rate (FDR) (column E). * indicates contamination as determined by Ayturk et al. 
 
Table B.14, Part I List of genes more highly expressed in control cortical bone of pOC-ERaKO animals 
at 24 hours 
 Gene Symbol Gene Fold 
Change 
FDR 
1 Myh4* myosin, heavy polypeptide 4, skeletal muscle 609.91 8.2E-04 
2 Myoz2* myozenin 2 506.34 2.7E-07 
3 Ear12 eosinophil-associated, ribonuclease A family, member 3; eosinophil-
associated, ribonuclease A family, member 12; eosinophil-associated, 
ribonuclease A family, member 2 
454.02 6.1E-04 
4 Ppp1r3a* protein phosphatase 1, regulatory (inhibitor) subunit 3A 323.01 1.2E-07 
5 Vgll2 vestigial like 2 homolog (Drosophila) 301.32 4.0E-06 
6 Myh1* myosin, heavy polypeptide 2, skeletal muscle, adult; myosin, heavy 
polypeptide 1, skeletal muscle, adult 
250.40 3.5E-07 
7 Smtnl1* smoothelin-like 1 204.21 7.1E-08 
8 Trim63* similar to tripartite motif-containing 63; tripartite motif-containing 63 179.43 9.5E-06 
9 Ckm* creatine kinase, muscle 178.74 1.1E-05 
10 Abra* actin-binding Rho activating protein 175.19 4.7E-06 
11 Mylk2* myosin, light polypeptide kinase 2, skeletal muscle 149.17 3.5E-08 
12 Myh2* myosin, heavy polypeptide 2, skeletal muscle, adult; myosin, heavy 
polypeptide 1, skeletal muscle, adult 
145.69 2.6E-05 
13 Eef1a2* eukaryotic translation elongation factor 1 alpha 2 137.37 4.7E-07 
14 Myot* myotilin 132.89 1.6E-08 
15 Myom2* myomesin 2 129.01 3.1E-06 
16 Dhrs7c* dehydrogenase/reductase (SDR family) member 7C 127.38 1.0E-06 
  319 
Table B.14, Part I Continued 
 Gene Symbol Gene Fold 
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17 Ampd1* adenosine monophosphate deaminase 1 (isoform M) 122.12 3.1E-06 
18 Acta1* actin, alpha 1, skeletal muscle 113.98 3.2E-05 
19 Ano5* anoctamin 5 107.33 7.2E-06 
20 Xirp2* xin actin-binding repeat containing 2 99.81 9.8E-04 
21 Tcap* titin-cap 97.57 2.0E-10 
22 Atp2a1* ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 94.56 4.1E-07 
23 Mb* myoglobin 93.55 1.2E-05 
24 Smyd1* SET and MYND domain containing 1 90.83 7.1E-08 
25 Tnnt3* troponin T3, skeletal, fast 90.17 2.2E-06 
26 Trdn* triadin 88.29 1.2E-07 
27 Tnnc2* troponin C2, fast 87.00 4.1E-07 
28 Klhl40 kelch-like 40 86.38 3.6E-04 
29 Pvalb* parvalbumin 84.22 3.1E-04 
30 Sypl2* synaptophysin-like 2 78.39 3.0E-06 
31 Lmod2* leiomodin 2 (cardiac) 72.98 1.1E-06 
32 Ckmt2* creatine kinase, mitochondrial 2 68.20 3.5E-08 
33 Nctc1* non-coding transcript 1 67.93 1.8E-04 
34 Asb15* ankyrin repeat and SOCS box-containing 15 65.71 2.0E-04 
35 Hhatl* hedgehog acyltransferase-like 64.21 3.2E-05 
36 Hfe2* hemochromatosis type 2 (juvenile) (human homolog) 63.03 3.4E-06 
37 Casq1* calsequestrin 1 63.01 1.1E-06 
38 Mybpc1* myosin binding protein C, slow-type 62.95 1.0E-05 
39 Klhl31* kelch-like 31 (Drosophila) 56.14 1.1E-04 
40 Smpx* small muscle protein, X-linked 53.91 3.1E-06 
41 Trim54* tripartite motif-containing 54 46.54 3.2E-05 
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42 Cilp cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 46.46 2.5E-02 
43 Actn2* actinin alpha 2 46.18 6.1E-07 
44 Myoz1* myozenin 1 46.12 3.0E-06 
45 A930016O22Rik* RIKEN cDNA A930016O22 gene 44.46 7.8E-07 
46 Yipf7* Yip1 domain family, member 7 43.96 1.0E-04 
47 Murc* muscle-related coiled-coil protein 41.22 4.9E-06 
48 Cacna1s* calcium channel, voltage-dependent, L type, alpha 1S subunit 40.24 1.2E-07 
49 2310002L09Rik* RIKEN cDNA 2310002L09 gene 39.18 4.4E-04 
50 Jsrp1* junctional sarcoplasmic reticulum protein 1 38.79 1.0E-05 
51 Kcnc4* potassium voltage gated channel, Shaw-related subfamily, member 4 38.58 3.4E-05 
52 Tnni2* troponin I, skeletal, fast 2 37.61 4.0E-05 
53 Mylpf* myosin light chain, phosphorylatable, fast skeletal muscle 36.56 7.8E-07 
54 Mybpc2* myosin binding protein C, fast-type 35.43 1.4E-04 
55 Nrap* nebulin-related anchoring protein 34.37 6.6E-08 
56 Ankrd1 ankyrin repeat domain 1 (cardiac muscle) 33.68 8.3E-04 
57 Clcn1* chloride channel 1 32.74 1.4E-04 
58 Neb* nebulin 32.51 1.6E-06 
59 Myl1* myosin, light polypeptide 1 32.15 4.8E-06 
60 Ldb3* LIM domain binding 3 32.09 1.0E-06 
61 Rpl3l* ribosomal protein L3-like 31.66 2.9E-07 
62 Ttn* titin 31.13 8.6E-07 
63 Igfn1 immunoglobulin-like and fibronectin type III domain containing 1 30.65 8.6E-04 
64 Actn3* actinin alpha 3 29.95 1.1E-06 
65 Kcna7* potassium voltage-gated channel, shaker-related subfamily, member 7 26.17 1.3E-04 
66 Sgcg* sarcoglycan, gamma (dystrophin-associated glycoprotein) 24.56 4.4E-04 
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67 H19* H19 fetal liver mRNA 22.91 1.1E-07 
68 Fitm1* fat storage-inducing transmembrane protein 1 22.78 2.2E-04 
69 Dusp13* dual specificity phosphatase 13 21.12 2.4E-04 
70 Ryr1* ryanodine receptor 1, skeletal muscle 20.65 9.9E-06 
71 Myoz3* myozenin 3 20.59 3.6E-03 
72 Adamts8 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 8 
19.08 4.9E-06 
73 Myoc myocilin 19.03 1.2E-02 
74 Mylk4* myosin light chain kinase family, member 4 18.95 2.1E-04 
75 Mypn* myopalladin 18.86 1.3E-03 
76 Mybph myosin binding protein H 18.85 3.6E-02 
77 Des* desmin 18.28 1.4E-06 
78 Klhl41 kelch-like 41 18.21 6.2E-04 
79 Fbxo40* F-box protein 40 17.69 3.6E-03 
80 Thbs4 thrombospondin 4 17.29 3.7E-04 
81 Sh3bgr* similar to putative SH3BGR protein; SH3-binding domain glutamic acid-
rich protein 
16.37 4.3E-05 
82 Apobec2* apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2; similar to 
APOBEC-2 protein 
15.44 3.5E-04 
83 Xirp1* xin actin-binding repeat containing 1 14.87 1.4E-03 
84 Asb11* ankyrin repeat and SOCS box-containing 11 14.72 4.5E-03 
85 Lmod3* leiomodin 3 (fetal) 14.29 1.9E-04 
86 Cox8b* cytochrome c oxidase, subunit VIIIb 13.89 9.6E-04 
87 Synpo2l* synaptopodin 2-like 13.44 1.4E-03 
88 Pgam2* phosphoglycerate mutase 2 13.34 1.7E-04 
89 Cacng1* calcium channel, voltage-dependent, gamma subunit 1 13.17 1.1E-03 
90 Atp1a2* ATPase, Na+/K+ transporting, alpha 2 polypeptide 12.48 5.0E-05 
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 Gene Symbol Gene Fold 
Change 
FDR 
91 Scn4b* sodium channel, type IV, beta 11.95 4.5E-04 
92 Tigd4 tigger transposable element derived 4 11.27 1.1E-03 
93 Asb5* ankyrin repeat and SOCs box-containing 5 11.09 2.3E-02 
94 Ppp1r14c* protein phosphatase 1, regulatory (inhibitor) subunit 14c 10.65 1.2E-03 
95 Slc38a3* solute carrier family 38, member 3 10.28 1.3E-02 
96 Sel1l3* RIKEN cDNA 2310045A20 gene 10.18 1.0E-03 
97 Pdlim3* PDZ and LIM domain 3 10.03 1.1E-03 
98 Txlnb* taxilin beta 10.00 1.1E-04 
99 Prkag3* protein kinase, AMP-activated, gamma 3 non-catatlytic subunit 9.89 7.7E-03 
100 Kcnj11 potassium inwardly rectifying channel, subfamily J, member 11 9.70 3.0E-02 
101 Ostn osteocrin 9.56 1.6E-04 
102 Cox7a1* cytochrome c oxidase, subunit VIIa 1 9.51 3.6E-04 
103 Hspb7* heat shock protein family, member 7 (cardiovascular) 9.50 1.6E-05 
104 Myl2* myosin, light polypeptide 2, regulatory, cardiac, slow 9.06 2.1E-02 
105 Obscn* obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF 9.00 2.0E-04 
106 Alpk3* alpha-kinase 3 8.81 4.8E-04 
107 Myo18b* myosin XVIIIb 8.74 2.6E-04 
108 Tmod4* tropomodulin 4 8.50 1.8E-03 
109 Cilp2 cartilage intermediate layer protein 2 8.00 1.8E-03 
110 Trim72* tripartite motif-containing 72 7.95 8.2E-03 
111 Mfap4 microfibrillar-associated protein 4 7.91 7.0E-03 
112 C1qtnf9 C1q and tumor necrosis factor related protein 9 7.67 1.0E-05 
113 Hspb6* heat shock protein, alpha-crystallin-related, B6 7.57 6.2E-04 
114 Nos1 nitric oxide synthase 1, neuronal 7.49 5.4E-02 
115 Chad chondroadherin 7.34 5.7E-02 
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 Gene Symbol Gene Fold 
Change 
FDR 
116 Ankrd23* ankyrin repeat domain 23 7.32 5.5E-04 
117 Itgb1bp2* integrin beta 1 binding protein 2 7.26 2.3E-02 
118 Fndc5* fibronectin type III domain containing 5 7.25 4.9E-03 
119 Igfbp6 insulin-like growth factor binding protein 6 7.22 1.6E-04 
120 Rtn2* reticulon 2 (Z-band associated protein) 6.98 1.1E-03 
121 Lrrn1 leucine rich repeat protein 1, neuronal 6.96 1.9E-02 
122 Cox6a2* cytochrome c oxidase, subunit VI a, polypeptide 2 6.30 7.8E-03 
123 Fam180a cDNA sequence BC064033 5.85 2.7E-02 
124 Plekhb1 pleckstrin homology domain containing, family B (evectins) member 1 5.79 7.8E-03 
125 Pygm* muscle glycogen phosphorylase 5.73 1.7E-03 
126 Flnc* filamin C, gamma 5.72 2.1E-04 
127 Wnt16 wingless-related MMTV integration site 16 5.68 5.3E-03 
128 Cmya5* cardiomyopathy associated 5 5.58 7.3E-04 
129 Pkia* protein kinase inhibitor, alpha 5.32 9.8E-04 
130 Phkg1* phosphorylase kinase gamma 1 5.29 9.5E-03 
131 Tbx4 T-box 4 5.27 7.6E-06 
132 Meox2 mesenchyme homeobox 2 5.25 7.6E-05 
133 Dusp26 dual specificity phosphatase 26 (putative) 5.22 2.1E-02 
134 Apod apolipoprotein D 5.19 3.9E-04 
135 Itgbl1 integrin, beta-like 1 5.15 2.1E-03 
136 Sh3rf2 SH3 domain containing ring finger 2 5.09 3.0E-02 
137 Hspb8* heat shock protein 8 5.05 3.1E-04 
138 Aspn asporin 4.96 9.6E-05 
139 Scn4a* sodium channel, voltage-gated, type IV, alpha 4.92 1.6E-02 
140 3425401B19Rik* RIKEN cDNA 3425401B19 gene 4.88 3.8E-03 
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 Gene Symbol Gene Fold 
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FDR 
141 Pgm5 phosphoglucomutase 5 4.82 8.3E-05 
142 Mcpt4 mast cell protease 3; mast cell protease 4 4.76 4.6E-02 
143 Cntfr ciliary neurotrophic factor receptor 4.75 1.7E-02 
144 Rbm24* RNA binding motif protein 24 4.66 2.2E-02 
145 Ndrg2* N-myc downstream regulated gene 2 4.55 3.2E-03 
146 Eno3* enolase 3, beta muscle 4.53 4.2E-03 
147 Tpm2* tropomyosin 2, beta 4.52 8.6E-04 
148 Chst8 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 4.40 2.3E-03 
149 Me3 malic enzyme 3, NADP(+)-dependent, mitochondrial 4.37 1.7E-02 
150 Srl* sarcalumenin 4.33 2.7E-03 
151 Serinc2 serine incorporator 2; hypothetical protein LOC100044221 4.22 2.0E-02 
152 Tnn tenascin N 4.16 1.1E-07 
153 Wnk2 WNK lysine deficient protein kinase 2 4.16 2.7E-02 
154 Ablim3 actin binding LIM protein family, member 3 4.12 1.1E-03 
155 Tmem38a* transmembrane protein 38A 4.10 8.6E-03 
156 Myl3* myosin, light polypeptide 3 4.03 4.5E-02 
157 Jph2* junctophilin 2 4.01 1.2E-03 
158 Sall1 sal-like 1 (Drosophila) 4.01 5.1E-03 
159 Fndc1 fibronectin type III domain containing 1; similar to fibronectin type III 
domain containing 1 
3.98 3.4E-05 
160 Lrrc15 leucine rich repeat containing 15 3.91 6.7E-07 
161 Jph4 junctophilin 4 3.88 3.9E-02 
162 Tpd52l1 tumor protein D52-like 1 3.85 1.9E-02 
163 Fmod fibromodulin 3.81 4.7E-07 
164 Csrp3 cysteine and glycine-rich protein 3 3.73 2.7E-02 
165 Synpo2* synaptopodin 2 3.64 3.2E-02 
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 Gene Symbol Gene Fold 
Change 
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166 Mapt microtubule-associated protein tau 3.61 3.3E-02 
167 Duox1 dual oxidase 1 3.59 8.0E-03 
168 Ky* kyphoscoliosis peptidase 3.48 5.8E-02 
169 Sema3c sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3C 
3.46 3.5E-02 
170 Crabp2 cellular retinoic acid binding protein II 3.45 4.1E-03 
171 Tpsb2 tryptase beta 2 3.41 4.9E-02 
172 Col3a1 collagen, type III, alpha 1 3.39 1.7E-03 
173 Penk preproenkephalin 3.36 1.5E-02 
174 Cers1 ceramide synthase 1 3.36 3.2E-02 
175 Mrgprf MAS-related GPR, member F 3.24 1.3E-02 
176 C1qtnf2 C1q and tumor necrosis factor related protein 2 3.24 1.3E-02 
177 Megf6 multiple EGF-like-domains 6 3.23 8.0E-03 
178 Hspa1a heat shock protein 1B; heat shock protein 1A; heat shock protein 1-like 3.21 1.2E-02 
179 Nexn* nexilin 3.20 1.8E-02 
180 Rab15 RAB15, member RAS oncogene family 3.15 3.5E-04 
181 Prrx2 paired related homeobox 2 3.10 1.3E-02 
182 Ppp1r3c* protein phosphatase 1, regulatory (inhibitor) subunit 3C 3.09 2.9E-02 
183 Acta2 actin, alpha 2, smooth muscle, aorta 3.09 1.2E-03 
184 Pm20d2 peptidase M20 domain containing 2 2.98 2.4E-02 
185 P4ha3 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), 
alpha polypeptide III 
2.96 5.9E-03 
186 Angptl2 angiopoietin-like 2 2.94 3.7E-05 
187 Ssc5d scavenger receptor cysteine rich family, 5 domains 2.94 2.9E-05 
188 Angptl7 angiopoietin-like 7 2.88 4.3E-02 
189 Duoxa1 dual oxidase maturation factor 1 2.87 1.9E-02 
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190 Meg3 maternally expressed 3 2.81 2.3E-04 
191 Sparcl1 SPARC-like 1 2.80 4.5E-12 
192 Mustn1 musculoskeletal, embryonic nuclear protein 1 2.79 3.8E-02 
193 Kcns1 K+ voltage-gated channel, subfamily S, 1 2.77 1.8E-02 
194 Cacng7 calcium channel, voltage-dependent, gamma subunit 7 2.76 2.3E-03 
195 Zfp185 zinc finger protein 185 2.70 3.1E-02 
196 Pfkm* phosphofructokinase, muscle 2.68 2.4E-02 
197 Cdh13 cadherin 13 2.67 2.4E-06 
198 Miat myocardial infarction associated transcript (non-protein coding) 2.65 3.4E-05 
199 Aebp1 AE binding protein 1 2.64 7.1E-08 
200 Postn periostin, osteoblast specific factor 2.60 1.6E-03 
201 Tgfb2 transforming growth factor, beta 2 2.59 6.9E-07 
202 Thbs2 thrombospondin 2 2.56 1.5E-04 
203 Plekhg4 pleckstrin homology domain containing, family G (with RhoGef domain) 
member 4 
2.56 8.2E-03 
204 Sncg synuclein, gamma 2.56 5.8E-02 
205 Aldh1a3 aldehyde dehydrogenase family 1, subfamily A3 2.55 2.2E-05 
206 Tenm3 teneurin transmembrane protein 3 2.55 2.2E-05 
207 Anxa8 annexin A8 2.54 3.8E-02 
208 Cav3* caveolin 3 2.53 3.1E-02 
209 Myo16 myosin XVI 2.52 2.6E-02 
210 Usp13* ubiquitin specific peptidase 13 (isopeptidase T-3) 2.49 1.4E-02 
211 Spock2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 2 2.48 7.4E-03 
212 Sox8 SRY-box containing gene 8 2.47 4.8E-02 
213 Nptxr chromobox homolog 6; neuronal pentraxin receptor; Cbx6-Nptxr 
readthrough transcripts 
2.46 3.6E-02 
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214 Ptn pleiotrophin 2.45 6.1E-04 
215 Thbs3 thrombospondin 3 2.43 8.2E-03 
216 Bai2 brain-specific angiogenesis inhibitor 2 2.43 5.9E-03 
217 Efhd1 EF hand domain containing 1 2.42 4.8E-02 
218 Mmp12 matrix metallopeptidase 12 2.42 4.4E-02 
219 Col16a1 collagen, type XVI, alpha 1 2.41 1.7E-04 
220 Nox4 NADPH oxidase 4 2.40 1.1E-02 
221 Spock1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 1 2.39 4.7E-02 
222 Gpnmb glycoprotein (transmembrane) nmb 2.37 7.0E-04 
223 Tagln transgelin 2.34 6.6E-03 
224 Ptgs2 prostaglandin-endoperoxide synthase 2 2.33 4.4E-03 
225 Col12a1 collagen, type XII, alpha 1 2.32 2.0E-05 
226 Scube1 signal peptide, CUB domain, EGF-like 1 2.27 9.4E-03 
227 Jph1* junctophilin 1 2.26 4.9E-02 
228 Npy neuropeptide Y 2.25 3.4E-03 
229 Gng8 guanine nucleotide binding protein (G protein), gamma 8 2.24 5.5E-02 
230 Morn4 MORN repeat containing 4 2.23 2.8E-02 
231 Tbx3 T-box 3 2.20 2.1E-03 
232 Gpc3 glypican 3 2.19 1.1E-04 
233 Slc6a17 solute carrier family 6 (neurotransmitter transporter), member 17 2.19 4.7E-02 
234 Sema6c sema domain, transmembrane domain (TM), and cytoplasmic domain, 
(semaphorin) 6C 
2.16 4.6E-02 
235 Prnd prion protein dublet 2.13 2.0E-02 
236 Hr hairless 2.13 1.1E-03 
237 3632451O06Rik RIKEN cDNA 3632451O06 gene 2.13 2.0E-02 
238 Fabp3* fatty acid binding protein 3, muscle and heart 2.11 3.1E-02 
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239 Pacsin3* protein kinase C and casein kinase substrate in neurons 3 2.10 2.6E-02 
240 Edn1 endothelin 1 2.10 4.8E-02 
241 Tppp3 tubulin polymerization-promoting protein family member 3 2.09 2.4E-02 
242 Fzd2 frizzled homolog 2 (Drosophila) 2.06 1.9E-02 
243 Hapln3 hyaluronan and proteoglycan link protein 3 2.06 3.3E-02 
244 Nog noggin 2.05 6.7E-03 
245 Apln apelin 2.05 4.9E-03 
246 Asphd2 aspartate beta-hydroxylase domain containing 2 2.05 2.0E-02 
247 Meox1 mesenchyme homeobox 1 2.05 1.9E-02 
248 Gli1 GLI-Kruppel family member GLI1 2.03 2.0E-02 
249 Map6 microtubule-associated protein 6 2.03 4.2E-02 
250 Scx scleraxis 2.01 8.0E-03 
251 Cd248 CD248 antigen, endosialin 2.01 2.8E-03 
252 Htra1 HtrA serine peptidase 1 2.00 9.7E-06 
 
 
Table B14, Part II. List of genes more highly expressed in control cancellous bone of pOC-ERaKO 
animals at 24 hours 
 Gene Symbol Gene Fold 
Change 
FDR 
1 Ear7 eosinophil-associated, ribonuclease A family, member 7 460.22 1.4E-04 
2 Cbln1 cerebellin 1 precursor protein 3.37 3.6E-02 
3 Klre1 killer cell lectin-like receptor family E member 1 3.23 1.1E-02 
4 4930431P03Rik RIKEN cDNA 4930431P03 gene 2.67 2.0E-02 
5 Pdia2 protein disulfide isomerase associated 2 2.62 3.9E-03 
6 Nlrp6 NLR family, pyrin domain containing 6 2.58 2.5E-03 
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 Gene Symbol Gene Fold 
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7 G6b G6B protein 2.54 3.9E-03 
8 Ltb4r2 leukotriene B4 receptor 2 2.43 4.6E-02 
9 BC016579 cDNA sequence, BC016579 2.39 1.1E-02 
10 Fcer1a Fc receptor, IgE, high affinity I, alpha polypeptide 2.37 4.6E-02 
11 Pf4 platelet factor 4 2.36 1.1E-08 
12 Ubd ubiquitin D 2.35 1.5E-06 
13 Pdzd3 PDZ domain containing 3 2.31 8.2E-03 
14 Aldob aldolase B, fructose-bisphosphate 2.26 4.5E-04 
15 Gp9 glycoprotein 9 (platelet) 2.22 4.0E-10 
16 0610039K10Rik RIKEN cDNA 0610039K10 gene 2.22 3.3E-02 
17 Efemp1* epidermal growth factor-containing fibulin-like extracellular matrix protein 
1 
2.18 4.2E-03 
18 Esm1 endothelial cell-specific molecule 1 2.18 5.5E-07 
19 Slc35d3 solute carrier family 35, member D3 2.17 8.6E-05 
20 Gpr174 G protein-coupled receptor 174 2.17 2.8E-03 
21 Clec4g C-type lectin domain family 4, member g 2.16 2.9E-02 
22 Gm5483 predicted gene 5483 2.16 3.6E-02 
23 Ly6g6f lymphocyte antigen 6 complex, locus G6F 2.15 5.5E-07 
24 Cd226 CD226 antigen 2.15 1.1E-06 
25 Smim5 small integral membrane protein 5 2.14 1.2E-03 
26 Ifi47* interferon gamma inducible protein 47 2.14 1.4E-04 
27 Cd5l CD5 antigen-like 2.14 2.7E-05 
28 5033406O09Rik RIKEN cDNA 5033406O09 gene 2.13 1.1E-02 
29 Chrdl1 chordin-like 1 2.12 2.7E-08 
30 Serpinb2 serine (or cysteine) peptidase inhibitor, clade B, member 2 2.10 2.4E-03 
31 Serpina3f serine (or cysteine) peptidase inhibitor, clade A, member 3F 2.08 4.3E-05 
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 Gene Symbol Gene Fold 
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32 Cxcl5 similar to LPS-induced CXC chemokine; chemokine (C-X-C motif) ligand 
5 
2.08 1.1E-02 
33 Rgs18 regulator of G-protein signaling 18 2.08 1.1E-06 
34 Gm16548 predicted gene 16548 2.08 1.1E-04 
35 Slamf1 signaling lymphocytic activation molecule family member 1 2.07 1.4E-06 
36 Ppbp pro-platelet basic protein 2.06 3.4E-05 
37 D830046C22Rik RIKEN cDNA D830046C22 gene 2.06 4.2E-03 
38 Tacstd2 tumor-associated calcium signal transducer 2 2.06 4.0E-02 
39 Kcnj5 potassium inwardly-rectifying channel, subfamily J, member 5 2.05 1.4E-07 
40 Slc6a4 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 2.05 4.7E-07 
41 Tesc tescalcin; similar to Tescalcin 2.05 3.4E-05 
42 Slc30a10 solute carrier family 30, member 10 2.03 1.9E-02 
43 P2rx1 purinergic receptor P2X, ligand-gated ion channel, 1 2.03 1.5E-06 
44 Kng2 kininogen 2 2.03 3.3E-05 
45 Slc6a3 solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 2.03 8.4E-03 
46 Gp5 glycoprotein 5 (platelet) 2.01 2.8E-09 
47 F2rl3 coagulation factor II (thrombin) receptor-like 3 2.01 1.1E-04 
48 Gp6 glycoprotein 6 (platelet) 2.01 4.1E-07 
49 Kcna3 potassium voltage-gated channel, shaker-related subfamily, member 3 2.00 8.2E-03 
     
  total 301  
  *indicates contaminant 129  
  total without contaminants 172  
 
 
